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Preface
Day after day, healthcare providers administer powerful drugs with a myriad of side 
effects. Local anesthetics are, by far, the drugs most used in daily clinical practice with 
the goal of producing optimal analgesia and anesthesia without patients losing control 
of their alertness, which is the greatest advantage of local anesthetics. Regional 
anesthesia has proven to be the technique of choice in patients with alterations of the 
immune system, for example, cancer patients, favoring a better short- and long-term 
recovery. These drugs have also been investigated as antimicrobials, anti-asthmatics, 
anti-inflammatories, anti-neoplastics, and anti-arrhythmics.
This book, Topics in Local Anesthetics, reviews and updates some basic and selected 
clinical applications of anesthetics, as well as examines the prevention and manage-
ment of complications related to their use. The first three chapters discuss the aspects 
of pharmacokinetics and pharmacodynamics, especially the pharmacokinetics of 
bupivacaine in pregnant women. These aspects are essential to decrease the possibili-
ties of systemic toxicity as well as effects on the fetus and the newborn. The use of 
adjuvant drugs dates back to the beginning of the last century and the advent of novel 
drugs has resulted in the prolongation of analgesia and regional anesthesia, as well as 
the reduction of toxic effects as it is possible to decrease the dosage of local anesthetics.
The safe use of these drugs requires knowledge of anatomy and the various 
techniques used to administer anesthetics, including topical, local, intravenous, 
endotracheal anesthesia, peripheral nerve blocks, interpleural, intra-articular, 
epidural, spinal, or a combination of any of these. The book reviews some of 
these techniques, with special emphasis on dentistry, maxillofacial surgery, and 
spinal anesthesia in ambulatory surgery. It also provides updated information on 
the effect of local anesthetics on the wound healing process, and their potential 
non-anesthetic uses. There is also a chapter dedicated to systemic toxicity.
As the editor, I want to thank my friend and co-editor Enrique Hernández-Cortez 
for his invaluable support to finish the book. I also wish to thank the authors and 
friends who contributed to this project.
Finally, it is my pleasure to thank my beloved wife Teresa for her love, patience, and 
support in the edition of this book, as well as my children and grandchildren, from 
whom I used much of their family time to finish this project.
Victor Whizar-Lugo
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Abstract
The fascinating history of local anesthetics (LAs) began in South America with 
the herbal and traditional use of cocaine leaves by the indigenous peoples of Peru 
and Bolivia, the sacred plant of the Incas Erythroxylum coca. The use for anesthetic 
purposes dates back to 1884. Since then, the evolution of LAs has been closely 
related to research motivated by its efficacy and safety versus toxicity. According to 
their chemical structure, these drugs are classified into two main groups: esters and 
amino amides; however, there are three LAs with different characteristics: articaine, 
sameridine, and centbucridine. The pharmacological and toxic mode of action is 
primarily in the voltage-dependent sodium channels located in the cell membrane, 
which clinically produces analgesia, anesthesia, seizures, arrhythmias, and cardiac 
arrest. The quality of anesthesia and analgesia depends on the type of LA, dose, 
and application technique, while the deleterious effects are secondary to its plasma 
concentration. Nonanesthetic properties of LAs such as their antimicrobial, 
antineoplastic, antiarrhythmics, antitussive, and antiasthmatics effects have been 
described and are briefly reviewed.
Keywords: local anesthetics, pharmacology, toxicity
1. Introduction
Local anesthetics (LAs) are drugs commonly used in medicine and especially in 
anesthesiology, which when administered in the vicinity of peripheral neural tissue 
produce changes in the conformation of voltage-dependent sodium channels that 
depolarize the neural tissue and produce analgesia, anesthesia, and sympathetic and 
motor block in the dermatomes of the affected nerves without altering consciousness. 
This inhibitory phenomenon is reversible and transitory and is known as regional 
anesthesia and is classified into local, peripheral nerves, nervous plexuses, peridural, 
subarachnoid, and intravenous anesthesia.
LAs are safe and effective drugs, although when wrongly managed, they can reach 
high plasma concentrations and produce systemic toxicity (LAST) that manifests 
primarily in the central nervous system (CNS) and cardiovascular system (CVS), 
causing side effects that can occasionally lead to death. Local neuro toxicity has also 
been described when injected in the vicinity of the peripheral nervous system or at 
subarachnoid or epidural space. Myotoxic effects have also been described.
The main clinical use of LAs is to achieve pain insensitivity, although they 
have other pharmacological uses such as antiarrhythmic, anti-asthmatic, anti-
inflammatory, antithrombotic, bacteriostatic, and bactericidal effects that have 
been demonstrated, as well as antitumoral agent enhancer activity [1–3]. LAs are 
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group. They are the only drugs used in regional anesthesia, although it has been 
described that other drugs with different molecular structure such as amitriptyline, 
meperidine, eugenols, beta-adrenergic antagonists, alpha2 agonists, spasmolytics, 
anticonvulsants, and antihistamines have local anesthetic effects [4–6]. There are 
three LAs that due to their chemical structure differ from the classic LAs: articaine, 
sameridine, and centbucridine. Articaine is classified into the amide group, it is fat 
soluble and short acting and has intermediate potency, with rapid metabolism due 
to an ester group in its structure. Sameridine, on the other hand, has mixed effects 
as an opioid agonist and LA properties under investigation for intrathecal use [7, 8]. 
Centbucridine is a nonester, nonamide drug still under clinical investigation [9].
In this introductory chapter, the most important properties of LAs are detailed, 
emphasizing their pharmacological classification, pharmacokinetic profile, action 
mechanisms, side effects, and some relevant clinical aspects, as well as their 
nonanesthetic uses.
2. Brief history of the discovery and evolution of LAs
In the Andean Mountains, centuries ago, the Incas began using cocaine leaves 
which they chewed or ingested in the form of potions that provided them with 
plenty of energy to carry out their religious rituals. In addition, as a powerful 
stimulant, the coca leaf was chewed to mitigate the effects derived from altitude, 
hunger or fatigue and as a medicine for gastrointestinal discomfort, colds, or 
bruises. This sacred plant of the Incas, Erythroxylum coca, caught the attention of 
Europeans who took it to the old continent at the end of the 16th century. It was 
until 1859 when Paulo Mantegazza, an Italian physiologist, wrote Sulle virtu igien-
iche e Medicinale della Coca (On the hygienic and medicinal properties of coca and 
on nervine nourishment in general) where he pointed out its healing properties. The 
German chemist Albert Niemann isolated the active substance from these leaves 
and called it cocaine, noting its power to anesthetize the tongue. In 1884, Sigmund 
Freud wrote his famous monograph entitled Ueber coca. Like some of his contempo-
raries, Freud acknowledged that cocaine had local anesthetic effects when applied 
to the mucous membranes, but it was Karl Köller who used it for the first time for 
anesthetic purposes when applied in various mucous membranes and in the con-
junctiva for surgical purposes. It is Köller to whom it is attributed the beginning of 
local anesthesia [10–12].
The knowledge of the toxic and additive effects of cocaine became public 
quickly; it went from being the LA in vogue to a potent CNS stimulant that until 
today is a social stigma. This fired the investigation toward new LAs, and safer 
drugs were found. Benzocaine was synthesized in 1890, and in 1904, Alfred 
Einhorn introduced procaine by degrading cocaine, which was later marketed as 
novocaine® and was the most widely used LA in the world. Tetracaine was syn-
thesized in 1928 and introduced into clinical anesthesia in 1932. In 1943 Löfgren 
discovered lidocaine that was introduced for clinical use in 1947 and is currently 
the most used LA. Mepivacaine appeared in 1956, and in 1963, the clinical use of 
bupivacaine was introduced, while etidocaine began to be used in 1972. Other LAs 
appeared during the following years but were withdrawn from the market due 
to their toxic effects. In 1970, Albrigth [13] mentioned some deaths attributed to 
bupivacaine and etidocaine. His editorial was enough to start basic and clinical 
research in search of new drugs with a better safety profile. The result was the 
introduction of ropivacaine in 1997 and levobupivacaine in 1999, both levoisomeric 





The levoisomeric LAs did not replace other LAs but are complementary to the 
therapeutic armamentarium in regional anesthesia. Both ropivacaine and levobu-
pivacaine have been conquering a special place in regional anesthesia techniques, 
but their toxicity is still superior to procaine, chloroprocaine, and lidocaine. While 
these LAs are not comparable in potency and duration, they still have a place in 
anesthesiology, with the exception of intrathecal lidocaine. The history of these 
drugs will continue to be written as new results on therapeutic effectiveness and 
toxicity are obtained.
3. Basics data
It is necessary to know some elementary aspects of the structure and function of 
the cell membrane, as well as to understand the role of voltage-dependent sodium 
channels, which are protein structures that are located in the cell membrane and 
play a paramount role in cellular electrical activity and impulse transmission.
3.1 Cellular membrane
The cell membrane is a barrier of lipids and proteins, which forms the outer 
surface of eukaryotic cells. The lipid part of the membrane is formed by a bilayer 
with a thickness of 60–100 Å, which gives it structure and constitutes a barrier 
that prevents the passage of water-soluble substances. It has three important 
types of lipids: phospholipids, glycolipids and cholesterol. The membrane pro-
teins are suspended individually or in groups within the lipid structure and shape 
the various channels. The selectivity of transmembrane protein channels allows 
the cell to control the entry and exit of substances, as well as transport between 
cell compartments. Membrane proteins not only facilitate selective transport, but 
in addition, they are able to carry out active transport against the concentration 
gradient with special pumps, such as the sodium-potassium pump. Other func-
tions of the membrane, such as the recognition and binding of certain substances 
on the cell surface, are also determined by the protein part of the membrane. 
These proteins are called cell receptors.














Chronological appearance of local anesthetics.
Topics in Local Anesthetics
2
group. They are the only drugs used in regional anesthesia, although it has been 
described that other drugs with different molecular structure such as amitriptyline, 
meperidine, eugenols, beta-adrenergic antagonists, alpha2 agonists, spasmolytics, 
anticonvulsants, and antihistamines have local anesthetic effects [4–6]. There are 
three LAs that due to their chemical structure differ from the classic LAs: articaine, 
sameridine, and centbucridine. Articaine is classified into the amide group, it is fat 
soluble and short acting and has intermediate potency, with rapid metabolism due 
to an ester group in its structure. Sameridine, on the other hand, has mixed effects 
as an opioid agonist and LA properties under investigation for intrathecal use [7, 8]. 
Centbucridine is a nonester, nonamide drug still under clinical investigation [9].
In this introductory chapter, the most important properties of LAs are detailed, 
emphasizing their pharmacological classification, pharmacokinetic profile, action 
mechanisms, side effects, and some relevant clinical aspects, as well as their 
nonanesthetic uses.
2. Brief history of the discovery and evolution of LAs
In the Andean Mountains, centuries ago, the Incas began using cocaine leaves 
which they chewed or ingested in the form of potions that provided them with 
plenty of energy to carry out their religious rituals. In addition, as a powerful 
stimulant, the coca leaf was chewed to mitigate the effects derived from altitude, 
hunger or fatigue and as a medicine for gastrointestinal discomfort, colds, or 
bruises. This sacred plant of the Incas, Erythroxylum coca, caught the attention of 
Europeans who took it to the old continent at the end of the 16th century. It was 
until 1859 when Paulo Mantegazza, an Italian physiologist, wrote Sulle virtu igien-
iche e Medicinale della Coca (On the hygienic and medicinal properties of coca and 
on nervine nourishment in general) where he pointed out its healing properties. The 
German chemist Albert Niemann isolated the active substance from these leaves 
and called it cocaine, noting its power to anesthetize the tongue. In 1884, Sigmund 
Freud wrote his famous monograph entitled Ueber coca. Like some of his contempo-
raries, Freud acknowledged that cocaine had local anesthetic effects when applied 
to the mucous membranes, but it was Karl Köller who used it for the first time for 
anesthetic purposes when applied in various mucous membranes and in the con-
junctiva for surgical purposes. It is Köller to whom it is attributed the beginning of 
local anesthesia [10–12].
The knowledge of the toxic and additive effects of cocaine became public 
quickly; it went from being the LA in vogue to a potent CNS stimulant that until 
today is a social stigma. This fired the investigation toward new LAs, and safer 
drugs were found. Benzocaine was synthesized in 1890, and in 1904, Alfred 
Einhorn introduced procaine by degrading cocaine, which was later marketed as 
novocaine® and was the most widely used LA in the world. Tetracaine was syn-
thesized in 1928 and introduced into clinical anesthesia in 1932. In 1943 Löfgren 
discovered lidocaine that was introduced for clinical use in 1947 and is currently 
the most used LA. Mepivacaine appeared in 1956, and in 1963, the clinical use of 
bupivacaine was introduced, while etidocaine began to be used in 1972. Other LAs 
appeared during the following years but were withdrawn from the market due 
to their toxic effects. In 1970, Albrigth [13] mentioned some deaths attributed to 
bupivacaine and etidocaine. His editorial was enough to start basic and clinical 
research in search of new drugs with a better safety profile. The result was the 
introduction of ropivacaine in 1997 and levobupivacaine in 1999, both levoisomeric 





The levoisomeric LAs did not replace other LAs but are complementary to the 
therapeutic armamentarium in regional anesthesia. Both ropivacaine and levobu-
pivacaine have been conquering a special place in regional anesthesia techniques, 
but their toxicity is still superior to procaine, chloroprocaine, and lidocaine. While 
these LAs are not comparable in potency and duration, they still have a place in 
anesthesiology, with the exception of intrathecal lidocaine. The history of these 
drugs will continue to be written as new results on therapeutic effectiveness and 
toxicity are obtained.
3. Basics data
It is necessary to know some elementary aspects of the structure and function of 
the cell membrane, as well as to understand the role of voltage-dependent sodium 
channels, which are protein structures that are located in the cell membrane and 
play a paramount role in cellular electrical activity and impulse transmission.
3.1 Cellular membrane
The cell membrane is a barrier of lipids and proteins, which forms the outer 
surface of eukaryotic cells. The lipid part of the membrane is formed by a bilayer 
with a thickness of 60–100 Å, which gives it structure and constitutes a barrier 
that prevents the passage of water-soluble substances. It has three important 
types of lipids: phospholipids, glycolipids and cholesterol. The membrane pro-
teins are suspended individually or in groups within the lipid structure and shape 
the various channels. The selectivity of transmembrane protein channels allows 
the cell to control the entry and exit of substances, as well as transport between 
cell compartments. Membrane proteins not only facilitate selective transport, but 
in addition, they are able to carry out active transport against the concentration 
gradient with special pumps, such as the sodium-potassium pump. Other func-
tions of the membrane, such as the recognition and binding of certain substances 
on the cell surface, are also determined by the protein part of the membrane. 
These proteins are called cell receptors.














Chronological appearance of local anesthetics.
Topics in Local Anesthetics
4
Cellular receptors are connected to internal systems that only act when certain 
substances bind to the membrane surface. Many of the cell controls act through 
this mechanism. Some metabolic pathways do not take action unless the “signal” 
molecule—for example—a hormone, has reached the cell surface. Glycoproteins 
are located in the membrane that identify other cells as members of an individual or 
as strangers. The interactions between the cells that make up a tissue are based on 
membrane proteins. In this manner, the structure of the membranes depends on the 
lipids, while the functions depend on the proteins.
3.2 Physiology of nerve transmission
The resting cell membrane maintains a voltage difference of 40–90 mV between 
the inner and outer layers, the inside being negative and the outside positive. This 
is the so-called resting potential, which is maintained by an active mechanism of 
the Na/K pump. The polarized membrane does not allow the passage of sodium ions 
(Na+) through the voltage-dependent sodium channels that are in resting state. When 
an electrical stimulus arrives, the membrane depolarization begins by activating 
the sodium channels that open to give way to the Na+, which enter the intracellular 
medium, transforming the negativity of the transmembrane potential. This initiates 
a cycle of changes of sodium channels in four functional stages: resting, activated, 
inactivated, and deactivated. In the resting state, the outer gate of the sodium 
channel is closed, and the internal gate or closing gate is open. When a stimulus 
reaches the membrane, the sodium channel is activated by opening the external 
gate and letting Na+ pass. When the membrane potential rises to +20 mV, the 
closure of the internal gate is triggered, and it enters an inactive state. The channel 
is deactivated when the membrane potential reaches −60 mV. When the passage of 
Na+ ceases through the pore of the sodium channel, the potassium channel increases 
its permeability, allowing this ion to pass inside the cell due to differences in con-
centration (concentration gradient). Then the initial phase is restored; the Na-K 
pump mobilizes Na+ outside and K+ inside the cell. Sodium channels pass from the 
inactive-deactivated state to the initial resting state. All these movements of Na+ and 
K+ are manifested in changes in the transmembrane electrical potential, generating 
the action potential that is propagated along the nerve fiber (Figure 1) [14]. Because 
there is a potential difference across the cell membrane, the membrane is said to be 
polarized. If the membrane potential becomes more positive than it is at the resting 
potential, the membrane is said to be depolarized. This whole process lasts 1 mil-
lisecond; 30% is consumed by the depolarization phase. According to the electrical 
instant, the sodium channels dependent on voltage exist in four stages; resting 
(−90 mV), activated (−60 mV), inactivated (+20 mV) and deactivated (−60 mV).
3.3 Voltage-dependent sodium channels
Hodgkin and Huxley proposed that cell membranes contained channels that 
facilitated ionic passage through them, which was confirmed when ionic currents 
that selectively flow through these transmembrane pores were directly measured. 
In 1972, Singer and Nicolson [15–17] proposed the ¨Fluid Mosaic Model¨ in the 
structure of the cell membranes were they described the cell membrane as a two-
dimensional liquid that restricts the lateral diffusion of membrane components and 
includes the integral proteins inserted in the lipid bilayer, some of which completely 
cross it and others cross it partially. Of these membrane proteins, three primary 
groups stand out: the channels, pumps, and receptors that constitute the transport 
system through cell membranes and regulate the movements of small molecules and 




Sodium channels are protein structures that are integrated into the lipid bilayer 
of the cell membrane and are responsible for orchestrating the electrical signals 
that are transmitted by certain tissues, such as nerves and the heart’s electrical 
conduction system. They are tubular-shaped components that resemble pores filled 
with water and are distributed through the whole cell membrane, primarily at the 
beginning of axons and in Ranvier nodes. This ion channels are divided into three 
types; those regulated by voltage, those regulated by extracellular ligand and those 
regulated by intracellular ligands, although other authors classify them into only 
two groups; those regulated by voltage and those operated by receptors [18–20]. 
The family of voltage-regulated sodium channels is composed of nine members that 
have been described in mammals and a tenth component related to a protein. All of 
them are members of a super family of ion channels that also includes potassium 
and calcium channels. Its nomenclature is complex and the chemical symbol of 
sodium Na+ is used first, followed by V indicating voltage regulated (Na+ V). The 
next number indicates the subfamily gene (Na+ V1), and the next number identifies 
the specific isoform of the channel, for example Na+ V1.1. This last number was 
assigned in the chronological order in which the genes were discovered. There are 
variants that come together or splice in each family member, which are told apart 
from each other by a lowercase letter, for example Na+ V1.1. a. [18, 19].
The sodium channels are formed by an alpha subunit, a simple polypeptide 
with a relative molecular mass of ~260,000 and are responsible for the selectivity 
and gate voltage. Some sodium channels have beta 1 and 2 subunits. These sodium 
ionophores are made up of four homologous domains; each of these four domains 
contains six transmembrane segments known as alpha-helices. This causes each 
sodium channel to cross the cell membrane 24 times. The center of this structure is 
the channel pore through which the Na+ passes into the interior of the cell and also 
the LAs in their hydrophilic form on their way to be fixed in the internal pore of the 
Figure 1. 
Representation of the four structural phases of sodium channels and their relationship with the action potential. 
Modified from Columb MO, MacLennan K. Local anesthetics agents. Anaesth Intensive Care Med 2007;  
8: 159–162 [14].
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sodium channel, where the voltage sensor is located. This voltage sensor is located in 
the fourth segment of each domain, where the LAs are fixed in the sixth segment of 
Domains 3 and 4. The voltage sensor has a very high positive charge, and these four 
domains are connected to each other by segments or hydrophilic bridges formed by 
amino acids that are located on the extracellular side of the membrane. The bridge 
that joins segments 5 and 6 of each domain is known as a pore handle and covers 
the pore of the channel to allow only the passage of Na+. This channel structure is 
responsible for selectivity and is vulnerable to certain toxins that can inactivate the 
sodium channel, although another description mentions that the selectivity filter is 
given by a narrowing of the ionic pore located below its gate [19].
The gate of the ionic pore is the initial portion of the sodium channel on the 
outer side of the cell membrane, is made up of protein “walls” and has an aqueous 
cavity similar to an irregular cylinder, where the external vestibule is located, which 
contains the selectivity filter and the voltage sensor. The closure gate is located 
in the most distal portion of the sodium channel, on the intracellular side of the 
cell membrane. The sodium channel inlet measures about 1.2 nm and narrows to 
about 0.3 to 0.5 nm at the site where the selectivity filter is located, which consists 
of aspartic acid, glycine, lysine, and alanine. The exact mechanism of how these 
channels discriminate between different cations is not known [19].
Figure 2 shows a representation of a voltage-dependent sodium channel, 
which is in the lipid bilayer of the cell membrane. Its four domains (D1, D2, D3, 
and D4) are each made up of six segments (alpha helices) that cross the entire cell 
membrane, emphasizing segment 4, colored in black and corresponding to the 
voltage sensor, which has a positive charge. On the extracellular face of the cell 
membrane there are two types of structures that connect the six segments, the one 
marked with T between segments 5 and 6 of each domain represent the site where 
some toxins act. The FS selectivity filter in the initial portion of the ionic pore 
is shown. The site where LAs act is marked with an X. This site has been highly 
Figure 2. 
Diagram of the voltage-dependent sodium channel with its 4 domains. Each domain has 6 helices that cross 
the cell membrane. The black stars located at the junctions of the helices 5 and 6 of each domain (pore handle) 
are the sites where cellular toxins (TTX) act. The sodium channel inactivation gate (IC) is located on the 
intracellular face between domain 3 and 4. The effector site of local anesthetics is located on helix 6 (or segment 




controversial and is located in the final portion of the ionic pore near the intracel-
lular surface of the membrane. The available information suggests that domains 
3 and 4 appear to contain this point in segment 6, although some references also 
place it in segment 6 of Domain 1.
Among other tissues, sodium channels are located in excitable membranes such 
as the CNS membranes, peripheral nervous system, and the conduction system of 
the heart. During a nervous impulse, the cell goes through three different phases; it 
first depolarizes as the sodium channels open, then a refractory period follows until 
the cell finally repolarizes when the sodium channels become impermeable to Na+. 
The intracytoplasmic junction between Domain III and Domain IV (CI in Figure 2) 
is responsible for this inactivation according to the “ball and chain” model.
4. Mechanism of action of LAs
As mentioned before, LAs inhibit the electrical impulse by selectively interfering 
with the function of voltage-dependent sodium channels by preventing the trans-
port of Na+ through the ionic pore of sodium ionophores, from outside to inside of 
the cells. When an electrical impulse reaches the excitable cell, the sodium channel 
opens for a millisecond and about 7000 Na+ pass. A refractory period continues 
until the ionophores become impermeable to Na+, and the membrane repolar-
izes again and enters a phase of inactivation, which is due to the activation of the 
intracytoplasmic junction between Domain III and IV. Unlike the tetrodotoxin and 
saxitoxin that act outside the cell membrane, LAs are temporarily fixed to the alpha 
helices 6 of Domains 3 and 4, which alters the voltage sensor and closes the inactiva-
tion gate, which obstructs the sodium channel and results in blockage of the initial 
phase of the action potential [14, 21–23].
There are two ways by which LAs reach the internal gate of the sodium channel 
and reach their site of action;
a. It has been postulated that LAs in their neutral, lipophilic (hydrophobic, B) 
form easily enter the lipid cell membrane in free form and from there contribute 
to the closure of sodium channels by the expansion of the cell membrane. From 
this location, LAs also pass into the cellular interior where they ionize and 
transform into their charged form (hydrophilic, BH+), which reaches the site 
where they interact (segment 6 of Domains 3 and 4) in the internal gate of the 
sodium channel.
b. LAs in their cationic or hydrophilic form (BH+) enter the cell cytoplasm 
through the sodium channels when they are open and reach their site of action 
by closing the sodium channel [14, 20, 23, 24]. LAs have no effect on the resting 
phase or on the potential threshold, although they can prolong the refractory 
period and repolarization.
Figure 3 illustrates these two routes of arrival of LAs to their receptor site in 
segments 6 of Domains 3 and 4.
Another factor that determines the action of LAs is the impulse frequency, the 
basis of the modulated receptor hypothesis, which suggests that these drugs bind 
more closely to the receptor within the ionic gate of voltage-dependent sodium 
channels when these are in an open or inactive state, that is in the depolarization 
phase, that when they are in a resting state, at which time they are separated from 
them. LAs that bind and dissociate rapidly such as lidocaine are little affected 
by this phenomenon, which is not the case with molecules such as bupivacaine, 
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ropivacaine, or etidocaine that are benefitted when the stimulation frequency is 
high, since it does not give time to recover to their resting state. This phenomenon 
explains the greater toxicity of some LAs [24, 25].
The affinity of LAs for the sodium channel is what determines their pharmaco-
logical action and also their toxic effects. The most important clinical outcome of 
these events at the level of voltage-dependent sodium channels and their interaction 
with LAs molecules are two results: regional anesthesia-analgesia and/or deleterious 
toxic effects.
5. Chemical structure of LAs
LAs are divided into two groups according to their chemical structure: the amino 
esters (cocaine, procaine, chloroprocaine, and tetracaine) and the amino amides 
(lidocaine, bupivacaine, mepivacaine, ropivacaine, and prilocaine). The typical 
molecule of a LA consists of three components: a) an aromatic lipophilic ring, 
usually benzene, b) an amphipathic intermediate chain of about 6 to 9 Å, and c) 
a terminal tertiary amine, hydrophilic, which is a base proton acceptor (H+). The 
intermediate chain binds the basic amine with the aromatic ring and has an ester 
(CO)- or amide (CNH)-type bond. Each of these three parts of the LA formula 
contributes to different properties. The aromatic ring of the molecule improves 
the liposolubility of the compound that can be increased by aliphatic substitutions 
at certain sites (R). When the liposolubility of LAs is increased, its diffusion is 
increased through nerve structures (nerve sheaths and axonal membranes), which 
improves their anesthetic and toxic potency since a greater proportion of the drug 
enters the neural tissue and is fixed there with higher affinity. An example of this 
phenomenon is bupivacaine which has greater potency than lidocaine; the first 
Figure 3. 
Arrival pathways of LAs to the sodium channel. The hydrophobic pathway refers to the passage of LAs in their 
neutral (lipophilic) form that easily penetrate the cell membrane. Once in the cell membrane, the LA (B) 
expands it and by mechanical effect closes the sodium channel. This same neutral form of LA penetrates the 
cell, where it is protonized by incorporating an H+, (BH+ cationic form) that easily reaches the internal gate of 
the sodium channel and attaches to segment 6 of domains 3 and 4, activating the closure of the sodium channel. 
The hydrophilic pathway exemplified in the right portion of the scheme illustrates how a cationic LA (BH+) 




is prepared at 0.5% (5 mg/mL) and the second at 2% (20 mg/mL). The terminal 
amine may exist in tertiary form (3 junctions) that is liposoluble and facilitates 
cell membrane penetration, or as a quaternary form (4 junctions) that is positively 
charged and makes the molecule water soluble, which makes it difficult to pass 
through the lipid membranes [11, 25].
As stated before, the aromatic ring determines the degree of lipoafinity of the 
LA, and the terminal amine acts as an on-off switch, allowing the LA to exist as 
either lipoafin or water soluble. Both the tertiary and quaternary forms play a very 
important role in the sequence of events that lead to nerve conduction blockage. 
The tertiary hydrophilic amine, which is kept charged to the physiological pH 
and gives it its condition of weak bases with a positive charge, is the part that will 
be fixed to the receptor in the sodium channel of the cell membrane to exert the 
pharmacological effect. The presence of an ester or amide group in the intermediate 
chain provides the basis for their classification and also determines the metabolism 
of these substances. LAs with ester binding are readily hydrolyzed in the plasma by 
cholinesterase; instead, those with an amide junction are biotransformed by liver 
microsomes via the microsomal system. Figure 4 shows the elementary chemical 
structure of LAs.
If the size of the molecule of a LA is increased, its potency and duration of 
action increase but also its toxicity. There is a direct correlation between potency, 
duration of effect, lipophilic character, molecular size and toxicity. Chloroprocaine 
is the least toxic, followed by procaine, prilocaine, lidocaine, mepivacaine, etido-
caine, ropivacaine, bupivacaine, tetracaine and dibucaine, with cocaine being the 
most toxic LA.
Another aspect of capital importance is the stereoisomerism that some LAs 
have. It refers to the existence of molecules with the same structural and molecular 
formula, but with different spatial orientation around a particular atom, the chiral 
center. It is like a reflection in a mirror, like placing one hand next to the other; they 
are the same but cannot be superimposed, they are mirror images. LAs of the pipeco-
loxylidide family (mepivacaine, bupivacaine and ropivacaine), as well as etidocaine 
and prilocaine are chiral compounds, with an asymmetric carbon atom, which 
can exist in their enantiomeric form, such as mirror images. When the compound 
deflects the polarized light to the left it is an S-isomer (Sinus) or levo-isomer, if the 
light is rotated to the right it is an R-isomer (Rectus) or dextro-isomer. Although the S 
and R isomers have a similar pharmacological activity, the clinical importance of the 
isomerism is that the same drug can have different biological activity. For example, 
the S-enantiomers of amino-amide LAs produce greater vasoconstriction and have 
less systemic toxicity than D-isomer. The typical example of stereoisomerism is 
Figure 4. 
Typical structural formula of a local anesthetic.
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Typical structural formula of a local anesthetic.
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bupivacaine, which contains the dextro-isomer and levo-isomer. The mixture of 
both is known as racemic combination. Ropivacaine only has a L-isomer. Lidocaine 
and ametocaine are aquirales since they do not have stereoisomers. D-isomers have 
more affinity for sodium channels than L-isomers, this makes the former more toxic 
[26, 27]. Table 2 shows the chemical classification of LAs.
6. Physical properties, activity, and potency
LAs are small molecules 220–350 Daltons weight, weak bases, poorly soluble 
and unstable in water, and therefore, they must be combined with a strong acid to 
obtain a stable salt that is soluble in water at pH 4.7. The solubility in water is directly 
related to the degree of ionization and inversely related to the fat solubility. In 
solution, LAs exist in two forms: basic, nonionized (B) and acidic, cationic, ionized 
(BH+). The ratio between these two forms depends on the dissociation constant 
(Ka) of the conjugated acid and on the local concentration of H+ ions. At a specific 
pH for each LA, the concentration of B is equal to that of BH+. This pH is called pKa. 
The relationship can be expressed like this: pKa = pH-log (B) / (BH+). At a pH of 
7.40, the percentage of BH+ form will be higher the higher the pKa. Diffusion of a 
LA is passive. In order to act they must contact the axon and for this they must pass 
through the epineurium, perineurium and endoneurium of the peripheral nerve, as 
well as the myelin layer in the myelinated fibers (lipid-rich structures), and finally 
cross the cell membrane to be in contact with the receptor site on sodium channels. 
The fat-soluble basic form B diffuses easily through the perineural structures and 
the axonal membrane; once inside the cell it is protonized and it is this ionized form 
that occupies the aforementioned receptor site [23, 25].
The minimum inhibitory concentration (MIC) is necessary to block the con-
duction of a nerve impulse along a nerve fiber within a certain period. The MIC is 
different for each LA and allows to differentiate them according to their potency. 
Several factors can determine the Cm: the size of the fibers (higher MIC for the 
thicker ones), the pH (lower MIC at higher pH), calcium concentration (higher 
MIC at higher calcium concentration), and frequency of nerve stimulation (smaller 
MIC at higher frequency).
Due to the characteristics of the nerve fibers, LAs first block the unmyelinated 
fibers (C fibers, which correspond to the postganglionic neurons of the autonomic 
nervous system), those of nociceptive conduction (analgesia), propriocep-
tive, tactile sensitivity, and pressure (anesthesia), and finally, the motor fibers 
(motor block).














The latency period of a nerve block is not linked to the potency of the LA, but 
seems to depend on its lipid solubility and pKa, that is, on the pH in which 50% 
of the molecules are in ionized form and 50% in nonionized form. The higher the 
pKa, the greater the latency time of a LA. On the other hand, the decrease in tissue 
pH can lengthen the latency time by limiting the formation of free base; instead, 
carbonation of a LA solution shortens its latency time. Alkalinization has also 
been shown to produce a better sensory and motor quality nerve block and may 
increase diffusion of block height. By alkalinizing LAs, their ionization increases 
and the percentage of fat solubility of the LA increases, facilitating its diffu-
sion through the lipid structures of the nerves, including the axonal membrane. 
The addition of 1 mL of sodium bicarbonate to 10 mL of lidocaine improves the 
onset of extradural or peripheral block for 3–5 min, also increasing its duration 
of action.
With the exception of cocaine and ropivacaine, LAs produce vasodilation. 
Adding a vasoconstrictor to LAs is an acceptable routine since two basic actions 
were demonstrated: increased duration of action and decreased absorption. It 
also increases the intensity of sensory and motor block in neuroaxial anesthesia. 
Epinephrine was one of the first drugs to be injected into the subarachnoid space: 
however, its use was not widespread as the initial results were disappointing. The 
local vasoconstriction produced by adrenaline favors the decrease in the absorp-
tion of LAs, which favor a longer interaction, in addition to decreasing blood 
concentrations levels and thus their potential for systemic toxicity. On the other 
hand, epinephrine has an effect on alpha2 receptors in the CNS, especially in the 
spinal cord, which could be another factor for the improvement it has in neuroaxial 
blocks. Higher concentrations of adrenaline 2: 000,000 (5 μg/mL) do not offer 
major advantages in terms of prolonging anesthesia or reducing plasma concentra-
tions. Never use solutions with adrenaline to infiltrate areas with terminal arterial 
circulation such as the fingers, the penis, the nasal tip, or other areas with critical 
arterial circulation, since it may promote ischemia and local necrosis.
Physico-chemical characteristics Relative potency in different 
blocks








Epidural Spinal Peripheral 
nerve
• Bupivacaine 8.1 83 3420 95 4 9.6 3.6
• Levobupivacaine 8.1 83 3420 97 4 9.6 3.6
• Etidocaine 7.7 66 7317 94 2 6.7 0.7
• Lidocaine 7.9 76 366 64 1 1 1
• Mepivacaine 7.6 61 130 77 1 1 2.6
• Prilocaine 7.9 76 129 55 1 ¿ 0.8
• Ropivacaine 8.1 83 775 94 4 4.8 3.6
• Chloroprocaine 8.7 95 810 — 0.5 — —
• Procaine 8.9 97 100 6 — — —
• Tetracaine 8.5 93 5822 94 — — —
*Modified from Salinas FV, Liu SL, Schlz AM. Analgesics. Ion channel ligands/sodium channels blockers/local 
anesthetics. Chapter 30. In: Evers AS, Maze M. Editors. Anesthetic pharmacology. Physiologic principles and clinical 
practice. Editorial Churchill-Livingstone. Philadelphia, USA. 2004 pag 507–537.
Table 3. 
Physical and chemical characteristics and relative potency of some local anesthetics *
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The phenomenon of tachyphylaxis or acute tolerance to LAs is characterized by 
a decreased effectiveness of a LA with repeated administration of the same dose. Its 
prevalence and mechanisms have not been well defined. This phenomenon occurs 
with different anesthetics, with different application techniques, and has been seen 
to develop more frequently when redosing is administered after the analgesic effect 
of the previous dose has ended [28, 29]. It has been mentioned that it could be due 
to a progressive acidification of the injection site that is established more rapidly 
with weak pKa LAs. A central mechanism through spinal cord sensitization that 
could be avoided by pretreatment with NMDA or nitric oxide antagonists has also 
been described [29–31].
The potency of LAs refers to the sensitivity of the neural tissue to the different 
LAs. This potency increases with increasing affinity for lipids. The binding capacity 
of LAs to the phospholipid membrane as a result of the physicochemical character-
istics and the interaction in vivo is directly related to their potency. Other factors 
affecting the potency of a LA include: hydrogen ion balance, fiber size, type, and 
myelination, vasodilator/vasoconstrictive properties (affects vascular absorption 
rate), frequency of nerve stimulation, tissue pH, and electrolyte concentrations 
(hypokalemia and hypercalcemia antagonize the block).
Table 3 shows some physical and chemical characteristics as well as the relative 
potency of some frequently used LAs.
7. Pharmacokinetics
The anesthetic and analgesic results of the injection of a LA in the vicinity of the 
neural tissue depend on the factors that have already been described. Plasma levels 
are affected by the injection site, the degree of absorption, its tissue distribution, its 
metabolism, and elimination, among other factors that have already been discussed.
7.1 Absorption
The quantity of LA that is absorbed from its application site and reaches the 
bloodstream is an important toxicity and elimination factor. LAs with poor absorp-
tion are safer. The absorption depends, on one hand, on the characteristics of the 
tissue; it increases in very vascularized territories and diminishes in fatty tissue. 
The plasma concentration depends on the total dose administered rather than the 
concentration, for most LAs there is a linear relationship between total dose and 
blood concentration [32]. On the other hand, the physicochemical characteristics 
also modulate the absorption of the drug, for example, the most lipophilic LAs 
and with greater affinity for proteins will be absorbed more slowly than those with 
less affinity for fatty tissue. Remember that the most lipophilic are also the most 
potent LAs. The decrease in absorption when adrenaline is added is more effective 
for LAs of short action and lower potency [33, 34]. With this, gradual absorption is 
achieved, the duration of action is prolonged and plasma levels are decreased as well 
as hemorrhage in the operative field.
7.2 Distribution
It depends on the physicochemical characteristics of each LA, its coefficient of 
solubility and plasma protein binding. A higher coefficient of solubility together 
with a lower degree of protein binding favors an easier distribution in peripheral 




barriers by simple diffusion; this diffusion is greater when the ability to bind to 
plasma proteins is lower. Variable levels bind to plasma proteins in the bloodstream, 
particularly alpha-1- glycoprotein acid. This protein-binding property correlates 
with its affinity for sodium channels and predicts the duration of neural blockage. 
Bupivacaine has the highest percentage of protein binding and is therefore the LA 
with the longest duration of action.
7.3 Metabolism and elimination
LAs differ in their metabolism according to their chemical structure; those with 
ester-type binding (except cocaine) are rapidly hydrolyzed by plasma esterases, so 
the duration of their action increases with the deficit of this enzyme or the presence 
of atypical cholinesterase. Cocaine is hydrolyzed in the liver. The metabolites of the 
esters are eliminated by the kidney.
Amide LAs are metabolized in the liver. This is a slow process, which favors a 
longer half-life than esters and can accumulate when repeated doses or infusions are 
administered. Liver function interferes with the elimination of these drugs; extrac-
tion, perfusion and hepatic metabolism are definitive factors, as it is the degree of 
protein binding. The metabolites and the nonmetabolized drug are eliminated by 
urine and a small amount by feces. Elimination is favored by an acid urinary pH. 
Prilocaine is metabolized outside the liver.
The fact that amino ester-type LAs are rapidly metabolized favors that they 
remain in the blood for a short period of time, including placental blood and the 
fetus. Those of the amino-amide type pass more easily to the fetus, especially those 
with lower affinity to plasma proteins such as lidocaine, which can result in fetal 
toxicity. When the fetus has been compromised by any pathology and is acidotic, 
more ionization of the LA that has passed into its fetal circulation is favored. In this 
way the LA will remain longer in the fetus with the possibility of severe toxicity. 
In the newborn, this toxicity can be accentuated since there is no hepatocellular 
maturity.
8. Clinical aspects
LAs are one of the most commonly used drugs in clinical anesthesia; either by 
the neuroaxial route, in the vicinity of nerves and nerve plexuses, subcutaneous, 
transcutaneous, trans mucosal, intraarticular, and intravenously. The introduction 
of levoisomeric LAs, the evolution of regional anesthesia techniques with the rec-
ommendations of epidural test dose with a vasoactive marker, fractional peridural 
doses, low and intrathecal minidose, multiple injections with low volumes for nerve 
plexuses blocks, the use of nerve stimulator, guides with ultrasound and other 
imaging techniques, as well as the addition of adjuvant drugs such as opioids, alpha2 
agonists, NMDA receptor antagonists, among others have done regional anesthesia 
safer. Tables 4 and 5 categorize the most important formulas and characteristics of 
LAs most commonly used in anesthesiology.
8.1 Amino ester LAs
The precursor of this group is cocaine. They are characterized by being metabo-
lized by plasmatic esterases, short half-life and being related to allergic reactions. 
The most commonly used are procaine, chloroprocaine, and tetracaine. Benzocaine 
has no use in regional anesthesia.
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8.2 Amino amide LAs
They are the most used in regional anesthesia. Lidocaine is the typical anesthetic 
with which almost all new drugs in this group have been compared. Even when they 
have differences such as latency time, duration, and toxicity they have a mechanism 
of action common to all LAs. They can be divided into two large groups: those of 
short duration and those of long duration.
Slow long-release of LAs are recent advances that have improved the manage-
ment of postoperative pain. Nanostructured carriers, such as liposomes and 
polymers, facilitate the prolonged release of LAs. Exparel® was the first approved 
liposomal LA to combine racemic bupivacaine with liposomes. Polymersomes have 
advances over liposomes with complementary profiles, inspiring the emergence 
of hybrid carriers [35, 36]. Also, multilamellar vesicles with ropivacaine are being 
investigated to prolong its analgesic effect [37].
Formulae Important features
In addition to blocking the impulse of axonal conduction, it has the 
ability to inhibit neurotransmitter recapture in adrenergic neuronal 
endings, which means accumulation of norepinephrine in sympathetic 
synapses inducing vasoconstriction and cardiac stimulation. In the CNS, 
the accumulation of norepinephrine causes stimulation; however, some 
adrenergic neurotransmitters in the CNS are inhibited, in particular the 
dopamine recapture resulting in euphoria and abuse potential. Its clinical 
utility is limited to topical anesthesia, in solutions 4 and 10%. Due to its 
vasoconstrictor action, it has been used in anesthesia of the nasal mucosa to 
facilitate nasotracheal intubation.
It has been used at 0.5, 1, 2, 5, and 10% for infiltration, peripheral, and 
spinal blocks. Procaine is of special interest in dentistry in 2% solution 
with 1:50,000 adrenaline. The allergic capacity of para-aminobenzoic acid 
(PABA) limits its clinical utility. The maximum doses are 750 mg with 
adrenaline and 500 mg without vasoconstrictor. It has been used by the 
subarachnoid route in increasing concentrations to establish the differential 
diagnosis in some painful syndromes.
It is used in solutions 1, 2, and 3% for infiltration, peripheral blockages, 
and epidural anesthesia. Due to its brief time of action, it is very useful 
in peridural block in cesarean section. The neurotoxicity observed after 
intrathecal injection, attributed to the sodium bisulfite in the solution, has 
limited the wide use caused by its low systemic toxicity. The maximum 
recommended doses are 800 mg with adrenaline and 600 mg without it. 
There are studies that favor intrathecal injection of chloroprocaine without 
methylparaben.
Useful in topical anesthesia in the form of ointment, chewable tablets, and 
gel. It is poorly soluble and remains in the place of its application. It is not 
used in regional anesthesia.
It has pKa of 8.46, plasma protein binding of 75.6% and N-heptane / water 
partition coefficient of 4.1. Despite its high systemic toxicity, it has been 
used in subarachnoid anesthesia in hyperbaric solutions 1 and 2% due to its 
high efficacy. Its latency is not very long, and the duration of the anesthetic 
effect is 2 to 3 hours, because its plasma hydrolysis is quite slow. Its use has 
been replaced by levoisomeric anesthetics.
Table 4. 




Formulae Most important features
It is the prototype in this group. After intravenous administration, the 
apparent volume of distribution is 92 L. Its alpha half-life is 8.3 min, 
its beta half-life is 108 min, and its plasma clearance 0.77 L/min. Its 
metabolism is hepatic, with an extraction coefficient of 0.7. The 
addition of adrenaline decreases its passage to the blood by 30%. It 
has a duration of action that varies from 2 to 3 hours depending on 
the site of administration and the addition of adrenaline. The toxic 
neurological manifestations of lidocaine are directly proportional 
to plasma levels. If these are low (0.5 to 4 mg / mL); lidocaine is 
anticonvulsant, at higher levels (8 mg/mL) it can cause seizures.
In the heart, lidocaine blocks sodium channels, decreasing 
contraction (V max), the amplitude and duration of the action 
potential, and increases the duration of the refractory period. 
These effects are only observed with elevated plasma levels. The 
action on the heart can be summarized in: dose automatism: 
below 5 mg/mL, onset of sinus bradycardia; conduction: no 
modification (atrioventricular or intraventricular) at usual doses; 
contractility: decrease, but only at doses that cause frank toxicity. 
At low plasma levels, lidocaine increases vascular tone; at higher 
levels vasodilation occurs. Direct intravascular injection does not 
produce obvious hemodynamic alterations as long as the dose 
is not greater than 3 mg/kg. From 4 to 8 mg/kg, cardiovascular 
depression occurs, which is dangerous if the dose is greater than 
8 mg/kg. If there is heart failure, the toxicity threshold decreases.
Its pharmacokinetic properties are similar to those of lidocaine, 
although it is less vasodilator. It is used in infiltration for peripheral 
nerve and in epidural anesthesia. The usual concentrations range 
between 0.5 and 2%. It is 40 times less toxic than lidocaine. An 
ideal use is intravenous regional anesthesia. A potential risk is the 
appearance of methemoglobinemia (total doses greater than 500 to 
600 mg), so its use in obstetrics is restricted or contraindicated.
First approved in Germany in 1976, in Canada in 1982 and in 
2000 by the FDA. It has a thiophene group, an ester group and 
also an amide group. It has been classified in the amide group 
by its intermediate chain and because it is metabolized in the 
liver. However, its ester portion allows it to be degraded by 
plasma pseudocholinesterase. The mean maximum plasma drug 
concentration is about 400 μg/L for articaine with epinephrine 
1:200,000 and 580 μg/L without epinephrine. The elimination half-
time is approximately 20 min. The rapid breakdown to the inactive 
metabolite articainic acid is related to a very low systemic toxicity 
and consequently to the possibility of repeated injections. It has 
been associated with paresis and long-lasting paraesthesia, which 
are more frequent than those produced by lidocaine. It is commonly 
used in dentistry.
Its molecular formula is C15H22N2O-HCL, soluble in water and 
very resistant to acid and alkaline hydrolysis. It is available in 
concentrations of 1%, 1.5% and 2%. The latency and duration of 
action are similar to those of prilocaine and its potency resembles 
lidocaine. Useful concentrations range between 0.5 and 2%. It 
diffuses well through tissues, which allows favorable blocking 
despite a less optimal needle placement. It produces an intense 
motor block. It is used to perform infiltration, peridural and spinal 
anesthesia (with a lower incidence of neurological alterations than 
lidocaine). Its use is not advised in obstetrics based on its prolonged 
metabolism in the fetus and in the newborn. It is recommended for 
peripheral nerve blocks in certain conditions: patients with cardiac 
risk or with drugs that potentiate toxicity. Adrenaline decreases 
the absorption of mepivacaine but does not prolong its duration of 
action.
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8.2 Amino amide LAs
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short duration and those of long duration.
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ment of postoperative pain. Nanostructured carriers, such as liposomes and 
polymers, facilitate the prolonged release of LAs. Exparel® was the first approved 
liposomal LA to combine racemic bupivacaine with liposomes. Polymersomes have 
advances over liposomes with complementary profiles, inspiring the emergence 
of hybrid carriers [35, 36]. Also, multilamellar vesicles with ropivacaine are being 
investigated to prolong its analgesic effect [37].
Formulae Important features
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anesthesia (with a lower incidence of neurological alterations than 
lidocaine). Its use is not advised in obstetrics based on its prolonged 
metabolism in the fetus and in the newborn. It is recommended for 
peripheral nerve blocks in certain conditions: patients with cardiac 
risk or with drugs that potentiate toxicity. Adrenaline decreases 
the absorption of mepivacaine but does not prolong its duration of 
action.
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8.3  There are 3 LAs: articaine, sameridine, and centbucridine, which due to 
their special physico-chemical characteristics deserve a brief description
8.3.1 Articaine
It is a short-acting LA with intermediate potency. It has been included in the 
amide group, but it contains an additional ester group that is quickly hydrolyzed 
by esterases, a chemical characteristic that accelerates its metabolism. The plasma 
protein binding rate of articaine and articainic acid is 70%. I.V. articaine 80 mg 
does not produce toxic effects in healthy individuals. It has been used neuraxially, 
ocularly, intravenously, and in regional blocks. It is suitable and safe for procedures 
requiring a short duration of action in which a fast onset of anesthesia is desired, 
Formulae Most important features
It is more fat-soluble and has a higher degree of affinity to plasma 
proteins than lidocaine, has a short latency and longer duration. 
Epidural route is used at 0.5 to 1%. It produces greater motor 
blockage than sensitive which makes it useful in abdominal surgery, 
its use in obstetric analgesia anesthesia is not advised. Its beta half-
life is 2.5 hours, and care should be taken in liver disorders because 
of the prolonged action.
It is a racemic mixture, long-acting drug that produces a differential 
sensory-motor block at low concentrations. It has a limited placental 
transfer, so it is widely used in obstetrics in concentrations of up to 
0.5%. Higher concentrations are not recommended in obstetrics. It is 
the LA with greater cardio and neuro toxicity and greater difficulty 
in resuscitation since it has a great affinity for voltage-dependent 
sodium channels. However, after lidocaine, it is the most used. It is 
widely used in pain clinic.
It is bupivacaine levoisomer. It has pharmacological properties 
similar to bupivacaine but less toxicity. Its toxicity depends on 
the route of administration and the dose, its pharmacokinetic 
is similar to bupivacaine and its plasma peak is 30 min after 
epidural administration, with an alpha-glycoprotein and albumin 
binding greater than 97% at concentrations of 0.1 at 1 ug/mL. 
It is metabolized in the liver and the kidney does not seem to 
intervene in its elimination. Produces differential blockade similar 
to bupivacaine, which depends on the dose and concentration, 
which will be less than 0.25% such as 0.0625 and 0.125% for 
epidural analgesia, and 0.5% to 0.75% for neuroaxial anesthesia and 
peripheral nerve blocks.
The first levoisomeric LA for clinical use. The plasma alpha 
glycoprotein binding is 95%, with a pKa of 8.1 and a partition 
coefficient of 141. Due to its low absorption, it has a longer 
elimination half-life and its pharmacokinetic has a linear 
proportional to the dose, with a volume of distribution of 47 
liters. Like bupivacaine, it has a greater effect on C fibers than A, 
which produces a sensory rather than motor block. The clinical 
experience is excellent in neuroaxial anesthesia and peripheral 
nerve blocks. It is of great value by epidural route (obstetrics), and 
in postoperative analgesia. It is characterized by a block of greater 
latency and long duration. Less analgesic potency than bupivacaine 
and levobupivacaine. It is less cardiotoxic and neurotoxic than 
bupivacaine with a better response to resuscitation. Usefull in pain 
clinic.
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e.g., dental procedures and ambulatory spinal anesthesia. Its most frequent use is 
in dentistry, where it has demonstrated efficacy and safety. Complete anesthesia 
is achieved in 90% of cases, using articaine 4% 60–80 mg with epinephrine 1: 
200,000. It diffuses well through soft tissue and bone; concentration in the alveolus 
of a tooth in the upper jaw after extraction was about 100 times higher than that 
in systemic circulation. In comparative clinical trials, its effects were not gener-
ally significantly different from those of other short-acting LAs like lidocaine, 
prilocaine, and chloroprocaine. There is no conclusive evidence demonstrating 
above average neurotoxicity, although cases of frequent persistent paresthesia after 
articaine use have been described [38–41]. Saralaya et al. compared 4% articaine 
with 1:100,000 epinephrine versus 2% lidocaine with 1: 100,000 epinephrine in 
50 patients operated on the third molar. These authors found that the mean onset 
time for articaine and lidocaine was 3.16 ± 0.55 and 3.2 ± 0.48 min, respectively. 
Postoperative analgesia was longer in the articaine group and its duration of action 
was 289.04 ± 40 and 361.88 ± 40 min, respectively, compared to lidocaine, which 
is 144.2 ± 12 and 197.44 ± 25 min, respectively. These authors recommend articaine 
since it was more potent and with a longer duration of action with better postopera-
tive analgesia and could be considered as an alternative to lidocaine [42]. Even in the 
presence of pulpitis, articaine proved to be more effective than lidocaine in patients 
undergoing root canal treatment [43]. There is no information available on the use 
of articaine during lactation, so its use is not entirely recommended yet.
8.3.2 Sameridine
This drug has mixed characteristics: LA and μ-opioid partial agonist. It is 
structurally similar to meperidine. It is a compound that is still under investigation 
(N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidine carboxyamide hydrochloride) 
mainly for spinal anesthesia. Liver hydroxylation is the primary metabolic pathway, 
and no local neurotoxicity has been found in animal studies. Its effect on respiration 
is directly related to plasma levels. In healthy volunteers [44] 25 mg vs. intrathe-
cal bupivacaine 15 mg has similar effects on resting ventilation. The ventilatory 
response to hypoxia and hypercarbia were found to be discreetly diminished in 
the group treated with sameridine. Intravenous doses of 0.73 mg/kg depress the 
ventilatory response to hypercarbia [45]. The clinical doses of 150 μg/kg have no 
significant effects on ventilation [46]. Intrathecal doses of 15–25 mg of sameridine 
are sufficient for inguinal and orthopedic surgery, respectively. Doses of 5–20 mg 
are comparable with 100 mg of intrathecal lidocaine. The advantage is that sameri-
dine produces residual analgesia and reduces the need for opioids in the first hours 
of the postoperative period [7, 8], so it could have a role in the management of 
postoperative pain.
8.3.3 Centbucridine
It is a nonester, nonamide LA, chemically known as 4-N-butylamino-1,2,3,4-
tetrahydroacridine hydrochloride. It is a quinolone derivative drug with LA effects 
synthesized in 1982 by Patnaik et al. [47–49]. It is 5 to 8 times more potent than 
lidocaine, while its LD50 is one fourth that of lidocaine. It has vasoconstrictor 
and antihistamine effects, rapid onset of action (1–3 min), duration of action is 
prolonged (2.5 hours), and no events of cardiotoxicity or neurotoxicity have been 
reported. Centbucridine has been investigated for infiltration, conjunctival sur-
face, in peripheral nerves, neuroaxial anesthesia, intravenous regional anesthesia; 
however, the majority of studies are in dental anesthesia [9, 50–52]. Most studies 
compare 0.5% centbucridine vs. 2% lidocaine, with similar anesthetic results, 
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compare 0.5% centbucridine vs. 2% lidocaine, with similar anesthetic results, 
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although some have found longer anesthetic duration in patients who were treated 
with centbucridine [51, 53]. Centbucridine can be used with confidence in dental 
patients who cannot tolerate other LAs or when epinephrine is contraindicated.
8.4 Maximum dose of LAs
Another clinical aspect of capital interest is the maximum doses of each LA. 
The maximum recommended doses have been established arbitrarily by the phar-
maceutical industry [54] and vary according to the route of administration, the 
type of anesthetic, with or without vasoconstrictors, as well as the type of patient 
and surgery. Table 6 shows the maximum recommended doses for the most com-
monly used LAs, without these doses having been established by studies conducted 
specifically to determine the safest and most effective amounts of each. Note the 
variants, sometimes with important ranges; 200 mg of lidocaine is recommended in 
Europe, while in the United States this dose reaches 300 mg when epinephrine is not 
used. Notwithstanding these differences, it is advisable to stay below the maximum 
recommended dosage range to avoid undesirable toxic effects.
8.5 Adequate anesthetic technique
Regional anesthesia techniques are important not only in the expected results, 
but to reduce undesirable side effects of LAs. It is known that spinal anesthesia 
produces lower plasma concentrations of LAs, unlike interpleural injection that 
in theory results in higher concentrations, and therefore, could be the procedure 
that produces more toxic events. However, this situation is hypothetical, since toxic 
events occur more frequently in peripheral blockages and peridural injections. For 
different types of nerve blocks, the same total injected dose produces different 
blood concentrations for mepivacaine, lidocaine, prilocaine and etidocaine, with 
the intercostal block being the one that produces the highest blood absorption, 
followed by injections in the peridural space. Plexus nerve blocks and subcutaneous 
injection are those that have a lower degree of absorption of LAs.
8.6 Undesirable side effects
The anesthetic and analgesic effects of LAs and their toxicity originate in the 
same mechanism of action; its interaction in the sodium channels. The therapeutic 
efficacy and safety of LAs has been proven from the moment of their discovery and 
it was precisely the deleterious effects that prompted the search for safer agents.  
Maximum dose of lidocaine:
Without epinephrine
200 mg (in Europe), 300 mg (in USA)
With epinephrine (5 μg/mL)
500 mg in both regions




Epinephrine 1: 200,000 reduces absorption of subcutaneous lidocaine by 50%, intercostal, epidural and 
brachial by 20–30%
Table 6. 




In 1905 Braun mentioned the characteristics that a new LA should have: In addition 
to producing local anesthesia, any new drug in this abundant group should have the 
following properties: be less toxic than the standard available, it should not irritate or 
damage tissues, it must be soluble in water, and stable in solution, it must be able to mix 
with adrenaline, and must be rapidly absorbed into the cell membrane [55]. More than 
a century of these recommendations have passed, and we still use LAs that do not 
meet these characteristics. LAs are used with an acceptable safety margin, without 
being the ideal drug. The following paragraphs briefly describe the most interesting 
side effects due to their magnitude and frequency. For more information on toxicity 
read chapter 10 of this book.
8.6.1 Toxicity
The history of LAs toxicity began at the end of the 19th century, when clinicians 
of that time realized the deleterious effects of cocaine and began the search for 
better drugs. Albright’s editorial in 1979 [13] commented on six deaths due to car-
diovascular collapse after the administration of bupivacaine or etidocaine whipped 
up this investigation in such a rapid way that currently there are safer drugs. The 
most important systemic toxic reactions are on CNS and the cardiovascular system. 
The CNS is affected with lower plasma concentrations than those that cause cardio-
vascular toxicity and is manifested by alterations in cognition, seizures, and coma. 
Arrhythmias with or without cardiovascular collapse of difficult management and 
death occur in the cardiovascular system. The incidence of systemic toxicity has 
been reduced to 0.01%, with regional blockages being the most associated with 
these events (7.5/10,000). The current use of ultrasound-guided nerve blocks is 
likely to reduce these statistics. Toxic effects can be grouped into two large groups:
1. Toxic reactions to:
a. Systemic and local
b. Not related to the LAs
2. Allergic reactions
a. To the LA
b. To conservatives or antioxidants
Events due to toxicity still occur in expert hands and are more related to the type 
of block and the dose injected. Various factors have been described:
• Potency of the LA. The greater the fat solubility, the greater potency and more 
possibility of cardio and neuro toxicity.
• Isomerism. LAs that contain a dextroisomer are more toxic than levoisomers. 
The former have been shown to have a higher affinity for the effector site of 
sodium channels.
• Total administered dose (plasma concentration). Toxicity is related to plas-
matic concentration of AL, and this depends directly on the total administered 
dose. Epidural blocks and tumescent subcutaneous infiltrations use the highest 
doses of LAs and have been linked to toxic events.
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2. Allergic reactions
a. To the LA
b. To conservatives or antioxidants
Events due to toxicity still occur in expert hands and are more related to the type 
of block and the dose injected. Various factors have been described:
• Potency of the LA. The greater the fat solubility, the greater potency and more 
possibility of cardio and neuro toxicity.
• Isomerism. LAs that contain a dextroisomer are more toxic than levoisomers. 
The former have been shown to have a higher affinity for the effector site of 
sodium channels.
• Total administered dose (plasma concentration). Toxicity is related to plas-
matic concentration of AL, and this depends directly on the total administered 
dose. Epidural blocks and tumescent subcutaneous infiltrations use the highest 
doses of LAs and have been linked to toxic events.
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• Injection site. In general terms, the blood absorption of LAs varies according to 
the injection site, although it is modified by factors such as the type of anesthetic 
injected, the addition of vasoconstrictors, and the speed and frequency of injec-
tion. The interpleural route favors high absorptions due to the large injection 
surface and its vascularity. However, this route has not been more frequently 
related to systemic toxicity, perhaps due to the lung capacity to fix and eliminate 
the concentration of LA up to ~40%. Spinal administration does not produce 
systemic toxicity from small doses and decreased vascularity. Injections close 
to the brain (facial, nasal, oral, neck) have larger possibility of neurological 
systemic toxicity, either by direct intra-arterial injection or by retrograde flow 
that transports small doses of the LA directly to the brain tissue than induces 
seizures and coma [56].
• Patient’s health/ASA. Factors such as age, liver and kidney dysfunction, 
hypoxemia, acidosis, pregnancy, and pharmacological interactions (cyto-
chrome P450 inhibitors) modify the possibility of systemic toxicity.
In the ester group, cocaine remains the most toxic LA, and procaine and chloro-
procaine are the least potent and least toxic potency, not only in the ester group, but 
among all known LAs. In the amino-amide group racemic bupivacaine, etidocaine, 
and mepivacaine are more toxic than levobupivacaine and ropivacaine. Lidocaine 
and prilocaine are the least toxic in this group.
Cardiotoxicity. The toxic effects of LAs on the cardiovascular system are divided 
into two groups; the physiological changes that are generated with some regional 
anesthesia techniques and the effects that derive from the actions of these drugs 
on sodium, potassium, calcium channels, and beta myocardial receptors. These 
side effects on the cardiovascular system can be explained by the following four 
mechanisms:
1. Regional effect due to the blockage of sympathetic preganglionic fibers  
secondary to the neuroaxial injection of the LA.
2. A direct cardio depressant/arrhythmogenic effect due to sudden and elevated 
plasma concentrations of local anesthetic by intravascular injection or exag-
gerated absorption from the injection site.
3. Cardio depressant effect mediated through the CNS.
4. Systemic absorption of toxic dose can cause spinal depression and secondary 
circulatory collapse.
8.6.2 Neurotoxicity
The toxicity of LAs on the nervous system manifests itself in two areas; those 
that are triggered by high blood concentrations and are due to their action on 
sodium channels in the CNS, and those that are caused by the direct application of 
the anesthetic on or in the vicinity of neural structures, especially the injection of 
lidocaine in the subarachnoid space.
8.6.3 Myotoxicity
It is well known that continuous perineural injection and direct intramuscular 




changes. These drugs act on external cell membranes and on the membranes of 
intracytoplasmic organelles, especially on the double mitochondrial membrane. 
Bupivacaine produces alterations in active intracellular oxidative metabolism by 
depolarizing the mitochondrial membrane and oxidation of the pyridine nucleo-
tide. This results in the opening of permeability transition pore (PTP), a type of 
channel located in intracellular membranes that plays an important role in various 
forms of cell death. Injury mechanisms involved early and late abnormalities to 
cytoplasmic calcium (Ca2+) homeostasis by the sarcoplasmic reticulum Ca2+ ATPase 
and cytochrome C release. All of these alterations were dependent on bupivacaine 
concentration and were only found in voluntary striated muscle mitochondria, 
while mitochondria from esophageal muscle were resistant to bupivacaine [57]. In 
rabbits, continuous axillary block with placebo vs. 0.25% bupivacaine, at 24 hours 
neutrophilic infiltration was found in the placebo group, while the group receiv-
ing bupivacaine had a large amount of eosinophils. One week later, lymphocytes, 
plasma cells, macrophages and fibroblasts were found with data of muscle regenera-
tion [58]. Zink et al. [59] compared bupivacaine vs. ropivacaine and demonstrated 
that the former induced necrosis and apoptosis of muscle fibers, while the latter 
produced less severe changes in porcine skeletal muscle. These same researchers 
[60] confirmed their initial results that bupivacaine 0.5% is more myotoxic than 
ropivacaine 0.75%, by inducing irreversible myonecrosis with calcium deposits, 
scar formation, and muscle regeneration. The incidence of myotoxicity in ophthal-
mic studies was 0.77%. Inflammatory changes within a few days after exposure 
marked the onset of myotoxicity, and muscle degeneration continued within the 
first week after exposure. Recovery time in human muscles ranged from 4 days 
to 1 year. None partial and complete recovery was observed in 61% and 38% of 
patients, respectively [61]. All LAs that have been studied have a similar myotoxic 
potential in terms of the tissue alterations produced, but they differ in the intensity 
of these lesions. Bupivacaine and chloroprocaine are the most toxic and procaine 
and tetracaine are the ones that produce minor alterations.
8.6.4 Allergies
True allergies to LAs are rare and generally occur more with ester-type, although 
allergies have been reported with amino-amide LAs, including new levoisomeric 
anesthetics [62]. These allergies have a highly variable frequency that ranges from 
1: 350 to 1:20,000 and fortunately most are trivial, although occasionally they are 
factors of significant morbidity and mortality. The incidence of true IgE-mediated 
LA allergy remains unclear and is presumed to be as low as 0.7–1%. On some 
occasions these reactions have been attributed to preservatives (methylparaben) 
or antioxidants (bisulfites) that are contained in some commercial presentations 
[63, 64]. When someone is reactive to a LA, they will be allergic to it for the rest 
of their life due to the response of mast cells that release chemical mediators that 
are responsible for the clinical responses in each patient. These mediators include 
histamine, leukotrienes, chemotactic substances, lysosomal enzymes, prostaglan-
dins, kinins, and platelet activating factors that facilitate capillary permeation with 
plasma leakage in the surrounding area. The manifestations of true allergy range 
from mild to severe and sometimes are deadly. The faster the clinical manifesta-
tions occur, the more severe the reaction. The most frequent expression is contact 
dermatitis, but they can also manifest as urticaria, rash, rhinitis, bronchial spasm, 
angioneurotic edema, tachycardia, and hypotension and lead to anaphylactic 
shock. Immunoglobulin E-mediated anaphylaxis can induce respiratory failure and 
cardiopulmonary collapse. The treatment of true allergies to LAs depends on their 
severity; mild or moderate reactions disappear spontaneously. In severe reactions it 
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is recommended to use steroids, H1 blockers, antihistamines, or epinephrine. When 
there is a probable or proven history of allergy to LAs, caution should be exercised: 
if allergy to an ester compound is found, it should be switched to an amino-amide 
anesthetic, preferably one without methyl paraben or metabisulfite. When the 
allergy is to an amino-amide anesthetic, it is advisable to change to another anes-
thetic from the same group.
8.6.5 Methemoglobinemia
Prilocaine is metabolized to O-toluidine which can cause methemoglobinemia 
in susceptible individuals, especially when more than 500 mg is used. In pregnant 
women, this problem is even more critical since fetal blood poorly reduces methe-
moglobin. Management is with 1–5 mg of methylene blue.
8.6.6 Rebound pain
When the analgesic effect of a peripheral nerve block performed with LAs, a 
state of hyperalgesia known as rebound pain may occur 12–24 hours postopera-
tively, with intensity disproportionate for the type of the performed surgery. It has 
been classified as a complication of peripheral nerve blocks, the etiology of which is 
unknown. Several factors have been considered, including neurotoxicity of LAs, its 
effects on nociceptors, direct neurotrauma, the possibility of hyperalgesia induced 
by systemic opioids before or during the block. Its frequency is unknown, although 
it seems to be increasing, especially in outpatient surgery where it has been reported 
in up to 40%. It is a relevant complication since it hinders the postoperative evolu-
tion, disturbing sleep, increasing the opioid requirement and delaying hospital 
discharge. Preventive analgesia before the blockage subsides, intra-articular or 
intravenous anti-inflammatory drugs, and the use of adjuvants added to nerve-
block or systemic solutions can reduce rebound pain [65–67].
9. Nonanesthetic uses of LAs
Some nonanesthetic (off-label) uses of LAs have been described. Although 
these investigations have not been precisely determined, this topic deserves a brief 
description.
9.1 Cough, laryngospasm, and asthma
Lidocaine has been used successfully to prevent or treat cough and laryngospasm 
induced during tracheal extubation, as well as in patients with asthma and chronic 
cough difficult to treat [68–70]. The meta-analysis of Yang et al. found that iv 
lidocaine decreases postoperative airway complications [71]. Nebulized lidocaine 
has been used with encouraging results in patients with asthma, chronic cough, 
and laryngospasm; doses ranging from 10 to 400 mg are a therapeutic alternative in 
asthma and cough that is difficult to manage [72]. Its mechanism of action has been 
related to the decrease in airway inflammation via downregulation of TLR2 [73].
9.2 Effects of LAs on cancer
Regional anesthesia is preferably used in oncological surgery since it does 
not interfere with the immune system, and the postoperative outcome of these 




antineoplastic effects [74, 75]. Some malignancies have increased voltage-depen-
dent sodium channel activity. Blocking these channels with LAs may help inhibit 
tumor progression [76]. Zheng et al. found an anti-melanoma activity of ropiva-
caine and lidocaine but not bupivacaine, via targeting small GTPases [77].
9.3 Antibiotics
Besides pain insensitivity, it has been shown that the in vitro and in vivo use of 
LAs have bacteriostatic, bactericidal, fungistatic, and fungicidal properties against 
a wide spectrum of microorganisms, this action being attributed to the interrup-
tion of the membrane permeability of microbial cells, leading to leakage of cellular 
components and subsequent cell lysis. Different LAs showed varying degrees of 
antimicrobial capacity; bupivacaine and lidocaine, for example, inhibit growth to 
a significantly greater extent than ropivacaine. Higher concentrations, prolonged 
exposure, and higher temperature correlate with a proportional increase in inhibi-
tion of microbial growth. Reducing the incidence of endophthalmitis after intravit-
real injection, prophylaxis for surgical wound infections, preventing the incidence 
of catheter-associated infections, reducing oral biofilms in the oral mucosa, and 
preventing infection-causing bacteria nosocomial are some examples of antimicro-
bial application of lidocaine [2, 78–80].
10. Conclusions
The first LA anesthetic was derived from the plant Erythroxylum coca, and 
regional anesthesia began in 1884 when Karl Köller anesthetized the cornea of 
his patients for surgical purposes. Since then, a host of events, drugs, discoveries, 
and various anesthesia techniques have culminated in safer and more effective 
regional anesthesia. LAs have an impressive history of efficacy and safety in 
medical and dental practice, but still have deleterious effects that can—on rare 
occasions—cause the death of our patients. Knowing the basics of the substrates 
where LAs work makes it easier to understand the action mechanisms that these 
drugs have on voltage-dependent sodium channels. The sequence of events that 
occur from the choice of the patient, the preparation and injection of LAs to the 
production of regional anesthesia-analgesia and/or its toxic effects are complex. 
These physiological and pathophysiological events depend on features as varied as 
the structural and physico-chemical characteristics, total injected dose, injection 
site, adjuvant drugs, physical condition of the patient, among others. The safe 
practice of regional anesthesia definitely reduces catastrophes, but these disasters 
can appear at any time. LAs have an impressive history of efficacy and safety in 
medical and dental practice.
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Local anesthetics are basically weak bases whose structure consists of an aro-
matic half connected to a substituted amine through an ester amide linkage. The
pKa values of local anesthetics are close to physiological pH, both protonated and
unprotonated forms are present. The individual structures confer different
physiochemical and clinical characteristics. Potency is correlated to lipid solubility
in vitro, but less so in vivo. The duration of action is associated with the extent of
protein binding. The onset of action is related to pKa. The intrinsic vasodilator
activity varies between drugs and influences potency and duration of action. Local
anesthetics block nerve conduction and interact directly with specific receptor on
the Na+ channel, inhibiting Na+ ion influx and impairing Propagation of the action
potential in axons. There are some characteristics in the blocking of nerve conduc-
tion and are related to size and function of the peripheral nerves, and to the fact that
a specific concentration of local anesthetics may produce a different intensity of
block. Some pathological states like decreased cardiac output, severe hepatic dis-
ease, renal disease, cholinesterase activity, fetal acidosis, sepsis, etc. altered the
pharmacokinetics and pharmacodynamics of local anesthetics.
Keywords: esters, amides, pKa, Na+ channel, pH, nerve fibers kinetics, block
conduction
1. Introduction
When applied locally to nerve tissues in appropriate concentrations, local anes-
thetics (LAs) reversibly block the action potentials responsible for nerve conduc-
tion. They act anywhere in the nervous system and in any type of nerve fiber.
Therefore, a LA in contact with a nerve trunk can produce both sensory and motor
paralysis in the innervated region.
The practical advantage of LAs is that their action is reversible in concentrations
of clinical importance; their administration is followed by complete recovery of
nerve function [1] (Figure 1).
LAs are drugs primarily utilized in clinical settings to induce local anesthesia.
The term local anesthesia, unlike general anesthesia, is defined as loss of sensation
within a confined region without loss of the patient’s consciousness. LAs are pur-
posely used to relieve pain and induce numbness during surgical procedures and are
normally applied by local injection [2].
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2. Anatomy of the peripheral nerve
All peripheral nerves are similar in structure; neuron is the basic functional
neuronal unit responsible for the conduction of nerve impulses. A typical neuron
consists of a cell body (soma) that contains a large nucleus; the soma is attached to
several branching processes called dendrites and a single axon. Axons vary in
length and there is one only per neuron, they are a long and slender, and are also
called nerve fibers; while dendrites receive incoming information and axons con-
duct outgoing information. Individual nerve fibers bind together, like wires in an
electrical cable, and each axon is enveloped by the endoneurium (delicate layer of
loose connective tissue around each axon). Groups of axons are closely associated
within a bundle called a fascicle that is surrounded by perineurium (imparts
mechanical strength and also acts as a diffusion barrier). Epineurium is a denser
collagenous tissue that surrounds the entire nerve and holds it loosely to the con-
nective tissue through which it travels. The paraneurium consists of loose connec-
tive tissue that keeps a stable relationship between adjacent structures filling the
spaces in between them; this tissue promotes functional mobility of nerves during
joint and muscular motion.
Nerves take in blood from the contiguous blood vessels along their course. These
vessels that nourish larger nerves are macroscopic in bore and irregularly settled,
conceive anastomoses to put on longitudinally common vessels that provision the
nerve and emit subsidiary embranchments [3].
Each peripheral axon has its own cell membrane called axolemma, non-
myelinated nerves such as nociceptive afferent type C fibers, and autonomous
postganglionic efferent fibers contain axons coated by only one layer of cells. All
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which consist of the plasma membranes of Schawnn cells that wrap themselves
around the axon during growth.
Myelin considerably increases the speed of nerve conduction as it achieves that
action current generated by an action potential travels through the axoplasm to the
nodes of Ranvier, these are periodic interruptions of the myelin sheath, where
action potentials are regenerated.
In the nodes of Ranvier of the myelinated fibers, there is a high concentration of
sodium channels Na+, which serve to propagate the impulses, although they are also
observed along the axons of unmyelinated fibers.
During the transmission of an impulse, the intra and extracellular ratios of Na+
and K+ ions are inverted. Na+/K+-ATPase is stopped during depolarization and Na+
ion perviousness increases, leaving Na+ ions to move inside the cell and the resting
membrane potential be moved. An action potential is released when depolarization
enough for the membrane potential to come a threshold value, it is concerning
+15 mV. During repolarization, the electrical status of the cell is restored by K+
diffusing out of the cell, and at the end the resting membrane potential has been
restored; but the cell has effectively gained Na+ and lost K+. However, when
Na+/K+-ATPase is reactivated, the normal intra and extracellular ratios of Na+ and
K+ ions are restored.
In a depolarization stream, Na+ channels they are activated, admitting extracel-
lular Na+ ions influx into the cell. After that (ms), Na+ channels inactivate. The
channels get back to the initial repolarization state. The course that involves sodium
channels passing from an open or closed state is called a “gate.” Gate is the result of
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these channels, with the presence of voltage-dependent doors in the light of the
same (Figure 2).
The currents of depolarization and repolarization move longitudinally along the
nerve membrane and result in conduction of the nerve impulse. In unmyelinated
nerves, the impulses spread at speeds of about 2 m/s. In myelinated nerves, the
depolarization current jumps from node to node; this phenomenon, known as
saltatory conduction, increases conduction velocity to around 120 m/s and is highly
energy-efficient [4].
Neurons can usefully be classified according their diameter and speed of con-
duction (Table 1).
3. Local anesthetic molecule
The local anesthetic molecule consists of three components: (a) lipophilic aro-
matic ring, (b) intermediate ester or amide chain, and (c) terminal amine. Each of









Aα Proprioception, somatic motor Yes 12–20 70–120 0.4–0.5
Aβ Touch, pressure Yes 5–12 30–70 0.4–0.5
Aγ Motor to muscle spindle Yes 3–6 15–30 0.4–0.5
Aδ Pain, cold, touch Yes 2–5 12–30 0.4–0.5
C Pain, temperature (dr)
mechanoreception, reflex
responses
No 0.4–1.2 0.5–2 2
B Preganglionic autonomic Yes <3 3–15 1.2




Saltatory conduction. Wikiwand free Google.
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In this way, local anesthetics can be classified into two groups: aminoesters and
aminoamides. The aromatic ring provides a lipophilic character to the portion of the
molecule in which it is found, while the tertiary amine end is hydrophilic, because it
is protonated and has a positive charge in the physiological pH range [6] (Figure 3).
The ester-type LAs include benzocaine, procaine, cocaine, and tetracaine. The
amide-type LAs include mepivacaine, lidocaine, ropivacaine, bupivacaine, and
etidocaine. Lidocaine and bupivacaine are the most commonly used LAs, both are
amide-type compounds, which are much more resistant than ester-type compounds
to hydrolysis (Table 2).
In addition to the intrinsic binding affinities of LA drugs to the Na+ channel,
other variables also strongly influence the relative duration of local anesthesia; these
include the volume, concentration, lipophilicity, pKa, pH, repeated injections, the
presence of vasoconstrictors, and the precision of drug injection.
3.1 Hydrogen ion concentration
LAs in solution maintain a rapid chemical equilibrium between the basic
uncharged form (B) and the charged cationic form (BH+), the ratio of the two states
is given by the Henderson-Hasselbach equation (it was originally derived to
describe the pH changes resulting from the addition of H+ or OH ions to any buffer
system). At a certain concentration of hydrogen ion (log10ˉ1 [-pH]) specified for
each drug, the concentration of LA in its basic form in a solution is equal to the
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concentration of loaded cation. The logarithm of this concentration of hydrogen ion
is called pKa.
pH ¼ pKaþ log HCO3�½ �= H2CO3½ �
pKa ¼ pH� log base½ �= conjugate acid½ �
base½ �= conjugate acid½ � ¼ 1:0
The dissociation constant of LA (pKa value) is the highly significant fact affect-
ing the quickness of their beginning of action. The pKa values rule the ratio of the
LA that is present in nonprotonated pattern at physiological pH values and hence
disposable to spread through tissue walls to its spot of action.
Lower pKa values are conjoint with a prompt beginning of blockade, then more
of the drug is present as the unprotonated base at pH 7.4. In contradistinction,
bigger values are conjointed with a slower beginning, since fewer of the drug is
present as the nonprotonated base at pH 7.4. For instance, lidocaine has a pKa value
roughly 7.7. At pH 7.4, around one-third of these drugs is present in solution as the
nonprotonated base B and is disposable to spread through the nerve scabbard. In
contradistinction, bupivacaine and ropivacaine have a pKa value of 8.1, and at a
pH 7.4 only 17% is present in solution as nonprotonated, diffusible base. These
discrepancies are responsible for the more prompt beginning of action of lidocaine
and slower beginning of action of ropivacaine and bupivacaine.
3.2 Alkalization of local anesthetics
Factors that increase the conversion of the free LA base (B) to the active form
(BH+) in the neuroplasm increase the diffusion gradient and the concentration of
BH+ in the Na+ channel. This technique is of clinical interest because it is used to
shorten the latency of onset of effective anesthesia, particularly useful in the con-
text of extending an epidural block for urgent operative delivery.
The addition of bicarbonate will raise the pH of the weakly acidic solution nearer
the pKa. Example: addition of 1.0 mL NaHCO3 8.4% to 10.0 mL of lidocaine 2% will
raise its pH from 6.5 to 7.2; this means more drug will exist in the non-ionized form,
so penetration will be more rapid [7].
Carbonation is a variation on alkalization, and is based on a similar principle but
with a different site of action; when carbon dioxide diffuses across the neurilemma,
it is rapidly buffered by intracellular proteins, so that changes in pH are minimal.
Carbonated solutions are unstable, the LA may be precipitated and any added
vasoconstrictor is more easily hydrolyzed [8].
3.3 Chirality
Chirality is derived from Greek, and means “having handedness,” and is defined
a particular type of stereoisomerism. Right and left hands are mirror images of each
other but cannot be superimposed when the palms are facing in the same direction
(Figure 4) [9]. These particular isomers are known as enantiomers and this form of
stereoisomerism is dependent on the presence of one or more chiral centers, which
typically comprise a carbon atom with four groups attached. These enantiomers
have the capacity to rotate polarized light, and, so, are also known as optical
isomers.
Enantiomers that rotate polarized light to the right are described as (+), and are
the same as dextro or D isomers. Enantiomers that rotate polarized light to the left
are described as (�), and are the same as levo or L isomers. The currently accepted
36
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convention is that which assigns a sequence of priority to the four atoms or group
attached to the chiral center. The molecule is described as though it were being
viewed from the front with the smallest group extending away from the viewer. If
the arrangement of the largest to the smallest groups is clockwise, the enantiomer is
designated “R” for rectus. If the arrangement is anticlockwise it is designated “S”
for sinister. The optical direction is the added to complete the description. Most
synthetic chiral drugs are racemic mixtures, less potent because the D-forms are
much less active. The clinical behavior of the enantiomers, and in particular their
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vasoconstrictor is more easily hydrolyzed [8].
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Chirality is derived from Greek, and means “having handedness,” and is defined
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other but cannot be superimposed when the palms are facing in the same direction
(Figure 4) [9]. These particular isomers are known as enantiomers and this form of
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Enantiomers that rotate polarized light to the right are described as (+), and are
the same as dextro or D isomers. Enantiomers that rotate polarized light to the left
are described as (�), and are the same as levo or L isomers. The currently accepted
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convention is that which assigns a sequence of priority to the four atoms or group
attached to the chiral center. The molecule is described as though it were being
viewed from the front with the smallest group extending away from the viewer. If
the arrangement of the largest to the smallest groups is clockwise, the enantiomer is
designated “R” for rectus. If the arrangement is anticlockwise it is designated “S”
for sinister. The optical direction is the added to complete the description. Most
synthetic chiral drugs are racemic mixtures, less potent because the D-forms are
much less active. The clinical behavior of the enantiomers, and in particular their
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4. Pharmacodynamics
Most LA drugs are tertiary amine bases (B), which are dispensed as hydrochlo-
ride salts (B.HCL). In this way, their easily disband to pattern acidic solutions:
B:HCL< >BHþ þ CL�
After infiltrating the tissues, a ratio of the protonated basic pattern (BH+) is
turned to the unprotonated basic pattern (B) at the pH of the extracellular fluid:
BHþ þHCO3� < >BþH2Oþ CO2
Solely the unprotonated pattern B penetrates through the neurilemmal mem-
brane, captures H+ in the neuroplasm, and raises approach to its spot of action in the
open Na+ channel, inducing its blockade. The unprotonated pattern B may further
straight permeate to the Na+ channel across the neurilemma, and recruits H+ into
the Na+ channel.
It is able to induce blockade by membrane expansion (ME), bring about puffi-
ness of the lipoprotein matrix of the Na+ channel (e.g., benzocaine). Tetrodotoxin
and saxitoxin directly block the Na+ channel from the exterior of the membrane,
close to the external pore [11–13] (Figure 6).
The primary target of LAs is the voltage-gated Na+ channel, which is responsible
for the generation of action potentials in excitable membranes, there is an inverse
relationship between action potentials and local anesthesia [13]. LAs also interact
with many other types of ion channels, particularly K+ and Ca2+ channels, notwith-
standing they have a limited relationship at these sites. They do not mostly alter the
neuronal resting potential, save in exceedingly raised concentrations. In the same
way, they do not change the sill potential needed for impulse spread, even if the
gear of depolarization and repolarization is diminished, and conduction velocity is
reduced and may cause undesirable side effects, usually considered that the toxic
effects of bupivacaine on the heart are partially related to its effects on K+ and Ca2+
channels.
Mammalian voltage-gated Na+ channels exist in different isoforms in various
excitable tissues such as skeletal muscles, cardiac tissues, central nervous system
(CNS), and peripheral nervous system (PNS) [14]. In addition, multiple major
isoforms are present in CNS and PNS, some of these neuronal Na+ channels are
sensitive to tetrodotoxin (TTX) and some are resistant. Tetrodotoxin (TTX) is a
potent naturally occurring neurotoxin isolated from puffer fish; it has been respon-
sible for human intoxications and fatalities. Its usual route of toxicity is via the
ingestion of contaminated puffer fish, which are a culinary delicacy, especially in
Bupivacaine: S(�) enantiomer has less affinity for, and dissociates quicker from myocardial Na+
channels. The cardio and central nervous system toxicity is reduced. S(�) exerts some vasoconstrictor
activity.
Ropivacaine: S(�) enantiomer is a safer cardiovascular profile.
Prilocaine: S(+) enantiomer is a stronger vasoconstrictor, metabolized slowly than the R(�) form






Topics in Local Anesthetics
Japan. TTX has been an invaluable tool for the identification of various neuronal
Na+ channel isoforms [11–13].
The concentration of LA in blood is determined by the amount injected, the rate
of absorption from the injection site, the rate of distribution by tissues, the rate of
biotransformation and drug elimination [14]. The patient’s factors, such as age,
cardiovascular situation, and hepatic function, influence the physiological disposi-
tion and the plasma concentration resulting from the LA injected [14, 15].
4.1 Mode and site of action of local anesthetics in Na+ channels
Mammalian voltage-gated Na+ channels are normally activated at a threshold
of around 50 mV, and the probability of channels being open is maximal around
+20 mV. At a single-channel level, the time course of Na+ channel activation is
strongly voltage dependent. The probability of being open during depolarization
rises slowly at the threshold and becomes rather fast at the more positive poten-
tials. In contrast, the open Na+ channels inactivate rapidly, with a dwell time that
is generally 1 ms or less. Unlike the activation process, the time course of inacti-
vation of the open Na+ channel is not voltage dependent [16]. At the level of
macroscopic currents, Na+ currents rise (activate) and decay (inactivate) with
overlapping time course, as would be expected from an ensemble of currents from
single channels [17, 18].
Detailed kinetic analyses of macroscopic Na+ currents in the presence of vari-
ous LAs reveal complicated pharmacological profiles under voltage-clamp condi-
tions. Voltage-sensitive Na+ channels are integral proteins that cross neuronal
membranes and surround an aqueous pore. Most Na+ channels consist of three
subunits (α1, β1, and β2), the largest subunit being α1, the site of ion conduction
and LAs binding; the external surface of the α-subunit is heavily glycosylated,
which serves to orient the channel properly within the plasma membrane. The α1
unit bears a molecular weight up of 260 kDa, and consists of an unique long
peptide chain holding four hydrophobic regions (domains I–IV), which go across
the membrane and symmetrically encircle the pore. The four domains are joined
to each other by intracellular bridgeworks.
Every domain includes six membrane-spanning somites (S1–S6). The S4 somite
is a potential sensor, and the brief curl among S5 and S6 forms portion of the




Pharmacokinetics and Pharmacodynamics of Local Anesthetics
DOI: http://dx.doi.org/10.5772/intechopen.91700
4. Pharmacodynamics
Most LA drugs are tertiary amine bases (B), which are dispensed as hydrochlo-
ride salts (B.HCL). In this way, their easily disband to pattern acidic solutions:
B:HCL< >BHþ þ CL�
After infiltrating the tissues, a ratio of the protonated basic pattern (BH+) is
turned to the unprotonated basic pattern (B) at the pH of the extracellular fluid:
BHþ þHCO3� < >BþH2Oþ CO2
Solely the unprotonated pattern B penetrates through the neurilemmal mem-
brane, captures H+ in the neuroplasm, and raises approach to its spot of action in the
open Na+ channel, inducing its blockade. The unprotonated pattern B may further
straight permeate to the Na+ channel across the neurilemma, and recruits H+ into
the Na+ channel.
It is able to induce blockade by membrane expansion (ME), bring about puffi-
ness of the lipoprotein matrix of the Na+ channel (e.g., benzocaine). Tetrodotoxin
and saxitoxin directly block the Na+ channel from the exterior of the membrane,
close to the external pore [11–13] (Figure 6).
The primary target of LAs is the voltage-gated Na+ channel, which is responsible
for the generation of action potentials in excitable membranes, there is an inverse
relationship between action potentials and local anesthesia [13]. LAs also interact
with many other types of ion channels, particularly K+ and Ca2+ channels, notwith-
standing they have a limited relationship at these sites. They do not mostly alter the
neuronal resting potential, save in exceedingly raised concentrations. In the same
way, they do not change the sill potential needed for impulse spread, even if the
gear of depolarization and repolarization is diminished, and conduction velocity is
reduced and may cause undesirable side effects, usually considered that the toxic
effects of bupivacaine on the heart are partially related to its effects on K+ and Ca2+
channels.
Mammalian voltage-gated Na+ channels exist in different isoforms in various
excitable tissues such as skeletal muscles, cardiac tissues, central nervous system
(CNS), and peripheral nervous system (PNS) [14]. In addition, multiple major
isoforms are present in CNS and PNS, some of these neuronal Na+ channels are
sensitive to tetrodotoxin (TTX) and some are resistant. Tetrodotoxin (TTX) is a
potent naturally occurring neurotoxin isolated from puffer fish; it has been respon-
sible for human intoxications and fatalities. Its usual route of toxicity is via the
ingestion of contaminated puffer fish, which are a culinary delicacy, especially in
Bupivacaine: S(�) enantiomer has less affinity for, and dissociates quicker from myocardial Na+
channels. The cardio and central nervous system toxicity is reduced. S(�) exerts some vasoconstrictor
activity.
Ropivacaine: S(�) enantiomer is a safer cardiovascular profile.
Prilocaine: S(+) enantiomer is a stronger vasoconstrictor, metabolized slowly than the R(�) form






Topics in Local Anesthetics
Japan. TTX has been an invaluable tool for the identification of various neuronal
Na+ channel isoforms [11–13].
The concentration of LA in blood is determined by the amount injected, the rate
of absorption from the injection site, the rate of distribution by tissues, the rate of
biotransformation and drug elimination [14]. The patient’s factors, such as age,
cardiovascular situation, and hepatic function, influence the physiological disposi-
tion and the plasma concentration resulting from the LA injected [14, 15].
4.1 Mode and site of action of local anesthetics in Na+ channels
Mammalian voltage-gated Na+ channels are normally activated at a threshold
of around 50 mV, and the probability of channels being open is maximal around
+20 mV. At a single-channel level, the time course of Na+ channel activation is
strongly voltage dependent. The probability of being open during depolarization
rises slowly at the threshold and becomes rather fast at the more positive poten-
tials. In contrast, the open Na+ channels inactivate rapidly, with a dwell time that
is generally 1 ms or less. Unlike the activation process, the time course of inacti-
vation of the open Na+ channel is not voltage dependent [16]. At the level of
macroscopic currents, Na+ currents rise (activate) and decay (inactivate) with
overlapping time course, as would be expected from an ensemble of currents from
single channels [17, 18].
Detailed kinetic analyses of macroscopic Na+ currents in the presence of vari-
ous LAs reveal complicated pharmacological profiles under voltage-clamp condi-
tions. Voltage-sensitive Na+ channels are integral proteins that cross neuronal
membranes and surround an aqueous pore. Most Na+ channels consist of three
subunits (α1, β1, and β2), the largest subunit being α1, the site of ion conduction
and LAs binding; the external surface of the α-subunit is heavily glycosylated,
which serves to orient the channel properly within the plasma membrane. The α1
unit bears a molecular weight up of 260 kDa, and consists of an unique long
peptide chain holding four hydrophobic regions (domains I–IV), which go across
the membrane and symmetrically encircle the pore. The four domains are joined
to each other by intracellular bridgeworks.
Every domain includes six membrane-spanning somites (S1–S6). The S4 somite
is a potential sensor, and the brief curl among S5 and S6 forms portion of the




Pharmacokinetics and Pharmacodynamics of Local Anesthetics
DOI: http://dx.doi.org/10.5772/intechopen.91700
two of the domains (III and IV) is the speedy inactivation gateway. This gateway is
liable for the speedy inactivation of Na+ channels.
LAs reduce peak Na+ currents during the test potential a few minutes after
external perfusion of the drug solution at the holding potential (<�100 mV). This
reduction in peak current is dose dependent, and the potency ranking of various
LAs derived from their dose-response curves correlates well with the relative dura-
tion of local anesthesia they elicit in vivo. This LA block of the Na+ channel at
resting potential is termed “tonic block.”
Most LAs are found to shift the apparent steady-state inactivation curve to the
hyperpolarizing direction. Steady-state inactivation measures the availability of
resting Na+ channels at various prepulse voltages at which Na+ channels normally
do not open [7]. This closed-channel inactivation is strongly voltage dependent,
unlike the open channel inactivation. A shift of the steady-state inactivation curve
by LA toward the hyperpolarizing direction has significant physiological conse-
quences. To begin with, if the steady-state inactivation curve is indeed shifted by
LAs upon binding, a large fraction of Na+ channels with LAs bound will be in their
inactivated state at the resting potential and therefore will be unavailable to carry
currents for the generation of action potentials. Another implication is that the
inactivated state of the Na+ channel binds more strongly than other channel states
(generalized modulated receptor hypothesis envisioned by Hondeghem and
Katzung [19]). They proposed that different states of Na+ channels (open, resting,
and inactivated) have different binding affinities for LAs, and that the affinity of
the inactivated state is the highest.
Repetitive pulses produce an additional block of Na+ currents in the presence of
LA. This additional block of Na+ currents is termed “use-dependent block” or
“frequency-dependent block,” with the two terms used interchangeably. The use-
dependent block by LAs may be physiologically important for pain therapy, as
many afferent fibers fire action potentials at a high frequency, particularly in the
pathological states. In theory, LAs with a potent use-dependent attribute will be
more effective than LAs without this attribute in blocking the high-frequency
abnormal firings of sensory afferent fibers.
4.2 Potency of local anesthetic
The potency of a LA is regulated mainly by lipid solubility, the time of onset by
the pKa of the substance, and the duration of action by protein binding. The more
lipophilic the LA, the more potent it is [20, 21]. Nerve-blocking potency of LAs
increases also with increasing molecular weight [22].
LA appears to have a ceiling effect. Above a partition coefficient of 4 there is no
observed increase in potency [23]. Unfortunately, greater lipid solubility also
increases toxicity, decreasing the therapeutic index for more hydrophobic drugs.
Larger more lipophilic LAs permeate nerve membrane more readily and bind Na+
channels with greater affinity (Table 4).
More lipid-soluble LAs are relatively water insoluble, high protein bound in
blood, and less readily removed by bloodstream from nerve membranes, and this
affinity of the drug to lipid membranes and therefore greater proximity to its site of
action in the Na+ channel.
4.3 Onset and duration of action of local anesthetics
The onset of nerve conduction blockade depends on the physicochemical prop-
erties of each LA. The latency also depends on the dose or concentration of the drug
used. The duration of the effect of local anesthetics is very variable (Table 5).
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The peripheral vascular effects of the local anesthetic have significant effects;
many anesthetics have a biphasic effect on vascular smooth muscle, at low concen-
trations they produce vasoconstriction and at higher concentrations they produce
vasodilation. However, the vasodilator effect differs between the different drugs,
the effects on vascular blood flow and its tone are complex, and vary among other
factors, depending on the concentration, time, and vascular bed near the point of
application.
5. Pharmacokinetics
Pharmacokinetics was originally described as the quantitative studio and math-
ematical review of drug and it’s metabolite in the organism. The concept has been
mostly obsequious to the prosecution of drug absorption, distribution, metabolism
and excretion, and to their explanation in numerical terminus. Pharmacokinetics is
once in a while portrayed as “what the body does to drugs.” The two highly large
pharmacokinetic uniforms are:
• Volume of distribution (V)
• Clearance (CL)
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The volume of distribution depicts the seeming volume disposable in the organ-
ism for the allocation of the drug, whereas the clearance shows capacity of the
organism to eliminate the drug. These two uniforms are kindred to the terminal or
elimination half-life of the drug. In other words, after one half-life, the concentra-
tion of the drug in the body will be half of the starting dose. Half-life is defined as
the time required for the plasma concentration to decrease by 50% during the
terminal phase of decline, by the following expression:
t½ ¼ 0:693� Vd=CL:
Accordingly, the terminal half-life is regularly heterogeneous, which depends on
the early pharmacokinetics constant volume (V) and clearance (CL). A prolonged
terminal half-life can throw back an enhanced volume of distribution, a narrow
clearance, or together these changes, while a brief terminal half-life can reflect a
decreased volume of distribution, an enhanced clearance or both together [8]
(Table 6).
Clearance depicts the quantity of blood or plasma since that a drug would need
to be thoroughly eliminated in unit time in order to guarantee its put-out from the
body. It is a theoretic thought, inasmuch as in practice drugs are incompletely
withdrawn from a nay larger quantity of plasma. Clearance values are generally
expressed as a quantity cleared in unit time and are generally measured in
mL min�1 or L h�1.
Also, clearance can be determined as the timing of drug elimination (mg min�1)
per unit of blood or plasma concentration (mg mL�1).
plasma clearance mL min �1
  ¼ timing of drug removal mg min
�1 
plasma centralization mg mL�1
 
Plasma clearance is as a rule steadfast; the cadence of drug removal is right away
proportional to plasma concentration. Total body clearance is the addition of vari-
ous ways of drug elimination that are carried out by various organs in the body:
CL ¼ CLR þ CLH þ CLX
where CL is total clearance, CLR is renal clearance, CLH is hepatic clearance and
CLX is clearance by other routes (Table 7).
After absorption from the site of injection, the plasma concentration of LAs
depends on their rate of distribution in tissues and their elimination from the body.
Subsequent to an intravenous injection, the plasma concentration of all LAs in
general falls in a biexponential ways. There is an incipient quick allocation time
(half-life 1–3 min), conjoint with their rapid inlet by greatly perfused organs (e.g.,
lung, liver, kidney). Afterward, there is a slower reduction in plasma centralization,
which depicts the put-out of LAs by metabolism and excretion. The final half-life of
most ester anesthetics is comparatively brief (10 min) owing to their prompt
Drug Volume of distribution (ml/kg) Volume of distribution (L 70 kg)
Lidocaine 900 (500�1300) 63 (35�91)
Bupivacaine 1050 (650�1450) 74 (46�104)
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hydrolysis by plasma cholinesterase, in hallmark, the terminal half-life of the
amides oscillates from 100 min (lidocaine) to 200 min (bupivacaine).
Their volume of distribution is rather greater than total body water, while their
plasma clearance is usually less than liver blood flow (Table 8).
Some clinical conditions can modify the pharmacokinetics of LAs, specially
cardiovascular disorders and chronic hepatic diseases like cirrhosis can decline the
clearance and volume of distribution of LAs, with changeable impact on the termi-
nal half-life. In neonates, the clearance of LAs is diminished and their half-life is
sustained.
6. Conclusions
LAs are drugs widely used in medicine and dentistry. These medications cause
reversible neural block by their action in the sodium channels (Figure 7) located in
Drug Hepatic clearance (mL min�1 kg�1) Hepatic clearance (mL min�1 70 kg�1)










Cocaine 48 31 2.0 Norcocaine
Ecgonine
Benzoylated
Procaine 8 60 0.7 Diethylaminoethanol
p-aminobenzoate
Tetracaine 15 47 1.0 Butyl-aminobenzoate
Dimethyl-aminoethanol





Prilocaine 100 34 2.7 N-propylamine
o-toluidine
Bupivacaine 200 9 1.1 Pipecolic acid
Pipecolyl-xylidide
Levobupivacaine 200 9 1.1 Pipecolic acid
Pipecolyl-xylidide
Ropivacaine 110 7 0.7 3-Hydroxy-ropivacain
4-Hydroxy-ropivacain
Table 8.
Pharmacokinetics and metabolism of local anesthetics.
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the nerve membranes. The unprotonated molecule configuration of the LA is intro-
duced through the membrane from the outside and the protonated molecule acts
with the sodium channel from the inside. The potency of a LA is given by
liposolubility, the onset time by dissociation constant (pKa), and the duration of
action by protein binding. Local anesthetics are weak bases whose structure consists
of an aromatic moiety connected to a substituted amine through an ester or amide
linkage. Consequently, LAs are classified as aminoester or aminoamide compounds.
Amino acids are hydrolyzed by plasma cholinesterase, while aminoamides are
metabolized in the liver. Aminoamides cause less allergic reactions.
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the nerve membranes. The unprotonated molecule configuration of the LA is intro-
duced through the membrane from the outside and the protonated molecule acts
with the sodium channel from the inside. The potency of a LA is given by
liposolubility, the onset time by dissociation constant (pKa), and the duration of
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linkage. Consequently, LAs are classified as aminoester or aminoamide compounds.
Amino acids are hydrolyzed by plasma cholinesterase, while aminoamides are
metabolized in the liver. Aminoamides cause less allergic reactions.
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Pregnancy, labor, and delivery are accompanied by physiological changes that 
impact on the use of the drugs to which they are exposed. The anesthesiologist 
needs to understand the principal differences in management of this particular 
population. The study of the main pharmacokinetic changes associated with preg-
nancy is relevant for the proper management of drugs to avoid adverse effects. The 
objective of this chapter is to review the physiological changes that impact on the 
pharmacokinetics of the pregnant woman with a focus on local anesthetics of  
the amide type, specifically bupivacaine, and the main studies that have led to a 
deeper understanding.
Keywords: pharmacokinetics, pregnant, bupivacaine
1. Introduction
Pregnancy and labor are accompanied by important physiological and anatomi-
cal changes. There is a modification in the metabolism of drugs and changes in their 
pharmacokinetics as well as their interaction with organs and systems. Anesthesia 
in the obstetric patient is influenced by physiological changes, concomitant dis-
eases, and preferences for a specific drug. Local anesthetics are a special topic due 
to the frequent use of them during labor, the performance of cesarean section, or 
another non-obstetric procedure in the pregnant patient. It is necessary to know 
the pharmacokinetics of the local anesthetic most frequently used in our practice, 
bupivacaine, plain or hyperbaric, or one of its enantiomers. The objective of this 
review is to know the main studies that have evaluated pharmacokinetics and their 
interaction with systems and organs in the mother and placental passage.
2. Cardiovascular changes of pregnancy
During pregnancy many hemodynamic and hormonal changes occur like cardio-
vascular adaptations such as increased heart rate, plasmatic volume, cardiac output 
and sympathetic tone, or a reduction in peripheral resistances. The heart moves to 
the left and up during pregnancy, since the diaphragm progressively rises through 
the gravid uterus. These changes may be more important in post-term periods that 
are defined as pregnancies greater than 294 days (≥42 weeks of gestation periods) 
[1]. The increase in cardiac output and blood volume may increase the distribution 
of some drugs; the water-soluble ones will increase in their absorption as well as the 
liposoluble by the augmentation of the maternal fat, and there is an increase of the 
interactions of antiarrhythmic drugs
with cardiac sodium channels.
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glomerular filtration and the renal sanguineous irrigation, which will produce an 
increase in the clearance of the drug [2].
The blood volume increases by 30–50%, and this rise begins in the first trimester 
and continues rising until week 30 of gestation and returns to its normal volume 
after pregnancy. A phenomenon is a dilutional anemia since the proportion of 
plasma volumes in relation to blood volume increases proportionally greater than 
red cells, and the hemoglobin concentrations will vary between 11 and 12 g/100 mL 
at the end of pregnancy. The increase in plasma volume is related to the size of the 
fetus; one theory is that the adrenal glands of the fetus can initiate an increase in 
blood volume by providing dehydroepiandrosterone (precursor of estrogen) to the 
placenta, stimulating the liver to produce angiotensin, which increases aldosterone 
production and fluid retention [3].
Increased blood volume and increased cardiac output may respond to an initial 
vasodilation caused by a vasodilating substance that may be prostacyclin or the 
endothelial-derived relaxing factor. This increase in blood volume is necessary 
to meet the needs of the fetus and compensate for the loss of maternal blood at 
delivery; the mother can lose up to 20% of their blood volume without a significant 
change in his hematocrit [3]. Cardiac output increases to 30–50% during preg-
nancy, peaks at weeks 28–32, and then decreases a little during the last weeks. The 
values increase to 4.5–6.5 L/min and decrease as the term of pregnancy approaches 
but are considerably lower in the lateral position than in the supine position. The 
supine position during labor is associated with an 8% incidence of hypotension, and 
15–20% of patients will have aortoiliac and vena cava compression. The reduced 
cardiac output lowers uterine blood flow, and this adversely affects the fetus. The 
cardiac return is diverted from the vena cava through the vertebral and azygos 
systems to the superior vena cava, and this enlarges the epidural veins and provides 
an explanation for the reduced amount of local anesthetic needed for spinal or 
epidural analgesia in pregnancy, and there is an increase in sympathetic activity that 
results in vasoconstriction that reduced the degree of hypotension observed [4].
Uterine blood flow increases to 200 mL/min by week 28 and 500 mL/min by 
the end of pregnancy, the uterine musculature receives approximately 20% of the 
total uterine blood flow, while the area of the placenta receives 80% by what to the 
placenta, that is to say, 400 mL of blood per minute or approximately 80 mL of 
blood per 100 g of tissue per minute [4].
3. Pharmacokinetics of bupivacaine and main studies
Bupivacaine is a local anesthetic amide type, synthesized in 1957 by Ekenstam 
in Switzerland, and has a mechanism of action through the obstruction of sodium 
channels to the nerve membrane, preventing the generation of an action potential. 
It is used for intraoperative local anesthesia, postoperative analgesia, and chronic 
pain treatment. It is widely used in pregnant patients and provides excellent sensory 
anesthesia with reported concentrations at 0.5% [5].
The effectiveness of bupivacaine was evaluated by the toxicity, the latency,  
and the degree of motor block, the sympathetic block, and the sensory block, 
as well as the elimination time. The absorption and distribution are influenced 
by the vascularity of the injection site, the mode of injection, and the degree of 
ionization of the drug. After IV administration, its half-life is 45 min correspond-
ing to redistribution and 2.5 h due to elimination. It is metabolized by the liver by 
N-dealkylation and glucuronide conjugation. Elimination is urinary. Although some 
metabolites are eliminated via the pulmonary and bile fluid, the portion bound to 
proteins is the active part, and the unbound is responsible for the toxic effects [5].
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The pharmacokinetics in the mother-fetus binomial changes, the fetus and the 
placenta function as deposits, the placenta has the capacity to metabolize drugs, and 
it is possible to modulate the elimination of the drug by producing metabolites and 
retaining large quantities for its release back to the fetus [6].
The apparent volume of distribution increases during pregnancy with the 
increase in plasma volume, approximately 40–50% from the beginning of preg-
nancy to a maximum of 32 weeks. During the placental growth phase, the periph-
eral hairy surface increases from 3.7 m2 in week 25 to 11 m2 during the last month of 
gestation, and the fetal-mother exchange surface decreases from 92 to 767 m2 due to 
a decrease in density of the microvilli [6].
Since the drugs that cross the placenta reach the fetus via the umbilical venous 
blood and 50% of it enters the liver circulation and the rest goes through the venous 
duct, then half of the transported drug is susceptible to hepatic metabolism and the 
other half enters the fetal circulation directly. The distribution of a drug in the fetus 
is regulated by variations in pH and protein binding [6].
The drugs once inside the organism move between the compartments, and to 
analyze it the changes in the concentration of the drug in a compartment as a func-
tion of time are studied, according to the following formula [7]:
  dC ___dt = − kCn (1)
where dC/dt equals the change in concentration in relation to time and −kCn 
refers to the decrease in the concentration of a drug which is an exponential type 
function [7].
When the rate of change is independent of the concentration of the drug, it 
is called a zero-order process, and when the process and the rate of change are 
proportional to the concentration of the drug, it is called a first-order process, the 
mother-fetus, which behaves like a model of two compartments with bidirectional 
distribution [7].
Bupivacaine has an asymmetric carbon atom and can take the form of two 
enantiomers (R + dextrobupivacaine and S-levobupivacaine), form different three-
dimensional relationships in the asymmetric medium of receptors and enzymes, 
and result in differences in toxicity, distribution, cardiotoxicity, and neurotoxicity 
[8]. Levobupivacaine is soluble in water with a molecular weight of 325, a partition 
coefficient of 1624, and a pKa of 8.09. Both the partition coefficient and the pKa 
are very similar to those of bupivacaine. Its pH is 4.0–6.5. Its maximum plasma 
concentration reaches 30 min, and its volume of distribution is 67 L [8]. Liposomal 
bupivacaine is composed of multivesicular liposomes with 10–30 micrometers in 
diameter and has a duration of analgesia of up to 72 h [9].
Bupivacaine has a pKa of 8.1, ionized fraction of 15% at a pH of 7.4, fat/buffer 
coefficient of 115, protein binding 95%, molecular weight of 288 Daltons, and 
an effective anesthetic concentration in the rat sciatic nerve of 0.25. The main 
determinant of adverse systemic effects is the free fraction, which is not bound 
to proteins [10].
4. Studies of bupivacaine in QT interval
Spinal anesthesia involves changes in the mother’s hemodynamic, including 
decreased venous return, decreased systemic vascular resistance, and a compensa-
tory increase in cardiac output. These changes increase the risk of intraoperative 
arrhythmias in patients [1].
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Local anesthetics routinely used include bupivacaine and its enantiomer levobu-
pivacaine, the latter having a clinical profile close to bupivacaine, but it is less toxic 
to both the nervous system and the cardiovascular system, which makes it useful in 
obstetric anesthesia, where large volumes of local anesthetics may be required. It has 
been reported that bupivacaine and levobupivacaine cause a concentration-dependent 
inhibition of the amplitude of gravid myometrial contractions in rats [11].
Local anesthetics are amphiphilic and can enter a variety of cellular compart-
ments and potentially interact with many different cell membranes, organelles 
(including the inhibition of mitochondrial adenosine production), and a variety of 
membrane junctions and charged cytosol molecules. Other mechanisms, which can 
contribute to myometrial inhibition, include the blocking of ionotropic signaling 
pathways (sodium, potassium, or calcium) and interference with protein modula-
tion of calcium and potassium channels [11].
The practice of using low concentrations (0.125–0.25%) makes it less likely that 
the inhibitory concentrations in the plasma reach the clinical practice [11]. The 
toxic effect of local anesthetics on myocardial contractility and cardiac conduction 
is due to the alteration of the calcium channel [12]. In a study by Mahmut et al., 
40 healthy pregnant patients were included; they evaluated QT interval, which 
increased significantly in the post-term group, which makes them susceptible to the 
development of arrhythmias; and they concluded that care must be taken during 
the induction of spinal anesthesia in term pregnancies as well as cardiovascular 
monitoring should be prolonged in this type of patients [13].
The Dogan et al. study used 12 mg of 0.5% hyperbaric bupivacaine or 0.5% of 
levobupivacaine for the spinal levobupivacaine group and calculated the QTc with 
the Bazzett formula and the QT dispersion (difference between the maximum and 
minimum QTc). They studied 60 patients. The mean maximum QTc was longer in 
levobupivacaine, and the minimum mean QTc was also longer. In the bupivacaine 
group, the maximum QTc was longer than levobupivacaine [14].
5. Pharmacokinetic studies in rats
It is known that the placenta does not limit the fetal transfer of local anesthetics 
administered to the mother; using a human placental model in rats, it is suggested 
that bupivacaine accumulates in the placenta [15]. The study of Morishima et al., 
a study in the University of Columbia with a model of rats, administered 1 mg/kg 
of bupivacaine followed by an infusion of 0.33 mg/kg/min, over a total period of 
15 min. The maximum dose of bupivacaine was 1200–1400 ng/mL, which is similar 
to the concentration of plasma bupivacaine in pregnant women under cesarean 
section with epidural anesthesia [1].
The pharmacokinetic analysis of bupivacaine was assumed as an open two-
compartment model. A transient reduction in heart rate occurred during the 
infusion of bupivacaine [1].
5.1 Pharmacokinetic parameters
The mean peak concentration of bupivacaine in maternal plasma was 
3123 ± 370 ng/mL, the concentration decreased to 26 ± 12 ng/mL at 180 min, 
and after 240 min, it became undetectable. In plasma 4′-hydroxybupivacaine 
and 2,6-pipecoloxylidine were not detected. The half-life of distribution was 
37.7 ± 2.4 min, the volume of distribution in stable state 3.86 ± 0.29 l/kg, and the 
total clearance 93.3 ± 8.6 mL/min−1.kg−1; other parameters were K12 0.462 ± 0.066; 
K21 0.081 ± 0.008 and K10 0.166 ± 0.021. In fetal plasma, a bupivacaine peak of 
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320 ± 38 ng/mL was detected rapidly, and the drug became undetectable at 4 h. A 
bupivacaine concentration of 4817 ± 976 ng/g in the amnion at the end of the infu-
sion was the highest sample of those obtained at any time [1].
While the dose of bupivacaine decreases, 3-hydroxybupivacaine remains virtually 
constant in the amnion and myometrium, and the 3-hydroxybupivacaine also kept 
increasing. Despite a high concentration of 3-hydroxybupivacaine in these tissues, the 
amniotic fluid concentration was not as high as expected. The 4-hydroxybupivacaine 
and the 2.6 pipecoloxylidide were only detected in traces in samples obtained in 2 h. 
The largest metabolite detected in rats was 3-hydroxybupivacaine [1].
In the fetus, the 3-hydroxybupivacaine remains detectable in the liver up to 4 h, 
while it virtually disappears from other tissues, because most of the umbilical venous 
blood perfused in fetal liver, and bupivacaine transmitted to the fetus, can directly 
enter the fetal liver; this may suggest that the fetal liver is capable of metabolizing 
bupivacaine. However, because polar metabolites do not cross the placental mem-
brane bidirectionally, 3-hydroxybupivacaine probably accumulates in the fetus [1].
6. Studies about bupivacaine in multimodal analgesia
6.1 Blockage of the transverse abdominal muscle
In the study by Eslamian et al., a randomized, double-blind, placebo-controlled 
study of 50 pregnant women under elective cesarean section, transverse abdominis 
plane (TAP) block was used. The preparation was performed with 40 mL of 0.25% 
hyperbaric bupivacaine plus 2 mL of normal saline for the placebo group of 400 mL 
of 0.25% hyperbaric bupivacaine plus 2 mL of sufentanil for the study group. The 
block was guided with ultrasound; the patients who received 40 mL of hyperbaric 
bupivacaine 0.25% plus 10 μg of sufentanil consumed less morphine during 24 h after 
surgery compared to the control group (p = 0.002); the mean difference in morphine 
consumption was 15.6 mg in the first 24 h of the postoperative period. There were no 
differences in the EVA scale between one group and another with>0.05 [15].
In the Trabelsi et al. study, a group of 17 pregnant patients were administered 
with spinal anesthesia with hyperbaric bupivacaine with 5 μg of sufentanil, and 
abdominal ultrasound-guided TAP block was placed with 20 mL 0.25% bupivacaine 
bilaterally. They found an accumulated average of bupivacaine of 1.4 ± 0.2 mg/kg 
(range of 1.05–1.79 mg/kg); the CMAX was 802.36 ng/mL (231.8–3504.5 ng/mL) and 
was reached at 30 min (TMAX). The mean area under the curve (AUC) (0–24 h) was 
4505.4 ng/mL, and the elimination half-life was 8.75 h for bupivacaine, demonstrat-
ing that bilateral blockade increases the total concentration of bupivacaine in the 
plasma after administering spinal anesthesia with bupivacaine. Plasma concentra-
tions occurred at 30 min after injection, all peak concentrations were reached 
between 10 and 90 min and a second delayed peak of 90 min [10].
In the Lacassie study, in 12 pregnant women and 11 healthy volunteers, the 
transverse muscle was blocked with levobupivacaine 0.25%, 20 mL with epineph-
rine 5 μg/ml−1, venous concentrations were 2.62 mg/L−1, below the level toxic, the 
volume of distribution of levobupivacaine was 172 L (70 kg) (IC 95% 137–207) 
higher than in healthy volunteers [16].
6.2 Use of patient-controlled analgesia (PCA pumps) in different combinations
The Stourac study worked with pregnant women under epidural analgesia; they 
used 12.5 mg of bupivacaine and 5 μg of sufentanil in 10 mL of normal saline, and 
boluses of half the dose every 60–90 min were administered. Another group using 
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Local anesthetics routinely used include bupivacaine and its enantiomer levobu-
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In the Lacassie study, in 12 pregnant women and 11 healthy volunteers, the 
transverse muscle was blocked with levobupivacaine 0.25%, 20 mL with epineph-
rine 5 μg/ml−1, venous concentrations were 2.62 mg/L−1, below the level toxic, the 
volume of distribution of levobupivacaine was 172 L (70 kg) (IC 95% 137–207) 
higher than in healthy volunteers [16].
6.2 Use of patient-controlled analgesia (PCA pumps) in different combinations
The Stourac study worked with pregnant women under epidural analgesia; they 
used 12.5 mg of bupivacaine and 5 μg of sufentanil in 10 mL of normal saline, and 
boluses of half the dose every 60–90 min were administered. Another group using 
Topics in Local Anesthetics
52
PCA pumps with remifentanil connecting a 50 mL syringe with remifentanil at a 
concentration of 20 μg/mL studied a total of 24 patients, and there was no signifi-
cant difference between the groups. The level of satisfaction of the patients was 
88% with epidural analgesia and 85% with PCA pump. Among the complications, 
only one had hypotension, with remifentanil, and experienced drowsiness and 
dizziness as well as temporary anxiolysis [8].
In the Chen et al. study, they determined the lowest effective concentration of 
levobupivacaine and levobupivacaine with fentanyl, and one group received 1.2 mg/mL 
of levobupivacaine and 2 μg/mL of fentanyl. They determined that the concentrations 
of 0.6 mg/mL of levobupivacaine plus 2 μg/mL of fentanyl and 1 mg/mL of levobupiva-
caine were the lowest concentrations of the drugs required for effective analgesia, and 
they analyzed a total of 83 pregnant women and showed that levobupivacaine alone 
produces a comparable analgesia with levobupivacaine with narcotic; in addition, those 
who received narcotics had more adverse effects [17].
6.3 Studies in the capacity of blocking muscle fibers
In the Fanning et al. study, pregnant patients received spinal anesthesia with 
10–12 mg at 0.5% hyperbaric bupivacaine with 20–25 μg of intrathecal fentanyl and 
100–150 μg of intrathecal morphine. After the placental extraction, a small segment 
of the myometrium was removed from the incisional surface of the lower uterine 
segment. Each sample was dissected in four longitudinal muscles. The muscle 
was exposed to bupivacaine or levobupivacaine and chemical contractions were 
induced. Eight muscle samples were included. Bupivacaine and levobupivacaine 
caused a concentration-dependent decrease in the amplitude of the contractions 
reaching a statistical significance of p = 0.002 for bupivacaine and p = 0.001 for 
levobupivacaine compared to the control period before the administration of any 
drug [18]. There was no significant difference between bupivacaine and levobu-
pivacaine in its effects on contraction of the myometrium, in the amplitude of the 
contractions, and in the interval between contractions for bupivacaine and levobu-
pivacaine; there was no difference between the EC50 (effective concentration 50)  
and the effect of both drugs in contractility which was reversible. No increase in 
contractile amplitude was observed. The maximum concentrations in plasma were 
1053 μg/mL (3.24 × 10–6 m) for bupivacaine and 1017 μg/mL (3.13 × 10–6 m) for 
levobupivacaine. They concluded that bupivacaine and its enantiomer levobupiva-
caine cause a similar decrease in concentration-dependent contractions. The con-
centrations required for their inhibitory effect on the amplitude of the contractions 
were much higher (33 times) than the clinically relevant plasma concentrations of 
these drugs after epidural administration and are unlikely to be significant in the 
low epidural dose scenario to analgesia in labor periods [18].
The combination with clonidine, a partial agonist of alpha 2 adrenergic recep-
tors, interacts with the local anesthetic in the neural axis. The analgesic effect 
is due to its action in spinal and supraspinal α-adrenergic receptors, including 
the activation of postsynaptic α-2 receptors, since the noradrenergic descending 
pathways of cholinergic neurons and the release of nitric oxide and substances such 
as enkephalin reduce the absorption of local anesthetics by a vasoconstrictor effect, 
improving quality and increasing the duration of anesthetic blockade. It is recom-
mended at doses of 1 μg/kg combined with bupivacaine [12]. In a Brazilian study, 
66 pregnant patients were divided into two groups: a group with 8 mg of bupiva-
caine +75 μg of clonidine and 100 μg of morphine +0.9% saline and another group 
with 10 mg of bupivacaine +75 μg of clonidine +100 μg of morphine + saline 0.9%; 
the total volume administered was 4 ml in both groups, and there was no difference 
in hemodynamic parameters, adverse effects, and level of consciousness, only the 
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regression time of the motor block, in group 1, of 198.48 ± 47.63 min, and in group 2 
of 232.84 ± 63.66 min; p = 0.00073. They concluded that morphine and clonidine at 
low doses produce adequate postoperative analgesia in pregnant patients [12].
In the study Zhan et al., 70 pregnant or obstetric patients were studied; 0.5% 
spinal isobaric bupivacaine was 4 mg; the ED50 of intrathecal bupivacaine for 
motor block was 3.96 mg (IC 95% 3.83–4.98) for pregnant women versus 4.51 mg 
(95% CI 4.27–4.76) for nonpregnant women. The potency of bupivacaine for 
motor block in pregnant versus non-pregnant women was 1.14 times higher  
(95% CI 1.05–1.24). This is because the supine position can increase the dis-
semination of the injected drugs due to the increase in intra-abdominal pressure, 
in addition to the increase in blood flow in the vasculature in the epidural veins, 
which distends and compresses the intraspinal space decreasing the volume of the 
spinal fluid cerebral [19].
7. Bupivacaine and placental transfer to fetus
The analysis of the placental intervillous space shows to be an appropriate place 
of investigation because this space is initially filled with blood coming from the 
maternal spiral arteries that interchange with the fetal venous blood, when the 
blood of the mother flows toward the branched villi. Although it is an important 
interchange interface, the intervillous space has been studied as the transport of 
substances between the mother, the placenta, and the fetus; obtaining blood from 
this compartment has provided a unique opportunity to study the maternal-fetal 
physiological relationship in a more physiological way [20]. The importance of this 
is that the reduced ability of the fetus to eliminate drugs can cause prolonged effects 
on the fetus, since half of the fetal circulation reaches the umbilical vein and directly 
reaches the fetal heart and brain by passing to the fetus. Liver immaturity contributes 
to the presentation of adverse effects, the fetus eliminates the drug by diffusion into 
the maternal compartment, although the majority of the metabolites are more polar 
and it is unlikely that the placental membrane crosses the placental membrane back 
to the compartment maternal, possibly resulting in the accumulation of metabolites 
in various fetal tissues [20].
In the study by Barros et al., a Brazilian study, the concentrations of bupivacaine 
and lidocaine as well as its metabolite (MEGX) and its placental transfer were 
analyzed in 10 healthy pregnant patients, under elective cesarean and epidural 
anesthesia. The administration of the medication was epidural of 0.1 mg of fentanyl 
citrate, 112.5 mg of 0.5% bupivacaine with 2:200000 epinephrine, and 200 mg 
of lidocaine 2% without vasoconstrictor injected into the epidural space [11]. The 
concentrations of bupivacaine enantiomers were high in the maternal plasma and 
placental intervillous space than in the umbilical vein and the umbilical artery. 
The concentrations of S-bupivacaine in the maternal plasma were higher than the 
R-bupivacaine concentrations, and the values  were 195.2 and 186.0 ng/mL. There 
were no significant differences (P < 0.05) between their concentrations in umbilical 
fetal vessels [11]. The placental transfer was 33% for R-bupivacaine and 31% for the 
S-bupivacaine. The concentrations of the enantiomer S-bupivacaine were 3.5 and 
3.82 times higher in the placental intervillous space than that of the umbilical vein 
and the umbilical artery, respectively [11].
The R-bupivacaine concentrations were 2.9 times higher in the placental inter-
villous space than the fetal umbilical vein concentrations and 3.16 times higher than 
the concentrations in the fetal umbilical artery. There were no cardiocirculatory 
changes, neonatal repercussions in the APGAR, or respiratory depression. There 
was no significant difference in the ratio of enantiomer concentrations between the 
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different compartments, maternal or fetal. This study showed that the intervillous 
space acts as a drug reservoir [11].
8. Conclusion
In conclusion, local anesthetics, including bupivacaine, are among the drugs 
most commonly used in clinical practice for the management of pregnant patients 
for obstetric or non-obstetric procedures. It is essential to know the pharmacokinet-
ics of the drug in order to understand the concentrations of the drugs which we 
can obtain adequate analgesic and anesthetic effects, trying to diminish the toxic 
effects.
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Adjuvant Drugs to Local 
Anesthetics
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Abstract
Local anesthetics have a potential to be used in a wide variety of situations 
including central neuraxial blocks, peripheral nerve blocks, intravenous, and local 
infiltration both for surgeries and acute and chronic pain management. Their use 
can be limited by their duration of action and the dose-dependent adverse effects 
on the cardiac and central nervous system. Adjuvants are drugs which, when co-
administered along with local anesthetic agents, improve the latency of onset and 
duration of analgesia and counteract disadvantageous effects of local anesthetics. 
There is a wide armamentarium of adjuvant drugs to choose to be added in neur-
axial and peripheral nerve blocks. They can be broadly divided into non-opioids 
and opioids, with non-opioids being vasoconstrictors, α2-adrenoceptor agonists, 
anti-inflammatory agents, acetylcholine esterase inhibitors (neostigmine), adenos-
ine, ketorolac, midazolam, magnesium, and sodium bicarbonate and opioids being 
lipophilic (fentanyl and sufentanil) and hydrophilic (morphine).
Keywords: local anesthetics, adjuvants, neuraxial blocks, peripheral nerve blocks, 
opioids, neurotoxicity
1. Introduction
Local anesthetics (LA) are widely used in clinical practice for regional anesthe-
sia or analgesia in various locations like central neuraxial blockade, peripheral nerve 
block, intravenously, and local infiltration. Infiltration with LA around the nerve 
produces analgesia by interrupting pain signals to the brain. The analgesic effect of 
a nerve block with LAs lasts only a few hours. Therefore, after surgery patients may 
suffer from moderate to severe acute pain. The duration of the action of LA can be 
prolonged by either increasing the dose or administering a continuous infusion of 
the drug, which can lead to dose-dependent side effects on the cardiovascular sys-
tem and/or central nervous system (CNS) [1, 2]. The popularity of peripheral nerve 
blocks for surgical anesthesia as well as for postoperative analgesia has increased 
significantly due to anesthetists becoming more familiar with ultrasound-guided 
techniques. While the use of catheters for continuous infusions allows for sustained 
pain relief during the perioperative period, they can increase the challenges related 
to patient management, catheter displacement, and the potential for increased 
infection risk. In the case a long-acting LA or continuous block is used, sensory 
block is also associated with prolonged motor block in the postoperative period. 
Prolonged motor blockade in the postoperative period is undesirable as it leads to 
delayed mobilization of the patient and hence increased risk of complications.
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1. Introduction
Local anesthetics (LA) are widely used in clinical practice for regional anesthe-
sia or analgesia in various locations like central neuraxial blockade, peripheral nerve 
block, intravenously, and local infiltration. Infiltration with LA around the nerve 
produces analgesia by interrupting pain signals to the brain. The analgesic effect of 
a nerve block with LAs lasts only a few hours. Therefore, after surgery patients may 
suffer from moderate to severe acute pain. The duration of the action of LA can be 
prolonged by either increasing the dose or administering a continuous infusion of 
the drug, which can lead to dose-dependent side effects on the cardiovascular sys-
tem and/or central nervous system (CNS) [1, 2]. The popularity of peripheral nerve 
blocks for surgical anesthesia as well as for postoperative analgesia has increased 
significantly due to anesthetists becoming more familiar with ultrasound-guided 
techniques. While the use of catheters for continuous infusions allows for sustained 
pain relief during the perioperative period, they can increase the challenges related 
to patient management, catheter displacement, and the potential for increased 
infection risk. In the case a long-acting LA or continuous block is used, sensory 
block is also associated with prolonged motor block in the postoperative period. 
Prolonged motor blockade in the postoperative period is undesirable as it leads to 
delayed mobilization of the patient and hence increased risk of complications.
Topics in Local Anesthetics
58
The adjuvant drugs of regional LAs improve the quality and duration of anesthe-
sia and analgesia and patient safety, thus increasing patient satisfaction and comfort 
[3, 4]. The aim of this chapter is to discuss the past, present, and future trends in 
the use of adjuvants, as well as their benefits and side effects.
2. Adjuvants drugs
Adjuvants are drugs which, when administered along with LA agents, may 
improve the latency of onset and duration of analgesia and counteract the undesir-
able effects associated with large doses of LAs. The use of adjuvant drugs has the 
potential to improve the efficacy of peripheral and central neuraxial blocks and 
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enhancing motor blockade, and limiting the overall dose requirement of LAs. An 
ideal adjuvant should not only shorten the speed of onset of action of the LA drug 
but also reduce its dosage along with providing hemodynamic stability, optimal 
sedation, and minimum adverse effects.
A wide variety of adjuvant drugs have been used for both neuraxial and peripheral 
nerve blocks (Table 1). They can be broadly divided into non-opioids and opioids.
Current research is directed toward a search for agents and techniques which 
would prolong LA action while limiting its side effects and giving the patient its 
maximum benefit. These include techniques like the use of charged molecules to 
produce LA action (tonicaine and n-butyl tetracaine), newer delivery mechanisms 
for prolonged bioavailability (liposomal, cyclodextrin, and microsphere systems), 
and the use of other drugs (dextrans, adenosine, neuromuscular blockers) [3, 4].
While the use of LA adjuvants in regional anesthesia [5, 6] is in widespread 
clinical off-label use and has been subject to multiple clinical trials, we would like 
to emphasize on the fact that only a few adjuvants have been approved by the Food 
and Drug Administration (FDA), so absolute caution must be exercised while using 
these adjuvants.
3. Opioids
Opioids are the most common and the earliest used LA adjuvants. Their use in 
neuraxial and peripheral nerve blocks has evolved greatly over the last 30 years. It 
is advisable to use specific opioids, at appropriate doses and routes of administra-
tion that result in a primarily spinal site of action rather than a systemic opioid [7]. 
Afferent noxious stimuli from peripheral tissues converge in the dorsal horn of the 
spinal cord, where the primary nociceptive neuron synapses with the interneurons 
and the second-order nociceptive neuron in the spinothalamic tract. Blockade of 
these opioid receptors by agonists helps to suppress afferent nociceptive input 
from pain sites by modulating the release of pain-pathway associated peptides [8]. 
Opioids produce analgesia by mimicking the actions at specific receptors of endog-
enous opioid peptides. These peptides are beta-endorphin, met-enkephalin, and 
dynorphin. The three main types of opiate receptors, each with its own subtypes, 
are mu (μ), delta (δ), and kappa (ĸ) [9]. The most important target for opioids is 
the μ-receptor (endorphin), and intrathecal opioids appear to selectively modulate 
C- and A-fibers with minimal impact on dorsal root axons. The enkephalins are 
the primary endogenous ligands of the delta receptor and are involved with spinal 
analgesia. Dynorphin is the ligand for the kappa receptor. Activation of the kappa 
receptor results in segmental spinal analgesia and sedation. Most of the mixed 
agonist–antagonist opioids like butorphanol bind to the kappa receptor.
The exact mechanism of action of opioids at peripheral nerve is still uncertain. 
Evidences have begun to support the presence of peripheral opioid receptors [10]. 
The possible mechanism of prolonged analgesia by peripheral opioid administra-
tion could be through direct binding at opioid receptors of dorsal nerve root aided 
by axonal flow, diffusion through brachial plexus sheath to extradural or subarach-
noid space to dorsal horn, and central action after peripheral systemic uptake [11].
3.1 Morphine
The first opioid to be used intrathecally was morphine with the initial clinical 
study published in 1979 [12]. Morphine being relatively less hydrophobic than other 
opioids remains in the CSF for a longer time and therefore occupies the rostral 
receptor sites for a longer duration than other opioids [13]. Consequently, morphine 
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ideal adjuvant should not only shorten the speed of onset of action of the LA drug 
but also reduce its dosage along with providing hemodynamic stability, optimal 
sedation, and minimum adverse effects.
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clinical off-label use and has been subject to multiple clinical trials, we would like 
to emphasize on the fact that only a few adjuvants have been approved by the Food 
and Drug Administration (FDA), so absolute caution must be exercised while using 
these adjuvants.
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Opioids are the most common and the earliest used LA adjuvants. Their use in 
neuraxial and peripheral nerve blocks has evolved greatly over the last 30 years. It 
is advisable to use specific opioids, at appropriate doses and routes of administra-
tion that result in a primarily spinal site of action rather than a systemic opioid [7]. 
Afferent noxious stimuli from peripheral tissues converge in the dorsal horn of the 
spinal cord, where the primary nociceptive neuron synapses with the interneurons 
and the second-order nociceptive neuron in the spinothalamic tract. Blockade of 
these opioid receptors by agonists helps to suppress afferent nociceptive input 
from pain sites by modulating the release of pain-pathway associated peptides [8]. 
Opioids produce analgesia by mimicking the actions at specific receptors of endog-
enous opioid peptides. These peptides are beta-endorphin, met-enkephalin, and 
dynorphin. The three main types of opiate receptors, each with its own subtypes, 
are mu (μ), delta (δ), and kappa (ĸ) [9]. The most important target for opioids is 
the μ-receptor (endorphin), and intrathecal opioids appear to selectively modulate 
C- and A-fibers with minimal impact on dorsal root axons. The enkephalins are 
the primary endogenous ligands of the delta receptor and are involved with spinal 
analgesia. Dynorphin is the ligand for the kappa receptor. Activation of the kappa 
receptor results in segmental spinal analgesia and sedation. Most of the mixed 
agonist–antagonist opioids like butorphanol bind to the kappa receptor.
The exact mechanism of action of opioids at peripheral nerve is still uncertain. 
Evidences have begun to support the presence of peripheral opioid receptors [10]. 
The possible mechanism of prolonged analgesia by peripheral opioid administra-
tion could be through direct binding at opioid receptors of dorsal nerve root aided 
by axonal flow, diffusion through brachial plexus sheath to extradural or subarach-
noid space to dorsal horn, and central action after peripheral systemic uptake [11].
3.1 Morphine
The first opioid to be used intrathecally was morphine with the initial clinical 
study published in 1979 [12]. Morphine being relatively less hydrophobic than other 
opioids remains in the CSF for a longer time and therefore occupies the rostral 
receptor sites for a longer duration than other opioids [13]. Consequently, morphine 
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produces a long-lasting and adequate analgesia with intrathecal use [14]. However, 
this huge advantage is offset by the increased risk of adverse effects, especially post-
operative respiratory depression [15], which remains a particular concern among 
anesthetists. Intrathecal and epidural morphine are associated with a high incidence 
of side effects like nausea, vomiting, pruritus, urinary retention, sedation, and 
delayed respiratory depression [13, 16]. The recommended dose for intrathecal 
administration is 50–300 μg, while as 2–5 mg of epidural loading dose is considered 
adequate. The risk of side effects increases exponentially with the increase in the 
dose [16, 17].
3.2 Pethidine
Pethidine (meperidine) is a lipophilic phenylpiperidine derivate that is 30 times 
more lipid soluble and 10 times less potent than morphine, leading to a faster onset 
and a shorter duration of action than morphine. Pethidine possesses some local 
anesthetic properties (motor and sensory fiber block) which lets it stand out from 
the rest of the opioid agents. Pethidine is a popular choice for obstetric analgesia 
used mainly in epidural analgesia during labor. Intrathecal use of pethidine is 
not recommended. The incidence of nausea, vomiting, and hypotension is more 
with pethidine than with morphine. Pethidine can be injected as a loading dose of 
25–50 mg in the epidural space.
3.3 Fentanyl
In addition to acting on the spinal cord receptors and peripheral receptors, 
fentanyl is also reported to have a local anesthetic like action, but this requires a 
very high concentration (50 g/mL) which is not clinically feasible [18]. Fentanyl 
as an adjuvant to LA causes significant prolongation of duration of analgesia but 
delays the onset of both sensory and motor blockade compared to LAs alone [19]. 
The change in pH of the anesthetic solution resulting in slower penetration of nerve 
membrane by LA is considered to be responsible for this effect [20]. The recom-
mended intrathecal dose is 10–25 μg, and the epidural loading dose is 50–100 μg. 
Fentanyl as adjuvant does not prolong motor block, so it allows early ambulation, 
thereby reducing the morbidity. The duration of action is 2–4 h, and the risk of 
respiratory depression is very low and of short duration [17].
3.4 Sufentanil
A potent agonistic opioid was synthesized in the mid-1970s. A piperidine 
derivative is 6–10 times more potent than fentanyl, depending on the route of 
administration; it has been registered for intravenous, epidural, and subarachnoid 
administration. It is considered to be more lipid soluble than its counterparts, a bet-
ter μ receptor ligand. It is an extremely potent opioid with a faster onset of action 
than its counterparts. Its use in clinical practice is limited by its short duration of 
action and high side effect profile. The recommended intrathecal dose is 2.5–10 μg, 
and epidural loading dose is 10–50 μg [17].
3.5 Hydromorphone
This opioid has intermediate lipid solubility. Due to its hydrophilicity, epidural 
hydromorphone can cross the blood-brain barrier faster and provide fast onset and 
modest duration of action.
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3.6 Buprenorphine
Buprenorphine is a highly lipophilic partial opioid receptor agonist. It is also 
considered to have local-anesthetic-like capacity by blocking voltage-gated sodium 
channels. Buprenorphine and its metabolite nor-buprenorphine have been shown to 
act on κ and δ opioid receptors in addition to μ receptors which account for its anti-
hyperalgesic effects. The risk of side effects like postoperative nausea and vomiting 
(PONV) is more with the use of perineural buprenorphine [21].
3.7 Diamorphine
It is a diacetylated analogue of morphine with a potency of approximately 1.5–2 
times that of morphine. This leads to a faster onset and slightly shorter duration of 
action than morphine. It is a lipophilic semi-synthetic opioid and is a prodrug that 
is converted to its active metabolites (morphine and 6-monoacetyl morphine) by 
deacetylation in the liver and neural tissues. The recommended intrathecal dose is 
300–400 μg, and epidural loading dose is 2–5 mg [17, 22].
3.8 Tramadol
Tramadol is a weak centrally acting opioid. A potency ratio of oral morphine 
to oral tramadol has been reported to be between 1:4 and 1:10. It has been shown 
to have Na+ and K+ channel blocking properties and can block motor and nocicep-
tive signals similar to that of LAs. The central and peripheral analgesic effects of 
tramadol have not been fully explained, but it is a selective agonist of μ-receptors. 
Tramadol also prevents reuptake of noradrenaline and enhances both serotonin 
and noradrenaline release. The monoaminergic activity of tramadol increases the 
inhibitory activity of the descending pain pathways, resulting in a suppression of 
nociceptive transmission at the spinal level [23].
4. Vasoactive agents
Vasoactive drugs are the oldest adjuvants that have been used, although at the 
beginning their action was attributed more to the fact that their vasoconstric-
tor effect prolonged the anesthetic and analgesic results of LAs by decreasing 
the blood flow of the site where they were injected. Adrenaline was the first 
 vasopressor used.
4.1 Epinephrine
Epinephrine has been used along with LA in neuraxial and peripheral nerve 
blocks since Heinrich Braun first experimented with its use as a “chemical tourni-
quet” in the early 1900s [24]. Epinephrine potentiates the LA action. The substantia 
gelatinosa of the dorsal horn of the spinal cord houses alpha-2 adrenoreceptors 
wherein the epinephrine by its direct action mediates its antinociceptive properties 
resulting in presynaptic inhibition of transmitter release from Aδ and C fibers. 
Also its vasoconstrictive properties limit the systemic absorption of LA leading to 
prolonged duration of action. There are concerns about epinephrine being a potent 
vasoconstrictive agent can place the blood supply of the spinal cord at risk and may 
lead to ischemia of the spinal cord leading to permanent damage. Epinephrine is 
typically administered in doses of 0.2–0.3 mg [25].
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produces a long-lasting and adequate analgesia with intrathecal use [14]. However, 
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with pethidine than with morphine. Pethidine can be injected as a loading dose of 
25–50 mg in the epidural space.
3.3 Fentanyl
In addition to acting on the spinal cord receptors and peripheral receptors, 
fentanyl is also reported to have a local anesthetic like action, but this requires a 
very high concentration (50 g/mL) which is not clinically feasible [18]. Fentanyl 
as an adjuvant to LA causes significant prolongation of duration of analgesia but 
delays the onset of both sensory and motor blockade compared to LAs alone [19]. 
The change in pH of the anesthetic solution resulting in slower penetration of nerve 
membrane by LA is considered to be responsible for this effect [20]. The recom-
mended intrathecal dose is 10–25 μg, and the epidural loading dose is 50–100 μg. 
Fentanyl as adjuvant does not prolong motor block, so it allows early ambulation, 
thereby reducing the morbidity. The duration of action is 2–4 h, and the risk of 
respiratory depression is very low and of short duration [17].
3.4 Sufentanil
A potent agonistic opioid was synthesized in the mid-1970s. A piperidine 
derivative is 6–10 times more potent than fentanyl, depending on the route of 
administration; it has been registered for intravenous, epidural, and subarachnoid 
administration. It is considered to be more lipid soluble than its counterparts, a bet-
ter μ receptor ligand. It is an extremely potent opioid with a faster onset of action 
than its counterparts. Its use in clinical practice is limited by its short duration of 
action and high side effect profile. The recommended intrathecal dose is 2.5–10 μg, 
and epidural loading dose is 10–50 μg [17].
3.5 Hydromorphone
This opioid has intermediate lipid solubility. Due to its hydrophilicity, epidural 
hydromorphone can cross the blood-brain barrier faster and provide fast onset and 
modest duration of action.
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considered to have local-anesthetic-like capacity by blocking voltage-gated sodium 
channels. Buprenorphine and its metabolite nor-buprenorphine have been shown to 
act on κ and δ opioid receptors in addition to μ receptors which account for its anti-
hyperalgesic effects. The risk of side effects like postoperative nausea and vomiting 
(PONV) is more with the use of perineural buprenorphine [21].
3.7 Diamorphine
It is a diacetylated analogue of morphine with a potency of approximately 1.5–2 
times that of morphine. This leads to a faster onset and slightly shorter duration of 
action than morphine. It is a lipophilic semi-synthetic opioid and is a prodrug that 
is converted to its active metabolites (morphine and 6-monoacetyl morphine) by 
deacetylation in the liver and neural tissues. The recommended intrathecal dose is 
300–400 μg, and epidural loading dose is 2–5 mg [17, 22].
3.8 Tramadol
Tramadol is a weak centrally acting opioid. A potency ratio of oral morphine 
to oral tramadol has been reported to be between 1:4 and 1:10. It has been shown 
to have Na+ and K+ channel blocking properties and can block motor and nocicep-
tive signals similar to that of LAs. The central and peripheral analgesic effects of 
tramadol have not been fully explained, but it is a selective agonist of μ-receptors. 
Tramadol also prevents reuptake of noradrenaline and enhances both serotonin 
and noradrenaline release. The monoaminergic activity of tramadol increases the 
inhibitory activity of the descending pain pathways, resulting in a suppression of 
nociceptive transmission at the spinal level [23].
4. Vasoactive agents
Vasoactive drugs are the oldest adjuvants that have been used, although at the 
beginning their action was attributed more to the fact that their vasoconstric-
tor effect prolonged the anesthetic and analgesic results of LAs by decreasing 
the blood flow of the site where they were injected. Adrenaline was the first 
 vasopressor used.
4.1 Epinephrine
Epinephrine has been used along with LA in neuraxial and peripheral nerve 
blocks since Heinrich Braun first experimented with its use as a “chemical tourni-
quet” in the early 1900s [24]. Epinephrine potentiates the LA action. The substantia 
gelatinosa of the dorsal horn of the spinal cord houses alpha-2 adrenoreceptors 
wherein the epinephrine by its direct action mediates its antinociceptive properties 
resulting in presynaptic inhibition of transmitter release from Aδ and C fibers. 
Also its vasoconstrictive properties limit the systemic absorption of LA leading to 
prolonged duration of action. There are concerns about epinephrine being a potent 
vasoconstrictive agent can place the blood supply of the spinal cord at risk and may 
lead to ischemia of the spinal cord leading to permanent damage. Epinephrine is 
typically administered in doses of 0.2–0.3 mg [25].
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4.2 Phenylephrine
Phenylephrine has a mechanism of action similar to that of epinephrine. It has 
vasoconstrictive abilities, thus limiting the uptake of LA and prolonging their 
duration of action. Phenylephrine in the dose of 2–5 mg prolongs both lidocaine 
and tetracaine spinal anesthesia to a similar extent as epinephrine. The use of 
phenylephrine has declined in popularity because of its association with transient 
neurologic symptoms (TNS) [26].
5. Alpha-2 adrenergic agonists
Alpha-2 adrenergic receptor agonists have recently been the focus of interest 
for their sedative, analgesic, perioperative sympatholytic, anesthetic sparing, and 
hemodynamic stabilizing properties. The central α-2-AR agonists inhibit nocicep-
tive impulses by activating post-junctional α-2-adrenoceptors in the dorsal horn 
of the spinal cord. These receptors are located on primary afferent terminals (both 
at peripheral and at spinal endings), on neurons in the superficial lamina of the 
spinal cord, and within several brainstem nuclei responsible for analgesia. They 
block the conduction of C- and A-delta fibers and increase potassium conductance, 
thus intensifying conduction block. They also cause local vasoconstriction, thereby 
reducing vascular uptake of the LA from around the neural structures and in turn 
prolonging the duration of action [27–29].
5.1 Clonidine
Clonidine is an imidazole derivative with selective partial agonist properties 
which inhibit the nociceptive impulses by acting on the post-junctional alpha-2 adr-
enoreceptors in the dorsal horn of the spinal cord. In neuraxial blocks, it has a local 
effect leading to decreased sympathetic outflow, while in peripheral nerve blocks it 
prolongs the duration of analgesia by hyperpolarization of cyclic nucleotide-gated 
cation channels. Clonidine enhances and prolongs sensory and enhances motor 
blockade when used along with LA for epidural or peripheral nerve blocks [30]. 
The alpha-2 adrenergic agonists also enhance analgesia from intraspinal opioids by 
interactions with both pre- and post-synaptic receptors within the spinal cord.
Although there is no agreement on the doses of intrathecal clonidine [31], 
the most commonly used doses vary widely. The most recommended dose for 
intrathecal use is 15–150 μg, with the incidence of adverse effects (bradycardia, 
sedation, hypotension) increasing with doses above 150 μg. Clonidine can be used 
via epidural route with a bolus dose of 75–150 μg. In pediatric anesthesia, the use 
of clonidine (1 μg/kg) as an adjuvant along with LA for caudal blocks doubles the 
duration of analgesia when compared to LA alone but causes marked sedation [17].
Clonidine has been found to prolong the action of local anesthetics in peripheral 
blocks in the postoperative period. This effect of clonidine is dose-related. After 
brachial plexus block with mepivacaine, the minimum doses which significantly 
prolong analgesia and anesthesia are 0.1 and 0.5 μg/kg, respectively [32].
5.2 Dexmedetomidine
Dexmedetomidine is seven times more selective agonist to alpha-2 receptor than 
clonidine (seven times more specific for alpha-2 than alpha-1) but has a similar 
mechanism of blocking hyperpolarization-activated cation channels. When used 
as an adjuvant to LA for neuraxial block, dexmedetomidine leads to reduced onset 
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time of sensory and motor block, increased duration of sensory block, and delayed 
recovery from motor blockade. It leads to prolongation of postoperative analgesia, 
decreased requirement of additional analgesics, delayed first rescue analgesic, and 
decreased postoperative shivering. Dose in spinal anesthesia varies from 3 to 15 μg 
as an adjuvant to LA [33]. For caudal epidural block, 1–2 μg/kg of dexmedetomidine 
along with bupivacaine can lead to prolonged analgesia without significant side 
effects [34].
The most common reported adverse effects are bradycardia and hypotension. 
Bradycardia due to dexmedetomidine is resistant to atropine, and higher doses are 
needed; although rare, even cardiac arrest can occur.
It has been shown that clonidine and dexmedetomidine administered orally, 
intramuscularly, and intravenously also prolong the anesthetic effect of intrathecal 
LA [35–40].
6. Steroids: dexamethasone
Acute inflammation from tissue injury has an important role in surgical pain, 
and glucocorticoids may be useful for its anti-inflammatory effect. Johansson et al. 
[41] investigated the corticosteroid effect on the plantar nerve of rats finding that 
methylprednisolone suppresses transmission in thin unmyelinated C fibers but not 
in myelinated A-beta fibers. The effect was reversed when the corticosteroid was 
removed, suggesting a direct action in the membrane.
Dexamethasone-induced prolongation of peripheral nerve blockade follow-
ing LA injection is commonly attributed to its anti-inflammatory action. It also 
improves the quality and duration of analgesia over LAs alone. This is thought to 
be mediated by its capacity to alter the release of inflammatory mediators, reduce 
ectopic neuronal discharge, and inhibit potassium channel-mediated discharge of 
nociceptive C fibers [41]. Its action on glucocorticoid receptor is considered to alter 
the functioning of ion channels and produce acidosis around the nerve cell, thereby 
reducing the concentration of LA required to produce blockade of signal transmis-
sion or trapping the highly ionized bupivacaine molecule into the neuronal cell. 
Studies using dexamethasone for postoperative pain relief have produced positive 
results mainly in surgery involving large amounts of tissue trauma. A systematic 
review and meta-analysis included 1695 patients distributed in 29 controlled 
clinical trials where dexamethasone 4 and 8 mg perineural was used as adjuvant 
to LA. These authors found that dexamethasone increased the mean (95% CI) 
duration of analgesia by 233 (172–295) min when injected with short- or medium-
term action LA and by 488 (419–557) min when injected with long-term action 
LA, p < 0.00001 for both. However, these results should be taken with caution 
due to the great heterogeneity of results, with I2 exceeding 90% for both analysis. 
Meta-regression did not show an interaction between dose of perineural dexa-
methasone (4–10 mg) and duration of analgesia (r2 = 0.02, p = 0.54). There were 
no differences between 4 and 8 mg dexamethasone on subgroup analysis [42]. After 
reviewing the current literature, Wiesmann et al. [43] prefer a systemic application 
mode (intravenously) over a perineural route of dexamethasone administration as a 
complement to peripheral nerve blocks. A single dose of dexamethasone could be a 
useful complement to prolong peripheral nerve blocks. In a randomized controlled 
triple-blind crossover study in 24 male volunteers, the authors used ultrasound-
guided ulnar nerve blocks (ropivacaine 0.75% wt/vol, 3 ml, with saline 1 ml with 
or without dexamethasone 4 mg) which were performed on three occasions in each 
volunteer along with an IV injection of saline 1 ml with or without dexamethasone 
4 mg. The median [inter-quartile range (IQR)] duration of sensory block was 6.87 
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4.2 Phenylephrine
Phenylephrine has a mechanism of action similar to that of epinephrine. It has 
vasoconstrictive abilities, thus limiting the uptake of LA and prolonging their 
duration of action. Phenylephrine in the dose of 2–5 mg prolongs both lidocaine 
and tetracaine spinal anesthesia to a similar extent as epinephrine. The use of 
phenylephrine has declined in popularity because of its association with transient 
neurologic symptoms (TNS) [26].
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for their sedative, analgesic, perioperative sympatholytic, anesthetic sparing, and 
hemodynamic stabilizing properties. The central α-2-AR agonists inhibit nocicep-
tive impulses by activating post-junctional α-2-adrenoceptors in the dorsal horn 
of the spinal cord. These receptors are located on primary afferent terminals (both 
at peripheral and at spinal endings), on neurons in the superficial lamina of the 
spinal cord, and within several brainstem nuclei responsible for analgesia. They 
block the conduction of C- and A-delta fibers and increase potassium conductance, 
thus intensifying conduction block. They also cause local vasoconstriction, thereby 
reducing vascular uptake of the LA from around the neural structures and in turn 
prolonging the duration of action [27–29].
5.1 Clonidine
Clonidine is an imidazole derivative with selective partial agonist properties 
which inhibit the nociceptive impulses by acting on the post-junctional alpha-2 adr-
enoreceptors in the dorsal horn of the spinal cord. In neuraxial blocks, it has a local 
effect leading to decreased sympathetic outflow, while in peripheral nerve blocks it 
prolongs the duration of analgesia by hyperpolarization of cyclic nucleotide-gated 
cation channels. Clonidine enhances and prolongs sensory and enhances motor 
blockade when used along with LA for epidural or peripheral nerve blocks [30]. 
The alpha-2 adrenergic agonists also enhance analgesia from intraspinal opioids by 
interactions with both pre- and post-synaptic receptors within the spinal cord.
Although there is no agreement on the doses of intrathecal clonidine [31], 
the most commonly used doses vary widely. The most recommended dose for 
intrathecal use is 15–150 μg, with the incidence of adverse effects (bradycardia, 
sedation, hypotension) increasing with doses above 150 μg. Clonidine can be used 
via epidural route with a bolus dose of 75–150 μg. In pediatric anesthesia, the use 
of clonidine (1 μg/kg) as an adjuvant along with LA for caudal blocks doubles the 
duration of analgesia when compared to LA alone but causes marked sedation [17].
Clonidine has been found to prolong the action of local anesthetics in peripheral 
blocks in the postoperative period. This effect of clonidine is dose-related. After 
brachial plexus block with mepivacaine, the minimum doses which significantly 
prolong analgesia and anesthesia are 0.1 and 0.5 μg/kg, respectively [32].
5.2 Dexmedetomidine
Dexmedetomidine is seven times more selective agonist to alpha-2 receptor than 
clonidine (seven times more specific for alpha-2 than alpha-1) but has a similar 
mechanism of blocking hyperpolarization-activated cation channels. When used 
as an adjuvant to LA for neuraxial block, dexmedetomidine leads to reduced onset 
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time of sensory and motor block, increased duration of sensory block, and delayed 
recovery from motor blockade. It leads to prolongation of postoperative analgesia, 
decreased requirement of additional analgesics, delayed first rescue analgesic, and 
decreased postoperative shivering. Dose in spinal anesthesia varies from 3 to 15 μg 
as an adjuvant to LA [33]. For caudal epidural block, 1–2 μg/kg of dexmedetomidine 
along with bupivacaine can lead to prolonged analgesia without significant side 
effects [34].
The most common reported adverse effects are bradycardia and hypotension. 
Bradycardia due to dexmedetomidine is resistant to atropine, and higher doses are 
needed; although rare, even cardiac arrest can occur.
It has been shown that clonidine and dexmedetomidine administered orally, 
intramuscularly, and intravenously also prolong the anesthetic effect of intrathecal 
LA [35–40].
6. Steroids: dexamethasone
Acute inflammation from tissue injury has an important role in surgical pain, 
and glucocorticoids may be useful for its anti-inflammatory effect. Johansson et al. 
[41] investigated the corticosteroid effect on the plantar nerve of rats finding that 
methylprednisolone suppresses transmission in thin unmyelinated C fibers but not 
in myelinated A-beta fibers. The effect was reversed when the corticosteroid was 
removed, suggesting a direct action in the membrane.
Dexamethasone-induced prolongation of peripheral nerve blockade follow-
ing LA injection is commonly attributed to its anti-inflammatory action. It also 
improves the quality and duration of analgesia over LAs alone. This is thought to 
be mediated by its capacity to alter the release of inflammatory mediators, reduce 
ectopic neuronal discharge, and inhibit potassium channel-mediated discharge of 
nociceptive C fibers [41]. Its action on glucocorticoid receptor is considered to alter 
the functioning of ion channels and produce acidosis around the nerve cell, thereby 
reducing the concentration of LA required to produce blockade of signal transmis-
sion or trapping the highly ionized bupivacaine molecule into the neuronal cell. 
Studies using dexamethasone for postoperative pain relief have produced positive 
results mainly in surgery involving large amounts of tissue trauma. A systematic 
review and meta-analysis included 1695 patients distributed in 29 controlled 
clinical trials where dexamethasone 4 and 8 mg perineural was used as adjuvant 
to LA. These authors found that dexamethasone increased the mean (95% CI) 
duration of analgesia by 233 (172–295) min when injected with short- or medium-
term action LA and by 488 (419–557) min when injected with long-term action 
LA, p < 0.00001 for both. However, these results should be taken with caution 
due to the great heterogeneity of results, with I2 exceeding 90% for both analysis. 
Meta-regression did not show an interaction between dose of perineural dexa-
methasone (4–10 mg) and duration of analgesia (r2 = 0.02, p = 0.54). There were 
no differences between 4 and 8 mg dexamethasone on subgroup analysis [42]. After 
reviewing the current literature, Wiesmann et al. [43] prefer a systemic application 
mode (intravenously) over a perineural route of dexamethasone administration as a 
complement to peripheral nerve blocks. A single dose of dexamethasone could be a 
useful complement to prolong peripheral nerve blocks. In a randomized controlled 
triple-blind crossover study in 24 male volunteers, the authors used ultrasound-
guided ulnar nerve blocks (ropivacaine 0.75% wt/vol, 3 ml, with saline 1 ml with 
or without dexamethasone 4 mg) which were performed on three occasions in each 
volunteer along with an IV injection of saline 1 ml with or without dexamethasone 
4 mg. The median [inter-quartile range (IQR)] duration of sensory block was 6.87 
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(5.85–7.62) h in the control group, 7.37 (5.78–7.93) h in the perineural group, and 7.37 
(6.10–7.97) h in the IV group (P = 0.61). There was also no significant difference in 
block onset time between the three groups. Dexamethasone 4 mg had no clinically 
significant effect on the duration of sensory block provided by ropivacaine applied 
to the ulnar nerve [44]. The role of dexamethasone as an adjunct in peripheral nerve 
blockades is still unclear.
7. Nonsteroidal anti-inflammatory drugs (NSAIDs)
Several studies have demonstrated that the presence of COX-2 receptors in 
the dorsal horn of the spinal cord could regulate spinal nociceptive transmission 
[45]. Some studies suggest that administering a COX-2 antagonist directly on the 
central or peripheral nerve might have a better analgesic profile than intravenous 
administration of the same drug [46]. Basically COX-2 inhibitors reduce inflamma-
tion and pain sensation by inhibiting prostaglandin production. However, the role 
of COX-2 in the central nervous system is of more importance. Inflammation can 
induce COX-2 production and will lead to the release of prostanoids that sensitize 
the peripheral nociceptor terminals and produce localized hyperalgesia. It is hence 
thought that the administration of COX-2 antagonist on spinal or peripheral nerves 
may be a more effective mode of pain relief than the intravenous or intramuscular 
route. There are very less studies on this subject. Further research and studies need 
to be conducted to verify the use of NSAIDs as adjuvants.
8. Miscellaneous agents
8.1 Ketamine
Ketamine is a noncompetitive antagonist of NMDA receptor that has been 
shown to have local anesthetic properties. Ketamine acts on more than one region. 
It has actions at monoaminergic receptors, opioid receptors, voltage-sensitive 
calcium channels, and muscarinic receptors, in addition to local anesthetic actions 
through sodium channel blockade. Systemic ketamine causes central summation 
in the second-order pain neuron and decreases severe pain [3, 47, 48]. Epidural 
administration of ketamine at 0.5–1 mg/kg has been shown to reduce intraopera-
tive and postoperative analgesic requirements without increased side effects [25]. 
Preservative-free S(+)-ketamine administered during caudal block for children at 
a dose of 0.5 mg/kg has been shown to extend analgesia time by several hours [17]. 
Intrathecal administration of ketamine is not recommended.
The risk of psychomimetic adverse effects such as hallucinations is a worrying 
factor for most anesthetists, limiting its use, but it can be easily overcome by using 
intravenous benzodiazepines as premedication prior to the block.
8.2 Midazolam
Midazolam, a water-soluble benzodiazepine, an indirect agonist of the gamma-
aminobutyric acid (GABA) receptor, has been studied primarily as an adjuvant for 
neuraxial anesthesia. Addition of preservative-free midazolam to 0.5% hyperbaric 
bupivacaine for subarachnoid block in infraumbilical surgery has been found to 
prolong the duration of effective analgesia as compared to the same concentra-
tion of bupivacaine alone and delays the need for postoperative rescue analgesics 
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without having any reported significant side effects or hemodynamic instability. 
The use of intrathecal midazolam also decreases the incidence of postoperative nau-
sea and vomiting. A small diluted intrathecal dose (1–2.5 mg) of preservative-free 
midazolam is reported to have few systemic side effects and is free of short-term 
neurotoxicity [49]. An infusion of epidural midazolam at 10–20 μg/kg/h for up to 
12 h is considered safe.
8.3 Neostigmine
Neostigmine is an acetylcholinesterase inhibitor that can enhance analgesia by 
acting on muscarinic receptors and increasing endogenous acetylcholine at the 
nerve terminal. It produces spinal analgesia in the preclinical models. Intrathecal 
neostigmine produces analgesia by the inhibition of (endogenous spinal neu-
rotransmitter) acetylcholine destruction via muscarinic and cholinergic receptors 
located at dorsal horn of spinal cord, substantia gelatinosa, and in lesser amounts 
at laminae III and V [50]. There is a high incidence of nausea and vomiting and 
prolongation of recovery from spinal anesthesia following intrathecal administra-
tion of neostigmine, implying that it may not be a useful additive for ambulatory 
spinal anesthesia. The dose of intrathecal neostigmine ranges from 10 to 50 μg with 
the side effects increasing as the dose rises.
8.4 Magnesium sulfate
Magnesium is an N-methyl-D-aspartate (NMDA) antagonist that plays a role in 
moderating calcium influx into neurons. Research has demonstrated that magne-
sium decreases peripheral nerve excitability and enhances the ability of lidocaine to 
raise the excitation threshold of A-beta fibers.
Intrathecal and epidural use of magnesium has shown variable results. It may 
prolong LA/opioid block in women in labor at a dose of 50 mg, but a very high dose 
of magnesium has been reported to produce transient neurological toxicity [17]. 
Farzanegan et al. compared the combination of bupivacaine 12.5 mg and morphine 
2 mg versus bupivacaine 12.5 mg and morphine 2 mg and magnesium 50 mg versus 
placebo epidurally for postoperative analgesia after thoracotomy. These authors 
achieved better analgesia and lower consumption of postoperative morphine 
significantly in the magnesium group [51]. In preeclamptic parturients doses of 
50 mg of intrathecal magnesium with epidural ropivacaine significantly prolonged 
postoperative analgesia compared with 1 mg intrathecal midazolam without any 
complications [52]. In a recent meta-analysis, 11 studies showed that the use of 
epidural magnesium as an adjuvant to bupivacaine is still controversial. Although 
epidural magnesium prolonged the time of the first rescue analgesic and reduced 
the number of patients who required rescue analgesics, as well as the requirement of 
these analgesics, further studies are needed to assess their usefulness [53].
8.5 Sodium bicarbonate
Local anesthetic agents are usually packed at low pH to enhance their shelf 
life. In anesthetic practice, there has been considerable interest in studying the 
effect of pH on the onset, duration, and potency of blockade of LAs. It is proven 
that alkalinization of the LA improves the quality of block by influencing the 
portioning coefficient of anesthetic between aqueous solution and biological 
membranes [20]. Adding sodium bicarbonate to lidocaine decreases the latency of 
onset and enhances the depth of epidural blockade by increasing the concentration 
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(6.10–7.97) h in the IV group (P = 0.61). There was also no significant difference in 
block onset time between the three groups. Dexamethasone 4 mg had no clinically 
significant effect on the duration of sensory block provided by ropivacaine applied 
to the ulnar nerve [44]. The role of dexamethasone as an adjunct in peripheral nerve 
blockades is still unclear.
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Several studies have demonstrated that the presence of COX-2 receptors in 
the dorsal horn of the spinal cord could regulate spinal nociceptive transmission 
[45]. Some studies suggest that administering a COX-2 antagonist directly on the 
central or peripheral nerve might have a better analgesic profile than intravenous 
administration of the same drug [46]. Basically COX-2 inhibitors reduce inflamma-
tion and pain sensation by inhibiting prostaglandin production. However, the role 
of COX-2 in the central nervous system is of more importance. Inflammation can 
induce COX-2 production and will lead to the release of prostanoids that sensitize 
the peripheral nociceptor terminals and produce localized hyperalgesia. It is hence 
thought that the administration of COX-2 antagonist on spinal or peripheral nerves 
may be a more effective mode of pain relief than the intravenous or intramuscular 
route. There are very less studies on this subject. Further research and studies need 
to be conducted to verify the use of NSAIDs as adjuvants.
8. Miscellaneous agents
8.1 Ketamine
Ketamine is a noncompetitive antagonist of NMDA receptor that has been 
shown to have local anesthetic properties. Ketamine acts on more than one region. 
It has actions at monoaminergic receptors, opioid receptors, voltage-sensitive 
calcium channels, and muscarinic receptors, in addition to local anesthetic actions 
through sodium channel blockade. Systemic ketamine causes central summation 
in the second-order pain neuron and decreases severe pain [3, 47, 48]. Epidural 
administration of ketamine at 0.5–1 mg/kg has been shown to reduce intraopera-
tive and postoperative analgesic requirements without increased side effects [25]. 
Preservative-free S(+)-ketamine administered during caudal block for children at 
a dose of 0.5 mg/kg has been shown to extend analgesia time by several hours [17]. 
Intrathecal administration of ketamine is not recommended.
The risk of psychomimetic adverse effects such as hallucinations is a worrying 
factor for most anesthetists, limiting its use, but it can be easily overcome by using 
intravenous benzodiazepines as premedication prior to the block.
8.2 Midazolam
Midazolam, a water-soluble benzodiazepine, an indirect agonist of the gamma-
aminobutyric acid (GABA) receptor, has been studied primarily as an adjuvant for 
neuraxial anesthesia. Addition of preservative-free midazolam to 0.5% hyperbaric 
bupivacaine for subarachnoid block in infraumbilical surgery has been found to 
prolong the duration of effective analgesia as compared to the same concentra-
tion of bupivacaine alone and delays the need for postoperative rescue analgesics 
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without having any reported significant side effects or hemodynamic instability. 
The use of intrathecal midazolam also decreases the incidence of postoperative nau-
sea and vomiting. A small diluted intrathecal dose (1–2.5 mg) of preservative-free 
midazolam is reported to have few systemic side effects and is free of short-term 
neurotoxicity [49]. An infusion of epidural midazolam at 10–20 μg/kg/h for up to 
12 h is considered safe.
8.3 Neostigmine
Neostigmine is an acetylcholinesterase inhibitor that can enhance analgesia by 
acting on muscarinic receptors and increasing endogenous acetylcholine at the 
nerve terminal. It produces spinal analgesia in the preclinical models. Intrathecal 
neostigmine produces analgesia by the inhibition of (endogenous spinal neu-
rotransmitter) acetylcholine destruction via muscarinic and cholinergic receptors 
located at dorsal horn of spinal cord, substantia gelatinosa, and in lesser amounts 
at laminae III and V [50]. There is a high incidence of nausea and vomiting and 
prolongation of recovery from spinal anesthesia following intrathecal administra-
tion of neostigmine, implying that it may not be a useful additive for ambulatory 
spinal anesthesia. The dose of intrathecal neostigmine ranges from 10 to 50 μg with 
the side effects increasing as the dose rises.
8.4 Magnesium sulfate
Magnesium is an N-methyl-D-aspartate (NMDA) antagonist that plays a role in 
moderating calcium influx into neurons. Research has demonstrated that magne-
sium decreases peripheral nerve excitability and enhances the ability of lidocaine to 
raise the excitation threshold of A-beta fibers.
Intrathecal and epidural use of magnesium has shown variable results. It may 
prolong LA/opioid block in women in labor at a dose of 50 mg, but a very high dose 
of magnesium has been reported to produce transient neurological toxicity [17]. 
Farzanegan et al. compared the combination of bupivacaine 12.5 mg and morphine 
2 mg versus bupivacaine 12.5 mg and morphine 2 mg and magnesium 50 mg versus 
placebo epidurally for postoperative analgesia after thoracotomy. These authors 
achieved better analgesia and lower consumption of postoperative morphine 
significantly in the magnesium group [51]. In preeclamptic parturients doses of 
50 mg of intrathecal magnesium with epidural ropivacaine significantly prolonged 
postoperative analgesia compared with 1 mg intrathecal midazolam without any 
complications [52]. In a recent meta-analysis, 11 studies showed that the use of 
epidural magnesium as an adjuvant to bupivacaine is still controversial. Although 
epidural magnesium prolonged the time of the first rescue analgesic and reduced 
the number of patients who required rescue analgesics, as well as the requirement of 
these analgesics, further studies are needed to assess their usefulness [53].
8.5 Sodium bicarbonate
Local anesthetic agents are usually packed at low pH to enhance their shelf 
life. In anesthetic practice, there has been considerable interest in studying the 
effect of pH on the onset, duration, and potency of blockade of LAs. It is proven 
that alkalinization of the LA improves the quality of block by influencing the 
portioning coefficient of anesthetic between aqueous solution and biological 
membranes [20]. Adding sodium bicarbonate to lidocaine decreases the latency of 
onset and enhances the depth of epidural blockade by increasing the concentration 
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of non-ionized drug. The alkaline pH increases the extraneural amount of non-
ionized LA, which is the form that diffuses through the lipid phase of the neural 
membrane leading to more rapid diffusion across perineural tissue barriers [54]. 
CO2 produced by the addition of bicarbonate and bicarbonate per se reduces the 
margin of conduction safety of the neural membrane. Moreover, CO2 penetrates 
into the nerve, where it may determine trapping of the active cationic form of LA by 
acidifying the axoplasm [55].
8.6 Potassium chloride
Movements of ions through the nerve membrane are considered one of the main 
steps in the process of excitation and propagation of nerve stimuli. A nerve impulse 
can be effectively blocked by accumulation of potassium ions outside the neuron 
[56]. Thus, administration of exogenous potassium chloride will reinforce and 
prolong the blockade produced by LA. The addition of potassium chloride to LA 
increases the extracellular concentration and depolarizes the nerve membrane and 
thus blocks the conduction of nerve impulses. Potassium chloride up to 4 mmol/l to 
isotonic solutions of lidocaine enhances the clinical effectiveness of the combina-
tion [57]. The addition of physiological amounts of potassium chloride shortens the 
latency period and prolongs the duration of the blockade.
8.7 Adenosine
Adenosine receptors are expressed on the surface of most cells. Five classes of 
adenosine receptors have been identified. The A1 and A2 receptors are present 
centrally and peripherally, with agonism of the A1 receptor leading to antinocicep-
tive response and that of the A2 receptor being algogenic (i.e., activation results in 
pain). The diagnostic and therapeutic role for intrathecal adenosine in acute and 
chronic pain states is under investigation by several research groups. Intrathecal 
adenosine decreases the spontaneous and evoked pain intensity in patients with 
neuropathic pain involving hyperalgesia/dysesthesia/allodynia [58]. Its interaction 
along with spinal LA is just beginning to be studied.
8.8 Dextran
Low molecular weight dextran (LMWD) was used as an adjuvant with LA 
as early as in the 1970s, but the efficacy of dextrans including LMWD remained 
controversial, as several studies reported an absence of any substantial difference 
in analgesic duration with their addition. That might have been due to poor tech-
niques of regional anesthesia. The use of USG regional blocks has rekindled the use 
of LMWD as adjuvant. The addition of LMWD to a LA and epinephrine mixture 
when used as an infiltration anesthesia [59], or to a LA alone when performing 
a regional block [33], safely prolongs the effective action by reducing systemic 
absorption. More studies need to be conducted to elicit the exact mechanism and 
dosing ranges.
A word of caution regarding the use of additives in LAs is that only preparations 
without preservatives should be used, since these can be neurotoxic. Also, only 
adjuvants in clinically safe doses should be used in order to avoid getting the side 
effects due to excessive dosages.
Hence further research is required to find the exact mechanism of action and 
the safe dose of various adjuvants in order to avoid cardiovascular and neurological 
complications. The practice of making off-label use of drugs without getting FDA 
approval should be discouraged.
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9. Conclusion
Locoregional anesthesia is increasingly used as it has demonstrated efficacy, 
safety, and low costs. Patients and surgeons have realized its enormous advantages. 
Although the use of LA in the management of locoregional anesthesia, postopera-
tive pain, and chronic pain is limited by its duration of action and dose-dependent 
adverse effects that mainly affect the cardiovascular and CNS systems, this has been 
improved with the use of various LA adjuvant drugs. Adjuvants are medications 
that work synergistically with LAs to improve the onset, duration, and quality of 
anesthesia-analgesia in regional techniques, as well as greatly reducing the use of 
opioid analgesics.
The arsenal of adjuvants has developed from adrenaline, opioids, to a large 
group of non-opioid medications with various mechanisms of action. Opioids are 
the most commonly used adjuvants and range from morphine, fentanyl, and sufent-
anil to hydromorphone, buprenorphine, and tramadol with very different results. 
Its use has been limited by its adverse effects such as respiratory depression, nausea, 
vomiting, and pruritus, especially with its neuraxial use. Other adjuvants include 
alpha-2 agonists such as clonidine and dexmedetomidine, midazolam, NMDA 
antagonists including ketamine and magnesium, neostigmine, sodium bicarbonate, 
and nonsteroidal anti-inflammatory drugs. Concern regarding the safety profile of 
these adjuvants is due to their potential neurotoxicity and neurological complica-
tions that may limit their use and require further investigation.
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Current Local Anesthetic 
Applications in Regional 
Anesthesia
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Abstract
Complete anesthesia is often described using terminology that pertains 
to the pharmacodynamic effects of the medications administered. This 
vocabulary often includes akinesia, analgesia, amnesia and hypnosis. Local 
anesthesia is more specific and represents the administration of an amide or 
ester local anesthetic, to affect analgesia, at or around the site of administra-
tion. Anesthesiologists employ a breadth of different clinical techniques that 
utilize local anesthetic medications. These techniques include topical, mucosal, 
endotracheal, intravenous, peripheral nerve block, epidural, and intrathecal 
(spinal) administration. Unique to the fields of anesthesiology and pain medi-
cine, however, is the administration of epidural and intrathecal local anesthetic. 
Together, these routes are jointly referred to as neuraxial anesthesia and are often 
utilized to facilitate surgical intervention, labor analgesia, or pain therapy. The 
history of neuraxial local anesthetic administration is rich and intriguing. The 
anatomy of the spinal cord and surrounding structures is complex and pertinent 
to the pharmacologic discussion of neuraxial local anesthetic administration. 
The pharmacodynamic and pharmacokinetic interactions of local anesthetics, 
when administered via the neuraxial route, are unique and worthy of continued 
investigation. Much has been studied, but there is still more to be discovered. 
These topics will be the focus of our discussion.
Keywords: anesthetics, local, anesthesia, conduction, pharmacology,  
administration and dosage pharmacokinetics, drug-related side effects and adverse 
reactions, injections, spinal, injections, epidural, epidural space, analgesia, epidural, 
anesthesia, epidural, ropivacaine, bupivacaine, lidocaine, chloroprocaine
1. Introduction
Anesthesia is often described using terminology that references the pharma-
codynamic effects of a medication. This terminology often includes akinesia (loss 
or impairment of voluntary movement), analgesia (insensibility to pain), amnesia 
(loss of memory) and hypnosis (any of various conditions that resemble sleep). 
Local anesthesia is more specific and represents the administration of a medica-
tion, typically an amide or ester local anesthetic, to affect analgesia, and possibly 
akinesia, at or around the site of administration. Anesthesiologists employ a 
breadth of different clinical techniques that utilize local anesthetic medications. 
These techniques include topical, mucosal, endotracheal, intravenous, peripheral 
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nerve block, epidural, and intrathecal (spinal) administration. Unique to the 
fields of anesthesiology and pain medicine, however, is the administration of 
local anesthetics via the epidural and intrathecal routes. Together, these routes 
are jointly referred to as neuraxial anesthesia and are often utilized to facilitate 
surgical intervention, labor analgesia, or pain therapy. Much has been studied, 




To understand the pharmacokinetic, pharmacodynamic, and pharmacothera-
peutic activity of local anesthetics in this region, one needs a thorough understand-
ing of neuraxial anatomy. The term neuraxis refers to the axial unpaired portion 
of the central nervous system. Of great importance to the discussion of neuraxial 
anesthesia is the spinal cord, nerve roots, and the meninges and vertebral bodies 
that house and protect them.
2.1.1 Membranes
The spinal cord is surrounded by three protective membranes which delineate 
potential and actual neuraxial spaces. Listed from outermost to innermost, these 
membranes are termed meninges and refer to the dura mater, the arachnoid mater 
and the pia mater. The pia mater directly envelops the spinal cord (Figure 1). 
Epidural refers to the potential space between the ligamentum flavum and the outer 
surface of the dura mater. Subdural refers to a potential space between the dura 
mater and the arachnoid mater. The term intrathecal refers to the thecal sac or the 
dura mater enclosure of the cerebrospinal fluid-filled sub-arachnoid (i.e., sub-
arachnoid mater) space. This space remains outside of the pia mater. These spaces 
are surrounded by the bony architecture created by the vertebrae.
Figure 1. 
Meninges—protective membranes of the spinal cord.
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2.1.2 Bones and ligaments
The vertebral column protects the spinal cord and provides support for standing 
and walking. The vertebral column is easily recognized by its three curvatures (cer-
vical lordosis, thoracic kyphosis, and lumbar lordosis) and five sections, to include 
the cervical, thoracic, lumbar, sacral and coccygeal regions. Each region consists 
of seven, twelve, five, five, and four vertebrae respectively for a total of 33. Each 
vertebra consists of two components: a vertebral body and the remaining vertebral 
arch. The vertebral arch is composed of several components to include laminae, 
pedicles, spinous, and transverse processes (Figure 2). Access to the epidural and 
intrathecal space for neuraxial local anesthetic administration is obtained via the 
spaces between each vertebra. Variation in bony structure between lumbar, tho-
racic, and cervical vertebrae will dictate the approach to these specific regions (e.g., 
the greater downward angle of the thoracic spinous processes necessitates a steeper 
midline approach). Between each of the vertebra are several ligaments that are also 
typically traversed when administering neuraxial local anesthetics. From superficial 
to deep are the supraspinous ligament, interspinous ligament, and the ligamentum 
flavum (named for its yellow pigmentation). The interspinous ligament is affixed 
to the inferior and superior aspect of the spinous processes. The supraspinous 
ligament attaches to the tips of the vertebral spinous processes (Figure 3) and runs 
from the level of C7 to the sacrum.
2.1.3 Vasculature/adipose tissue
The epidural space contains several anatomic structures and tissues to include 
vasculature, nerve roots, and adipose tissue. The internal vertebral venous plexus, 
also known as the epidural venous plexus, assists with vertebral venous drainage 
and serves as an alternate conduit for venous return in the setting of compro-
mised caval blood flow. The plexus consists of two larger anterior longitudinal 
veins, located in the anterior aspect of the spinal canal, and two smaller posterior 
longitudinal veins. These veins are connected by transverse veins, completing 
the plexus. The longitudinal veins are located more posteriorly at the level of the 
cervical and lumbar vertebrae, and more posterolaterally at the level of the thorax 
[1]. The plexus is surrounded by epidural adipose tissue. Combined with reported 
Figure 2. 
Human vertebral column and vertebrae. The human vertebral column consists of 33 vertebrae.
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nerve block, epidural, and intrathecal (spinal) administration. Unique to the 
fields of anesthesiology and pain medicine, however, is the administration of 
local anesthetics via the epidural and intrathecal routes. Together, these routes 
are jointly referred to as neuraxial anesthesia and are often utilized to facilitate 
surgical intervention, labor analgesia, or pain therapy. Much has been studied, 
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that house and protect them.
2.1.1 Membranes
The spinal cord is surrounded by three protective membranes which delineate 
potential and actual neuraxial spaces. Listed from outermost to innermost, these 
membranes are termed meninges and refer to the dura mater, the arachnoid mater 
and the pia mater. The pia mater directly envelops the spinal cord (Figure 1). 
Epidural refers to the potential space between the ligamentum flavum and the outer 
surface of the dura mater. Subdural refers to a potential space between the dura 
mater and the arachnoid mater. The term intrathecal refers to the thecal sac or the 
dura mater enclosure of the cerebrospinal fluid-filled sub-arachnoid (i.e., sub-
arachnoid mater) space. This space remains outside of the pia mater. These spaces 
are surrounded by the bony architecture created by the vertebrae.
Figure 1. 
Meninges—protective membranes of the spinal cord.
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2.1.2 Bones and ligaments
The vertebral column protects the spinal cord and provides support for standing 
and walking. The vertebral column is easily recognized by its three curvatures (cer-
vical lordosis, thoracic kyphosis, and lumbar lordosis) and five sections, to include 
the cervical, thoracic, lumbar, sacral and coccygeal regions. Each region consists 
of seven, twelve, five, five, and four vertebrae respectively for a total of 33. Each 
vertebra consists of two components: a vertebral body and the remaining vertebral 
arch. The vertebral arch is composed of several components to include laminae, 
pedicles, spinous, and transverse processes (Figure 2). Access to the epidural and 
intrathecal space for neuraxial local anesthetic administration is obtained via the 
spaces between each vertebra. Variation in bony structure between lumbar, tho-
racic, and cervical vertebrae will dictate the approach to these specific regions (e.g., 
the greater downward angle of the thoracic spinous processes necessitates a steeper 
midline approach). Between each of the vertebra are several ligaments that are also 
typically traversed when administering neuraxial local anesthetics. From superficial 
to deep are the supraspinous ligament, interspinous ligament, and the ligamentum 
flavum (named for its yellow pigmentation). The interspinous ligament is affixed 
to the inferior and superior aspect of the spinous processes. The supraspinous 
ligament attaches to the tips of the vertebral spinous processes (Figure 3) and runs 
from the level of C7 to the sacrum.
2.1.3 Vasculature/adipose tissue
The epidural space contains several anatomic structures and tissues to include 
vasculature, nerve roots, and adipose tissue. The internal vertebral venous plexus, 
also known as the epidural venous plexus, assists with vertebral venous drainage 
and serves as an alternate conduit for venous return in the setting of compro-
mised caval blood flow. The plexus consists of two larger anterior longitudinal 
veins, located in the anterior aspect of the spinal canal, and two smaller posterior 
longitudinal veins. These veins are connected by transverse veins, completing 
the plexus. The longitudinal veins are located more posteriorly at the level of the 
cervical and lumbar vertebrae, and more posterolaterally at the level of the thorax 
[1]. The plexus is surrounded by epidural adipose tissue. Combined with reported 
Figure 2. 
Human vertebral column and vertebrae. The human vertebral column consists of 33 vertebrae.
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disruptions in the posterior fusions of the left and right ligamentum flavum, the 
adipose tissue and vasculature serve to provide variation in the construct of this 
potential space when expanded by local anesthetic.
2.2 Intrathecal administration
2.2.1 History of spinal anesthesia
Various local anesthetics have been investigated for surgical anesthesia (Table 1). 
These are divided into two primary categories of local anesthetics (i.e., esters and 
amides). Initial studies began with the investigation of the spinal effects of esters 
such as cocaine. This was followed by investigation of amylocaine (no longer utilized 
in clinical practice), procaine (also known as Novocain), dibucaine and tetracaine. 
Of note, amylocaine was first synthesized circa 1903 and is referenced as the first 
synthetic local anesthetic to be utilized in spinal anesthesia [2]. This was followed 
by the synthesis of procaine (circa 1904) with subsequent early twentieth-century 
investigation into its intrathecal administration. Procaine likely found greater 
clinical application as a result of the presumed systemic effects (to include physical 
dependence) and presumed neurotoxic effects of spinal cocaine administration [3]. 
Of note, however, is the side effect profile of procaine, which commonly includes 
nausea, vasomotor paralysis, and a greater risk for anaphylaxis associated with its 
metabolite para-aminobenzoic acid (PABA) [3, 4]. The period of 1930 through the 
early 1940s saw the discovery and intrathecal employment of longer acting local 
anesthetics (i.e., dibucaine and tetracaine). In 1930, Jones described his experiences 
with the administration of dibucaine (also known as cinchocaine or nupercaine) 
[5, 6]. With a shorter duration of action compared to dibucaine, a more favorable 
ratio of sensory to motor fiber blockade, less sympathetic blockade than procaine, 
and less perceived toxicity, initial studies into the administration of tetracaine 
showed significant promise [7, 8]. In 1945, lidocaine (originally called Xylocaine 
as it is a xylidine derivative) was initially administered as a spinal anesthetic. As a 
Figure 3. 
Spinal ligaments—this file is licensed under the Creative Commons Public Domain Mark 1.0—https://
commons.wikimedia.org/wiki/File:Gray301.png.
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short-acting amide local anesthetic, its pharmacologic profile was deemed ideal for 
short to moderate duration operative procedures [9]. Subsequently, in 1946, procaine 
was used to synthesize chloroprocaine. Initial reports for the use of chloroprocaine 
for spinal anesthesia were positive [10], and chloroprocaine was approved for spinal 
anesthesia by the United States Food and Drug Administration in 1955. With rapid 
ester hydrolysis neutralizing the effects of chloroprocaine, it became the local 
anesthetic of choice for the fastest onset and fastest resolution of spinal blockade. 
The rapid ester hydrolysis also created an environment in which almost twice the 
amount of chloroprocaine could be administered, compared to procaine, without 
toxicity. The improved safety profile also likely contributed to the popularity of this 
medication [10]. Despite investigations into other spinally administered local anes-
thetics, these three local anesthetics (i.e., chloroprocaine, lidocaine, and tetracaine) 
would find widespread use for short duration, moderate duration, and long duration 
operative procedures for the next half of a century. Shortly after the approval of 
chloroprocaine, mepivacaine (1956) [11] and prilocaine (1965) [12] would see their 
first usage in spinal anesthesia. These two medications, both xylidine derivatives as 
well, demonstrate similar potency when compared to lidocaine [9]. With subsequent 
studies demonstrating a risk for the development of transient neurologic symptoms 
associated with intrathecal lidocaine administration, it would seem that mepivacaine 
and prilocaine are currently undergoing further investigation and may serve as 
alternatives to lidocaine for ambulatory or surgical procedures of short to moderate 
duration [13–15]. The mid-1960s discovery, synthesis, and spinal administration 
of bupivacaine, an intermediate to long-acting amide local anesthetic, resulted in 
widespread popular clinical application [16, 17]. When evidence surfaced regarding 
the potential for racemic bupivacaine toxicity, two (S)-enantiomers of bupivacaine 
were researched and scrutinized for spinal anesthesia administration. Initial studies 
utilizing spinal ropivacaine (S-enantiomer of bupivacaine) were conducted in the 
early 1990s [18–20]. Additional studies regarding the other pure (S)-enantiomer of 
bupivacaine, levobupivacaine, were initiated in 1999 [21–23]. Intrathecal administra-
tion of both levobupivacaine and ropivacaine continue.
Table 1. 
Local anesthetics for spinal anesthesia.
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first usage in spinal anesthesia. These two medications, both xylidine derivatives as 
well, demonstrate similar potency when compared to lidocaine [9]. With subsequent 
studies demonstrating a risk for the development of transient neurologic symptoms 
associated with intrathecal lidocaine administration, it would seem that mepivacaine 
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2.2.2 Pharmacokinetics of intrathecal local anesthetic administration
The exact mechanism and site of action of local anesthetics in the intrathecal 
space are not clear. Some evidence suggest that local anesthetics work to directly 
inhibit Na+ and K+ ion channel conduction at the peripheral dorsal nerve root and the 
spinal cord within the thecal sac [9, 24]. For this to occur, the local anesthetic must be 
absorbed by the neuron and bind to an intracellular site on the Na+/K+ ion channels. 
This may only occur when the channels are seen in a conformation associated with 
depolarization. Thus, the activity of local anesthetics is referred to as “use-dependent” 
activity [25, 26]. Understandably, there are a minimum number of axonal Na+/K+ 
channels which must depolarize to continue the propagation of the neuronal impulse. 
The term “conduction safety” has been utilized to refer to the overabundance of sum-
mation action potential necessary at the axonal regional level to facilitate continued 
propagation of this impulse. Due to the decreased conduction safety at the telodendron 
of the axon, as compared to the trunk, it is believed that the local anesthetic blockade 
has a greater effect in this region [27]. Recognizing the complexity of the neuro-
physiology of pain, this view of an isolated Na+/K+ channel mechanism may be too 
simplistic [24]. Primary, secondary, and tertiary synaptic activity occurs as sensory 
input is transmitted from the peripheral nervous system to the central nervous system 
and ultimately to the primary sensory cortex of the brain. It is widely recognized that 
neuronal transmission relies on both excitatory and inhibitory post-synaptic potentials 
for inter-neuronal transmission. Liu et al. summarized the current understanding of 
the research, which considers a multitude of potential sites for the activity of spinally 
administered local anesthetics, to include neuronal transmission at the level of the 
dorsal and anterior horn of the spinal cord [9]. It has been postulated that there may 
be a role for calcium ion channel manipulation (low voltage and high voltage L-type 
calcium channels) in this region [28]. Furthermore, it has been proposed that local 
anesthetics administered in the intrathecal space may contribute to the inhibition of 
substance P activity at the level of the dorsal root ganglion and the dorsal horn of the 
spinal cord [29]. Local anesthetics may also contribute to γ-aminobutyric acid inhibi-
tory potentiation resulting in the inhibition of sensory transmission [30].
Even more fascinating is the discussion and research regarding alteration in elec-
trical “coding” by disruption or alteration in “after-potentials” or “after-oscillations.” 
This begins with interruption in neuronal transmission by an incomplete local 
anesthetic neuronal blockade due to sub-blocking concentrations of local anesthetic. 
Inhibition of sequential firing, or the depolarization of specific neurons, or disrup-
tion of weighted telodendron discharge patterns on a single neuron may contribute 
to changes in temporal excitability patterns sufficient to disrupt sensory input [27].
The extent of clinical activity depends upon several pharmacokinetic fac-
tors which can modify the overall visible clinical effects of the local anesthetic. 
By report, there are over 25 different factors, some theoretical, which can affect 
the spread and distribution of local anesthetics within the neuraxis [31]. Patient 
characteristics include age, height, intra-abdominal pressure, patient position, 
CSF currents, and CSF volume. Local anesthetic characteristics include potency, 
dosage, baricity, lipid solubility, degree of protein binding, and the log of the acid 
dissociation constant (i.e., the pKa). These local anesthetic characteristics further 
determine the amount of local anesthetic absorption (neuronal, myelin, adipose, or 
vasculature) and will ultimately contribute to the observed clinical effect.
2.2.2.1 Cerebrospinal fluid
The intrathecal route of local anesthetic administration is unique in that it bypasses 
first pass metabolism by the liver and mechanically penetrates the blood-brain 
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barrier. This deposition into the cerebrospinal fluid generates unique pharmacokinetic 
considerations. As Greene et al. states, “Uptake of local anesthetic injected into the 
CSF determines which neuronal functions are affected, elimination from the CSF 
determines the duration, and distribution within the CSF determines the extent of 
altered neuronal function” [31]. A discussion of CSF is therefore critical.
Cerebrospinal fluid is maintained within the ventricular system of the brain, to 
include the cisterns and the intracranial subarachnoid space, as well as the spinal 
subarachnoid space (i.e., the thecal sac). There is approximately 150 ml of cerebro-
spinal fluid in the healthy, adult patient. CSF is continuously produced by the cho-
roid plexus, and absorbed via arachnoid villi, at a rate of ~20 ml/h with 400–600 ml 
of CSF generated daily [32]. Decreased CSF volume at the time of injection increases 
the concentration of local anesthetic in the administered region and influences the 
clinical effect. Conditions which increase intra-abdominal pressure, and redistribute 
CSF, will mimic CSF volume depletion (i.e., obesity, pregnancy, etc.), amplify CSF 
oscillation, and potentially modify the effects of the local anesthetic as well [33].
2.2.2.2  Absorption, mechanism, onset and duration of action of spinal local 
anesthetics
The uptake or absorption of local anesthetic into the vasculature also limits 
the distribution and clinical effects of spinal anesthesia. As vascular absorption is 
greatest in the epidural space, and the meninges are permeable to local anesthetic, a 
concentration gradient is established between the spinal cord, intrathecal  
space, and the epidural space [34]. While there is little intrathecal vascular absorp-
tion, some local anesthetic may penetrate the pia mater and be absorbed by vascula-
ture in the spinal cord directly. It is also believed that a more efficient mechanism is 
vascular absorption via the increased surface area in the perivascular space (where 
blood vessels perforate the pia mater) [24, 34]. Of additional interest is consider-
ation of the effects that local anesthetics have on spinal vasculature. Bupivacaine 
and ropivacaine have been shown to decrease spinal blood flow, whereas tetracaine 
and lidocaine have been shown to increase spinal blood flow [35, 36].
With regard to absorption, local anesthetic must be in an electrically neutral 
configuration (i.e., as an uncharged hydrophobic form of the medication) to 
penetrate neuronal tissue. This concept necessitates further discussion of acid 
dissociation. Becker and Reed provide a summary for reference [37]. In order to 
maintain stability in solution, local anesthetics are formulated as a hydrochloride 
salt creating a quaternary amine formulation that is electrically charged to enable 
water solubility (hydrophilic). The local anesthetic must, therefore, revert to the 
uncharged lipophilic (hydrophobic) tertiary amine form for neuronal penetration 
(i.e., the electrically neutral form). The more a local anesthetic dissociates and 
releases hydrogen ions at the body’s physiologically neutral pH of 7.4, the more local 
anesthetic will remain in the tertiary form and the greater the neuronal absorption 
(Figure 4). Understanding the resting pH of the medication is useful, as is under-
standing hydrogen ion dissociation. The dissociation equilibrium between hydrogen 
ions and the deprotonated local anesthetic constitutes the equilibrium that deter-
mines the Ka (acid dissociation constant) of the drug. It is expressed as a ratio of 
hydrogen ion dissociation at equilibrium by the following equation:
  K a =   [B] [H+]  _BH+ (1)
Ka values are typically very small (i.e., 1 × 10−3), making comparison and 
manipulation more challenging. However, the inverse logarithmic value of the 
Ka can be utilized to express pKa. These pKa values represent the log of the Ka 
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ture in the spinal cord directly. It is also believed that a more efficient mechanism is 
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configuration (i.e., as an uncharged hydrophobic form of the medication) to 
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dissociation. Becker and Reed provide a summary for reference [37]. In order to 
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water solubility (hydrophilic). The local anesthetic must, therefore, revert to the 
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(acid dissociation constant), or the pH at which 50% of the drug is in the proton-
ated electrically charged hydrophilic quaternary amine form, and 50% is in the 
uncharged, lipophilic tertiary amine form. Values range from 7.6 ➔ ~9.0, meaning 
that no local anesthetics reach complete equilibrium within the body’s normal pH 
range of 7.35–7.45. The pKa values for mepivacaine (~7.6), prilocaine (~7.9) and 
lidocaine (~7.9) most closely approximate physiologic pH, suggesting that their 
neuronal absorption occurs more quickly, leading to faster onset of clinical symp-
toms. The pKa values of bupivacaine (~8.1) and ropivacaine (~8.1) have a somewhat 
slower onset of clinical effect [37].
In addition to neuronal and vascular absorption, the lipid absorption of a local 
anesthetic also plays a role in the time of onset—the greater the lipid solubility, the 
faster the myelin/neuronal penetration. As reported by Becker and Reed, however, 
this appears only to be true in vitro. They hypothesize that the higher lipid solubility 
“may impede dispersion throughout tissue fluids.” When applied in vivo, the lipid 
solubility appears to promote adipose tissue absorption over neuronal absorption 
leading to a delayed onset of clinical effect [37]. This helps to explain the clinically 
observed pharmacologic effects of long-acting local anesthetics (i.e., bupivacaine/
ropivacaine/tetracaine) versus shorter-acting local anesthetics such as lidocaine 
and mepivacaine. Lidocaine and mepivacaine have a much faster onset of action 
compared to bupivacaine and ropivacaine when administered intrathecally (despite 
the increased lipid solubility of bupivacaine/ropivacaine).
The pharmacokinetic variable that appears to have the greatest influence on 
the duration of action is the degree of intrathecal protein binding. Clement et al. 
demonstrated that the non-protein bound or unbound fraction of intrathecal bupi-
vacaine is lower than lidocaine. Because bupivacaine has a higher degree of protein 
binding, it has a longer observed clinical effect [38].
2.2.3 Pharmacodynamics of intrathecal local anesthetic administration
The nature of the surgical procedure, or site of pain origination, will dictate 
pursuit of a specific distribution of anesthesia. The distributed effect of intrathe-
cal local anesthetic administration is often measured via perceived differences in 
sensation of temperature or sharp tactile stimulation. Each spinal nerve provides a 
specific anatomic distribution of sensation, or dermatome, which may be measured. 
In addition to the desired clinical sensory blockade, pharmacodynamic effects may 
be seen throughout several organ systems to include the cardiovascular, respiratory, 
gastrointestinal, renal, and immune systems.
Figure 4. 
Mechanism of action of local anesthetics—this file is licensed under the Creative Commons Attribution-Share 
Alike 3.0 Unported license. https://commons.wikimedia.org/wiki/File:LA_andNaV.svg.
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2.2.3.1 Cardiovascular
Undoubtedly, the spinal administration of local anesthesia can result in hypo-
tension. This is largely believed to be secondary to a sympathetic nervous system 
blockade in the region of the pre-ganglionic neuron prior to its synapse on the sym-
pathetic chain ganglion. This blockade results in vascular dilation, which produces a 
decrease in systemic vascular resistance (SVR) (venous > arterial). This decrease in 
SVR, and the associated decrease in preload, may stimulate a reflexive baroreceptor 
response increasing the heart rate to maintain cardiac output. However, it has been 
well reported that patients may also experience a different type of cardiac reflex 
known as the Reverse Bainbridge (atrial), or Bezold-Jarisch reflex (ventricular). 
These reflexes stem from the recognition of a decreased preload to either the atria 
or ventricle, which results in reflexive bradycardia to slow the heart and allow for 
increased filling time. This ultimately results in a lower cardiac output.
Additionally, the distribution of local anesthetic can block cardiac accelerator fibers 
which stem from thoracic sympathetic ganglia T1-T4, further preventing the reflexive 
cardiac baroreceptor response. Due to the complexity of these interacting variables, 
changes to cardiac output with spinal anesthesia are also variable. Ultimately, spinal 
anesthesia often results in a decrease in mean arterial pressure (MAP), though this is 
not necessarily true for pre-eclamptic patients with non-sympathetically mediated 
elevations in blood pressure. When untreated, depressed cardiovascular effects may 
result in decreased cerebral perfusion, nausea/vomiting, and cardiovascular collapse.
2.2.3.2 Respiratory
In 1991, Steinbrook et al. investigated the effects of spinal lidocaine and bupivacaine 
on resting pulmonary function in eleven volunteers. They identified a slight decrease in 
end-tidal CO2 (34 mmHg ➔ 31 mmHg) with an inverse age correlation (i.e., younger 
patients had a greater drop in end-tidal CO2). They reported the absence of significant 
change in tidal volume, respiratory rate, and minute ventilation, hypothesizing instead 
an increase in dead space ventilation associated with spinal administration. They fur-
ther comment on the paralysis of abdominal musculature leading to an increase in chest 
wall compliance and a decrease in mechanical work of breathing. It is interesting to 
note their comments regarding increased chest wall compliance and increased respira-
tory frequency variation [39]. Of note, they also allude to spinal level deafferentation of 
the chest wall receptors, but make no specific reference to intercostal involvement.
2.2.3.3 Renal
It is well recognized that the kidney receives direct sympathetic innervation 
from renal sympathetic nerve fibers derived from the sympathetic chain ganglia. In 
addition, the kidney auto-regulates its blood flow utilizing humoral/endocrine fac-
tors released as a result of changes sensed in the macula densa. It is believed that this 
mechanism functions both interdependently and independently from sympathetic 
function, enabling the preservation of renal blood flow in the absence of sympa-
thetic directive. As described by Smith et al. [40], “It is possible to assume that the 
renal vascular bed acquires autonomy de novo only as a consequence of denerva-
tion, but in view of the rapidity and smoothness of anesthetic denervation any such 
assumption seems quite superfluous.” It is now understood that there is little effect 
on overall renal function as a result of spinal or epidural sympathetic blockade from 
local anesthetic administration. Glomerular filtration and renal blood flow are 
recognized to only decrease slightly in direct relation to decreases in mean arterial 
pressure associated with the sympathetic blockade [40–42].
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(acid dissociation constant), or the pH at which 50% of the drug is in the proton-
ated electrically charged hydrophilic quaternary amine form, and 50% is in the 
uncharged, lipophilic tertiary amine form. Values range from 7.6 ➔ ~9.0, meaning 
that no local anesthetics reach complete equilibrium within the body’s normal pH 
range of 7.35–7.45. The pKa values for mepivacaine (~7.6), prilocaine (~7.9) and 
lidocaine (~7.9) most closely approximate physiologic pH, suggesting that their 
neuronal absorption occurs more quickly, leading to faster onset of clinical symp-
toms. The pKa values of bupivacaine (~8.1) and ropivacaine (~8.1) have a somewhat 
slower onset of clinical effect [37].
In addition to neuronal and vascular absorption, the lipid absorption of a local 
anesthetic also plays a role in the time of onset—the greater the lipid solubility, the 
faster the myelin/neuronal penetration. As reported by Becker and Reed, however, 
this appears only to be true in vitro. They hypothesize that the higher lipid solubility 
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ropivacaine/tetracaine) versus shorter-acting local anesthetics such as lidocaine 
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compared to bupivacaine and ropivacaine when administered intrathecally (despite 
the increased lipid solubility of bupivacaine/ropivacaine).
The pharmacokinetic variable that appears to have the greatest influence on 
the duration of action is the degree of intrathecal protein binding. Clement et al. 
demonstrated that the non-protein bound or unbound fraction of intrathecal bupi-
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2.2.3 Pharmacodynamics of intrathecal local anesthetic administration
The nature of the surgical procedure, or site of pain origination, will dictate 
pursuit of a specific distribution of anesthesia. The distributed effect of intrathe-
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gastrointestinal, renal, and immune systems.
Figure 4. 
Mechanism of action of local anesthetics—this file is licensed under the Creative Commons Attribution-Share 
Alike 3.0 Unported license. https://commons.wikimedia.org/wiki/File:LA_andNaV.svg.
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2.2.3.1 Cardiovascular
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pathetic chain ganglion. This blockade results in vascular dilation, which produces a 
decrease in systemic vascular resistance (SVR) (venous > arterial). This decrease in 
SVR, and the associated decrease in preload, may stimulate a reflexive baroreceptor 
response increasing the heart rate to maintain cardiac output. However, it has been 
well reported that patients may also experience a different type of cardiac reflex 
known as the Reverse Bainbridge (atrial), or Bezold-Jarisch reflex (ventricular). 
These reflexes stem from the recognition of a decreased preload to either the atria 
or ventricle, which results in reflexive bradycardia to slow the heart and allow for 
increased filling time. This ultimately results in a lower cardiac output.
Additionally, the distribution of local anesthetic can block cardiac accelerator fibers 
which stem from thoracic sympathetic ganglia T1-T4, further preventing the reflexive 
cardiac baroreceptor response. Due to the complexity of these interacting variables, 
changes to cardiac output with spinal anesthesia are also variable. Ultimately, spinal 
anesthesia often results in a decrease in mean arterial pressure (MAP), though this is 
not necessarily true for pre-eclamptic patients with non-sympathetically mediated 
elevations in blood pressure. When untreated, depressed cardiovascular effects may 
result in decreased cerebral perfusion, nausea/vomiting, and cardiovascular collapse.
2.2.3.2 Respiratory
In 1991, Steinbrook et al. investigated the effects of spinal lidocaine and bupivacaine 
on resting pulmonary function in eleven volunteers. They identified a slight decrease in 
end-tidal CO2 (34 mmHg ➔ 31 mmHg) with an inverse age correlation (i.e., younger 
patients had a greater drop in end-tidal CO2). They reported the absence of significant 
change in tidal volume, respiratory rate, and minute ventilation, hypothesizing instead 
an increase in dead space ventilation associated with spinal administration. They fur-
ther comment on the paralysis of abdominal musculature leading to an increase in chest 
wall compliance and a decrease in mechanical work of breathing. It is interesting to 
note their comments regarding increased chest wall compliance and increased respira-
tory frequency variation [39]. Of note, they also allude to spinal level deafferentation of 
the chest wall receptors, but make no specific reference to intercostal involvement.
2.2.3.3 Renal
It is well recognized that the kidney receives direct sympathetic innervation 
from renal sympathetic nerve fibers derived from the sympathetic chain ganglia. In 
addition, the kidney auto-regulates its blood flow utilizing humoral/endocrine fac-
tors released as a result of changes sensed in the macula densa. It is believed that this 
mechanism functions both interdependently and independently from sympathetic 
function, enabling the preservation of renal blood flow in the absence of sympa-
thetic directive. As described by Smith et al. [40], “It is possible to assume that the 
renal vascular bed acquires autonomy de novo only as a consequence of denerva-
tion, but in view of the rapidity and smoothness of anesthetic denervation any such 
assumption seems quite superfluous.” It is now understood that there is little effect 
on overall renal function as a result of spinal or epidural sympathetic blockade from 
local anesthetic administration. Glomerular filtration and renal blood flow are 
recognized to only decrease slightly in direct relation to decreases in mean arterial 
pressure associated with the sympathetic blockade [40–42].
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2.2.3.4 Digestive
Sympathetic nervous system blockade as a consequence of spinal local anesthetic 
administration leads to unimpeded parasympathetic nervous system activity and 
gastrointestinal hyperactivity. Hypotension encountered as a result of spinal local 
anesthesia may lead to gastrointestinal ischemia and the release of emetogenic sub-
stances such as serotonin. Furthermore, hypotension may lead to hypoperfusion of 
the area postrema of the medulla (brain stem—known chemoreceptor trigger zone 
for vomiting) resulting in increased serotonin release. The combination of these 
factors may contribute to intraoperative/postoperative nausea and vomiting. It is 
also important to recognize that hypotension associated with spinal local anesthetic 
administration may result in hypoperfusion of the liver. Because hepatic blood 
flow is not auto-regulated, this low perfusion pressure may result in impairment of 
metabolic functions to include subsequent drug metabolism [43].
2.2.3.5 Immune
Regarding the anti-inflammatory and immunomodulatory effects of local anes-
thetics, Cassuto et al. wrote that it is well recognized that the innate and adaptive 
immune systems contribute to the destruction of foreign substances and tissue repair 
following injury. The immune cells involved in these processes include neutrophils, 
macrophages, monocytes, mast cells, T-cells, and B-cells. These cells must undergo 
chemotactic targeting to the area of injury, adhere to blood vessel walls, traverse the 
blood vessel wall into the tissue, engulf the offending agent, and destroy it. Local 
anesthetics have been thought to interfere with every step of this process. They inhibit 
leukocyte adherence to the vascular endothelium by possibly interrupting interactions 
between leukocyte cell membrane integrins and their receptors (cellular adhesion 
molecules—CAMs) expressed on the vascular endothelium. Similarly, they inhibit 
the trans-endothelial migration and motility of leukocytes and may interfere with 
the “priming” of leukocytes, preventing their full pathogen-destroying capability by 
decreasing their free radical production. It has been suggested that local anesthetics 
further interrupt the normal cellular actomyosin filament activity resulting in disrup-
tion of the ability of the leukocyte to modulate the cell membrane to engulf the offend-
ing agent for lysosomal destruction. Furthermore, local anesthetics are responsible for 
a dose-dependent decrease in the release of lysosomal enzymes [44, 45].
Of additional interest are the anti-inflammatory properties of local anesthetics 
that are believed to stem from their inhibition of arachidonic acid derivative synthesis, 
their release of histamine, and their attenuation of cytokine release (i.e., IL-1, IL-6, 
IL-8, TNF-alpha, etc.). Inhibition of phospholipase A2 synthesis prevents arachidonic 
acid cleavage; inhibition of prostaglandin E1/E2 synthesis has been attributed to a 
potential reduction in inflammatory pain; inhibition of thromboxane A2 synthesis 
results in decreased platelet aggregation; and inhibition of leukotriene B4 synthesis 
has been implicated in the reduction of capillary hyper-permeability, resulting in 
decreased edema formation due to inflammatory plasma extravasation. Based on 
this aggregate model of cell membrane interference (i.e., ion channel inhibition, cell 
membrane protein cleavage, cell membrane receptor binding and inhibition, cell 
membrane actomyosin function disruption, etc.) researchers have targeted investiga-
tion of specific local anesthetics for their antibacterial and antiviral effects [44, 46].
2.2.3.6 Factors which effect intrathecal spread
Several factors are considered relevant to the intrathecal spread of local anes-
thetic. These factors may be divided into three categories: factors specific to the 
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local anesthetic solution, factors specific to the patient, and factors specific to the 
procedure itself. All of these have been described in an article by Hocking and 
Wildsmith which may be referenced for additional information [47].
With regard to the local anesthetic solution, the degree of intrathecal spread is 
related to the baricity, temperature, viscosity, and dosage of local anesthetic admin-
istered. Baricity is the ratio of substance density to CSF density. As such, there are 
hyperbaric, hypobaric or isobaric (i.e., denser than cerebrospinal fluid, less dense 
than cerebrospinal fluid, or similar density to cerebrospinal fluid) formulations of 
local anesthetic solution. Upon injection, baricity affects the caudal versus cephalad 
spread of solution within the CSF. Baricity, in combination with patient position-
ing, will ultimately determine the spread and distribution of local anesthetic within 
the thecal sac. Temperature also affects the density of a local anesthetic solution 
such that a refrigerated or warmed solution may possess a baricity different from its 
manufactured specification. Investigations evaluating the additional effect of local 
anesthetic solution viscosity on intrathecal spread suggest that increased viscosity is 
associated with increased local anesthetic distribution within the intrathecal space 
[48]. Finally, there is a relationship between dosage, volume, and concentration. 
Recognizably, changes in any of these variables influence the others as they pertain 
to the specific mixture of a local anesthetic solution prepared for administration. 
Though several studies have been performed to evaluate these factors, dosage seems 
to have the most significant impact on the intrathecal spread of local anesthetic.
In discussing patient factors, patient height, position, and age all contribute 
to the spread of intrathecal local anesthetic. Though it may affect spread, gross 
height is not a reliable characteristic for determination of local anesthetic dosing. 
Hartwell et al. demonstrated a correlation between vertebral column length and 
the level of local anesthetic sensory blockade. As a surrogate for height, the authors 
suggest the use of vertebral column length instead. This recommendation is based 
on the recognition that there may be patient height differences attributed to differ-
ences in extremity length, which have no reference value with regard to thecal sac 
dimensions or cerebrospinal fluid volume. Regarding thecal sac characteristics, it 
is recognized that the vertebral column curvatures (and thus variations in thecal 
sac positioning) influence the intrathecal spread of local anesthetic. The interplay 
between lumbar lordosis, thoracic kyphosis, and baricity helps to explain the 
largely “dependent” thoracic distribution of hyperbaric local anesthetic solutions 
after intrathecal injection and positioning of a patient in the supine position. With 
regard to baricity, it was demonstrated that the density of CSF varies between 
patients. CSF in women is less dense than in men. It is less dense in pregnant women 
than in non-pregnant women and is less dense in pre-menopausal women than 
in post-menopausal women. This fact has unique importance in that a significant 
portion of surgeries performed under spinal anesthesia are cesarean sections in pre-
menopausal, pregnant women who can be expected to have decreased CSF density. 
It has been further demonstrated that extremes of age can impact the spread of 
intrathecal local anesthetic. Veering et al. reported on the increasing length of time 
required for the maximum upper level of analgesia to be seen with advancing age. 
This was associated with an inverse onset of motor blockade relationship such that a 
faster onset of motor blockade was seen with advancing age. Furthermore, the time 
to peak plasma concentration of local anesthetic was increased, and the total plasma 
clearance decreased with advancing age [49–52].
Finally, procedural components may have an impact on the distribution of local 
anesthetic. It is known that the initial pressure generated by the injection of local 
anesthetic creates waves within the CSF. It was previously believed that generation of 
additional fluid waves, via a technique known as barbotage, would facilitate greater 
spread. Several investigations have demonstrated that barbotage does not affect the 
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local anesthetic solution, factors specific to the patient, and factors specific to the 
procedure itself. All of these have been described in an article by Hocking and 
Wildsmith which may be referenced for additional information [47].
With regard to the local anesthetic solution, the degree of intrathecal spread is 
related to the baricity, temperature, viscosity, and dosage of local anesthetic admin-
istered. Baricity is the ratio of substance density to CSF density. As such, there are 
hyperbaric, hypobaric or isobaric (i.e., denser than cerebrospinal fluid, less dense 
than cerebrospinal fluid, or similar density to cerebrospinal fluid) formulations of 
local anesthetic solution. Upon injection, baricity affects the caudal versus cephalad 
spread of solution within the CSF. Baricity, in combination with patient position-
ing, will ultimately determine the spread and distribution of local anesthetic within 
the thecal sac. Temperature also affects the density of a local anesthetic solution 
such that a refrigerated or warmed solution may possess a baricity different from its 
manufactured specification. Investigations evaluating the additional effect of local 
anesthetic solution viscosity on intrathecal spread suggest that increased viscosity is 
associated with increased local anesthetic distribution within the intrathecal space 
[48]. Finally, there is a relationship between dosage, volume, and concentration. 
Recognizably, changes in any of these variables influence the others as they pertain 
to the specific mixture of a local anesthetic solution prepared for administration. 
Though several studies have been performed to evaluate these factors, dosage seems 
to have the most significant impact on the intrathecal spread of local anesthetic.
In discussing patient factors, patient height, position, and age all contribute 
to the spread of intrathecal local anesthetic. Though it may affect spread, gross 
height is not a reliable characteristic for determination of local anesthetic dosing. 
Hartwell et al. demonstrated a correlation between vertebral column length and 
the level of local anesthetic sensory blockade. As a surrogate for height, the authors 
suggest the use of vertebral column length instead. This recommendation is based 
on the recognition that there may be patient height differences attributed to differ-
ences in extremity length, which have no reference value with regard to thecal sac 
dimensions or cerebrospinal fluid volume. Regarding thecal sac characteristics, it 
is recognized that the vertebral column curvatures (and thus variations in thecal 
sac positioning) influence the intrathecal spread of local anesthetic. The interplay 
between lumbar lordosis, thoracic kyphosis, and baricity helps to explain the 
largely “dependent” thoracic distribution of hyperbaric local anesthetic solutions 
after intrathecal injection and positioning of a patient in the supine position. With 
regard to baricity, it was demonstrated that the density of CSF varies between 
patients. CSF in women is less dense than in men. It is less dense in pregnant women 
than in non-pregnant women and is less dense in pre-menopausal women than 
in post-menopausal women. This fact has unique importance in that a significant 
portion of surgeries performed under spinal anesthesia are cesarean sections in pre-
menopausal, pregnant women who can be expected to have decreased CSF density. 
It has been further demonstrated that extremes of age can impact the spread of 
intrathecal local anesthetic. Veering et al. reported on the increasing length of time 
required for the maximum upper level of analgesia to be seen with advancing age. 
This was associated with an inverse onset of motor blockade relationship such that a 
faster onset of motor blockade was seen with advancing age. Furthermore, the time 
to peak plasma concentration of local anesthetic was increased, and the total plasma 
clearance decreased with advancing age [49–52].
Finally, procedural components may have an impact on the distribution of local 
anesthetic. It is known that the initial pressure generated by the injection of local 
anesthetic creates waves within the CSF. It was previously believed that generation of 
additional fluid waves, via a technique known as barbotage, would facilitate greater 
spread. Several investigations have demonstrated that barbotage does not affect the 
Topics in Local Anesthetics
84
ultimate height of the sensory blockade. It may, however, slightly decrease the time to 
achieve maximum sensory and motor blockade, though this may be of limited clinical 
value [53–55]. Regarding injection speed and pressure itself, studies have been mixed. 
It would seem that utilizing increasing speed, and pressure of injection potentially 
facilitates a greater spread of isobaric local anesthetic with diminishing effects seen 
with hyperbaric local anesthetic [47, 56]. Lastly, the needle orientation and approach 
(midline versus paramedian) to the neuraxis may alter local anesthetic distribution. 
James et al. demonstrated a faster onset of T4 block when the Sprotte needle was 
inserted with the side eye facing cephalad [57]. Urmey et al., similar to Neigh et al., 
also reported a higher dermatomal distribution when the side aperture of the needle 
was oriented in a cephalad manner [58, 59]. To the contrary, Masse et al. reported that 
the orientation of the aperture of the Whitacre needle did not influence the cephalad 
spread of hyperbaric bupivacaine in parturients [60]. Stienstra et al. demonstrated 
that a paramedian approach with steep angle (70–100 degrees from level) was also 
associated with a greater cephalad sensory blockade [61].
2.2.4 Adverse effects
2.2.4.1 Local anesthetic systemic toxicity
Each local anesthetic has a unique pharmacokinetic profile. This profile dictates 
the potential for adverse events that may be seen with local anesthetic administra-
tion. One of the most concerning adverse effects is local anesthetic systemic toxicity 
(LAST). Inadvertent vascular administration or changes in vascular absorption 
may result in a constellation of symptoms, dependent upon the rate of increase in 
serum concentration and the injection location. Symptoms are typically classified 
into two groups: central nervous system or cardiovascular. Central nervous system 
(CNS) symptoms may include dizziness, perioral numbness, tinnitus, metallic 
taste, agitation, seizures, and coma. Cardiovascular (CV) symptoms, usually seen 
with increasing serum concentrations, may include dysrhythmias (i.e., tachycardia, 
bradycardia, and ventricular ectopy), myocardial depression, hypotension, and 
asystole. It is important to note, however, that CNS symptoms may not be noted 
prior to the onset of cardiovascular collapse. The potential for local anesthetic 
toxicity may be conceptualized using a metric estimation of the ratio of CV toxic 
dose: CNS toxic dose. This ratio is lower (i.e., more potential for cardiac toxicity) 
for amide anesthetics such as ropivacaine and bupivacaine (with bupivacaine 
having the lowest ratio and greatest potential for toxicity). This is due in part to 
its lipid solubility, greater protein binding, and hepatic metabolism [62, 63]. An 
exact mechanism for LAST has yet to be fully elucidated, but it has been suggested 
that the ultimate cause is likely a combination of Na+/K+/Ca2+ ion channel blockade 
(resulting in myocardial depression) in conjunction with metabotropic intracellular 
effects. These intracellular effects include a potential mitochondrial translocase 
inhibition, which may prevent the movement of the acyl portion of fats and ketones 
into the inner mitochondria for energy processing. This substrate reduction may 
create a synergistic depression of cardiac function as a consequence of the myocar-
dial reliance on mitochondrial oxidation of fatty acids and ketones for energy [63].
It is important to recognize that certain pathophysiologic states will also affect the 
toxicity of local anesthetics. These include renal dysfunction, cardiac dysfunction, and 
hepatic dysfunction. In patients with renal dysfunction, a greater volume of distribu-
tion and greater alpha-1 glycoprotein binding would portend a lower free fraction 
serum concentration. However, there is often a hyperdynamic circulation associated 
with diminished elimination of the agent leading to a variable serum concentration 
and recommendations for reduced dosages [63]. Patients with severe heart failure 
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experience a decreased intravascular uptake portending a lower serum concentration. 
However, they often experience diminished renal and hepatic perfusion leading to 
a decreased rate of metabolism and elimination necessitating recommendations for 
reduced dosages as well. Finally, severe hepatic disease, with its associated decreased 
hepatic metabolism, necessitates decreased local anesthetic administration to offset 
the delayed metabolism and elimination of the local anesthetic from the body [63].
Regardless of the manifestation, the key to successful treatment is early consider-
ation of the diagnosis. The development and widespread distribution of lipid emulsion 
has improved the survival of such cases via a mechanism that includes a combination 
of reduced tissue binding and improved energetic-metabolic effects. Since the first 
report of a patient saved by lipid rescue in 2006 [64] case reports and clinical experi-
ence have continued to add to the body of evidence suggesting its efficacy.
2.2.4.2 Neurotoxicity
Initial concerns regarding the administration of lidocaine for spinal anesthesia 
surfaced in the early 1990s. At that time, microcatheters were being employed for the 
continuous intrathecal administration of lidocaine. A case report in 1991 brought to 
light the potential for cauda equina syndrome associated with intrathecal lidocaine 
administration. This was believed to be a result of pooling of high concentration (5%) 
lidocaine inside the caudal dural sac [65]. Ongoing surveillance and reporting, how-
ever, indicated a continuum of symptoms. This was described at the time as Transient 
Radicular Irritation (TRI) associated with intrathecal bolus lidocaine administration 
for spinal anesthesia. These symptoms were later reclassified and have come to be 
better known as Transient Neurologic Symptoms (i.e., the occurrence of sensory 
radicular neuropathic pain in the absence of motor dysfunction that resolves within 
72 h) [66]. Additional studies were performed to evaluate for contributing causes 
to include concentration, baricity, dosage, and adjuncts (i.e., epinephrine, dextrose, 
etc.). Furthermore, the occurrence of TNS with alternative local anesthetics, such as 
bupivacaine, mepivacaine, etc., have been investigated as well.
2.2.4.2.1 Reported incidence of neurotoxicity
According to data presented by Brull et al., the incidence of radiculopathy or neu-
ropathy following contemporary spinal local anesthetic administration is believed to 
occur in 3.78 out of 10,000 spinal esthetics. They further report that the risk of cauda 
equina syndrome with spinal anesthesia is less frequent, occurring in ~0.11/10,000, 
and the risk of permanent neurologic injury is reportedly exceedingly rare [67].
2.2.4.2.2 Neurotoxicity mechanism
The exact mechanism for the occurrence of neurologic injury or production of 
transient neurologic symptoms is unknown. Recognizably, each local anesthetic has 
a different pharmacodynamic profile resulting in greater frequency (i.e., lidocaine) 
versus lesser frequency (i.e., bupivacaine) of neurologic symptoms believed to be 
secondary to neuronal insult. There has been a suggestion that neurologic symp-
toms following spinal local anesthetic administration may stem from the local 
vasoconstrictive properties of the local anesthetic [68]. It is understood that differ-
ent local anesthetics have different vasoconstrictive effects and that these effects 
are also dose-dependent. High concentrations of local anesthetic result in vasodila-
tion, whereas low concentrations have a more vasoconstrictive effect [68]. This 
vasoconstrictive effect at low dose may result in neuronal ischemia. Certainly, there 
is always the potential for mechanical trauma from the needle or intrafascicular 
Topics in Local Anesthetics
84
ultimate height of the sensory blockade. It may, however, slightly decrease the time to 
achieve maximum sensory and motor blockade, though this may be of limited clinical 
value [53–55]. Regarding injection speed and pressure itself, studies have been mixed. 
It would seem that utilizing increasing speed, and pressure of injection potentially 
facilitates a greater spread of isobaric local anesthetic with diminishing effects seen 
with hyperbaric local anesthetic [47, 56]. Lastly, the needle orientation and approach 
(midline versus paramedian) to the neuraxis may alter local anesthetic distribution. 
James et al. demonstrated a faster onset of T4 block when the Sprotte needle was 
inserted with the side eye facing cephalad [57]. Urmey et al., similar to Neigh et al., 
also reported a higher dermatomal distribution when the side aperture of the needle 
was oriented in a cephalad manner [58, 59]. To the contrary, Masse et al. reported that 
the orientation of the aperture of the Whitacre needle did not influence the cephalad 
spread of hyperbaric bupivacaine in parturients [60]. Stienstra et al. demonstrated 
that a paramedian approach with steep angle (70–100 degrees from level) was also 
associated with a greater cephalad sensory blockade [61].
2.2.4 Adverse effects
2.2.4.1 Local anesthetic systemic toxicity
Each local anesthetic has a unique pharmacokinetic profile. This profile dictates 
the potential for adverse events that may be seen with local anesthetic administra-
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experience a decreased intravascular uptake portending a lower serum concentration. 
However, they often experience diminished renal and hepatic perfusion leading to 
a decreased rate of metabolism and elimination necessitating recommendations for 
reduced dosages as well. Finally, severe hepatic disease, with its associated decreased 
hepatic metabolism, necessitates decreased local anesthetic administration to offset 
the delayed metabolism and elimination of the local anesthetic from the body [63].
Regardless of the manifestation, the key to successful treatment is early consider-
ation of the diagnosis. The development and widespread distribution of lipid emulsion 
has improved the survival of such cases via a mechanism that includes a combination 
of reduced tissue binding and improved energetic-metabolic effects. Since the first 
report of a patient saved by lipid rescue in 2006 [64] case reports and clinical experi-
ence have continued to add to the body of evidence suggesting its efficacy.
2.2.4.2 Neurotoxicity
Initial concerns regarding the administration of lidocaine for spinal anesthesia 
surfaced in the early 1990s. At that time, microcatheters were being employed for the 
continuous intrathecal administration of lidocaine. A case report in 1991 brought to 
light the potential for cauda equina syndrome associated with intrathecal lidocaine 
administration. This was believed to be a result of pooling of high concentration (5%) 
lidocaine inside the caudal dural sac [65]. Ongoing surveillance and reporting, how-
ever, indicated a continuum of symptoms. This was described at the time as Transient 
Radicular Irritation (TRI) associated with intrathecal bolus lidocaine administration 
for spinal anesthesia. These symptoms were later reclassified and have come to be 
better known as Transient Neurologic Symptoms (i.e., the occurrence of sensory 
radicular neuropathic pain in the absence of motor dysfunction that resolves within 
72 h) [66]. Additional studies were performed to evaluate for contributing causes 
to include concentration, baricity, dosage, and adjuncts (i.e., epinephrine, dextrose, 
etc.). Furthermore, the occurrence of TNS with alternative local anesthetics, such as 
bupivacaine, mepivacaine, etc., have been investigated as well.
2.2.4.2.1 Reported incidence of neurotoxicity
According to data presented by Brull et al., the incidence of radiculopathy or neu-
ropathy following contemporary spinal local anesthetic administration is believed to 
occur in 3.78 out of 10,000 spinal esthetics. They further report that the risk of cauda 
equina syndrome with spinal anesthesia is less frequent, occurring in ~0.11/10,000, 
and the risk of permanent neurologic injury is reportedly exceedingly rare [67].
2.2.4.2.2 Neurotoxicity mechanism
The exact mechanism for the occurrence of neurologic injury or production of 
transient neurologic symptoms is unknown. Recognizably, each local anesthetic has 
a different pharmacodynamic profile resulting in greater frequency (i.e., lidocaine) 
versus lesser frequency (i.e., bupivacaine) of neurologic symptoms believed to be 
secondary to neuronal insult. There has been a suggestion that neurologic symp-
toms following spinal local anesthetic administration may stem from the local 
vasoconstrictive properties of the local anesthetic [68]. It is understood that differ-
ent local anesthetics have different vasoconstrictive effects and that these effects 
are also dose-dependent. High concentrations of local anesthetic result in vasodila-
tion, whereas low concentrations have a more vasoconstrictive effect [68]. This 
vasoconstrictive effect at low dose may result in neuronal ischemia. Certainly, there 
is always the potential for mechanical trauma from the needle or intrafascicular 
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injection with increased intrafascicular administration pressures leading to neu-
ronal ischemia and injury [65]. This, however, is rare. There is research that sug-
gests the effects of local anesthetics are the result of their impact on intracellular 
metabolism, such as on the mitogen-activated protein kinase (MAPK) and caspase 
pathways. It is interesting to note the activation of different MAPK pathways with 
specific local anesthetics (i.e., tetracaine activates the c-Jun N-terminal kinase 
pathway versus lidocaine activation of the p38 MAPK pathway) [69]. Furthermore, 
use of lipoxygenase inhibitors seems to diminish the degree of neuronal apoptosis 
in response to lidocaine administration suggesting a potential role for inflammatory 
mediators in the generation of neurotoxicity [69]. Kan et al. further investigated 
an inflammatory component by demonstrating the ability to regulate levels of 
caspase-9 and matrix-metalloprotease-3 expression via preemptive incubation 
with subsequent inflammatory signaling pathway modification. This resulted in 
decreased apoptosis in response to in vitro neuronal lidocaine administration [70].
2.2.4.3 Other adverse effects
2.2.4.3.1 Hypotension
Hypotension after spinal local anesthetic administration is a well-known direct 
effect of sympathetic nervous system blockade with venous pooling of blood in the 
lower extremities. Defining hypotension is as challenging as determining treatment 
since the literature utilizes different definitions (i.e. <100 mmHg, <90 mmHg, <80% of 
baseline, etc.) [71]. Numerous studies have evaluated different methodologies for treat-
ing this hypotension. Definition and treatment are beyond the scope of this chapter.
2.2.4.3.2 Infectious complications
Historically, and anecdotally, spinal local anesthetic administration has a low 
reported incidence of infectious complications, and include, but are not limited to 
paraspinal abscesses, spinal/epidural abscesses, meningitis, arachnoiditis, and sys-
temic inflammation with sepsis. In reviewing the literature for infectious complica-
tions, a very low correlating incidence was discovered. Moore and Bridenbaugh, after 
reviewing 52,112 spinal anesthetics, reported the occurrence of three central nervous 
system infections (i.e., 0.06 cases per 1000) [72]. In a more recent review, Horlocker 
et al. reported on the occurrence of two infectious complications out of 4767 consecu-
tive spinal anesthetics which were reviewed (i.e., 0.4 cases per 1000). One case was a 
disc abscess and the other a paraspinal abscess. Both patients remained neurologically 
intact after appropriate treatment. Infections associated with spinal local anesthetic 
injection are infrequent and, as discussed previously, may be due in part to the 
concentration-dependent antibacterial effects of local anesthetic administration [73].
2.2.4.3.3 Vertebral canal hematoma
The etiology of vertebral canal hematoma after neuraxial local anesthetic 
administration appears multifactorial with patient-related (i.e., demographics, 
comorbidities, etc.), medication-related and procedural contributions [74]. Historical 
demographic data portrays a potential predisposition based upon age and gender [75]. 
The retrospectively reported incidence of vertebral canal hematoma varies widely 
and ranges from 1:3600 (seen in patients receiving a spinal local anesthetic for total 
knee arthroplasty), to 1:200,000 (as seen in obstetric patients receiving an epidural 
local anesthetic for labor analgesia) [74, 76, 77]. The report on the Third National 
Audit Project of the Royal College of Anesthetists further suggests a prospective 
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incidence of 8 vertebral canal hematomas in 707,425 (~ 1:88,000). Interestingly, 
46% of these neuraxial blocks were spinals, and there were zero vertebral canal 
hematomas associated with spinal instrumentation. Recognizably, this complication 
portends a notably poor prognosis associated with persistent neurologic deficit [78].
2.2.4.3.4 Thermoregulatory disruption
Administration of spinal anesthesia is associated with a disruption in thermo-
regulation. The threshold for vasoconstriction and shivering in response to hypo-
thermia becomes dysregulated. According to Kurz et al., the threshold for triggering 
a thermoregulatory response to hypothermia is decreased by ~0.5°C. Temperature 
is lost more quickly during the initial 30 min after spinal anesthesia (as a result 
of core-to-peripheral redistribution of heat) when compared to epidural local 
anesthetic administration. This is believed to be secondary to a lesser degree of 
autonomic thermal dysregulation in the lower extremities with epidural local 
anesthesia administration (i.e., failure to obtain a complete blockade with epidural 
versus spinal local anesthesia administration). This clinical effect garners greater 
importance when considering the detrimental effects of hypothermia (i.e., wound 
infection, coagulopathy, delayed arousal from anesthesia, etc.). Though beyond the 
scope of this chapter, yet still of clinical importance, is the potential additive effect 
of intrathecal opioid administration on the disruptive thermoregulatory effect of 
spinal local anesthetic administration [79–81].
2.2.4.3.5 Post-dural puncture headache
The term post-dural puncture headache often refers to a clinical constellation 
of symptoms seen after penetration of the dura mater. Symptoms include the 
presence of a transient, self-limited, positional, frontal-occipital headache tradi-
tionally believed to occur within 72 h of dural penetration. In addition, patients 
may complain of nausea (+/− vomiting), dizziness, tinnitus, neck stiffness, or 
photophobia. Studies indicate a significant association with specific types of needles 
used for spinal local anesthetic administration. Smaller gauge, pencil point needles 
(i.e., spinal needles) are less often associated with post-dural puncture headaches, 
as compared to larger gauge cutting needles (i.e., epidural needles). For this reason, 
post-dural puncture headache is less often associated with spinal local anesthetic 
administration, as compared to inadvertent puncture with epidural catheter place-
ment. Historically, treatments focused on bed rest, hydration, caffeine, and analge-
sics to include acetaminophen and NSAIDs. These conservative treatments are not 
currently supported by evidence of efficacy. The sterile epidural injection of blood 
(i.e., an epidural blood patch), is recognized as traditional therapy and is effective 
in providing adequate pain relief in ~65–70% of patients. Optimally, in light of the 
challenges with treating post-dural puncture headaches, it is best to avoid inadver-
tent dural puncture. If inadvertent dural puncture occurs, techniques to minimize 
the likelihood of post-dural puncture headache should be considered [82].
2.2.4.3.6 Hearing loss
Hearing loss after neuraxial local anesthetic administration deserves special 
consideration. Some providers remain unaware of the potential for this type of 
transient, self-limited low-frequency sensorineural hearing loss. This type of 
hearing loss may be as prevalent as 10–50% of all spinal local anesthetic administra-
tions (with such variable reported prevalence due to the limited degree of patient/
clinician awareness). Interestingly, it seems the same risk factors for a post-dural 
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as compared to larger gauge cutting needles (i.e., epidural needles). For this reason, 
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ment. Historically, treatments focused on bed rest, hydration, caffeine, and analge-
sics to include acetaminophen and NSAIDs. These conservative treatments are not 
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(i.e., an epidural blood patch), is recognized as traditional therapy and is effective 
in providing adequate pain relief in ~65–70% of patients. Optimally, in light of the 
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tent dural puncture. If inadvertent dural puncture occurs, techniques to minimize 
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tions (with such variable reported prevalence due to the limited degree of patient/
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puncture headache apply in the setting of post-spinal local anesthesia hearing loss. 
According to Sprung et al., the subarachnoid space is contiguous with a small canal 
in the ear (i.e., the cochlear aqueduct) that transmits cerebrospinal fluid pressure 
to the inner ear. Sound waves are theorized to be transmitted through the fluid 
in the middle ear onto the basilar membrane. Changes in transmitted pressure to 
the middle ear are hypothesized to distort the interpretation of these sound waves 
through the basilar membrane. Decreases in cerebrospinal fluid pressure, as trans-
mitted through the cochlear canal and into the fluid of the inner ear, is believed to 
be the mechanism by which patients suffer a loss of low-frequency sensorineural 
hearing after spinal anesthesia administration [83].
2.3 Epidural administration
2.3.1 Contents and structure of the epidural space
Transitioning to a discussion of epidural local anesthetic administration gener-
ates an opportunity for a brief discussion of the epidural anatomy to supplement 
the anatomy discussed at the beginning of the chapter.
2.3.1.1 Definition/surrounding bony construct
The epidural space is widest posteriorly in the midline and averages about 5 mm 
between the ligamentum flavum and the dura in the lumbar region. The boundaries 
of the epidural space are:
Above: the foramen magnum where the periosteal and spinal layers of the 
dura fuse
Below: the sacrococcygeal membrane
Anteriorly: the posterior longitudinal ligament covering the posterior aspect of 
the vertebral bodies and the intervertebral discs
Posteriorly: the anterior surfaces of the vertebral lamina and the ligamentum flavum
Laterally: the pedicles of the vertebrae and the intervertebral foramina [1, 84]
Interestingly, spinal nerve root cuffs are identified along the lateral aspect of the 
epidural space. These have previously been defined as “prolongations of the dura 
and arachnoid lamina” and are believed to enclose spinal nerve roots within this 
space. Previously referred to as “dural cuffs,” it is now believed that the cuffs include 
not only the dura mater but the arachnoid mater as well, thus making this previous 
term inaccurate [85]. This construct may influence the spread of local anesthetic 
when administered via the epidural route.
2.3.1.2 Adipose tissue
The contents of the spinal canal are cushioned in a packing of fat, through which 
injected solutions track while spreading to target receptors. This adipose tissue is richly 
vascularized [86, 87] yet lies mostly unattached in the spinal canal. In the region of 
nerve roots, collagen concentration increases and coalesces with the fat in the interver-
tebral foramina. Adipose tissue “competes” for its share of the drug, along with nervous 
tissue and vasculature, and is an important pharmacologic space and repository. 
Medications with high lipid solubility and/or lipoprotein binding tend to enter and 
remain in this tissue, depending on local blood flow, and can impact drug behavior in 
the epidural space profoundly. This competition with extraneural tissue then generates, 
when compared to spinal doses, a higher epidural medication dosage requirement [88].
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2.3.1.3 Vasculature
Spinal arteries, epidural veins, and lymphatics are all co-inhabitors of this 
space. Spinal arteries derive from the vertebral, ascending cervical, deep cervical, 
intercostal, lumbar, and iliolumbar arteries. They lie chiefly in the lateral epidural 
space. Epidural veins arise from the internal vertebral venous plexus and drain 
both the spinal cord and the spinal canal. Lying mainly anterolaterally, they pass 
through the intervertebral foramina on their journey toward the vertebral, posterior 
intercostal, lumbar and lateral sacral veins. It is through this network that increased 
pressures (intra-abdominal and intrathoracic) are transmitted to the epidural space 
[84]. The lack of valves in this system results in the distention of these vessels and a 
consequent reduction in epidural space volume. The lymphatic network is located 
anteriorly to the intervertebral foramen and aid in the cleansing of the subarach-
noid space, draining to the regional lymph nodes.
2.3.1.4 Rivulets
The interrelationship between the factors that influence epidural blockade and 
the clinical effect is surprisingly complex. Epidural analgesia is not a simple matter of 
spinal root or ganglion blockade, but rather is the end state of action at various sites 
after passage through multiple sites. Unique to epidural local anesthetic administra-
tion is the concept of rivulets. Hogan reported the spread of injected ink as “rivulets” 
through numerous small channels rather than as a unified advancing front [89]. 
Injection results in circumferential spread anteriorly and posteriorly around the thecal 
sac. Laterally, epidural solution extrudes beyond the intervertebral foramen following 
a parallel path along the paraspinous musculature fascial plane [89]. Hogan et al. also 
noted that the lateral spread of epidural solution sporadically encompassed the more 
proximal dorsal nerve root prior to the dorsal root ganglion in the “axilla” of the nerve 
root. This non-uniform distribution of solution, within the epidural space, may then 
correlate with clinical data suggesting that slow, not fast, injection rates (0.3–0.75 ml/s) 
result in the most effective spread of analgesia [89]. Undoubtedly, this variation in 
epidural space content combined with varying spread contributes to the somewhat 
unpredictable clinical effects seen with epidural local anesthetic administration.
2.3.2 Pharmacokinetics of epidural local anesthetic administration
2.3.2.1 Factors which affect epidural spread
As mentioned above, and contrary to the effects of intrathecal local anesthetic, 
the complex nature of epidural analgesia is suggested by the lack of relevance of 
physical factors affecting anatomical spread when compared to the clinically pres-
ent segmental analgesia.
2.3.2.2 Absorption, potency, duration, onset
Local anesthetics stabilize excitable cell membranes and block sodium and 
potassium flux through the axonal membrane ion pores. The anesthetic profile and 
clinical characteristics of a local anesthetic depends on its lipid solubility, protein 
binding, and dissociation constant (pKa). Lipid solubility is generally agreed to 
be the primary determinant of intrinsic anesthetic potency. Protein binding is the 
characteristic associated with duration of action of the agent since those that attach 
to protein components of nerve membranes are less likely to diffuse from the site of 
action to enter the systemic circulation. The pKa of a compound, as discussed earlier 
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2.3.2.1 Factors which affect epidural spread
As mentioned above, and contrary to the effects of intrathecal local anesthetic, 
the complex nature of epidural analgesia is suggested by the lack of relevance of 
physical factors affecting anatomical spread when compared to the clinically pres-
ent segmental analgesia.
2.3.2.2 Absorption, potency, duration, onset
Local anesthetics stabilize excitable cell membranes and block sodium and 
potassium flux through the axonal membrane ion pores. The anesthetic profile and 
clinical characteristics of a local anesthetic depends on its lipid solubility, protein 
binding, and dissociation constant (pKa). Lipid solubility is generally agreed to 
be the primary determinant of intrinsic anesthetic potency. Protein binding is the 
characteristic associated with duration of action of the agent since those that attach 
to protein components of nerve membranes are less likely to diffuse from the site of 
action to enter the systemic circulation. The pKa of a compound, as discussed earlier 
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in detail and defined as the pH at which there is equilibrium between the ionized 
and unionized states of the molecule, impacts the rate of onset of clinical effect. 
This value is important for effective anesthesia because the uncharged form of 
the molecule is essential for epineural diffusion across lipid nerve sheaths and cell 
membranes. Conversely, only the charged form can dissociate in water and diffuse 
through cellular fluid and intracellular metabolism [90, 91].
2.3.2.3 Metabolism
The metabolic mechanism of local anesthetics depends on their chemical  
classification. Amide-type local anesthetics, including ropivacaine, are primarily 
metabolized by the hepatic esterase activity seen in the P450 system in the liver  
[92, 93]. Ester-type local anesthetics (procaine, benzocaine, tetracaine) are predomi-
nantly hydrolyzed by plasma pseudocholinesterase.
2.3.3 Pharmacodynamics of epidural local anesthetic administration
2.3.3.1 Measuring effects
A discussion of clinical effect should include a comment on the differential 
blockade. Independent of differences in nerve fiber size and resistance to blockade, 
local anesthetics have varied differential blockade characteristics. Even within a single 
agent, the differential blockade can vary. As an example, bupivacaine, one of the best 
agents at producing effective analgesia while sparing motor loss, loses its motor-spar-
ing characteristics as the bupivacaine concentration is increased from 0.5 to 0.75%.
The mode of action of epidural analgesia is far from clear. Proposed sites of action 
have included: (1) mixed spinal nerves in the paravertebral space, (2) dorsal root ganglia, 
(3) spinal roots, and (4) the periphery of the spinal cord. Regardless, blockade of a nerve 
fiber varies based on the duration of exposure, the exposed length of the axon, the type 
and site of the axon, and the concentration of local anesthetic at the axonal membrane.
Tachyphylaxis describes the condition of acute tolerance to local anesthetic drugs, 
though its mechanism is not well understood. The relationship between the change 
of response and interval between injections is complicated. However, it is likely the 
interval between the disappearance of analgesia and the subsequently repeated injec-
tion of local anesthetic is primary. When it occurs, decreasing analgesic effectiveness 
is noted, including a decrease in the number of dermatomes blocked as well as a 
decrease in motor block, showing that all measurable components of anesthesia are 
affected. Simply, with repeated doses, fewer segments are anesthetized, the duration 
of action is decreased, and both motor and sensory blockade are less intense [94].
The response to epidural blockade includes both autonomic blockade as a result 
of sympathetic interruption and somatic pain blockade (similar to intrathecal 
injection of local anesthetic, but with a greater duration of time to achieve clinical 
effect). The sympathetic blockade has consequent effects on vascular beds, cardiac 
functioning, and other visceral structures as discussed previously. Somatic pain 
blockade provides for the potential of anatomic functional restoration secondary 
to pain responses. Both results can occur as a consequence of epidural blockade and 
may be utilized in the operating room, in the labor suite or the pain clinic.
3. Conclusions
In conclusion, the administration of local anesthetic via the intrathecal or epidural 
route possesses unique pharmacokinetic and pharmacodynamic properties. These 
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properties are influenced by the complex anatomy of bones, ligaments, membranes, 
vasculature, and adipose tissue. Understandably, the mechanism of action of local anes-
thetics is complex with primary Na+ and K+ ion channel activity. Additional involve-
ment of Ca2+ ion channels, γ-aminobutyric acid, and substance P have been proposed.
Pharmacokinetic variables affecting the clinical picture associated with local 
anesthetic administration include the protein binding, lipid solubility, and pKa. Spinal 
local anesthetic pharmacodynamic effects are variable and influenced by factors 
that are unique to the local anesthetic solution, factors that are unique to the patient, 
and factors that are associated with the method of local anesthetic administra-
tion. Epidural pharmacodynamic effects are characterized by a lack of relevance of 
physical factors affecting anatomical spread when compared to the clinically present 
segmental analgesia. Both spinal and epidural local anesthetic administration are 
associated with clinical effects that involve the cardiovascular, pulmonary, digestive, 
renal, and immune systems to varying degrees of significance. Local anesthetic toxic-
ity affects the nervous system and cardiovascular system to varying degrees based on 
the properties of the individual local anesthetic (i.e., lipid solubility, CV: CNS toxicity 
ratio, etc.) and the toxic dosage administered. Regardless of the manifestations of 
toxicity, the key to successful treatment is early consideration of the diagnosis. The 
development and widespread distribution of lipid emulsion has improved survival 
and should be considered in all cases where local anesthetic toxicity is a concern.
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Local Anaesthetics for Spinal 
Anaesthesia in Day-Case Surgery
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Abstract
Day-case procedures require a high turnover, high quality and low costs. 
Lidocaine has long been the gold standard for ambulatory spinal anaesthesia. 
However, the risk of transient neurological symptoms (TNS) limits its use. The 
perfect local anaesthetic for spinal anaesthesia in day-case surgery should have fast 
recovery, fast voiding time and a low risk on TNS and urinary retention. Urinary 
retention is a result of prolonged sensory blockade of the pelvic nerves and is local 
anaesthetic dose and potency dependent. As a substitute for lidocaine, several 
local anaesthetics have been suggested in various doses or combinations with or 
without additives. However, not all are registered for spinal use or have a short-
acting profile. The use of additives has been subject of debate because of possible 
delay in the recovery of bladder. Recently, the old local anaesthetics chloroprocaine 
and prilocaine were reintroduced in the market. They provide rapid recovery after 
spinal anaesthesia in day-case surgery. This chapter gives an overview of the local 
anaesthetics suitable for spinal anaesthesia in day-case surgery, the advantages 
and disadvantages and the influence on discharge time and recovery of bladder 
function.
Keywords: spinal anaesthesia, ambulatory surgery, local anaesthetics, urinary 
retention, transient neurological symptoms, lidocaine, bupivacaine, mepivacaine, 
prilocaine, chloroprocaine
1. Introduction
Day-case surgical procedures require an anaesthetic technique with the possibil-
ity of a high turnover, a high quality of care and low costs [1]. Spinal anaesthesia 
is an easy and cheap technique, has a fast onset and causes minimal side effects. 
Urinary retention and transient neurological symptom (TNS) are side effects 
of spinal anaesthesia and reason for some anaesthetists only to provide general 
anaesthesia in day-case surgery. Despite the fact that these side effects are mostly 
temporary, they affect the quality of care to a great extent.
Lidocaine is a short-acting local anaesthetic and was frequently used for spinal 
anaesthesia in day-case surgery until it became clear that the incidence of TNS is 
significantly higher than with other local anaesthetics [2].
The ideal spinal anaesthesia for day-case surgery provides a rapid onset and 
a short duration of action, allowing a fast turnover of patients for a double-bed 
planning. Spontaneous voiding is still a discharge criterion in our and many other 
hospitals: faster spontaneous voiding results in faster discharge.
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Urinary retention after spinal anaesthesia is most often a result of a prolonged 
sensory blockade of the pelvic nerves. The duration of a spinal block is local anaesthetic 
dose and potency dependent [3]. The dose of a local anaesthetic to provide adequate 
surgical anaesthesia can be lowered by using spinal additive drugs [4]. Opioids and 
clonidine prolong the duration and increase the quality of the sensory nerve block in 
spinal anaesthesia. By adding spinal clonidine, the local anaesthetic dose can be reduced 
without increasing the risk of block failure [5]. The question rises if the benefit of 
lowering local anaesthetic dose outweighs the side effects of the additive administered.
The incidence of urinary retention after spinal anaesthesia has been reported 
with a high variability. There is neither uniformity nor consensus when to catheter-
ise [6]. Fluid policy has also been a subject of debate. A restrictive fluid policy is a 
way of preventing bladder filling, but a more liberal schedule could speed up the 
time to void and fasten discharge time. Furthermore, there is an enormous inter-
patient variability in bladder capacity and in the definition of urinary retention.
Different techniques exist to perform spinal anaesthesia, producing selective 
spinal anaesthesia by changing baricity, dose and position, like a saddle block or 
unilateral anaesthesia. Little is known about the effects of these techniques on the 
restoration of bladder function.
2. Spinal anaesthesia in day-case surgery
2.1 History of local anaesthetics for day-case surgery
In 1954, lidocaine was introduced and became very popular for spinal anaes-
thesia because of its favourable profile for day-case surgery [7]. In 1993, TNS were 
described after its use [8]. Subsequently, additional case reports and prospective 
trials were published about the appearance of TNS with lidocaine [9–11]. In 2005, 
a meta-analysis from Zaric et al. clearly demonstrated an increased risk when 
lidocaine was used for spinal anaesthesia. However, many physicians were not really 
concerned by these symptoms because they were transient and lidocaine remained 
very popular. Even up to now, some clinicians still prefer lidocaine.
The appearance of TNS did initiate a quest for the replacement of lidocaine 
to provide cost-effective, short-acting spinal anaesthesia with a low incidence of 
side effects. It should also be noted that with the progression of modern medicine, 
patient satisfaction became more important as an indicator of the quality of care. 
Temporary side effects that were not considered very important previously now 
became clinically relevant.
2.2 Spinal anaesthesia: advantages and disadvantages
Spinal anaesthesia is an easy technique that has proven its benefit for many years 
[12]. After injection of the local anaesthetic solution in the CSF, it provides good 
surgical anaesthesia for procedures below the umbilicus. The incidence of PONV is 
low and allows eating and drinking immediately after the procedure.
Although the incidence is low, spinal anaesthesia can fail by producing an 
insufficient block height or a patchy block [13]. The duration of spinal anaesthesia 
cannot be extended when the duration of surgery outlasts surgical anaesthesia. 
When this happens a conversion to general anaesthesia must be made.
Several side effects can occur after injection of the local anaesthetic. 
Sympathetic block, hypotension and cardiovascular depression can occur, especially 
when block height exceeds the fifth thoracic dermatome or when patients are of 
older age [12].
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Late side effects from spinal anaesthesia are urinary retention, TNS, backache 
and PDPH. Bleeding or abscess formation are rare but can occur.
To prevent PDPH, smaller and non-cutting needles were developed with a 
pencil-point-shaped tip. This atraumatic needle tip separates the dural fibres rather 
than cutting them, with a lower risk of CSF leakage after puncture. After introduc-
tion of these needles, the incidence of PDPH dropped to 0.6–3% [14, 15].
TNS are described as a dull bouncing pain or dysesthesia at the gluteal region or 
lower limbs after spinal anaesthesia. The symptoms mostly occur within 24 h after 
block regression, and there is an interval of 2–5 h between mobilisation and onset 
of the symptoms [16]. The pain mostly disappears within 5 days, but a duration of 3 
weeks has been described [17]. The aetiology of these symptoms is not well under-
stood. A neurotoxic mechanism is suspected although no neurologic disorders are 
observed. Lidocaine and mepivacaine show the highest incidence of TNS, but they 
are described for other local anaesthetics as well [18]. Lidocaine concentration and 
osmolarity, early ambulation, age, needle size and level of puncture all have been 
suggested as contributing factors, but the evidence in literature is weak and contro-
versial. Ambulatory anaesthesia, the lithotomy position and knee arthroscopy are 
known to be risk factors [10, 11, 19–22].
2.3 Comparison with other anaesthetic techniques
Spinal and general anaesthesia have frequently been compared in literature. 
In 2005, a meta-analysis compared different locoregional techniques with general 
anaesthesia for ambulatory surgery [23]. After including 23 trials with more than 
1000 patients, it was concluded that general anaesthesia had a faster onset and a 
40 min faster discharge time than spinal anaesthesia. However postoperative pain 
scores and the incidence of PONV were higher for general anaesthesia. Patients were 
equally satisfied with all techniques. Comparison of costs was not part of the analy-
sis. After this meta-analysis, more recent studies confirmed the delay in discharge 
but also showed an increase in urinary retention for spinal anaesthesia. Less PONV 
and lower pain scores after spinal anaesthesia were consistent findings [24–28].
Spinal anaesthesia displays a clear advantage concerning PONV and postopera-
tive pain scores. It is clear that we should improve recovery time and lower the 
incidence of urinary retention and TNS when spinal anaesthesia has to compete 
with general anaesthesia. It is important to realise that the choice of drugs and 
equipment only has a minor contribution in anaesthesia expenses compared to 
personnel costs. Reducing turnover times and fasten recovery and discharge have an 
economical benefit because of saving manpower. Unanticipated admissions and the 
occurrence of side effects are cost-increasing factors [29, 30].
A limitation in many studies has been the use of long-acting local anaesthetics, 
while short-acting local anaesthetics might provide a faster recovery [31].
When it comes to difference on the longer-term outcome, there is not much evi-
dence of superiority of spinal or general anaesthesia. One prospective randomised 
trial with 200 patients suggests that success rate with in vitro fertilisation might 
be improved from 15 to 27% when spinal anaesthesia is used instead of general 
anaesthesia [32].
Postoperative cognitive dysfunction (POCD) is a decline in mental status after 
surgery. The mechanism is not understood. In 2007, a review by Newman showed 
that there is no difference in the incidence of POCD after general or spinal anaes-
thesia [33]. However, the author points out that many studies were underpowered 
and differences in surgery and testing provided difficulties in methodology. For 
elderly patients undergoing hip replacement, neuraxial anaesthesia lowers the risk 
of POCD than general anaesthesia [34].
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2.4 Spinal anaesthesia and bladder function
Neuraxial anaesthesia increases the risk of urinary retention since the neuro-
physiology of the bladder is temporarily disturbed. The duration is dependent on 
the local anaesthetic used [3, 35, 36]. The temporary malfunction of the detrusor 
muscle and the lack of urge sensation during spinal anaesthesia increase the risk of 
bladder distension.
The time for the bladder function to restore relates to the duration of the block, 
which is determined by local anaesthetic potency and dose. When long-acting local 
anaesthetics are used, more time is required before bladder function is restored 
than short-acting substances. When local anaesthetic dose is increased, the time to 
void is prolonged as well. This causes variable times to void after spinal anaesthesia, 
ranging from 103 (chloroprocaine) to 462 min (bupivacaine) [3, 37]. To prevent 
bladder retention in an outpatient setting, the use of short-acting local anaesthetics 
and voiding before surgery is recommended [38].
In a day-case setting, the incidence of urinary retention after spinal anaesthesia 
varies between 0 and 30%, although there is consensus that the mean incidence 
is around 2% [3]. This variability can be explained by the difference in definition, 
catheterisation protocol and surgical procedure between the reported trials. There 
are a lot of studies concerning spinal anaesthesia in day-case surgery where urinary 
retention is not even mentioned. It is remarkable though that when trials were 
designed to study bladder function, high incidences like 23–30% are found [39, 40]. 
This may be explained by the closer monitoring of bladder volume.
2.5 Modifying spinal anaesthesia
Different aspects of spinal anaesthesia can be modified (Figure 1). Changing the 
solution for spinal injection, the anaesthetic technique or fluid policy can influ-
ence the duration of the sensory and motor block, the risk of certain side effects or 
discharge time. Modifying certain discharge criteria, like the necessity to void, can 
influence discharge time as well.
Figure 1. 
Variables in spinal anaesthesia for day-case surgery.
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2.5.1 Local anaesthetics
When a local anaesthetic substance is injected into the CSF, it diffuses through 
the lipophilic nerve membrane and reaches the sodium channel [41]. As a conse-
quence, the sodium channel is blocked and impulses cannot be conducted along 
the different nerve fibres. This results in a sensory, motor and sympathetic block. 
After a certain period, the local anaesthetic molecules dissociate from the sodium 
channel and are absorbed in the blood stream to be degraded. Local anaesthetics 
are divided in two groups: amides and esters. Amides are degraded by the liver, and 
esters are rapidly hydrolysed by pseudocholinesterases in the blood stream. Every 
local anaesthetic has its own pharmacologic properties (pKa, liposolubility, protein 
binding), which not only determine the potency but also the onset and duration of 
the spinal block [42]. Since the first spinal anaesthesia was performed with cocaine, 
more local anaesthetics have been produced (Figure 2).
The duration of the sensory and motor block is dose dependent in neuraxial 
anaesthesia. Increasing local anaesthetic dose prolongs motor and sensory block. 
Winnie stated that locoregional anaesthesia always works provided you put the 
right dose of the right drug in the right place. This is also true for spinal anaes-
thesia. Unfortunately for spinal anaesthesia in day-case surgery, a working spinal 
Figure 2. 
Different local anaesthetics and year of production.
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anaesthesia is not enough. The duration of the spinal block should be short but long 
enough to do provide surgical anaesthesia with a minimal risk of insufficient block 
height and with minimal side effects.
Lidocaine has always been a popular drug for spinal anaesthesia. It can provide 
60 min of anaesthesia below the umbilicus with minimal time to achieve discharge 
criteria [43, 44]. The question arises if lidocaine should still be used in the twenty-
first century because of its side effects, and many studies have compared it to its 
alternatives [45, 46].
Bupivacaine is a long-acting local anaesthetic from the amide group and has a low 
incidence of TNS. It has been the most common alternative for lidocaine for years. 
Because of its pharmacological profile, the recovery of motor and sensory block is 
delayed compared to short-acting local anaesthetics. The incidence of postoperative 
urinary retention with long-acting local anaesthetics like bupivacaine and tetracaine 
is higher than with short-acting local anaesthetics [3, 47]. Successful spinal anaes-
thesia with low doses of bupivacaine between 5 and 10 mg without additives has 
been described for outpatients. The incidence of urinary retention was still 3.7–16% 
[48, 49]. Furthermore, with these low doses, block height becomes unpredictable 
and the risk of block failure is high [48, 50, 51]. A meta-analysis of 17 trials looked 
at the use of bupivacaine for ambulatory knee arthroscopy. This paper warned for 
an increased risk of a failed block with doses below 7.5 mg, unless a unilateral spinal 
technique was used or additives were administered to the solution [52].
Other local anaesthetics like procaine and mepivacaine also have a considerable 
risk of TNS or have an unfavourable profile regarding block resolution and dis-
charge times [53, 54].
Levobupivacaine and ropivacaine are both amide local anaesthetics that have 
similar properties to bupivacaine. Ropivacaine also is a pure enantiomer, is less 
potent and produces less motor block than bupivacaine. Both products are not 
officially registered for spinal use but used “off-label” frequently. The recovery and 
discharge for ambulatory surgery is not as fast as lidocaine, and micturition prob-
lems are comparable [55]. There is controversy about the suggested faster recovery 
of ropivacaine compared to bupivacaine [56].
Although there is enough literature to support the use of these two products for 
spinal anaesthesia for ambulatory surgery, reintroduction of chloroprocaine and 
prilocaine, which are in many countries registered for spinal use, seems to have 
more advantages [57–59].
Chloroprocaine is a local anaesthetic from the ester group. It has a fast- and 
short-acting profile. It became unpopular in the 1950s after the publication of toxic 
neurologic symptoms, which were probably caused by the additives in the solution. 
The additive-free form is now approved an available for spinal use in Europe and 
is considered safe [60–62]. It has been shown to be suitable for spinal anaesthesia 
in day-case surgery and has a faster regression than long-acting local anaesthetics 
and available short-acting local anaesthetics [60]. The recommended dose varies 
between 40 and 60 mg for ambulatory surgery. Discharge times between 178 and 
277 min are found. Up to date only one patient has been reported with TNS after 
spinal anaesthesia with chloroprocaine, demonstrating the low incidence of TNS 
and suitability for day-case surgery [63]. Furthermore the frequency of bladder 
retention is very low, even when a fluid preload is administered [64].
A meta-analyses of the advantage of the pharmacokinetic profile proofed to 
translate in a clinical advantage such as faster block regression, ambulation and 
discharge as well [65].
Prilocaine is an amide local anaesthetic with an intermediate duration of action 
after spinal administration. It never gained much attention because of the popular-
ity of lidocaine. It is available in the hyperbaric form and provides anaesthesia for 
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75–90 min after spinal administration. The duration of the spinal block is prolonged 
compared to an equal dose of lidocaine, but combined with fentanyl it is a better 
alternative than bupivacaine for ambulatory knee arthroscopy [66]. Doses between 
20 and 70 mg are described in literature, but 50 mg hyperbaric prilocaine seems 
sufficient for day-case arthroscopies, although rescue analgesia was necessary in 11 
and 7.5% of the patients [67, 68]. The ED90 was 38 mg for bilateral spinal anaesthe-
sia for knee arthroscopies [69].
The incidence of urinary retention after 60 mg prilocaine in a day-case setting 
was described as high as 23% [40]. Articaine is an amide local anaesthetic with 
intermediate potency and a short duration of action. It is an amide but differs 
slightly because it also contains an ester group and can be hydrolysed. Further 
metabolism and excretion is primarily in the kidneys [70]. Articaine provides faster 
motor and sensory block regression and earlier spontaneous voiding than prilo-
caine; low-dose bupivacaine and lidocaine A comparison of equal doses of spinal 
articaine and chloroprocaine showed faster block regression for chloroprocaine 
[71]. Unfortunately, articaine is not available everywhere and its use is off-label.
2.5.2 Baricity
The baricity of a local anaesthetic is defined as its density compared to the 
density of the CSF. Baricity partly determines the spread of the molecules in the 
CSF after injection. The molecules sink or float in the CSF depending on their 
relative gravity. Most local anaesthetics are isobaric or slightly hypobaric. It must 
be remembered that an increase in temperature of the solution can change baric-
ity, making isobaric substances slightly hypobaric once injected [72]. Hyperbaric 
substances are also available. These solutions contain glucose.
When hyperbaric or hypobaric substances are used for spinal anaesthesia, the 
spread of the local anaesthetic can be influenced by changing the position of the 
patient. Hyperbaric substances might have a more favourable profile because of 
faster block regression. Hyperbaric lidocaine, ropivacaine and bupivacaine showed 
faster recovery than the plain solutions and with higher or comparable cephalad 
spread [73–76]. No differences were found between hyperbaric and plain chloro-
procaine [77]. It is believed that hyperbaric substances produce a more cephalad 
block spread because the molecules are dragged down over the lumbar curve to 
the lowest level of the thoracic kyphosis when the patient is allowed to resume the 
supine position. This more cephalad spread of local anaesthetic might result in a 
dilution of molecules in the CSF and thus a lower “mg per segment” concentration. 
The time necessary to absorb the local anaesthetic molecules is shorter because of 
a lower concentration which might explain faster block regression of a hyperbaric 
substance than a plain local anaesthetic [78].
2.5.3 Additives
Local anaesthetics can be combined with other drugs to prolong the duration of 
sensory or motor block or increase the level or intensity of sensory analgesia. It also 
allows local anaesthetic dose reduction without shortening the duration of the block 
but with a more favourable recovery profile. For day-case surgery, several additives 
were studied to reduce local anaesthetic dose in a day-case setting.
Intrathecal opioids have a direct analgesic effect after binding on the opioids 
receptors that are present at the spinal cord level. This is mainly through their effect 
on the C and A-delta fibres. The mechanism by which opioids and local anaesthetics 
interact is not fully understood but results in an increased somatic analgesia without 
influencing motor or sympathetic blockade. Intrathecal lipophilic opioids, like 
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anaesthesia is not enough. The duration of the spinal block should be short but long 
enough to do provide surgical anaesthesia with a minimal risk of insufficient block 
height and with minimal side effects.
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in day-case surgery and has a faster regression than long-acting local anaesthetics 
and available short-acting local anaesthetics [60]. The recommended dose varies 
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discharge as well [65].
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after spinal administration. It never gained much attention because of the popular-
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the lowest level of the thoracic kyphosis when the patient is allowed to resume the 
supine position. This more cephalad spread of local anaesthetic might result in a 
dilution of molecules in the CSF and thus a lower “mg per segment” concentration. 
The time necessary to absorb the local anaesthetic molecules is shorter because of 
a lower concentration which might explain faster block regression of a hyperbaric 
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2.5.3 Additives
Local anaesthetics can be combined with other drugs to prolong the duration of 
sensory or motor block or increase the level or intensity of sensory analgesia. It also 
allows local anaesthetic dose reduction without shortening the duration of the block 
but with a more favourable recovery profile. For day-case surgery, several additives 
were studied to reduce local anaesthetic dose in a day-case setting.
Intrathecal opioids have a direct analgesic effect after binding on the opioids 
receptors that are present at the spinal cord level. This is mainly through their effect 
on the C and A-delta fibres. The mechanism by which opioids and local anaesthetics 
interact is not fully understood but results in an increased somatic analgesia without 
influencing motor or sympathetic blockade. Intrathecal lipophilic opioids, like 
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fentanyl and sufentanil, increase the quality and prolong the duration of sensory 
analgesia after spinal anaesthesia [4, 79].
For day-case surgery, the combination of a local anaesthetic with an opioid could 
provide fast-onset and sufficient analgesia without prolonged motor block. Side 
effects like respiratory depression, which can occur after spinal hydrophilic opioids, 
are not clinically relevant with low doses of lipophilic opioids [80].
However the incidence of pruritus after intrathecal opioids varies but can be 
severe [81]. A meta-analysis in 2011 evaluated the effect of intrathecal opioids. The 
analysis concluded that morphine provided longer postoperative analgesia up to 12 h 
but also increased the risk of respiratory depression and PONV. The addition of fen-
tanyl increased the risk of pruritus but had no effect on respiration [82]. Extremely 
small doses such as 3 mg of bupivacaine or 20 mg of lidocaine in combination with 
an opioid have been described [83–85]. However as described above, opioids will 
also decrease the sensation of bladder fullness and weaken the detrusor contraction. 
This might delay voiding [86, 87]. This possible delay in voiding time could not be 
confirmed by all studies, but it is clear that it is dose dependent [6, 88, 89].
Clonidine binds alpha-2 receptors on the presynaptic C fibres and the A-delta 
fibres. It intensifies sensory and motor block, but the exact working mechanism is 
not known [90]. Clonidine allows local anaesthetic dose reduction. The advantage of 
clonidine compared to opioids is the lack of respiratory depression and pruritus as a 
side effect. However, marked haemodynamic changes and sedation can occur [5].
Vasoconstrictors decrease local anaesthetic uptake by reducing spinal cord blood 
flow. Epinephrine prolongs the duration and improves the quality of a spinal block 
in a dose-dependent fashion. It allows local anaesthetic dose reduction in a day-
case setting but has a variable prolongation. Addition of epinephrine to lidocaine, 
procaine or bupivacaine caused a delay in discharge in a day-case setting [91, 92]. 
In combination with chloroprocaine in volunteers, it provided unexplained flu-like 
symptoms [93].
Several other additives, like neostigmine and magnesium, have been studied, but 
were not suitable because of side effects or prolonged time to ambulation [94–96].
2.5.4 Spinal anaesthetic technique
Several techniques are available to perform spinal anaesthesia. When isobaric 
solutions are injected, drug spread is affected by many factors, which mostly are 
patient dependent and can therefore not be influenced [78]. Urmey et al. showed 
that pointing the aperture of the spinal needle cephalad resulted in a more cephalad 
spread and faster block regression after 60 mg lidocaine in a day-case setting [97].
The availability of hyperbaric substances allows us to control intrathecal 
drug spread, by which a restriction of the sensory block to the surgical site can 
be obtained, like a saddle block or a unilateral block. Low doses of hyperbaric 
prilocaine or bupivacaine produce adequate analgesia limited to the sacral region 
for perianal surgery [98–101]. However a sitting position has to be obtained for at 
least 10 min or even more to prevent secondary spread of the local anaesthetic after 
repositioning the patient, what may result in an insufficient block [78].
Unilateral spinal blocks with a reduced local anaesthetic dose were compared to 
bilateral spinal anaesthesia in a day-case setting. Unilateral blocks resulted in faster 
recovery of sensory and motor block and more haemodynamic stability [102–105]. 
In a meta-analysis, Nair et al. concluded that a unilateral technique with small doses 
of bupivacaine (4–6 mg) is suitable for unilateral anaesthesia [52].
The duration of lateral decubitus, the amount of hip flexion and the position 
during injection were studied to improve the unilaterality and the success rate of 
the block [106, 107]. However, the idea that a spinal block is fixed after 15–30 min 
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is not correct, since redistribution can be seen up to 1.5 h after injection [78]. 
Unilateral spinal anaesthesia has been thought to reduce bladder disturbances, as 
only one side of bladder innervation would be impaired. Because the physiologic 
function of the detrusor reflex is complex, there is still controversy whether this is 
really true [39, 108, 109].
2.5.5 Fluid policy
Should patients receive a ‘normal’ or ‘restricted’ amount of intravenous and oral 
fluids? Restricting fluid can delay bladder filling and prevent urinary retention, 
but it can also delay voiding and discharge, when required [110–112]. Restriction 
of fluids might cause minor discomfort in outpatients. A fluid load can even reduce 
PONV after general anaesthesia [113–115]. However, if IV fluid is not restricted, the 
bladder may fill too early during anaesthesia, risking overdistension [35, 116, 117].
Different amounts of fluid between 750 and 1200 ml have been suggested as a 
maximum in order to prevent bladder retention. However in these papers, different 
local anaesthetics were used, fluid loads up to 4000 ml were administered, bladder 
volumes were not always measured, and most procedures were considered as high 
risk for urinary retention, such as inguinal hernia repair and urological procedures 
[118, 123].
There even is controversy weather fluid load always correlates with bladder 
filling in such a short period. When 800–1200 ml IV fluid was administered, 
neither correlation with bladder filling was found nor could a difference in voiding 
interval or urinary retention be detected compared to a restrictive regimen [37, 
113, 119, 120]. One study found a correlation between bladder volume and IV fluid 
when more than 900 ml was administered [121]. It may be concluded that excessive 
volumes should be avoided, but a restrictive policy may not be necessary to prevent 
urinary retention.
Moreover, with the common policy to freely allow patients to drink clear 
fluids up to 2 h before surgery, the bladder may fill intraoperatively regardless of 
restricted intravenous fluid administration.
2.5.6 Discharge criteria
Discharge time is an indicator of efficiency of an ambulatory surgery unit. For 
safe and good clinical practice, guidelines and criteria are useful. Depending on 
the healthcare system, discharge criteria can vary in different countries or regions. 
There are several scores that can be used to test home readiness for ambulatory sur-
gery. The modified Aldrete score [122] and the PADSS score [123] are two of them. 
Voiding and oral intake are parts of the PADSS and the modified Aldrete score as 
discharge criteria. In both scores, readiness for discharge can be achieved without 
voiding or oral intake, when all other variables are optimal.
Waiting for oral intake and voiding can delay discharge for both general and 
spinal anaesthesia. A large trial of 1184 patients showed that spinal anaesthesia was 
responsible for a 44 min delay in discharge for women [49, 124, 125]. There is agree-
ment in literature that after general anaesthesia and absence of patient or surgery-
related risk factors, patients can be discharged without voiding [126].
However, guidelines available are not clear weather voiding should be required 
after spinal anaesthesia. In the day-case and short-stay surgery guidelines from the 
British association of day surgery, the following guideline can be found: “Voiding 
is also not always required, although it is important to identify and retain patients 
who are at particular risk of developing later problems, such as those who have 
experienced prolonged instrumentation or manipulation of the bladder” [127]. 
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The American Society of Anesthesiologists (ASA) guidelines recommend void-
ing before discharge only when risk factors are present as well [128]. Since spinal 
anaesthesia is regarded as a risk factor on its own, the guidelines are subject to dif-
ferent interpretation [121]. Patients operated for urogenital surgery, hernia repair, 
those who had experienced bladder problems in the past, patients with prostate 
disease and aged persons should void before discharge [35, 37, 129, 130], regardless 
of anaesthetic technique.
An often-quoted abstract concludes that even high-risk patients can be dis-
charged without voiding. Although 1719 patients were included in the study, only 
30 patients were identified as high risk. Those patients could not void and were 
discharged and followed by a home nurse. Three patients had to be catheterised 
at home. No bladder volumes were measured [131]. Mulroy et al. compared an 
accelerated protocol where low-risk patients could be discharged after neuraxial 
anaesthesia when measured bladder volume was below 400 ml. He concluded, after 
examining 46 patients who went home without voiding, that discharge after spinal 
anaesthesia with short-acting local anaesthetics is safe without voiding when blad-
der volume is below 400 ml [110].
Other authors agree that short-acting local anaesthetics should be used and 
bladder volumes should be monitored when patients are discharged without 
voiding. Some advice patients to return to the hospital when no voiding took place 
within 8 h of interval after discharge or until the evening of the day of surgery 
[3, 35, 38, 132]. After anaesthesia, overdistension of the bladder is not always clear 
for the patient [121]. Instructions when to return to the hospital based on measured 
bladder volumes seem a better option [38].
3. Conclusions
Effective anaesthesia, fast block regression and fast voiding are of uppermost 
importance in creating a good flow for spinal anaesthesia in day-case surgery. For 
this, we need a local anaesthetic with a favourable pharmacokinetic profile.
For years, lidocaine has been the drug of choice for spinal use in day-case 
surgery. The importance of quality of care and the demand for a fast turnover in our 
modern ambulatory practice has increased. Therefore, nowadays, the intrathecal 
use of lidocaine is criticised because of its high incidence of TNS.
Different aspects of spinal anaesthesia were studied in order to minimise side 
effects and to obtain short discharge times. Discharge time is mainly affected by the 
time to void and the occurrence of micturition problems.
Not only the local anaesthetic choice but also dose contributes to the optimal 
flow in a day-case setting. Other factors are also important, such as spinal anaes-
thetic technique, fluid policy and discharge criteria.
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importance in creating a good flow for spinal anaesthesia in day-case surgery. For 
this, we need a local anaesthetic with a favourable pharmacokinetic profile.
For years, lidocaine has been the drug of choice for spinal use in day-case 
surgery. The importance of quality of care and the demand for a fast turnover in our 
modern ambulatory practice has increased. Therefore, nowadays, the intrathecal 
use of lidocaine is criticised because of its high incidence of TNS.
Different aspects of spinal anaesthesia were studied in order to minimise side 
effects and to obtain short discharge times. Discharge time is mainly affected by the 
time to void and the occurrence of micturition problems.
Not only the local anaesthetic choice but also dose contributes to the optimal 
flow in a day-case setting. Other factors are also important, such as spinal anaes-
thetic technique, fluid policy and discharge criteria.
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Local Anesthetics Infiltration and 
Wound Healing Process
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Abstract
It is a good practice, nowadays, to infiltrate local anesthetics along the  incision 
to prevent postoperative pain. This can reduce the use of opioids and the side 
effects they cause. It is known clearly that the surgical trauma causes inflammatory 
reaction, and this can be the beginning of a bad cicatrization or even a scar. The 
use of local anesthetics preventing the acute pain is a very simple technique and 
has proved to be useful. Nevertheless, the reaction that various anesthetics have 
over the tissues and the cicatrization process is yet controversial and deserves to 
be investigated deeply. The use of different formulations of these drugs has been 
stimulated. The duration and secureness have been the goals of many researches. 
Levobupivacaine, ropivacaine, and bupivacaine for their long action; lidocaine for 
less toxicity; and liposomal formulation for the longest duration ever seen, all of 
them have been indicated in the postoperative pain management. The aim of this 
chapter is to evaluate the role of long duration local anesthetics on the inflamma-
tory reaction and consequently the collagen production and resistance of the tissue 
to traction.
Keywords: local anesthetics, pharmacology, ropivacaine, bupivacaine, tensile 
strength, wound healing, drug effects
1.  Introduction (local anesthetics, general comments, classification 
regarding structure and duration)
Local anesthetics (LA) are widely used in clinical practice in anesthesiology. 
They possess the common property of transient interruption in the neural conduc-
tion, and in the fibers C and Aδ, they cause interruption of pain transmission. 
Pharmacologically, there is a selective blockade of Na+ channels [1, 2]. The mecha-
nism of action of LA is not related only to binding to the Na+ channels. LA have an 
important role in other targets (channels and receptors); for example, in K+ and 
Ca++ channels, they have an anti-inflammatory effect by bounding to G protein 
(inhibiting the adhesion of polymorphonuclear leukocytes, macrophages, and 
monocytes), increase the release of glutamate, as well as interfering in the activity 
of some intracellular signaling pathways [3, 4].
There are at least five applications for the use of LA in anesthesiology: local 
infiltration, regional intravenous anesthesia (Bier block), peripheral nerve 
block, central nervous system (CNS) blockade (spinal anesthesia, epidural, and 
caudal), and topical deposit (EMLA, eye drops in ophthalmology) [3]. In this 
Topics in Local Anesthetics
118
herniorrhaphy. American Journal of 
Surgery. 1991;161(4):431-433
[131] Fritz WT, George L, Krulll N, 
Krug J. Utilisation of a home nursing 
protocol allows ambulatory surgery 
patients to be discharged prior to 
voiding. Anesthesia and Analgesia. 
1998;84(2S):S6
[132] Mulroy MF. Outpatients 
do not need to void after short 





Local Anesthetics Infiltration and 
Wound Healing Process
João Abrão, Marcelo Antunes and Luis Vicente Garcia
Abstract
It is a good practice, nowadays, to infiltrate local anesthetics along the  incision 
to prevent postoperative pain. This can reduce the use of opioids and the side 
effects they cause. It is known clearly that the surgical trauma causes inflammatory 
reaction, and this can be the beginning of a bad cicatrization or even a scar. The 
use of local anesthetics preventing the acute pain is a very simple technique and 
has proved to be useful. Nevertheless, the reaction that various anesthetics have 
over the tissues and the cicatrization process is yet controversial and deserves to 
be investigated deeply. The use of different formulations of these drugs has been 
stimulated. The duration and secureness have been the goals of many researches. 
Levobupivacaine, ropivacaine, and bupivacaine for their long action; lidocaine for 
less toxicity; and liposomal formulation for the longest duration ever seen, all of 
them have been indicated in the postoperative pain management. The aim of this 
chapter is to evaluate the role of long duration local anesthetics on the inflamma-
tory reaction and consequently the collagen production and resistance of the tissue 
to traction.
Keywords: local anesthetics, pharmacology, ropivacaine, bupivacaine, tensile 
strength, wound healing, drug effects
1.  Introduction (local anesthetics, general comments, classification 
regarding structure and duration)
Local anesthetics (LA) are widely used in clinical practice in anesthesiology. 
They possess the common property of transient interruption in the neural conduc-
tion, and in the fibers C and Aδ, they cause interruption of pain transmission. 
Pharmacologically, there is a selective blockade of Na+ channels [1, 2]. The mecha-
nism of action of LA is not related only to binding to the Na+ channels. LA have an 
important role in other targets (channels and receptors); for example, in K+ and 
Ca++ channels, they have an anti-inflammatory effect by bounding to G protein 
(inhibiting the adhesion of polymorphonuclear leukocytes, macrophages, and 
monocytes), increase the release of glutamate, as well as interfering in the activity 
of some intracellular signaling pathways [3, 4].
There are at least five applications for the use of LA in anesthesiology: local 
infiltration, regional intravenous anesthesia (Bier block), peripheral nerve 
block, central nervous system (CNS) blockade (spinal anesthesia, epidural, and 
caudal), and topical deposit (EMLA, eye drops in ophthalmology) [3]. In this 
Topics in Local Anesthetics
120
chapter, we will discuss its application in the infiltration of the operative wound 
and its effects in the inflammatory process, after a brief discussion about the 
 pharmacological structure of LA.
2. Na+ channel structure: the main target of conventional LA
The Na+ channel is composed of one alpha subunit and one or two beta subunits, 
which can be present in three different states: resting, open, and inactivated (Figure 1). 
The AL binds to the Na+ channel after crossing the plasma membrane, that is, they 
bind to an internal portion of the alpha subunit preventing its activation and conse-
quent depolarization of the membrane (Figure 2). Thus, the impulse is not propagated 
through the neurons, which prevents the perception of nociceptive pain [5, 6].
3. Classification of AL (esters and amides and justify the use of each)
In its chemical structure, the LA are weak bases that possess in its molecule a 
lipophilic portion (aromatic ring) and another hydrophilic (tertiary amine) sepa-
rated by an intermediate chain (hydrocarbon chain containing an ester or an amide 
group) (Figure 3) [7, 8].
The latter allows the classification of LA in amino-esters or amino-amides. 
These two groups differ in relation to its biotransformation site (the ester forms 
are metabolized by plasmatic esterases, while amide forms are degraded by hepatic 
enzymes) [9, 10].
Figure 2. 
The electric stimuli are not able to open the Na+ channel because it is blocked by the LA.
Figure 1. 
Na+ channels—it opens with the voltage changes (depolarization) propagated by the electrical impulse.
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Regarding the allergenic potential—the para amino benzoic acid (PABA) is an 
allergenic metabolite of the amino esters. Caution must be observed with some LA 
formulations, because methylparaben and metabisulfite are allergenic used as a 
preservative [11].
The size of the alkyl chain, in the amino group or aromatic ring, confers the LA mol-
ecule its hydrophobic character and its permeability in the lipid bilayer. So, the larger 
the nitrogenated radicals will be their potency and duration of LA blockades [12].
4. LA toxicity
Followed by the application of AL in the patient, a fraction will be absorbed by 
the bloodstream (plasma). Depending on the dose administered, the LA may reach 
higher or lesser degree the noble organs (e.g., brain and heart) producing physi-
ological alterations in these tissues as well. The total dose used should comply with 
a maximum limit to try to avoid these undesirable effects, known as systemic LA 
toxicity [13]. Usually, in clinical practice, we must respect the maximum dose of 
each LA. Note that the CNS effects of lidocaine vary according to its plasma concen-
tration (Table 1)—the higher the plasma concentration, the greater the risk to the 
patient, even develop a cardio-respiratory arrest. Thus, it is mandatory to observe 
the maximum allowable doses for each LA.
LA may also induce cardiac toxicity depending on the dose employed, acting 
directly in the heart (specialized conduction tissues) and decreasing the contractil-
ity of ventricular myocytes. Bupivacaine is more cardio depressor than lidocaine 
[14–16].
Figure 3. 
LA generic structural formula.
Plasma concentration (mcg/mL) Effect
1–5 Analgesia
5–10 Numbness of tongue, tinnitus
10–15 Seizures
15–25 Coma, respiratory failure
>25 CV depression
Table 1. 
CNS toxicity—lidocaine plasma concentrations and its effects [17].
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5.  Long-term local anesthetics: ropivacaine, bupivacaine, and 
levobupivacaine. (Pharmacological characteristics: concentration 
used in practice, toxic dose and care). Liposome formulations
The duration of action of LA is influenced by its effect on the vascular smooth 
muscle tone (vasoconstriction/vasodilatation) adjacent to the place where it is 
deposited. Other factors that determine its duration include the volume and con-
centration used, the approach itself (infiltrative versus regional peripheral nerve 
versus CNS blocks), the target tissue (fiber’s diameter and myelin sheath), and the 
plasma protein binding (drug-specific affinity).
Long-term LA are the most used in clinical practice in anesthesiology at the fol-
lowing maximal allowed doses—bupivacaine (2 mg/kg), levobupivacaine (2 mg/kg), 
and ropivacaine (3 mg/kg).
5.1 Bupivacaine
Bupivacaine is presented as a racemic mixture of enantiomers R+ and S−. The 
optical isometry due to the presence of a chiral carbon (asymmetric) confers several 
possibilities in the formulation of the LA.
Bupivacaine promotes differential conduction blockade. As it produces more 
sensory than motor blockade, it plays an important role in the postoperative pain 
control. The use of epinephrine (5 μg/mL) gives a small increase in its duration of 
action (as opposed to lidocaine, which takes great advantage over this association). 
The use of large volumes for infiltration should be taken with cautious and done 
gradually and intermittently (3–5 mL at 5 min intervals). The patient should always 
be monitored to detect any unintentional intravascular injection of LA. Bupivacaine 
presents a higher risk of cardiac toxicity, when compared to levobupivacaine and 
ropivacaine. Every injection of this anesthetic should be done with the utmost care, 
always checking the positioning of the needle (by aspirating the syringe ensuring 
that the needle bevel is not intravascular).
5.2 Levobupivacaine
This anesthetic is the S-isomer of the bupivacaine, having the advantage of less 
neuro-cardio-toxicity due to lower affinity for these tissues. From a cardiac point 
of view, it causes a shorter prolongation of the QT interval and lower negative 
inotropism than racemic or R+ bupivacaine [18]. Its analgesic profile is similar to 
bupivacaine, because its duration of action is also long-lasting. Like ropivacaine, it 
has an intrinsic vasoconstrictor effect.
5.3 Ropivacaine
It is an anesthetic formulated by the pure enantiomer S of 1-propyl 2′-6′ pipeco-
loxylide [19]. As levobupivacaine, it has a safer profile than bupivacaine, because it 
has a lower toxicity in the CNS and heart. Its duration of action is long-lasting, like 
that of bupivacaine and levobupivacaine. It is widely used in infiltrative anesthesia 
and peripheral nerve blocks in anesthesiology. The same precautions should be 
taken with the use (intermittent and monitored injections). It is worth remember-
ing that ropivacaine possesses intrinsic vasoconstrictor effect, which confers lower 
vascular absorption and increases its duration of action (levobupivacaine also owns 
this property).
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6. Liposomal formulations
New methods of releasing the LA have been used in order to prolong the analge-
sia conferred by these anesthetic drugs. One of them is to produce liposomes spheres 
loaded with LA. This system allows LA deposit in the center of the liposomes, being 
involved by a double lipid layer. This setting allows a slower, controlled, and gradual 
release of LA, (72–96 h), consequently providing extended analgesic duration 
[20–23]. Liposomal bupivacaine (LB) has a decreased spread when compared with 
conventional bupivacaine. Therefore, several injections are needed and next to 
each other to obtain better results. In the infiltrative technique, it should be injected 
continuously from the fascia to the dermis. Unlike conventional formulations, which 
use bupivacaine HCl, the LB is produced only with its unprotonated basic form.
7. Infiltrative or transdermal techniques: practical recommendations
When the LA is used to infiltrate the operative wound, the anesthesiologist 
should seek a balance between the dose employed considering the size of the area 
to be anesthetized. In other words, it is sought to dilute the total dose used to cover 
most of the tissues operated. Thus, the same amount of LA used for infiltration on 
one side (e.g., right breast) needs to be diluted (doubling the volume) and to be 
employed bilaterally (e.g., right and left breast), always keep in mind that we must 
respect the maximum safety doses.
This approach allows an alternative to single dose injection of LA, namely the 
implantation of catheters for complementary use of the medication (continuous 
and/or in bolus, known as Patient Controlled Analgesia PCA) in order to prolong its 
therapeutic effect. In clinical practice, these resources increase costs because they 
need to be supervised, in addition to the increased risk of infection at the catheter 
implant site. New approaches are being investigated to optimize postoperative 
analgesia—use of newer drugs, innovative delivery systems (liposomal bupivacaine 
and ropivacaine), and the use of adjuvants along with LA.
8.  Non-anesthetic drugs (adjuvants) injected together with LA 
(magnesium, epinephrine, clonidine, morphine, dexmedetomidine, 
and steroids). Is it worth?
With the advent of several approaches in the treatment of postoperative pain, 
the anesthesiologist can associate the use of various drugs and techniques aiming 
at greater efficacy in their control. The simultaneous use of several drugs (with 
pharmacological synergism) allows the anesthesiologist to decrease the total dose 
employed, when compared to the isolated use of each of them. This is one of the 
reasons for the use of adjuvants with the LA [24–26]. Another reason is to reduce 
opioid consumption in the post-operative period and associated collateral effects.
Usually, there is a consensus about the use of adjuvants in anesthesia, that is, the 
anesthesiologist must balance risks versus benefits and mainly the common sense. It 
is his/her responsibility to do the best choice in each case.
8.1 Magnesium
Magnesium sulfate antagonizes ionotropic N-methyl-D-aspartate (NMDA) 
glutamatergic receptor interfering in calcium homeostasis (membrane potential). 
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and steroids). Is it worth?
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the anesthesiologist can associate the use of various drugs and techniques aiming 
at greater efficacy in their control. The simultaneous use of several drugs (with 
pharmacological synergism) allows the anesthesiologist to decrease the total dose 
employed, when compared to the isolated use of each of them. This is one of the 
reasons for the use of adjuvants with the LA [24–26]. Another reason is to reduce 
opioid consumption in the post-operative period and associated collateral effects.
Usually, there is a consensus about the use of adjuvants in anesthesia, that is, the 
anesthesiologist must balance risks versus benefits and mainly the common sense. It 
is his/her responsibility to do the best choice in each case.
8.1 Magnesium
Magnesium sulfate antagonizes ionotropic N-methyl-D-aspartate (NMDA) 
glutamatergic receptor interfering in calcium homeostasis (membrane potential). 
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When injected together with LA in regional anesthesia, some evidence suggest that 
its use is beneficial [27]. Conversely, the use of magnesium sulfate intravenously is 
controversial [28, 29].
8.2 Dexmedetomidine
Dexmedetomidine (DMD) is a strong and highly selective α2-adrenoceptor 
agonist. When added to local anesthetics can enhance the analgesic efficacy of the 
peripheral regional nerve block [30]. DMD is eight times more selective than cloni-
dine. It has analgesic, sedative, and antihypertensive effects, when used in systemic 
route. This substance has been associated with bupivacaine and lidocaine aiming 
prolonging the analgesic effect [31].
8.3 Epinephrine
Epinephrine has been used mixed to local anesthetics since a long time ago, 
and its recommended concentration is 5–10 μg/mL. It has, besides vasoconstrictive 
action that prolongates the local anesthesia, an analgesic effect mediated by alpha-2 
adrenoceptor activation [32]. The vasoconstrictor effect of epinephrine can prevent 
inadvertent intravascular administration of local anesthetic solutions. Nowadays, 
the use of ultrasonography made such use largely redundant [33].
The onset time of local anesthesia after single injection was considered clinically 
significantly reduced when epinephrine was added to lidocaine or bupivacaine, 
when performing peripheral nerve blocks [34]. Current recommendations, how-
ever, allow the use of epinephrine in peripheral blocks only when ultrasonography 
is not available [35].
8.4 Clonidine
Clonidine applied at perineural sites, in doses up to 1.5 mcg/kg, acts as an adjuvant 
to local anesthetics prolonging analgesia and sensory/motor blocks [36]. It has intrinsic 
analgesic properties, inhibiting action potentials of C and Aδ fibers, as well as modu-
lates the redistribution of local anesthetics through alpha1-receptors activation [37].
Side effects of this drug are dose dependent and include sedation, by decreasing 
sympathetic outflow (suppressing the release of norepinephrine in locus ceruleus 
(CNS) and substantia gelatinosa), hypotension, bradycardia, dry mouth, constipa-
tion, dizziness, and drowsiness [38].
Clonidine represents a good addition for the armamentarium of anesthesiolo-
gists because it prolongs the duration of analgesia, provides a faster onset of action, 
and improves the quality of nerve blocks (decreasing opioid consumption) [39, 40].
8.5 Morphine
Morphine is used by several routes and dosages (intrathecal: 100–200 mcg, 
epidural: 1–5 mg, peripheral nerve block: 75–100 mcg/kg, intravenous and intra-
muscular) [41]. Despite its use to prolong the analgesia, it is important to the 
anesthesiologist to pay attention at recommended doses to avoid the undesirable 
side effects (pruritus, nausea, vomiting, urinary retention, and respiratory failure). 
Always double check the vials before the administration of this medication because 
there are several vials currently in use (2, 4, 5, 8, and 10 mg/ml). All vital signals 
must be monitored at post-anesthetic care unit after the morphine use to early 
detect any cardiovascular or respiratory complications: bradycardia, hypotension, 
hypoxemia, and respiratory failure [42].
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8.6 Steroids
Dexamethasone, a potent anti-inflammatory agent, has been investigated for 
its role as an adjuvant to local anesthetics in neuraxial as well as peripheral nerve 
blocks. This steroid has been used in intrathecal anesthesia (8 mg preservative 
free), in epidural analgesia (4–8 mg) and as an adjuvant in a variety of peripheral 
blocks, like brachial plexus, ankle block, and TAP block. A meta-analysis has found 
it to significantly prolong the duration of brachial plexus block when using con-
ventional local anesthetics solutions [43]. Besides all the researches about the role 
of dexamethasone in neural block, one question has not been answered yet: is the 
better and prolonged analgesia caused by systemic effects of the steroid?
9. The four stages of wound healing
The wound healing is a continuous process, but for didactic understanding, 
it can be divided into four phases [44, 45]. The first phase occurs just after the 
incision or lesion of the skin, as soon as the blood leaks out of the body. There is a 
vasoconstriction, and the platelets stick together to initiate the coagulation. This 
phase is called the hemostasis phase. The platelet plug is reinforced by threads of 
fibrin. The hemostasis phase occurs very rapidly, in a question of seconds. As the 
fibrin mesh is formed, the blood is transformed from liquid to a gel state, that is, the 
pro-coagulant effect of prothrombin. This clot keeps the platelets and blood cells 
trapped in the wound area. Just after the injury of the skin, the epidermal tissue and 
the keratinocytes release the interleukin-1 (IL-1) pre-stored in these sites. The coag-
ulation process activates the clotting cascade which is responsible to give the matrix 
for the influx of inflammatory cells. The degranulation of the platelets releases 
alpha granules, which secrete growth factors, like epidermal growth factor (EGF), 
platelet derived growth factor (PDGF), and transforming growth factor-beta (TGF-
β). The PDGF and the IL-1 are responsible for attracting neutrophils to the wound 
site to remove bacteria [44]. The monocytes cells are converted to macrophages 
by influence of TGF-β, what has an important role in the initiation of the granula-
tion tissue and a many proinflammatory cytokines (IL-1 and IL-6), besides other 
growth factors, like fibroblast growth factor (FGF), EGF, TGF-β, and PDGF. All 
these growth factors and the added endothelial cell proliferation ensues the angio-
genesis beginning. During this hemostasis phase, the injured blood vessels leak 
transudate causing localized swelling and cell migrations to the site of wound. The 
damaged cells, pathogens, and bacteria are removed. White cells, growth factors, 
nutrients, and enzymes create the swelling, heat, pain, and redness, normally seen 
in the wound healing. This phase where all these signs appear is called the inflam-
matory phase. This phase is not a problem unless it is prolonged and excessive. After 
all the bacteria and debris are removed, the wound is rebuilt with a new tissue made 
up of collagen and extracellular matrix. This is the proliferative phase. In this phase, 
new blood vessels are formed, so that the granulation tissue can receive enough 
oxygen and nutrients. The myofibroblasts are responsible for the contraction of the 
wound, making the granulation tissue to take the ideal dimensions to the lesion. The 
granulation in this phase is pink or red. If there is a dark color is a sign of infection, 
ischemia or poor perfusion. At the end of this process the epitelial cells resurface 
the wound extension, what is called the maturation or remodelling phase. In this 
stage, it is wise to maintain the wound moist and hydrated to optimize the epitheli-
alization [46]. Some authors consider that the wound healing has only three phases, 
and this is comprehensible as long as the hemostasis phase and the inflammatory 
phase are so concomitant, dynamic, and interactive, that they consider it just as an 
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new blood vessels are formed, so that the granulation tissue can receive enough 
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wound, making the granulation tissue to take the ideal dimensions to the lesion. The 
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and this is comprehensible as long as the hemostasis phase and the inflammatory 
phase are so concomitant, dynamic, and interactive, that they consider it just as an 
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inflammation phase. In fact, the phases do not have a predetermined duration, as 
Witte and Barbul showed in their article (Figures 4 and 5), the migration of cells to 
the wound site and the matrix formation [47].
10. Local anesthetics can influence the process of wound healing?
When there is a rupture of vessels, there is an exposure of the subendothelial 
collagen to the platelets. This contact results in the aggregation and activation of the 
intrinsic factor of coagulation cascade. In the presence of thrombin, fibronectin, and 
their fragments, there is the release of cytokines and growth factors from platelets 
Figure 5. 
Deposition of wound matrix components over time [47].
Figure 4. 
The time course of different cells during healing process. Macrophages and neutrophils are predominant in 
inflammation phase, whereas lymphocytes peak somewhat later. In the proliferative phase, fibroblasts are more 
frequent [47].
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(PDGF), transforming growth factor-β (TGF-β), platelet-activating factor (PAF), 
fibronectin, and serotonin. All this form the local fibrin clot that is the scaffolding 
for invading cells such as neutrophils, monocytes, fibroblasts, and endothelial cells. 
The neutrophils are the first cells to invade the wound, increasing the vascular 
permeability due to inflammation and release of prostaglandins. In the same time, 
chemotactic substances like complement factors, interleukin, tumor necrosis 
factor-α (TNF-α), TGF-β, platelet factor 4, and stimulate neutrophil migration 
[47–49]. The factors associated with wound healing can be seen in Table 2.
When analyzing the possible action of the LAs in the wound healing process, 
many aspects can take role. Injecting any substance in the surgery site, it is 
expected that it can have at least a pH influence, as the anesthetic has a pH dif-
ferent of the physiologic one. Many times, epinephrine is used to prolong the 
duration and lower the toxicity of the drug used [50, 51]. The influence of pain 
in the wound healing has been studied too [52–54]. The wound healing in the 
fetus has also been the object of research [55, 56]. And last, the LA probably can 
have a direct action in the eicosanoids or in the fibroblast formation and so in the 
 cicatricial process [56].
These all are hypothesis that are discussed deeply, and many researches in 
human have to be done, unfortunately the majority of the manuscripts are in rats 
and they have a different immunologic system than humans.
The tissue injury caused by surgery produces directly and indirectly activa-
tion of nociceptors and higher expression of proinflammatory cytokines and 
cyclooxygenase-2 (COX-2), leading to peripheral and central sensitization with 
subsequent hyperalgesia. The pain and inflammation are maintained by abundant 
eicosanoids, like prostaglandin E2, released after surgical trauma. The long-acting 
local anesthetics such as bupivacaine and ropivacaine are used to provide prolonged 
perioperative pain relief and to diminish the occurrence of postoperative sensitiza-
tion that manifests with hyperalgesia after the anesthetic effect has dissipated. The 
occurrence of hyperalgesia is very common when high doses of anesthetic are used 
[57, 58]. The routine of infiltrating the surgical site reduces the postoperative pain 
Function
Hemostatic factors
Fibrin, plasma fibronectin Coagulation, chemo attraction
Structure for cell migration
Factor XIII (fibrin-stabilizing 
factor)
Circulatory growth factors
Chemo attraction and adhesion
Modulation of chemo attraction, mitogenesis, fibroplasia
Complement Antimicrobial activity, chemo attraction
Platelet-derived factors
Cytokines, growth factors Regulation of chemo attraction, mitogenesis, fibroplasia




Vasoconstriction, platelet aggregation, chemotaxis
Platelet factor IV Chemotactic for fibroblasts and monocytes, neutralizes activity of 
heparin, inhibits collagenase
Serotonin Induces vascular permeability, chemoattractant for neutrophils
Adenosine dinucleotide Stimulates cell proliferation and migration, induces platelet aggregation
Table 2. 
Hemostatic and platelet-derived factors associated with wound healing [47].
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fetus has also been the object of research [55, 56]. And last, the LA probably can 
have a direct action in the eicosanoids or in the fibroblast formation and so in the 
 cicatricial process [56].
These all are hypothesis that are discussed deeply, and many researches in 
human have to be done, unfortunately the majority of the manuscripts are in rats 
and they have a different immunologic system than humans.
The tissue injury caused by surgery produces directly and indirectly activa-
tion of nociceptors and higher expression of proinflammatory cytokines and 
cyclooxygenase-2 (COX-2), leading to peripheral and central sensitization with 
subsequent hyperalgesia. The pain and inflammation are maintained by abundant 
eicosanoids, like prostaglandin E2, released after surgical trauma. The long-acting 
local anesthetics such as bupivacaine and ropivacaine are used to provide prolonged 
perioperative pain relief and to diminish the occurrence of postoperative sensitiza-
tion that manifests with hyperalgesia after the anesthetic effect has dissipated. The 
occurrence of hyperalgesia is very common when high doses of anesthetic are used 
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and morbidity and accelerates the recovery. This can be explained by reducing the 
production of cytokines. Although LA action is to block the nerve conduction, they 
have other cellular targets that modulate the inflammation, suggesting that the 
LAs have an anti-inflammatory effect [59, 60]. Several studies have shown that LA 
dose-dependently inhibits leukocyte adhesion to synthetic material and to blood 
vessel walls. LA can induce the release of prostacyclin, and this causes the release of 
leukocytes previously firmly adherent to vascular endothelium. It is shown that the 
LA can in low concentration stimulate the phospholipase A2 (PLA2) while in higher 
concentrations inhibited this enzyme [61].
All these considerations are important, but what is important in clinical aspects 
are the fibroblast formation and the quality of the wound healing. The first question 
the patient formulates is when he will return to normal life activity. To answer this 
question, it is important to have not only histological analyzes of the wound but also 
mechanical testing to be sure that the tissue is ready to normal work. Vasseur and 
cols in 1984 studied the effects of local anesthetics on abdominal wounds of rabbits 
[62]; using mechanical testing device, they could demonstrate that the breaking 
strength in the groups infiltrated with lidocaine or bupivacaine, do not vary con-
sistently from the tissues infiltrated with saline solution, and so they conclude that 
the local infiltration with lidocaine and bupivacaine does not alter substantially the 
healing of midline abdominal incisions in rabbits. Abrão and cols in 2014 made a 
similar work using rats and long-lasting anesthetics, bupivacaine, and ropivacaine 
[63]. They used a computerized universal testing machine, and they concluded 
that there were no significant differences among the groups with respect to tensile 
strength after 14 days. These results, however, are not the same than Hanci and cols 
in 2012, who found that lidocaine and bupivacaine reduce the collagen production 
and the wound breaking strength in Wistar rats [64]. To further augment the argu-
ment, Kesici and cols in 2018 studied the effect of bupivacaine, levobupivacaine, 
and procaine in the Sprague Dawley rats [65]. They found that bupivacaine and 
levobupivacaine affect negatively the wound healing, especially at the late period 
(21 days). The differences in these studies increase the uncertainty and discussion 
regarding the effects of local anesthetics. Many aspects must be considered like the 
animal gender, the use of other analgesic like paracetamol, the infiltration method, 
and the time of evaluation. Interestingly, there is no work done on humans, who 
certainly have a different response to pain. Probably, the reason is the difficulty to 
use the same methodology. All the researches in humans have only clinic evaluation, 
it is almost impossible to make mechanical tests. Uncertainties in this field only will 
be clarified with new studies. The clinical studies in human beings have a very sub-
jective way to follow the wound healing. They constitute another subject that must 
be studied separately. The analogic scale of pain as the consume of opioids has been 
used as parameters to analyze the efficacy of the method. These studies conclude 
that ropivacaine (0.3%) can be used alone or with the addition of DMD (1 μg/kg), 
and there is no effect on wound healing [31, 66]. We must bear in mind that some 
authors only used a clinic evaluation, what can vary a lot from one researcher to 
another.
11. Conclusion
Nowadays, all the anesthesiologists are engaged in avoiding the excessive use 
of opioids for their side effects in the postoperative pain treatment. In fact, the 
μ-opioid receptors are impaired by the unrestricted use of morphine like drugs, 
besides there is an inhibition of the beta-endorphin release. Considering that the 
infiltration of LA in the surgical site does not produce, clinically any significant 
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μ-opioid receptors are impaired by the unrestricted use of morphine like drugs, 
besides there is an inhibition of the beta-endorphin release. Considering that the 
infiltration of LA in the surgical site does not produce, clinically any significant 
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Abstract
Pain has been a faithful companion of human beings and is a result of most 
of the dental procedures and illness; therefore a good control of dental pain is 
inevitable and feasible. The administration of local anesthetics has come to be 
the standard of care of dental profession. All local anesthetics are effective and 
high safety margin in all patients including childhood. The choice of using a local 
anesthetic depends on time of the surgical procedure, patient’s medical history, 
and the interaction between local anesthetics and patient usual medications. The 
use of vasoconstrictors is priority in surgical/dental bleeding, but it must be used 
with caution in patients with cardiovascular disease to avoid a dental catastrophe. 
Dentists should be experts in dental-anesthetic techniques and in pharmacology 
of local anesthetics, since they are the most used medications in odontology. The 
accidental injection or a high absorption of local anesthetics in blood results in sys-
temic toxicity. In such situation sedation, stunning, diplopia, sensory disturbances, 
disorientation, muscles spasm, respiratory depression, seizures, or cardiac arrest 
may be present; the dentist must immediately recognize this clinical complication 
to stablish an early treatment.
Keywords: local anesthetics, dental, local anesthesia, local analgesia, complications
1. Introduction
Local anesthetics (LAs) are the most used drugs by dentists. Actually, they 
are safer drugs. More than 40% or urgent dental procedures cause pain that needs 
and injection of LA. Therefore, dentists should be experts in dental-anesthetic 
techniques and in pharmacology of LA drugs. The safe administration of LA is the 
standard of care of dentists.
Pain has been a companion of human beings since their appearance on earth. 
Before local anesthetics, natural medicine was first used to relieve dental pain. Such 
medicine has evolved since ancient Egypt and Greek culture until the nineteenth 
century when LA developed. Actually, LAs are the most secure and effective drugs 
in medicine for pain prevention and treatment. There are no drugs more effective 
than LAs to avoid pain; no other drug prevents a nociceptive impulse from reach-
ing the patient’s brain, to finally be interpreted as pain. Whenever local anesthetics 
are administered near a sensitive nerve, it produces an adequate control pain for a 
limited time with the aids of been a reversible and temporary effect without harm 
of the anesthetized nervous structure.
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Local anesthetics (LAs) are the most used drugs by dentists. Actually, they 
are safer drugs. More than 40% or urgent dental procedures cause pain that needs 
and injection of LA. Therefore, dentists should be experts in dental-anesthetic 
techniques and in pharmacology of LA drugs. The safe administration of LA is the 
standard of care of dentists.
Pain has been a companion of human beings since their appearance on earth. 
Before local anesthetics, natural medicine was first used to relieve dental pain. Such 
medicine has evolved since ancient Egypt and Greek culture until the nineteenth 
century when LA developed. Actually, LAs are the most secure and effective drugs 
in medicine for pain prevention and treatment. There are no drugs more effective 
than LAs to avoid pain; no other drug prevents a nociceptive impulse from reach-
ing the patient’s brain, to finally be interpreted as pain. Whenever local anesthetics 
are administered near a sensitive nerve, it produces an adequate control pain for a 
limited time with the aids of been a reversible and temporary effect without harm 
of the anesthetized nervous structure.
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The first registered dental anesthesia in history was in 1885 of the alveolar infe-
rior nervous, applied by the medical surgeon William Stewart Halsted. The injected 
drug was a combination of cocaine and epinephrine [1]. In 1905, 2% procaine with 
epinephrine 1:50,000 was introduced, giving a quick access to dentists worldwide. 
Procaine, propoxycaine, and tetracaine were the most used LAs until the middle 
1940s. Lidocaine was synthetized in Sweden in 1948 [2]. Articaine was synthetized 
in 1973 and introduced in dental clinic in 1976 and approved in Canada in 1984 and 
in the USA until 2000. Articaine has special characteristics of both amino amide 
and amino ester anesthetics. Its popularity has increased rapidly and is currently 
displacing the use of lidocaine in dental anesthesia [3].
Annually, a dentist in Canada applies 1800 LA cartridges, while in the USA, 
more than 300 million of cartridges are administered each year. Therefore, dentists 
should be experts in pharmacology, complications, and secondary effects of LA. In 
daily practice there are few complications related to LA, owing its security and the 
relative low doses that are applied. Nonetheless, it is necessary to consider possible 
complications, to detect it as soon as possible.
2. Pharmacology of LA
The synthetic LA has a common chemical structure, constituted by an aromatic 
ring, a hydrocarbon channel, and an amino group; the hydrocarbon channel 
and aromatic ring are joined by an ester or amide bond. Most of LAs are tertiary 
amines. The lipophilic portion is the biggest of the molecule. The aromatic portion 
proceeds from benzoic acid, aniline, or thiophene (articaine) and is the lipophilic 
portion. This portion is responsible for the affinity of nerve cells. The hydrophilic 
portion is an amino ethanol or acetic acid derivative and is responsible of water 
solubility and diffusion across tissues. LAs are amphipathic; that is, they have 
lipophilic and hydrophilic characteristics at their opposite ends of their molecules 
(Figure 1) [4]. Amides are the most common molecules; procaine is the prototype 
of this group and benzocaine for topic application. The minimal concentration of 
LA to block the conduction of a nociceptive impulse is named potency. The thera-
peutic value of the drug in terms of efficacy and tolerability is called toxicity. The 
ability of the drug to reach tissues far from the site of administration of LA is called 
diffusion. Time between the action of LA and the metabolism of its compounds is 
named time of action [5].
3. Mechanism of action of LA
The type of nervous blockade produced by LA is named non-depolarizing ner-
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inhibit the maximum permeability to sodium, whose values usually are five to six 
times greater than the necessary minimum to conduct the impulse, when this value 
fail, and the nerve block occurs. In other words, local anesthesia is induced when 
the spread of action potential is inhibited, so a painful sensation cannot be trans-
mitted from the site of origin to the brain. Or, LA alter the mechanism to sodium 
ions to gain access to the axoplasm nerve. The nerve membrane stays in a polarized 
state due to the impossibility of ionic movement responsible of action potential. LA 
blocks the entrance of sodium ions into their channels in the nerve cellular mem-
brane. The permeability to sodium is necessary to generate a new action potential 
to transmit nerve impulses to the brain [6]. The sequence of action mechanism 
proposed for LA is described in Table 1.
LAs are classified into two large groups depending on its chemical bond: 
amides or ester; the latter are almost disappearing in dentistry. The ester LAs 
are easily hydrolyzed in aqueous solution, while amide bond LAs are relatively 
resistant to hydrolysis. The most important factors that affect onset and duration 
of action of LA are tissue pH, drug pKa, diffusion time from the tip of the needle 
to nerve, nerve morphology, drug concentration, and drug solubility in lipids [7]. 
The most important of the abovementioned factors are tissue pH and drug pKa. 
The pH may be reduced in infection sites, so the result would be a delay in the 
LA onset. In clinics, the amides pK is similar, with the exception of bupivacaine 
that has a slightly greater pK and an onset time more prolonged. The proximity 
of the anesthetic to the nerve is another factor that influences the action time of 
LA; a very clear example is the Gow-Gates blockade, very slow in its installation. 
The nerve morphology is also an important factor, which thin fibers are quickly 
anesthetized compared to thicker ones. The duration of action depends on the 
depth at which the drug may be blocking the sodium channels in the nerve mem-
brane. If the LA causes vasodilatation, it allows a more or less rapid diffusion in 
the site of action and therefore a short duration of action, especially if the drug is 
administered alone. This diffusion may be reduced with the aid of vasoconstric-
tors like epinephrine, although bupivacaine is the only LA that has a prolonged 
action duration [8]. The two most important factors involved in the action of LA 
are the drug diffusion across the nerve sheath and the bind to the receptor in the 
ionic channel; a lipid-soluble free base and without electric charge is responsible 
of the diffusion across the nerve sheath.
The biotransformation of amides occurs mainly in the liver, although prilocaine 
is metabolized in plasma and eliminated in the kidney. One of its metabolites could 
be the origin of methemoglobinemia [9]. The ester LAs are biotransformed in 
plasma by enzymes called cholinesterase or pseudocholinesterase produced in the 
liver [10].
1. Displacement of sodium ions from the sodium channel receptor
2. Binding of the LA molecule to the receptor
3. Block of the sodium channel
4. Decreased sodium conduction
5. Depressed velocity of electric depolarization
6. Failed to teach the value of umbral potential
7. Absence of propagated action potentials
8. Conduction block
Table 1. 
Sequence of mechanisms of LA to produce conduction block.
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inhibit the maximum permeability to sodium, whose values usually are five to six 
times greater than the necessary minimum to conduct the impulse, when this value 
fail, and the nerve block occurs. In other words, local anesthesia is induced when 
the spread of action potential is inhibited, so a painful sensation cannot be trans-
mitted from the site of origin to the brain. Or, LA alter the mechanism to sodium 
ions to gain access to the axoplasm nerve. The nerve membrane stays in a polarized 
state due to the impossibility of ionic movement responsible of action potential. LA 
blocks the entrance of sodium ions into their channels in the nerve cellular mem-
brane. The permeability to sodium is necessary to generate a new action potential 
to transmit nerve impulses to the brain [6]. The sequence of action mechanism 
proposed for LA is described in Table 1.
LAs are classified into two large groups depending on its chemical bond: 
amides or ester; the latter are almost disappearing in dentistry. The ester LAs 
are easily hydrolyzed in aqueous solution, while amide bond LAs are relatively 
resistant to hydrolysis. The most important factors that affect onset and duration 
of action of LA are tissue pH, drug pKa, diffusion time from the tip of the needle 
to nerve, nerve morphology, drug concentration, and drug solubility in lipids [7]. 
The most important of the abovementioned factors are tissue pH and drug pKa. 
The pH may be reduced in infection sites, so the result would be a delay in the 
LA onset. In clinics, the amides pK is similar, with the exception of bupivacaine 
that has a slightly greater pK and an onset time more prolonged. The proximity 
of the anesthetic to the nerve is another factor that influences the action time of 
LA; a very clear example is the Gow-Gates blockade, very slow in its installation. 
The nerve morphology is also an important factor, which thin fibers are quickly 
anesthetized compared to thicker ones. The duration of action depends on the 
depth at which the drug may be blocking the sodium channels in the nerve mem-
brane. If the LA causes vasodilatation, it allows a more or less rapid diffusion in 
the site of action and therefore a short duration of action, especially if the drug is 
administered alone. This diffusion may be reduced with the aid of vasoconstric-
tors like epinephrine, although bupivacaine is the only LA that has a prolonged 
action duration [8]. The two most important factors involved in the action of LA 
are the drug diffusion across the nerve sheath and the bind to the receptor in the 
ionic channel; a lipid-soluble free base and without electric charge is responsible 
of the diffusion across the nerve sheath.
The biotransformation of amides occurs mainly in the liver, although prilocaine 
is metabolized in plasma and eliminated in the kidney. One of its metabolites could 
be the origin of methemoglobinemia [9]. The ester LAs are biotransformed in 
plasma by enzymes called cholinesterase or pseudocholinesterase produced in the 
liver [10].
1. Displacement of sodium ions from the sodium channel receptor
2. Binding of the LA molecule to the receptor
3. Block of the sodium channel
4. Decreased sodium conduction
5. Depressed velocity of electric depolarization
6. Failed to teach the value of umbral potential
7. Absence of propagated action potentials
8. Conduction block
Table 1. 
Sequence of mechanisms of LA to produce conduction block.
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Despite the great advances in the field or anesthetics in dentistry, the ideal agent 
do not exist; however, new ALs are increasingly safer. Some of its most important 
properties are listed in Table 2.
4. Most commonly used LA in dentistry
4.1 Lidocaine
This is the most common used LA in dentistry since its introduction in 1948 and 
now considered the gold standard for clinical use. It was the drug that displaced 
older anesthetics like procaine (Novocain). It has fast onset between 2 and 3 min-
utes with a longer and profound anesthesia. It is available in various concentrations; 
the most used are 1 and 2% cartridges with 1:100,000 and 1:50,000 epinephrine. 
Using lidocaine without a vasoconstrictor is rare in dentistry because of rapid 
vasodilation and high plasma concentrations as well as higher adverse reaction. 
For patients who are sensitive to epinephrine, they should limit the amount to 
a maximum of two cartridges per procedure. Thus, it is true for hypertensive 
patients, patients with coronary heart disease, and the elderly. Lidocaine combined 
with 1:50,000 epinephrine is commonly used in active dental bleeding because of 
diminishing up to 50%. It gives a pulpal anesthesia for up to 90 minutes and some-
times may be comparable to articaine (3–5 hours). Today, lidocaine is referred to 
local anesthetics toxicity. The maximum recommended dose in combination with 
epinephrine is 7 mg/kg for an adult or children over 15 kg, not exceeding 500 mg. 
Lidocaine alone is limited to 4.4 mg/kg, not exceeding 300 mg [11].
4.2 Mepivacaine
This is an amide type LA, available only in cartridge formed at concentration 
of 2 and 3%. Mepivacaine combined with a vasoconstrictor in 2% concentration. 




Adequate duration of action
Active, injected, or topically administered
Non-irritating
Non-permanent harm




Ability to combine with other agents without losing their properties
Sterilizable without losing its properties
Slight allergenic
Table 2. 
Important properties of LA.
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A maximum recommended dose in adult or children is 4.4 mg/kg without exceeding 
300 mg a day. Simple mepivacaine at 3% gives anesthesia for about 20–40 minutes 
in gums, 40 minutes in nerve blocks, and a maximum of 3 hours in soft tissue. It 
is the most commonly used LA in pediatric patients because of its rapid onset and 
short dental procedures. It is available in 1:20,000 combination with levonordefrin 
which is a different profile compared to epinephrine. Their affinity to alpha and 
beta receptors is 75:25, a low effect on beta receptors. Levonordefrin is one-sixth of 
the potency of epinephrine. It has the lowest pKa of all LA used in dentistry, which 
explains the rapid onset [11]. Compared with lidocaine it has a potency of 2 and is 
metabolized thru oxidase in the liver, and renal elimination in 16% is unchanged.
4.3 Articaine
It is most recently introduced to dental practice. It is an amide type but possesses an 
ester group, making it the only hybrid LA, thus metabolizing in plasma as well as by 
the liver in which most of the process takes place, giving a result an inactive metabolite 
named articainic acid. It is equivalent to lidocaine in its vasodilation effect. It has a 
fast elimination time of approximately 27 minutes, compared to 40 minutes in amide 
anesthetics. It offers 90 minutes of pulpal anesthesia and 3 hours in soft tissue, being 
a reasonable choice in most dental procedures. This is available in dental cartridges 
at 4%, with epinephrine in 1:100,000 and 1:200,000 concentrations. The maximum 
dose is 7 mg/kg (72 mg per cartridge) for adults and 5 mg/kg for children under 15 kg 
[12]. It is the LA with higher risk of postoperative paresthesia in the jaw while rarely 
happening in other non-dental specialties such as orthopedic, spinal, or eye [13, 14].
4.4 Bupivacaine
It is a long-acting amide LA. Intrapulpal anesthesia as long as offers 6 hours 
and solf tissue up to 12 hours. It is also the most toxic drug, characterized by 
cardiovascular affection, inducing sudden collapse. In the same way it can induce 
longer duration of seizures which may be explained by its slower elimination 
(0.58 L/minute clearance) and a long half-life. It is four times more potent than 
lidocaine [15]. Although related to mepivacaine because of their molecular com-
position they differ chemically, it is 35 times more liposoluble, easily crossing the 
membrane in nerve cells, binding strongly at receptor sites with greater inactiva-
tion of sodium channels which make slow recovery, hence the saying that it is not 
easily uncoupled from the receptor.
Nancarrow et al. studied fatal doses in several LA: for lidocaine 30.8 ± 5.8 mg/
kg/h, ropivacaine 7.3 ± 1.0 mg/kg, and bupivacaine 3.7 ± 1.1 mg/kg. Due to this 
finding, the toxicity threshold of bupivacaine in dental procedures is low and, 
an unnoticed injection during infiltration is dangerous and not recommended or 
approved by the FDA in children [16].
Bupivacaine is available in dental cartridges in 0.5% with 1:200,000. 
Ropivacaine has demonstrated a 75% safer profile than bupivacaine. It is a long-
acting LA with the highest pKa (8.1) and binding to plasmatic proteins in 95% 
compared to the rest of the drugs used in dentistry, which gives a slowest onset, 
although in dental procedures this is usually not an issue. With a fast onset of 4-8 
minutes after injection, 99% of patients reported low sensitivity in the lips vs. 
100% reported with lidocaine [17]. The majority of reports of bupivacaine used in 
third molar extractions and root canal has confirmed its efficiency and security.
It is four times more toxic than lidocaine, so the use in dentistry is in lower doses 
than other areas in anesthesiology. A low incidence in paresthesia near 0.5% with 
this LA in combination with epinephrine at 1:200000 in an inferior alveolar nerve 
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Despite the great advances in the field or anesthetics in dentistry, the ideal agent 
do not exist; however, new ALs are increasingly safer. Some of its most important 
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the most used are 1 and 2% cartridges with 1:100,000 and 1:50,000 epinephrine. 
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Adequate duration of action
Active, injected, or topically administered
Non-irritating
Non-permanent harm




Ability to combine with other agents without losing their properties
Sterilizable without losing its properties
Slight allergenic
Table 2. 
Important properties of LA.
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kg/h, ropivacaine 7.3 ± 1.0 mg/kg, and bupivacaine 3.7 ± 1.1 mg/kg. Due to this 
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approved by the FDA in children [16].
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acting LA with the highest pKa (8.1) and binding to plasmatic proteins in 95% 
compared to the rest of the drugs used in dentistry, which gives a slowest onset, 
although in dental procedures this is usually not an issue. With a fast onset of 4-8 
minutes after injection, 99% of patients reported low sensitivity in the lips vs. 
100% reported with lidocaine [17]. The majority of reports of bupivacaine used in 
third molar extractions and root canal has confirmed its efficiency and security.
It is four times more toxic than lidocaine, so the use in dentistry is in lower doses 
than other areas in anesthesiology. A low incidence in paresthesia near 0.5% with 
this LA in combination with epinephrine at 1:200000 in an inferior alveolar nerve 
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block has been reported [18]. Chapman and Ganendran reported that patients 
blocked with bupivacaine and epinephrine for the third molar extractions did 
not need pain medication at 4 hours after surgery compared to the control group 
(lidocaine 2%) in which all of the patients were given pain medication at the same 
time. Seventy percent of the bupivacaine group received medication at 8 hours after 
surgery, versus 100% in the lidocaine 2% group [19].
4.5 Prilocaine
For dental anesthesia, it is available in 4% concentration with or without epi-
nephrine 1:200,000. Prilocaine by itself induces more vasodilation than mepivacaine 
and less than lidocaine. It shares the same length of action, although a slower onset. 
Toxicity is lower than lidocaine. At doses above 600 mg, there is a higher risk of 
developing methemoglobinemia. In levels below 20%, clinical symptoms such as 
cyanosis, respiratory distress, and cardiovascular collapse are not seen. Mainstay 
treatment for methemoglobinemia is 1% methylene blue, 1–2 mg/kg intravenously 
slow 10-minute drip. Toxicity signs less severe than lidocaine. Prilocaine at 4% is con-
tained in cream form commercially named EMLA (lidocaine-prilocaine) commonly 
used to produce skin numbness before any type of procedure such as phlebotomy; 
the downside is the time (30 minutes) to prepare the skin completely. The maximum 
recommended dose in adults is 600 mg and 400 mg in children. It may provide anes-
thesia up to 60 minutes in an inferior alveolar block or even 4 hours in soft tissue. It is 
important to remember that prilocaine is contraindicated in patients with congenital 
or idiopathic methemoglobinemia, heart failure, or chronic pulmonary disease.
5. Pharmacology of vasoconstrictors
The LAs commonly used in dental anesthesia are vasodilators, so they increase 
the blood flow in the injected site and perhaps enhance the concentration of the 
drug in blood and the probability of anesthetic overdose. The increase in blood flow 
also results in a short duration of action, although it depends on other factors, such 
as protein binding capacity.
Vasoconstrictors are adjuvant substances to LA that play an important role 
in dental anesthesia, producing deeper anesthesia and greater action duration, 
decreased systemic toxicity possibility, as well as bleeding reduction.
The most used vasoconstrictor in dental anesthesia is epinephrine, available in 
concentrations of 1:50,000; 1:100,000; and 1:200,000. It is rapidly metabolized by 
oxidation or conjugation, and its half-life is a few minutes, but its effects can last up 
to several hours. Malamed et al. showed in experimental animals that the applica-
tion of 2% lidocaine with epinephrine 1:100,000 around the sciatic nerve reduces 
the blood flow in 79% (Table 3) [20]. Other vasoconstrictors used in this clinical 
setting are norepinephrine and levonordefrin [21]. Low plasmatic concentrations of 
adrenaline can raise heart rate, cardiac output, and systemic vasodilation because 
of its β1 adrenergic effect. The stimulation of adrenergic receptors alpha and beta 
occurs in 50/50 proportion; so that alpha-adrenergic stimulation causes peripheral 
vasoconstriction, while beta-adrenergic stimulation produces tachycardia. It is used 
to prolong the action time of LA, decrease dental bleeding, and improve the visibil-
ity of the surgical field. Its effect limits the diffusion of LA from the injection site 
and its systemic absorption reducing the possibility of systemic toxicity. Although, 
in general, vasoconstrictors are not contraindicated, the risk level depends on the 
characteristics of each patient; people with certain cardiac or endocrine diseases or 
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taking medicines that affect the sympathetic nervous system have a greater risk of 
having deleterious side effects.
The LA with epinephrine for dental use are in the following proportions: 
1:50,000 (0.02 mg/mL), 1:100,000 (0.01 mg/mL), or 1:200,000 (0.004 mg/mL) 
[22]. The administration of 2% lidocaine with epinephrine 1:100,000 (a cartridge) 
produces plasmatic concentration of 240 ± 69ρ g/mL. With the administration of 
three cartridges of epinephrine or 54 μg, the blood concentration is 302 ± 142 ρg/mL.
Usually, the administration of one cartridge of LA with epinephrine is not asso-
ciated with cardiovascular changes, while the administration of three cartridges 
of LA with epinephrine at the same concentration is associated with five times the 
concentration of epinephrine in plasma, and with it there may be systemic cardio-
vascular alterations. However, it is not necessarily associated with the dose [23].
The umbral value of plasmatic epinephrine to develop hypertension is between 
50 and 100 ρg/mL; the umbral value for systolic blood pressure is 75–125 ρg/mL, 
while the umbral value to rise the diastolic blood pressure is 150–200 ρg/mL. Barkin 
et al. found that 2% lidocaine 1:100,000 can produce non-serious cardiac arrhyth-
mias in 16% of dental patients. The study does not specify with was the most 
frequent arrhythmia or if any treatment was administered [24].
Unfortunately, the vasoconstrictor effects are not always beneficial. In special 
situations vasoconstrictors can affect the patient; an example of this are the patients 
with limited cardiovascular systemic reserves, such angina pectoris, previous 
myocardial infarction, systemic hypertension, and non-controlled hypothyroid-
ism. In such patients, epinephrine can produce indirectly central nervous system 
excitation, including systemic hypertension, tachycardia, tremors, headache, 
palpitations, cardiac arrhythmias, and stroke. Comorbidities recommendable to use 
lidocaine with epinephrine 1:100,000 to epinephrine dose of 0.04 mg = 40 μg as a 
total dose.
Procaine is a potent vasodilator and cannot produce adequate anesthesia if it 
is used without a vasoconstrictor. Lidocaine is also a vasodilator but has enough 
potency to be used alone. In contrast, mepivacaine has minor vasodilator properties 
and can be used with or without vasoconstrictors [25].
Norepinephrine as a vasoconstrictor is seldom used since fatalities due to hyper-
tension have been reported. Another disadvantage at a local level is being a quarter 
less vasoconstrictor than epinephrine and having a shorter half-life.
6. Local and systemic complications of LA
Local anesthesia is the gold standard for surgical dental procedures; it 




1 epinephrine cartridge 1:200,000 = 9 μg/mL
1 epinephrine cartridge 1:100,000 = 18 μg/mL
1 epinephrine cartridge 1:50,000 = 36 μg/mL
1 levonordefrin cartridge 1:20,000 = 90 μg/mL
Table 3. 
Vasoconstrictor concentrations in mg/mL.
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or idiopathic methemoglobinemia, heart failure, or chronic pulmonary disease.
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The LAs commonly used in dental anesthesia are vasodilators, so they increase 
the blood flow in the injected site and perhaps enhance the concentration of the 
drug in blood and the probability of anesthetic overdose. The increase in blood flow 
also results in a short duration of action, although it depends on other factors, such 
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Vasoconstrictors are adjuvant substances to LA that play an important role 
in dental anesthesia, producing deeper anesthesia and greater action duration, 
decreased systemic toxicity possibility, as well as bleeding reduction.
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oxidation or conjugation, and its half-life is a few minutes, but its effects can last up 
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of its β1 adrenergic effect. The stimulation of adrenergic receptors alpha and beta 
occurs in 50/50 proportion; so that alpha-adrenergic stimulation causes peripheral 
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Usually, the administration of one cartridge of LA with epinephrine is not asso-
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of LA with epinephrine at the same concentration is associated with five times the 
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vascular alterations. However, it is not necessarily associated with the dose [23].
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et al. found that 2% lidocaine 1:100,000 can produce non-serious cardiac arrhyth-
mias in 16% of dental patients. The study does not specify with was the most 
frequent arrhythmia or if any treatment was administered [24].
Unfortunately, the vasoconstrictor effects are not always beneficial. In special 
situations vasoconstrictors can affect the patient; an example of this are the patients 
with limited cardiovascular systemic reserves, such angina pectoris, previous 
myocardial infarction, systemic hypertension, and non-controlled hypothyroid-
ism. In such patients, epinephrine can produce indirectly central nervous system 
excitation, including systemic hypertension, tachycardia, tremors, headache, 
palpitations, cardiac arrhythmias, and stroke. Comorbidities recommendable to use 
lidocaine with epinephrine 1:100,000 to epinephrine dose of 0.04 mg = 40 μg as a 
total dose.
Procaine is a potent vasodilator and cannot produce adequate anesthesia if it 
is used without a vasoconstrictor. Lidocaine is also a vasodilator but has enough 
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consciousness. Although anesthetics are defined as safe medications, some compli-
cations have been described.
The incidence of complications related to dental anesthesia is 4.5%, and the 
most common are needle break, paresthesia, transient facial paralysis, hematoma, 
toxicity and rarely allergy, dizziness 1.3%, tachycardia 1.1%, agitation 1.1%, nausea 
0.8%, chills 0.7%, syncope, seizures, and bronchospasm [26].
As the same way, it can be complications related to additional vasoconstrictors 
of LA. It has been shown that the increases in plasmatic catecholamines observed 
after the LA infiltration are mainly due to higher doses of vasoconstrictors. 
Vasoconstrictors increase heart rate in 4.1% of patients and increase 20% with 
respect to baseline. Coronary insufficiency, arterial hypertension, myocardial 
infarction (in the last 6 months), congestive heart failure, pheochromocytoma, 
hyperthyroidism, and diabetes mellitus are risk factors for the use of vasoconstric-
tors during dental anesthesia [27].
Patients receiving LA are not always healthy; they can have hypertension, 
history of myocardial infarction, sequelae of diabetic neuropathy, cardiac disease, 
serious dental infections, are patients in extremes of life. Some are taking aspirin for 
various reasons: this drug inhibits the secretion of thromboxane, adenosine diphos-
phate, and serotonin, chemicals mediators necessary to the platelet plug formation. 
Therefore, all patients taking aspirin should be recommended to suppress it at least 
6 or 7 days before the dental intervention. The aspirin binds to the platelet during 
its half-life of approximately 7 days, so by removing aspirin, the new platelets will 
function adequately. In arrhythmic patients the use of anesthetics with vasocon-
strictors is not recommended.
More than 45% of dental patients have one or more concomitant disease in 
their medical history, and near 20% of patients will have some disease and drug 
or food allergy. The secondary effects of LA are mainly present in patients with 
risk factors; in such patients the secondary effects can raise to 5.7% [28], which 
may result in greater morbidity. Nowadays, although lidocaine is the most used 
LA in dentistry, there are other LAs such as articaine that could displace the use 
of lidocaine.
Complications of LA include local and systemic effects. Local complications 
include:
6.1 LA failure
The possibility that local dental anesthesia fails is remote. Timely identification 
of the reasons of regional anesthesia failure in dental or maxillofacial surgery is 
essential to adopt the measures required for its correction. Some factors of anes-
thetic failure involve bifid inferior alveolar nerve, retromolar foramen associated to 
accessory innervation, double or accessory mental foramen, the relation between 
the infiltration technique and bone density, accessory innervation in the case of 
the mylohyoid nerve and first cervical branches, cross innervation of the incisors, 
inactivity in the presence of tissue inflammation, inactive LA, incorrect technique, 
and subjective perception on the part of anxious patients [12]. Table 4 lists other 
important factors.
6.2 Hematoma
Damage to blood vessels is usually caused by the tip needle, the blood accu-
mulated inside the oral tissues, and the swelling located in any tissue which acts 
as an irritant of the tissue and causes pain and trismus. Accumulated blood can 
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be a culture medium for oral bacteria, especially in diabetic patients or those with 
immune deficiency.
6.3 Nerve damage
The needle can damage a nerve which produces a partial or complete deficit with 
motor or sensory abnormalities that usually have a full recovery.
6.4 Transient facial nerve paralysis
This complication is caused by the introduction of LA into the parotid gland 
capsule, which is located at the back of the edge of the mandibular branch. If the 
LA is deposited on this site, a transient paralysis of muscles of the face occurs. 
The LA is applied next to the facial nerve, so the motor blockade would cause a 
temporary paralysis of the muscles of the face; clinically a modification in the face 
expression appears. The duration of motor paralysis lasts between 3 and 5 hours, 
and treatment is not required. An important clinical situation is that patient cannot 
close the affected eye and is necessary to avoid the dry eye during this period of 
involvement [29].
6.5 Needle rupture
Since the introduction of non-reusable needles in dental anesthesia, needle 
rupture has been an extremely rare complication. Progrel et al. estimated this risk 
at 1:14 million, more specifically in the case of inferior alveolar nerve block. In 
the analysis of broken needles, it was found that the majority were short or G30 
ultra-short needles (20 and 10 mm). The inferior alveolar nerve block was the most 
frequent in 79% of the cases and the alveolar superior posterior nerve in the rest 
of the cases. Additional factors are pre-bending of the needle before injection, the 
unexpected and sudden movement of the patient at the time the needle is entering 
the soft tissue, and strong contact of the needle with the bone [30].
6.6 Systemic complications of LA
Local anesthetic-related systemic complications are associated with the nature 
of the drug and/or their composition. Systemic complications are as followed:
6.6.1 Systemic or local infection
Spreading the potentially dangerous infection within mouth soft tissue to 
neck or head may be caused by needle trauma. Dental abscess is a great danger to 
1. Inadequate anatomical selection
2. Insufficient LA dose
3. Insufficient time for the LA diffusion
4. Administration of LA in swelling or infected tissue
5. Use of expired LA
Table 4. 
LA failure in dental practice.
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and subjective perception on the part of anxious patients [12]. Table 4 lists other 
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Damage to blood vessels is usually caused by the tip needle, the blood accu-
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be a culture medium for oral bacteria, especially in diabetic patients or those with 
immune deficiency.
6.3 Nerve damage
The needle can damage a nerve which produces a partial or complete deficit with 
motor or sensory abnormalities that usually have a full recovery.
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This complication is caused by the introduction of LA into the parotid gland 
capsule, which is located at the back of the edge of the mandibular branch. If the 
LA is deposited on this site, a transient paralysis of muscles of the face occurs. 
The LA is applied next to the facial nerve, so the motor blockade would cause a 
temporary paralysis of the muscles of the face; clinically a modification in the face 
expression appears. The duration of motor paralysis lasts between 3 and 5 hours, 
and treatment is not required. An important clinical situation is that patient cannot 
close the affected eye and is necessary to avoid the dry eye during this period of 
involvement [29].
6.5 Needle rupture
Since the introduction of non-reusable needles in dental anesthesia, needle 
rupture has been an extremely rare complication. Progrel et al. estimated this risk 
at 1:14 million, more specifically in the case of inferior alveolar nerve block. In 
the analysis of broken needles, it was found that the majority were short or G30 
ultra-short needles (20 and 10 mm). The inferior alveolar nerve block was the most 
frequent in 79% of the cases and the alveolar superior posterior nerve in the rest 
of the cases. Additional factors are pre-bending of the needle before injection, the 
unexpected and sudden movement of the patient at the time the needle is entering 
the soft tissue, and strong contact of the needle with the bone [30].
6.6 Systemic complications of LA
Local anesthetic-related systemic complications are associated with the nature 
of the drug and/or their composition. Systemic complications are as followed:
6.6.1 Systemic or local infection
Spreading the potentially dangerous infection within mouth soft tissue to 
neck or head may be caused by needle trauma. Dental abscess is a great danger to 
1. Inadequate anatomical selection
2. Insufficient LA dose
3. Insufficient time for the LA diffusion
4. Administration of LA in swelling or infected tissue
5. Use of expired LA
Table 4. 
LA failure in dental practice.
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patient’s health and a high risk for airway management by the anesthesiologist due 
to the possibility of rupturing it during the intubation. It is important to emphasize 
that LA should not be applied in infected soft tissue.
Bacterial endocarditis is not a complication related to the use of LA per se; 
however it can be related as a post procedure bacteremia after any type of injection 
to the mouth. Dental surgery that involves mucosa o contaminated tissue such as 
a molar extraction can produce a transient bacteremia and facilitate infections at a 
distance, especially in cardiac valves or endocardium. The most common bacteria is 
hemolytic streptococcus viridians. Patients with dentures can develop bacteremia 
from gum ulcers or gingivitis. Numerous studies have shown a possible odontology-
related etiology of bacterial endocarditis in up to 20% of the patients. Although 
prophylactic antibiotics are a commonly accepted practice, the American Heart 
Association (AHA) in 1997 described multiple prophylactic strategies: (a) amoxicil-
lin 2 g, 1 hour prior to the treatment, and (b) clindamycin 600 mg, 1 hour prior to 
treatment [31].
6.7 Cardiovascular manifestations
Heart complications related to dental procedures may increase up to a 5.7% in 
patients with identified risk factors. Patients with coronary heart disease, cardiac sur-
gery, or heart failure show greater plasmatic lidocaine levels; therefore a 50% reduc-
tion in maximum dosage of LA is recommended. Potassium levels and acidosis may 
worsen the adverse effects in the myocardium. High-risk patients should be limited to 
30-minute dental surgery; after that time complications may rise up to 15% [32].
Cardiovascular collapse is described as the most severe LA complication, asso-
ciated with high mortality. It is produced by intravascular injection of AL and is 
manifested by arrhythmias, heart failure, and arterial hypotension that can end in 
death if not treated in a timely manner. Usually, the doses of LA used in dentistry 
rarely exceed the limits to cause cardiovascular problems, although in exceptional 
cases, small amounts of AL may be capable of cardiac arrest [33]. For more informa-
tion, we refer the reader to the chapter on LA systemic toxicity included in this book.
6.8 Local anesthetic overdose
Most overdose reactions occur during LA injection or within the next 5–10 min-
utes. Clinical symptoms involving the CNS are, for example, generalized numbness, 
facial numbing, anxiety, restlessness, confusion, chills, seizures, or respiratory 
arrest [7]. A simple way to avoid LA injection into the blood vessels is to aspirate 
before and during the injection. Systemic toxicity depends on several factors such as 
speed of injection, site, and combination with vasoconstrictors. For example, maxi-
mum dose of LA in a pediatric patient may be mistaken with an adult and cause an 
overdose. High concentrations of LA articaine and prilocaine may exacerbate and 
overdose. Serum concentration of LA less than 5 μg/mL produce moderate sedation 
and analgesia, but at concentrations as high as 5–10 μg/mL, it can cause incoherent 
talk, dysphoria, diplopia, muscle contractions, or seizures [34].
6.9 Plasma cholinesterase deficiency
Esther-type LA should be avoided in patients that may carry this rare enzyme 
deficiency, due to the metabolism of this anesthetic. Methemoglobinemia is a 
rare complication associated with excessive metabolites of certain LA, mainly 
prilocaine, causing oxidation of the ferrous component in the blood to a ferric 
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form, and poorly delivered oxygen to tissues commonly expressed as hypoxia. 
Unique features, such as a saturation gap and chocolate-brown-colored blood, 
can raise suspicion for methemoglobinemia. The use of articaine and benzocaine 
have also been associated with methemoglobinemia and manifests with cyanosis 
that does not respond with supplemental oxygen. When high methemoglobinemia 
levels are present, clinical symptoms such as nausea, sedation, seizures, and coma 
may appear. Treatment is with methylene blue. Thus, patients with congenital or 
acquired plasma cholinesterase deficiency should avoid exposure to these LAs [34].
6.10 Allergic reactions
These reactions are extremely rare in dentistry. The most common allergic 
 reactions are allergies to latex, acrylates, and formaldehyde. While polymethyl-
methacrylate and latex trigger delayed hypersensitivity reactions, sodium metabi-
sulphite and nickel cause immediate reactions. Most adverse reactions are caused by 
systemic complications or anxiety as a result of pain or needles, generating hyper-
ventilation or syncope that may be confused with a faulty allergic reaction. True 
allergic reactions are caused mainly by ester LA. They are not dose related. Only 
0.7–1% of all allergies are authentic hypersensitivity reactions and caused after 
administering LA [35]. It is fundamental to have previous contact with the allergen, 
and then a usual latency period occurs until a second exposure. Hypersensitivity 
reactions related to LA are classified into two types: type I reactions or humoral 
are immediate and severe such as anaphylactic shock, angioedema, fever, and 
photo sensibility. Type IV or cellular are delayed and manifested through moderate 
dermatologic reactions such as hives or cutaneous rash. Anaphylactic shock usually 
occurs within a short exposure to the antigen, and symptoms include cardiovascular 
collapse in 76.3%, bronchospasm in 44.2%, and skin in 69.9%. Cardiovascular 
 collapse presents as abrupt drop in blood pressure, bradycardia, and desaturation 
followed by bronchospasm and redness in thoracic area and face are common. 
Initial management is epinephrine 1-5 mcg/kg [36]. Intramuscular application, fluid 
bolus, secured airway, and increase in oxygen concentration. There is a frequently 
reported contact dermatitis in healthcare workers that are exposed to parabens and 
bisulfates used as preservatives in local anesthetic preparations which can cause an 
allergic reaction [37, 38].
6.11 Drug interactions
There are some well-known interactions with LA, such as tricyclic antidepres-
sants and beta blockers. The first act is by inhibiting the catecholamine reuptake, 
thus increasing the concentration at the presynaptic sympathetic binding site. In 
patients taking this kind of medication, it is recommended to limit the amount 
of epinephrine to a maximum of 0.05 mg/dose. Beta blockers, on the other hand, 
inhibit arteriolar vasodilation effect of drugs as epinephrine in combination with 
LA, which increase the predominant vasoconstrictor alpha adrenergic effect. The 
end result could be an increase of arterial blood pressure and sympathetic effects. 
Another reported interaction is the diminished metabolism of amide LA. Sedatives, 
opioids, opioids, antihistamines, magnesium sulfate, and LA may increase CNS 
depression and respiratory drive which has to be titrated with caution. LA and some 
antiarrhythmic like quinidine may increase myocardial depression. Antimyasthenic 
agents such as neostigmine could antagonize the effect or muscle contraction. 
Anticholinesterase lowers the metabolism of ester LA. Ester LA such as procaine 
combined with sulfas could inhibit antimicrobial action [34].
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7. Conclusions
Anxiety, stress, and pain are very frequent characteristics in dentistry. Dental 
anxiety can be considered as a universal phenomenon with a high prevalence, being 
one of the main causes of medical emergencies in the dental office, so its preven-
tion is an essential part of patient safety and quality of care. The LA used in this 
clinical setting must be selective in nerve tissue; be powerful enough to produce 
complete anesthesia without tissue damage; have a reversible action within a 
predictable time; have minimal side effects and, also, reduced systemic toxicity, and 
few hypersensitivity reactions; have a short latency period with the duration of the 
effect adaptable to the desired; not cause pain during injection; be compatible with 
other components in the solution and not easily modified by sterilization processes; 
not be sensitive to variations in pH; be stable in the solution; and have sufficient 
penetration. Lidocaine and articaine with epinephrine are the most used, although 
mepivacaine and prilocaine are still options. It is mandatory to monitor side reac-
tions, especially systemic toxicity.
147
Local Anesthetics in Odontology
DOI: http://dx.doi.org/10.5772/intechopen.91738
[1] López-Valverde A, de Vicente J, 
Cutando A. The surgeons Halsted and 
Hall, cocaine and the discovery of dental 
anaesthesia by nerve blocking. British 
Dental Journal. 2011;2011:485-487
[2] Lofgren N. Studies on Local 
Anesthetics: Xylocaine, a New Synthetic 
Drug. Hoeggstroms: Stockhlm; 1948
[3] Vree TB, Gielen MJ. Clinical 
pharmacology and the use of articaine 
for local and regional anaesthesia. 
Best Practice and Research in Clinical 
Anaesthesiology. 2005;19(2):293-308
[4] Yagiela JA. Recent developments 
in local anesthesia and oral sedation. The 
Compendium of Continuing Education 
in Dentistry. 2004;25(9):697-706
[5] Suresh S, Ecoffey C, Bosenberg A,  
Lonnqvist PA, De Oliveira GS,  
De Leon CO, et al. Recommendations 
ESRA/ASRA on local anesthetics 
and adjuvants dosage in pediatric 
Regional anesthesia. The European 
Society of Regional Anaesthesia 
and Pain Therapy/American Society 




[6] De B, Reed KL. Local anesthetics: 
Review of pharmacological 
considerations. Anesthesia Progress. 
2013;59:90-102
[7] Has DA. An update of local anesthetics 
in dentistry. Journal of the Canadian 
Dental Association. 2002;68(9):546-551
[8] Alcaina-Lorente MA, Cortes-Lillo O,  
German Cecilia C, Castejon-Navas I.  
Parestesia con el uso de anestésicos 
locales. A propósito de dos casos. 
Odontologia Pediátrica. 2010;18(3): 
201-2008
[9] Manani G, Charanda M, Benatti M, 
Narne S, Zanardi L, Rusca F, et al. 
Gow-gates block for beginners. 
Giornale di Anestesia Stomatologica. 
1989;18(3):7-17
[10] Johnson TM, Badovinac R, Shaefer J. 
Teaching alternatives to the standard 
inferior alveolar nerve block in dental 
education: Outcomes in clinical 
practice. Journal of Dental Education. 
2007;71(9):1145-1152
[11] Malamed SF, Reed KL, Okundeye A, 
Fonner A. Local and regional anesthesia 
in dental and oral surgery. Complications 
of Regional Anesthesia. 2017. DOI: 
10.1007/978-3-319-49386-2_21
[12] Boronat López A, Peñarrocha DM. 
Failure of locoregional anesthesia in 
dental practice. Review of the literature. 
Medicina Oral, Patología Oral y Cirugía 
Bucal. 2006;11(6):E510-E513
[13] Malamed SF. Local anesthetics 
dentistry’s most important drugs, 
clinical update 2006: CDA. Journal 
of the California Dental Association. 
2006;34(12):971-976
[14] Batista da Silva C, Berto LA, 
Volpato MC, Ramacciato JC, Motta RH, 
Ranali J, et al. Anesthetic efficacy of 
articaine and lidocaine for incisive/
mental nerve block. Journal of 
Endodontics. 2010;36(3):438-441
[15] Sambrook PJ, Smith W, Elijah J, 
Goss AN. Severe adverse reactions to 
dental local anaesthetics: Systemic 
reactions. Australian Dental 
Journal. 2011;56:148-153. DOI: 
10.1111/j.1834-7819.2011.01316.x
[16] Liu W, Yang X, Li C, Mo A. Adverse 
drug reactions to local anesthetics: 
A systematic review. Oral Surgery, 
Oral Medicine, Oral Pathology, Oral 
Radiology. 2013;115(3):319-327. DOI: 
10.1016/j.oooo
[17] Sancho-Puchades M, Vilchez-
Perez MA, Valmaseda-Castellon E, 
References
Topics in Local Anesthetics
146
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Enrique Hernández-Cortez1*, Cecilia G. Sandoval Larios2  
and Juan Carlos Flores-Carrillo3
1 Department of Anesthesia, Federación Mexicana de Colegios de Anestesiología, 
A.C., León, México
2 Anesthesia and Cardiovascular Anesthesia, Airway Committee Federación 
Mexicana de Colegios de Anestesiologia AC, Hospital Angeles León, México
3 Anesthesia and Critical Care Medicine, Hospital Angeles Tijuana, México
*Address all correspondence to: kikinhedz@gmail.com
7. Conclusions
Anxiety, stress, and pain are very frequent characteristics in dentistry. Dental 
anxiety can be considered as a universal phenomenon with a high prevalence, being 
one of the main causes of medical emergencies in the dental office, so its preven-
tion is an essential part of patient safety and quality of care. The LA used in this 
clinical setting must be selective in nerve tissue; be powerful enough to produce 
complete anesthesia without tissue damage; have a reversible action within a 
predictable time; have minimal side effects and, also, reduced systemic toxicity, and 
few hypersensitivity reactions; have a short latency period with the duration of the 
effect adaptable to the desired; not cause pain during injection; be compatible with 
other components in the solution and not easily modified by sterilization processes; 
not be sensitive to variations in pH; be stable in the solution; and have sufficient 
penetration. Lidocaine and articaine with epinephrine are the most used, although 
mepivacaine and prilocaine are still options. It is mandatory to monitor side reac-
tions, especially systemic toxicity.
147
Local Anesthetics in Odontology
DOI: http://dx.doi.org/10.5772/intechopen.91738
[1] López-Valverde A, de Vicente J, 
Cutando A. The surgeons Halsted and 
Hall, cocaine and the discovery of dental 
anaesthesia by nerve blocking. British 
Dental Journal. 2011;2011:485-487
[2] Lofgren N. Studies on Local 
Anesthetics: Xylocaine, a New Synthetic 
Drug. Hoeggstroms: Stockhlm; 1948
[3] Vree TB, Gielen MJ. Clinical 
pharmacology and the use of articaine 
for local and regional anaesthesia. 
Best Practice and Research in Clinical 
Anaesthesiology. 2005;19(2):293-308
[4] Yagiela JA. Recent developments 
in local anesthesia and oral sedation. The 
Compendium of Continuing Education 
in Dentistry. 2004;25(9):697-706
[5] Suresh S, Ecoffey C, Bosenberg A,  
Lonnqvist PA, De Oliveira GS,  
De Leon CO, et al. Recommendations 
ESRA/ASRA on local anesthetics 
and adjuvants dosage in pediatric 
Regional anesthesia. The European 
Society of Regional Anaesthesia 
and Pain Therapy/American Society 




[6] De B, Reed KL. Local anesthetics: 
Review of pharmacological 
considerations. Anesthesia Progress. 
2013;59:90-102
[7] Has DA. An update of local anesthetics 
in dentistry. Journal of the Canadian 
Dental Association. 2002;68(9):546-551
[8] Alcaina-Lorente MA, Cortes-Lillo O,  
German Cecilia C, Castejon-Navas I.  
Parestesia con el uso de anestésicos 
locales. A propósito de dos casos. 
Odontologia Pediátrica. 2010;18(3): 
201-2008
[9] Manani G, Charanda M, Benatti M, 
Narne S, Zanardi L, Rusca F, et al. 
Gow-gates block for beginners. 
Giornale di Anestesia Stomatologica. 
1989;18(3):7-17
[10] Johnson TM, Badovinac R, Shaefer J. 
Teaching alternatives to the standard 
inferior alveolar nerve block in dental 
education: Outcomes in clinical 
practice. Journal of Dental Education. 
2007;71(9):1145-1152
[11] Malamed SF, Reed KL, Okundeye A, 
Fonner A. Local and regional anesthesia 
in dental and oral surgery. Complications 
of Regional Anesthesia. 2017. DOI: 
10.1007/978-3-319-49386-2_21
[12] Boronat López A, Peñarrocha DM. 
Failure of locoregional anesthesia in 
dental practice. Review of the literature. 
Medicina Oral, Patología Oral y Cirugía 
Bucal. 2006;11(6):E510-E513
[13] Malamed SF. Local anesthetics 
dentistry’s most important drugs, 
clinical update 2006: CDA. Journal 
of the California Dental Association. 
2006;34(12):971-976
[14] Batista da Silva C, Berto LA, 
Volpato MC, Ramacciato JC, Motta RH, 
Ranali J, et al. Anesthetic efficacy of 
articaine and lidocaine for incisive/
mental nerve block. Journal of 
Endodontics. 2010;36(3):438-441
[15] Sambrook PJ, Smith W, Elijah J, 
Goss AN. Severe adverse reactions to 
dental local anaesthetics: Systemic 
reactions. Australian Dental 
Journal. 2011;56:148-153. DOI: 
10.1111/j.1834-7819.2011.01316.x
[16] Liu W, Yang X, Li C, Mo A. Adverse 
drug reactions to local anesthetics: 
A systematic review. Oral Surgery, 
Oral Medicine, Oral Pathology, Oral 
Radiology. 2013;115(3):319-327. DOI: 
10.1016/j.oooo
[17] Sancho-Puchades M, Vilchez-
Perez MA, Valmaseda-Castellon E, 
References
Topics in Local Anesthetics
148
Paredes-Garcia J, Berini-Aytes L, 
Gay-Escoda C. Bupivacaine 0.5% 
versus articaine 4% for the removal 
of lower third molars. A crossover 
randomized controlled trial. Medicina 
Oral, Patología Oral y Cirugía Bucal. 
2012;17(3):e462-e468
[18] Feldman G, Nordenram A. 
Bupivacaine in oral surgery. Acta 
Anaesthesiologica Scandinavica. 
1983;23:409-413
[19] Sisk AL. Long-acting local 
anesthetics in dentistry. Anesthesia 
Progress. 1992;39:53-60
[20] Malamed SF, Gagnon S, Lebalanc D. 
Efficacy of articaine: A new amide 
local anesthetic. Journal of the 
American Dental Association (1939). 
2000;131(5):635-642
[21] James O, Ladeinde AL, 
Ogunlewe MO, Ajuluchukwu JN, 
Adeyemo WL. Hemodynamic response 
after injection of local anesthetics with 
or without adrenaline in adult Nigerian 
subjects undergoing simple tooth 
extraction. Journal of Clinical Sciences. 
2015;12:90-95
[22] Lawaty I, Drum M, Reader A, 
Nusstein J. A prospective, randomized, 
double-blind comparison of 
2% mepivacaine with 1 : 20,000 
levonordefrin versus 2% lidocaine 
with 1 : 100,000 epinephrine for 
maxillary infiltrations. Anesthesia 
Progress. 2010;57(4):139-144. DOI: 
10.2344/0003-3006-57.4.139
[23] Sisk AL. Vasoconstrictors in local 
anesthesia for dentistry. Anesthesia 
Progress. 1992;39:187-193
[24] Becker DE, Reed KL. Essentials 
of local anesthetics pharmacology. 
Anesthesia Progress. 2006;53:98-109
[25] Hass DA. Drugs in dentistry. In: 
Compendium of Pharmaceuticals and 
Specialties. 37th ed. Canada: Canadian 
Pharmaceurical Association; 2002. 
pp. L26-L29
[26] Daublander M, Muller R, Lipp MDW. 
The incidence of complications 
associated with local anesthesia in 
dentistry. American Dental Society of 
Anesthesiology. 1997;44:132-141
[27] Seminario-Amez M, 
González-Navarro B, Velasco-Ortega E, 
Jane-Salas E, Lopéz-Lopéz J. Use 
of local anesthetics associated with 
vasoconstrictors in dentistry. Is it a 
safe treatment? A literature update. EC 
Anesthesia. 2017;3.2:50-54
[28] Daublander M, Muller R,  
Lipp MDW. The incidence of 
complications associated with local 
anesthesia in dentistry. American 
Dental Society of Anesthesiology. 
1999;50:102-106
[29] Malamed SF. Nerve injury caused 
by mandibular block analgesia. 
International Journal of Oral and 
Maxillofacial Surgery. 2006;35:876-877
[30] Progrel MA. Broken local anesthetic 
needle: A series of 16 patients, 
with recommendations. Journal of 
the American Dental Association. 
2009;140:1517-1522
[31] Tomás-Carmona I, Diz-Dios P, 
Limeres-Posse J, Outumuro-Rial M, 
Caamaño-Durán F, Fernández-Feijoo J, 
et al. Pautas de profilaxis antibiótica de 
Endocarditis Bacteriana, recomendadas 
por los odontólogos en España. Medicina 
Oral. 2004;9:56-62
[32] Bahl R. Local anesthesia in 
dentistry. Anesthesia Progress. 2004;51: 
138-142
[33] Becker DE, Reed KL. Local 
anesthetics: Review of pharmacological 
considerations. Anesthesia Progress. 
2012;59:90-101
[34] Yagiela JA. Local anesthetics. 
Anesthesia Progress. 1991;38:128-141
149
Local Anesthetics in Odontology
DOI: http://dx.doi.org/10.5772/intechopen.91738
[35] Speca SJ, Boynes SG, Cuddy MA. 
Allergic reactions to local anesthetic 
formulations. Dental Clinics of North 
America. 2010;54:655-664
[36] Truhlar A, Deakin CD, Soar J,  
Khalifa GE, Alfonzo A, Bierens JJ.  
European resuscitation council 
guidelines for resuscitation. Cardiac 
arrest in special circumstances. 
Resuscitation. 2015;95:148-201
[37] Gaitan-Padron MA, 
Hernández-Cortez E. Alergia al latex 
en el paciente pediátrico. Anestesia en 
México. 2013;25(S1):25-32
[38] Bina B, Hersh EV, Hilario M, 
Alvarez K, McLaughlin B. True allergy 
to amide local anesthetics: A review and 
case presentation. Anesthesia Progress. 
2018;65(2):119-123. DOI: 10.2344/
anpr-65-03-06
Topics in Local Anesthetics
148
Paredes-Garcia J, Berini-Aytes L, 
Gay-Escoda C. Bupivacaine 0.5% 
versus articaine 4% for the removal 
of lower third molars. A crossover 
randomized controlled trial. Medicina 
Oral, Patología Oral y Cirugía Bucal. 
2012;17(3):e462-e468
[18] Feldman G, Nordenram A. 
Bupivacaine in oral surgery. Acta 
Anaesthesiologica Scandinavica. 
1983;23:409-413
[19] Sisk AL. Long-acting local 
anesthetics in dentistry. Anesthesia 
Progress. 1992;39:53-60
[20] Malamed SF, Gagnon S, Lebalanc D. 
Efficacy of articaine: A new amide 
local anesthetic. Journal of the 
American Dental Association (1939). 
2000;131(5):635-642
[21] James O, Ladeinde AL, 
Ogunlewe MO, Ajuluchukwu JN, 
Adeyemo WL. Hemodynamic response 
after injection of local anesthetics with 
or without adrenaline in adult Nigerian 
subjects undergoing simple tooth 
extraction. Journal of Clinical Sciences. 
2015;12:90-95
[22] Lawaty I, Drum M, Reader A, 
Nusstein J. A prospective, randomized, 
double-blind comparison of 
2% mepivacaine with 1 : 20,000 
levonordefrin versus 2% lidocaine 
with 1 : 100,000 epinephrine for 
maxillary infiltrations. Anesthesia 
Progress. 2010;57(4):139-144. DOI: 
10.2344/0003-3006-57.4.139
[23] Sisk AL. Vasoconstrictors in local 
anesthesia for dentistry. Anesthesia 
Progress. 1992;39:187-193
[24] Becker DE, Reed KL. Essentials 
of local anesthetics pharmacology. 
Anesthesia Progress. 2006;53:98-109
[25] Hass DA. Drugs in dentistry. In: 
Compendium of Pharmaceuticals and 
Specialties. 37th ed. Canada: Canadian 
Pharmaceurical Association; 2002. 
pp. L26-L29
[26] Daublander M, Muller R, Lipp MDW. 
The incidence of complications 
associated with local anesthesia in 
dentistry. American Dental Society of 
Anesthesiology. 1997;44:132-141
[27] Seminario-Amez M, 
González-Navarro B, Velasco-Ortega E, 
Jane-Salas E, Lopéz-Lopéz J. Use 
of local anesthetics associated with 
vasoconstrictors in dentistry. Is it a 
safe treatment? A literature update. EC 
Anesthesia. 2017;3.2:50-54
[28] Daublander M, Muller R,  
Lipp MDW. The incidence of 
complications associated with local 
anesthesia in dentistry. American 
Dental Society of Anesthesiology. 
1999;50:102-106
[29] Malamed SF. Nerve injury caused 
by mandibular block analgesia. 
International Journal of Oral and 
Maxillofacial Surgery. 2006;35:876-877
[30] Progrel MA. Broken local anesthetic 
needle: A series of 16 patients, 
with recommendations. Journal of 
the American Dental Association. 
2009;140:1517-1522
[31] Tomás-Carmona I, Diz-Dios P, 
Limeres-Posse J, Outumuro-Rial M, 
Caamaño-Durán F, Fernández-Feijoo J, 
et al. Pautas de profilaxis antibiótica de 
Endocarditis Bacteriana, recomendadas 
por los odontólogos en España. Medicina 
Oral. 2004;9:56-62
[32] Bahl R. Local anesthesia in 
dentistry. Anesthesia Progress. 2004;51: 
138-142
[33] Becker DE, Reed KL. Local 
anesthetics: Review of pharmacological 
considerations. Anesthesia Progress. 
2012;59:90-101
[34] Yagiela JA. Local anesthetics. 
Anesthesia Progress. 1991;38:128-141
149
Local Anesthetics in Odontology
DOI: http://dx.doi.org/10.5772/intechopen.91738
[35] Speca SJ, Boynes SG, Cuddy MA. 
Allergic reactions to local anesthetic 
formulations. Dental Clinics of North 
America. 2010;54:655-664
[36] Truhlar A, Deakin CD, Soar J,  
Khalifa GE, Alfonzo A, Bierens JJ.  
European resuscitation council 
guidelines for resuscitation. Cardiac 
arrest in special circumstances. 
Resuscitation. 2015;95:148-201
[37] Gaitan-Padron MA, 
Hernández-Cortez E. Alergia al latex 
en el paciente pediátrico. Anestesia en 
México. 2013;25(S1):25-32
[38] Bina B, Hersh EV, Hilario M, 
Alvarez K, McLaughlin B. True allergy 
to amide local anesthetics: A review and 





Complications Associated with 




One of the important attempts in clinical oral surgery practice is to maintain 
safe and effective local anesthesia. Dental procedures are frequently performed 
under local anesthesia; thus, drug-related complications are often encountered. It is 
mandatory to have a preoperative evaluation of the patient and choosing the proper 
local anesthetic agent. Various complications including hypersensitivity, allergy, 
overdosage, toxicity, hematoma, trismus, paresthesia, or neuralgia can be observed 
during practice. Therefore, the practitioner should be aware of the possible compli-
cations and management methods. The aim of this chapter is to review the preop-
erative and postoperative complications associated with the local anesthetic in oral 
and maxillofacial surgery practice. The prevention of measures and treatment of 
the complications is also emphasized.
Keywords: local anesthesia, complication, local complications, systemic 
complications, treatment
1. Introduction
Local anesthetic agents have been used in clinical dentistry to allay or eliminate 
pain associated with invasive operations as early as the nineteenth century [1]. 
Local anesthetics are used routinely also in oral and maxillofacial surgery. Despite 
that local anesthetics are reliable and efficient drugs, the risks that practitioners 
need to be aware of were also reported [2].
Complications associated with local anesthetics can be evaluated systemically 
and locally. Common systemic reactions due to local anesthesia are reported as psy-
chogenic reactions, systemic toxicity, allergy, and methemoglobinemia. Common 
local complications associated with local anesthesia are reported as pain at injec-
tion, needle fracture, prolongation of anesthesia and various sensory disorders, lack 
of effect, trismus, infection, edema, hematoma, gingival lesions, soft tissue injury, 
and ophthalmologic complications [2, 3].
This chapter is presenting the local and systemic complications associated with 
the local anesthetics used in oral and maxillofacial surgery. The prevention of 
complications and management methods are also emphasized.
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2. Classification and chemical structure of local anesthetics
Local anesthetics can be classified according to their chemical structure, 
a rate of onset, potency, and duration of action. Chemically, they are either 
amino esters or amino amides (i.e., an aromatic, lipophilic ring connected to a 
hydrophilic amine group by an intermediate chain containing either an ester or 
amide linkage). Ester local anesthetics are hydrolyzed in the plasma by pseu-
docholinesterase into para-aminobenzoic acid (PABA) and other derivatives, 
whereas amide-type local anesthetics are metabolized by the liver. The rate of 
hydrolysis has an effect on the potential toxicity of a local anesthetic. Allergic 
reactions that occur in response to ester local anesthetics usually are related 
to para-aminobenzoic acid, which is a major metabolic product of many ester 
local anesthetics. The rates of biotransformation of amide group lidocaine, 
mepivacaine, etidocaine, and bupivacaine are similar. Articaine, which contains 
both amide and ester, metabolizes both in the liver and blood. The ester group 
(cenzoic acid esters) includes cocaine, procaine, chloroprocaine, tetracaine, and 
benzocaine. The amide group includes lidocaine, mepivacaine (Carbocaine), 
prilocaine (Citanest), bupivacaine (Marcaine), etidocaine (curanest), dibucaine 
(nupercaine), and ropivacaine (Naropin).
Ester local anesthetics are not available in dental cartridges essentially because 
of several reasons such as the lack of efficacy, the potential for allergenicity, and the 
advantages of amino amides [4–7].
3. Systemic reactions due to local anesthesia
3.1 Psychogenic reactions
This psychogenic answer is associated with either the patient’s body coun-
terbalance to an anxiety-inducing situation or due to adrenaline secreted by 
the vasoconstrictor agent. As a result of mood changes, heart rate, respiratory 
rate, and blood pressure are altered. Patients often have a blush or erythema 
which mimics allergic reactions, hyperventilation, nausea, and vomiting [3]. 
It is important to understand the patient and make them relax. In more severe 
cases, these reactions should be maintained as syncope and hyperventilation. For 
preventing psychogenic reactions, the patient should be relaxed before adminis-
tering local anesthetic injections. Using oral sedatives is an efficacious method to 
manage dental fears. Initial dosage should be dependent on patient health, age, 
weight, and duration of the operation. For healthy adult patients in short-term 
operations antihistamine-diphenhydramine (Benadryl) 50 mg 1 hour prior to 
the operation, moderate length (1–2 hours) operation benzodiazepine, triazolam 
(Halcion) 0.125–0.5 mg 1 hour before the operation triazolam, for longer duration 
(2–4 hours) benzodiazepine such as lorazepam (Ativan) 1–4 mg may be given 
1–2 hours prior to the operation or 30–60 minutes prior for the sublingual prepa-
ration may be described and given. Pharmacologically, mildly and moderately 
anxious dental patients can be managed using sedation or extremely anxious or 
phobic patients using general anesthesia [8, 9].
3.2 Systemic toxicity
Local anesthetic systemic toxicity develops when a sufficient (toxic) concentra-
tion of anesthetic drug in the blood level reaches to the central nervous system and 
cardiovascular systems.
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Initial symptoms are characterized by central nervous system signs such as 
excitation, convulsions, followed by loss of consciousness and respiratory arrest. 
These symptoms are often accompanied by cardiovascular signs such as hyperten-
sion, tachycardia, and premature ventricular contractions. The clinical signs and 
symptoms usually show objective symptoms such as quick talking, flicker, and 
tremor in the extremities [10, 11].
Predisposing factors are associated with age, weight, other drugs, gender, the 
presence of disease, genetics, vasoactivity, concentration, dose, route of adminis-
tration, the rate of injection, vascularity of the injection site, and the presence of 
vasoconstrictors [7].
In order to prevent systemic toxicity, the patient should be evaluated. The 
volume of local anesthesia should be decreased, young or lightweight patients 
should not be treated all four quadrants at one visit using local anesthetic alone; 
accurate and slow injection technique, adjustment of dosage divided administra-
tion and aspirating technique, using agents with low toxicity such as ropivacaine 
and levobupivacaine, and performing an aspiration test are recommended [11]. 
Preventing from a toxic dose complication, it should be evoked that for healthy 
adults, the suggested maximum safe dose of 2% lignocaine in 1:80,000 adrenaline 
is four-and-a-half 2 or 2.2 mL cartridges (180–198 mg lignocaine); for 3% prilo-
caine and felypressin 0.03 i.u./mL, the maximum safe dose is 400 mg (six 2 mL 
cartridges) [12]. Another strategy to reduce toxicity is using the guideline of 1/10th 
cartridge per kilo as a rough guide to the maximum dose [13].
Dentists should be aware that excessive doses of topical anesthetics while these 
agents are more concentrated to facilitate infiltration may lead to toxic effects, 
particularly in children.
Treatment at the office includes airway support, administration of 100% oxygen, 
supine positioning, and protection from injury in the event of seizure activity, 
 treating convulsions (benzodiazepines or thiopental; propofol cannot be used 
in patients with unstable blood pressure, heartbeat) [14]. If severe hypotension 
arrhythmia occurs, administration of the infusion of a 1.5 mL/kg 20% lipid emul-
sion over approximately 1 minute and then starting with continuous application 
at 0.25 mL/kg/min = 1000 mL/h. Studies have reported a resuscitation effect at a 
total dose of ≤10 mL/kg; therefore, 12 mL/kg can be used as an approximate esti-
mate for the maximum dose. The adrenaline dose should be based on resuscitation 
guidelines such as those of the American Heart Association. The American Society 
of Regional Anesthesia and Pain Medicine standard of <1 μg/kg does not need to be 
strictly adhered to [11].
3.3 Allergy
Allergy is also known as hypersensitive reactions, initiated by immunological 
mechanisms acquired through exposure to a specific allergen; re-exposure to which 
produces a heightened capacity to react. The prevalence of allergic reactions to 
amide group local anesthetics is rare. It is predicted that less than 1% of all compli-
cations are caused by an allergy. Many of the complications doubt to be allergic are 
actually anxiety-induced reactions [15].
Ester-type local anesthetics are more allergenic than amide-type local anesthet-
ics. Therefore, amide-type anesthetics are broadly used, among which lidocaine 
is the most commonly used for dental anesthesia epinephrine involving form. 
Adverse reactions to local anesthesia are caused by preservatives (e.g., methyl-p-
hydroxybenzoate), antioxidants (e.g., bisulfate), antiseptics (e.g., chlorhexidine), 
vasoconstrictor (e.g., sulfites), and other antigens such as latex, as well as local 
anesthetic drugs themselves [5].
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Allergic reactions may include mild symptoms, such as urticaria, erythema, and 
intense itching, as well as severe reactions in the form of angioedema and/or respi-
ratory distress. Even more severe life-threatening anaphylactic responses include 
symptoms of apnea, hypotension, and loss of consciousness [15].
In order to diagnose allergies, the skin prick test is the most endorsed. When 
skin prick test results are determined to be negative, intradermal testing should be 
performed for patients who have a history of allergy to local anesthetics intradermal 
tests become obligatory [15, 16].
The following treatments a local anesthetic patient had tested negative in the 
allergy tests, should be used.
The initial treatment for an allergic reaction in office at the first step should 
be the removal of the causative agent. For the management of mild symptoms, 
oral or intramuscular antihistamine-diphenhydramine (Benadryl), 25 or 50 mg, 
should be given. Additionally, hydrocortisone cream may be prescribed to relieve 
skin itching or erythema. In life-threatening cases basic life support, intramus-
cular or subcutaneous epinephrine 0.3–0.5 mg, and hospitalization services 
should be given.
Anaphylaxis is an acute potentially life-threatening hypersensitivity reaction. 
The clinical symptoms of anaphylaxis are depending on the organ systems involved. 
Uncontrolled co-existing asthma, mast cell disorders, and patients with specific 
allergens such as peanut and tree nut allergy are the risk factors for anaphylaxis. 
In emergency management of anaphylaxis in the office, due to guidelines of the 
Australasian Society of Clinical Immunology and Allergy should be in these steps, 
the patient should lie flat, but also in the case of breathing difficulty, the patient 
is allowed to sit. Adrenaline 1:1000 dilution (0.01 mg/kg up to 0.5 mg per dose) 
should be administered intramuscular with 1-mL syringes, 21 gauge needles, 
and should be repeated every 5 minutes as needed. Another recommendation 
for epinephrine is or children and adults who weigh 30 kg or over is 0.3 mg. For 
those weighing 15 to 30 kg, the epinephrine dose is 0.15 mg. The use of adrenaline 
auto-injector can also be chosen, which is carried mostly by heavy allergic patients 
themselves.
Adrenaline should be administered for anaphylaxis by intravenous (IV) route 
only in the case of profoundly hypotensive patients or patients who develop a car-
diopulmonary arrest or those who fail to respond to multiple doses of IM adrenaline 
because of the potential cardiovascular adverse effects of IV administration of 
adrenaline [17, 18].
Estelle and Simons evaluated evidence-based pharmacologic treatment of anaphy-
laxis. They agreed using epinephrine at the first step intramuscular in the treatment 
of anaphylaxis. But the use of antihistamines and glucocorticoids is controversial. 
Some authors claim using antihistamines is not effective because they are not effective 
on upper or lower airway obstruction, hypotension, or shock, while others advocate 
that these drugs decrease the side effects urticaria, flushing, headache, hypotension, 
and rhinorrhea. In the World Allergy Organization survey, glucocorticoids were 
reported to be the second most widely available medications (after epinephrine) 
for anaphylaxis treatment globally, even though some claim glucocorticoids have no 
proven benefit in anaphylaxis [19].
As a result first step of treatment must be epinephrine additionally glucocorti-
coids and antihistamines may use to treat severe systemic reactions.
3.4 Methemoglobinemia
Methemoglobinemia is a unique dose-dependent reaction where the iron in 
hemoglobin is stabilized in the ferric (Fe3+) form, unable to attach oxygen, leading 
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to tissue hypoxia and causing a varying degree of cyanosis. Methemoglobinemia 
can be either inherited or acquired [20].
The risk of methemoglobinemia increased in infants and the elderly. Patients 
with underlying health problems; liver cirrhosis, with underdeveloped hepatic 
and renal function; heart disease; and pulmonary disease (chronic obstructive 
pulmonary disease, pneumonia) are under the risk of methemoglobinemia. When 
administered in excessive doses, the local anesthetics mostly prilocaine and benzo-
caine (90% of reported cases) and barely lidocaine and articaine may also lead to 
methemoglobinemia [21].
Symptoms of cyanosis will be observed in nail beds and mucous membranes. In 
more severe cases, headache, dizziness, fatigue, dyspnea, and tachycardia are seen. 
For diagnosis in the dental clinic, pulse oximetry and in-hospital arterial blood 
analysis play an essential role [21].
Management of methemoglobinemia begins with supplemental oxygen (100%) 
immediately. As a guideline, methylene blue, which is a heterocyclic aromatic chemi-
cal compound increasing the rate of conversion of methemoglobin to hemoglobin, 
may be given to a symptomatic patient. For severe cases, hyperbaric oxygenation 
may also be used if available. Methylene blue should be administrated in 1 to 2 mg/kg 
doses, given as 0.1 mL/kg of a 1% solution (10 mg/mL) intravenously over 5–10 min-
utes every hour up to a 7 mg/kg maximum. Repeated doses may be necessary within 
30–60 minutes of the initial dose [22, 23]. Guay summarizes 242 cases of methemo-
globinemia complications related to dental local anesthetics lidocaine, bupivacaine, 
cocaine, mepivacaine, prilocaine, and tetracaine in children and adults. He concluded 
that benzocaine should be out of usage. In a specific patient group, in children 
younger than 6 months, in pregnant women, or in patients taking other oxidizing 
drugs, prilocaine should not be used. The dose should be limited to 2.5 mg/kg [21].
4. Local complications associated with local anesthesia
4.1 Pain on injection
Pain on injection can be due to specific circumstances such a temperate of the 
solution, velocity of injection, dull needles, needles with barbs, or aggressive inser-
tion of the needle, damaging soft tissues, blood vessels, nerves, or the periosteum 
and causing more pain and other complications.
The burning is dependent on the rate of injection and the acidity of the solu-
tion. Lidocaine causes an intense burning sensation when injected locally. When 
the needle penetrates a nerve, the patient may also feel a sudden “electric” shock, 
suddenly moving the head, with the risk of self-inflicted damage [24].
In order to prevent discomfort, topical anesthetic application, warming anes-
thetics to body temperature, using a smaller-gauge needle (27 gauge), switching 
to a fresh needle when you have to inject multiple times in the same lesion or when 
you have multiple injection sites, and injecting slowly and with low pressure which 
reduces pain are done. A rate of 30 seconds per mL of solution is recommended. An 
inadequate injection site can lead to an intramuscular or intraneural injection blunt-
ing of the needle, side of injection anatomic structure (palate) it is unacceptable to 
feel a little pain during injection [13, 24, 25].
4.2 Needle fracture
Needle breakage in the oral cavity after local anesthesia is a rare complication, 
since the establishment of non-reusable, stainless steel dental local anesthetic 
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Allergic reactions may include mild symptoms, such as urticaria, erythema, and 
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be the removal of the causative agent. For the management of mild symptoms, 
oral or intramuscular antihistamine-diphenhydramine (Benadryl), 25 or 50 mg, 
should be given. Additionally, hydrocortisone cream may be prescribed to relieve 
skin itching or erythema. In life-threatening cases basic life support, intramus-
cular or subcutaneous epinephrine 0.3–0.5 mg, and hospitalization services 
should be given.
Anaphylaxis is an acute potentially life-threatening hypersensitivity reaction. 
The clinical symptoms of anaphylaxis are depending on the organ systems involved. 
Uncontrolled co-existing asthma, mast cell disorders, and patients with specific 
allergens such as peanut and tree nut allergy are the risk factors for anaphylaxis. 
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diopulmonary arrest or those who fail to respond to multiple doses of IM adrenaline 
because of the potential cardiovascular adverse effects of IV administration of 
adrenaline [17, 18].
Estelle and Simons evaluated evidence-based pharmacologic treatment of anaphy-
laxis. They agreed using epinephrine at the first step intramuscular in the treatment 
of anaphylaxis. But the use of antihistamines and glucocorticoids is controversial. 
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3.4 Methemoglobinemia
Methemoglobinemia is a unique dose-dependent reaction where the iron in 
hemoglobin is stabilized in the ferric (Fe3+) form, unable to attach oxygen, leading 
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to tissue hypoxia and causing a varying degree of cyanosis. Methemoglobinemia 
can be either inherited or acquired [20].
The risk of methemoglobinemia increased in infants and the elderly. Patients 
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methemoglobinemia [21].
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30–60 minutes of the initial dose [22, 23]. Guay summarizes 242 cases of methemo-
globinemia complications related to dental local anesthetics lidocaine, bupivacaine, 
cocaine, mepivacaine, prilocaine, and tetracaine in children and adults. He concluded 
that benzocaine should be out of usage. In a specific patient group, in children 
younger than 6 months, in pregnant women, or in patients taking other oxidizing 
drugs, prilocaine should not be used. The dose should be limited to 2.5 mg/kg [21].
4. Local complications associated with local anesthesia
4.1 Pain on injection
Pain on injection can be due to specific circumstances such a temperate of the 
solution, velocity of injection, dull needles, needles with barbs, or aggressive inser-
tion of the needle, damaging soft tissues, blood vessels, nerves, or the periosteum 
and causing more pain and other complications.
The burning is dependent on the rate of injection and the acidity of the solu-
tion. Lidocaine causes an intense burning sensation when injected locally. When 
the needle penetrates a nerve, the patient may also feel a sudden “electric” shock, 
suddenly moving the head, with the risk of self-inflicted damage [24].
In order to prevent discomfort, topical anesthetic application, warming anes-
thetics to body temperature, using a smaller-gauge needle (27 gauge), switching 
to a fresh needle when you have to inject multiple times in the same lesion or when 
you have multiple injection sites, and injecting slowly and with low pressure which 
reduces pain are done. A rate of 30 seconds per mL of solution is recommended. An 
inadequate injection site can lead to an intramuscular or intraneural injection blunt-
ing of the needle, side of injection anatomic structure (palate) it is unacceptable to 
feel a little pain during injection [13, 24, 25].
4.2 Needle fracture
Needle breakage in the oral cavity after local anesthesia is a rare complication, 
since the establishment of non-reusable, stainless steel dental local anesthetic 
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needles. In most cases, needle fracture happened with 30-gauge needles and during 
inferior alveolar nerve block, as a result of either incorrect injection technique, 
improper choice of hypodermic needle magnitude, or unexpected motion of the 
patient or assistants [26].
In order to prevent needle fracture, first the injection needles should be checked; 
30-gauge and short needles should not be used for inferior alveolar nerve block in 
adults or children (25–27 should be chosen). Needles should not bend while insert-
ing them into soft tissue [26, 27].
In the case of a broken needle, if visible, it should be removed immediately 
with a hemostat. If this is inaccessible, computed tomographic (CT) scanning 
should be taken to ensure the location of the needle, and under general anes-
thesia, the patient should be operated. In the literature for the removal of the 
fragment, mostly superficial mucosal incision perpendicular to the trajectory of 
the needle followed by blunt supra-periosteal dissection to spare vital structures is 
recommended [28, 29].
Acham et al. in 2018 made an analysis of the literature complication of needle 
fracture following dental local anesthesia on 36 reports and 59 needle breakage 
events; they concluded that three-dimensional imaging techniques should be taken 
to see the broken fragment and also surrounding structures like vessels and the the 
parotid gland. It is important because 27 out of 57 cannula fragments were located 
in the pterygomandibular space, and the choice of the removal of the fragment, 
whether general or local anesthesia, should be dependent on the patient’s systemic 
condition [30].
4.3 Prolongation of anesthesia and various sensory disorders
Prolonged anesthesia, paresthesia, or neuralgia may occur following dental 
local anesthetic blocks. This may be temporary, where after a few days, weeks, or 
months, sensation returns or it may be permanent [31]. This mostly involves nervus 
lingualis or nervus mandibularis or both [32]. The nerve may be damaged during 
injection by direct injury, or the needle may damage the intraneural blood supply, 
resulting in a hematoma, or the needle may traumatize the medial pterygoid muscle 
which results in trismus. Neurotoxicity of the local anesthetic is another theory for 
nerve damage [33]. Procaine and tetracaine cause more damage than bupivacaine 
or lidocaine [34]. Paresthesia or neuralgia complication is mostly transient but may 
also be permanent if the anesthetic solution is injected directly into the nerve. Due 
to a numb feeling, the patient may have discomfort such as tongue biting, drool-
ing, loss of taste, and speech impediment. Sullivan et al. conducted a randomized, 
double-blind, placebo-controlled trial on 496 patients with Bell’s palsy. They main-
tain treatment with steroids within 3 days after onset quite advances the chance for 
full recovery at 3 or 9 months [35]. Piccinni et al. conducted an analysis of reports 
to the FDA Adverse Event Reporting System; about 573 cases of paresthesia and 
dysesthesia after local anesthetics between 2004 and 2011 were performed. They 
concluded that the use of prilocaine, articaine, or both drugs has a higher risk of 
paresthesia [36].
If a nerve is damaged due to dental local anesthesia, the first treatment should 
be managing the pain. In order to decrease local anesthesia-dependent nerve injury, 
avoiding high concentration of anesthetic agent for inferior alveolar nerve blocks 
(use 2% lidocaine as standard), preventing iterative injections, and avoiding infe-
rior alveolar nerve blocks are done by using high concentration agents (articaine) 
infiltrations only. The use of a low daily dose of multivitamin B, to regaining nerve 
healing and function, has been recommended [37, 38].
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4.4 Lack of effect
Reasons for unsuccess in obtaining local anesthesia can be dependent on ana-
tomical variants, pathological and psychological factors, choice of technique and 
solution, and poor technique [24].
Anatomical factors comprise accessory nerve supply, alteration in foramen 
location, atypical development of the nerves (bifid mandibular canals), and bone 
density [39, 40].
Pathological reasons for the failure of anesthesia are trismus, infection, inflam-
mation, and previous surgery or trauma. Inflammatory diseases altering the 
pharmacokinetics and pharmacodynamics of local anesthetics cause a response to 
decrease and unfavorable effects to increase [41].
Local anesthetic failure or difficulty to obtain satisfactory analgesia commonly 
occurs in the situations with inflammations such as pulpitis and apical periodontitis 
acute periodontal abscess or pericoronitis [42]. Psychological determinants such as 
angst and anxiety can also cause local anesthesia failure [39].
Poor technique failure mostly occurs to obtain mandibular anesthesia. If the 
needle is inserted and advanced too deeply and too far dorsally, the terminal 
branches of the facial nerve within the deep lobe of the parotid gland are affected. 
Direct anesthesia to the facial nerve can force a rapid onset that occurs while the 
anesthetic agent is being injected; reflex vasospasms of the external carotid artery 
can lead to ischemia of the facial nerve, so facial nerve palsy occurs. The patient is 
unable to wrinkle the forehead, raise the eyebrow, close the upper eyelid, retract the 
commissure of the lips to smile, and turn down the lower lip on the affected side. 
The removal of contact lenses and closing of the eye on the affected side in Bell’s 
palsy prevent corneal abrasion or drying [43, 44].
In most cases, paralysis occurs immediately after mandibular anesthesia injec-
tion, but there are also some cases in which paralysis starts lately. Cakarer et al. 
have a case report for late paralyses. They extracted simple teeth, without any 
complication, and 1 day after the patient returned with complaints of a weakness 
of the muscles of the left side of his face. On the examination, they observed Bell’s 
palsy sign on the left side and unilateral expressionless, and there was no patho-
logic sign in the wound or any herpetic lesions. They consulted the patient with 
the Department of Ophthalmology and the Department of Physical Therapy and 
Rehabilitation. For the treatment lubricant eye drop (4 × 1), tobramycin ophthalmic 
solution (4 × 1) and lanolin eye ointment (during night) supported by eye patch 
were used. For 4 weeks, galvanic stimulation of the affected side of the facial nerve 
was performed, and mime therapy was recommended. In 2 weeks all of the symp-
toms disappeared [45].
If the needle is inserted too high and deep, N. auriculotemporalis will be 
affected, and the feeling of “numbness” will occur. There has been a report of sud-
den unilateral deafness following inferior dental nerve anesthesia.
4.5 Trismus
Trismus is defined as a painful circumstance with inability to open the mouth 
normally. Several factors cause trismus such as multiple injections in a short period 
of time in the same area, intramuscular injections inside the muscle or trauma to 
muscles (either the lateral pterygoid muscle or the temporal muscle) which cause 
hematoma formation and fibrosis, needle fracture in the muscles inserting to 
styloid process, inaccurate positioning of the needle when giving the inferior nerve 
block or maxillary posterior injections or inflammation of the masseter and other 
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needles. In most cases, needle fracture happened with 30-gauge needles and during 
inferior alveolar nerve block, as a result of either incorrect injection technique, 
improper choice of hypodermic needle magnitude, or unexpected motion of the 
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30-gauge and short needles should not be used for inferior alveolar nerve block in 
adults or children (25–27 should be chosen). Needles should not bend while insert-
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In the case of a broken needle, if visible, it should be removed immediately 
with a hemostat. If this is inaccessible, computed tomographic (CT) scanning 
should be taken to ensure the location of the needle, and under general anes-
thesia, the patient should be operated. In the literature for the removal of the 
fragment, mostly superficial mucosal incision perpendicular to the trajectory of 
the needle followed by blunt supra-periosteal dissection to spare vital structures is 
recommended [28, 29].
Acham et al. in 2018 made an analysis of the literature complication of needle 
fracture following dental local anesthesia on 36 reports and 59 needle breakage 
events; they concluded that three-dimensional imaging techniques should be taken 
to see the broken fragment and also surrounding structures like vessels and the the 
parotid gland. It is important because 27 out of 57 cannula fragments were located 
in the pterygomandibular space, and the choice of the removal of the fragment, 
whether general or local anesthesia, should be dependent on the patient’s systemic 
condition [30].
4.3 Prolongation of anesthesia and various sensory disorders
Prolonged anesthesia, paresthesia, or neuralgia may occur following dental 
local anesthetic blocks. This may be temporary, where after a few days, weeks, or 
months, sensation returns or it may be permanent [31]. This mostly involves nervus 
lingualis or nervus mandibularis or both [32]. The nerve may be damaged during 
injection by direct injury, or the needle may damage the intraneural blood supply, 
resulting in a hematoma, or the needle may traumatize the medial pterygoid muscle 
which results in trismus. Neurotoxicity of the local anesthetic is another theory for 
nerve damage [33]. Procaine and tetracaine cause more damage than bupivacaine 
or lidocaine [34]. Paresthesia or neuralgia complication is mostly transient but may 
also be permanent if the anesthetic solution is injected directly into the nerve. Due 
to a numb feeling, the patient may have discomfort such as tongue biting, drool-
ing, loss of taste, and speech impediment. Sullivan et al. conducted a randomized, 
double-blind, placebo-controlled trial on 496 patients with Bell’s palsy. They main-
tain treatment with steroids within 3 days after onset quite advances the chance for 
full recovery at 3 or 9 months [35]. Piccinni et al. conducted an analysis of reports 
to the FDA Adverse Event Reporting System; about 573 cases of paresthesia and 
dysesthesia after local anesthetics between 2004 and 2011 were performed. They 
concluded that the use of prilocaine, articaine, or both drugs has a higher risk of 
paresthesia [36].
If a nerve is damaged due to dental local anesthesia, the first treatment should 
be managing the pain. In order to decrease local anesthesia-dependent nerve injury, 
avoiding high concentration of anesthetic agent for inferior alveolar nerve blocks 
(use 2% lidocaine as standard), preventing iterative injections, and avoiding infe-
rior alveolar nerve blocks are done by using high concentration agents (articaine) 
infiltrations only. The use of a low daily dose of multivitamin B, to regaining nerve 
healing and function, has been recommended [37, 38].
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4.4 Lack of effect
Reasons for unsuccess in obtaining local anesthesia can be dependent on ana-
tomical variants, pathological and psychological factors, choice of technique and 
solution, and poor technique [24].
Anatomical factors comprise accessory nerve supply, alteration in foramen 
location, atypical development of the nerves (bifid mandibular canals), and bone 
density [39, 40].
Pathological reasons for the failure of anesthesia are trismus, infection, inflam-
mation, and previous surgery or trauma. Inflammatory diseases altering the 
pharmacokinetics and pharmacodynamics of local anesthetics cause a response to 
decrease and unfavorable effects to increase [41].
Local anesthetic failure or difficulty to obtain satisfactory analgesia commonly 
occurs in the situations with inflammations such as pulpitis and apical periodontitis 
acute periodontal abscess or pericoronitis [42]. Psychological determinants such as 
angst and anxiety can also cause local anesthesia failure [39].
Poor technique failure mostly occurs to obtain mandibular anesthesia. If the 
needle is inserted and advanced too deeply and too far dorsally, the terminal 
branches of the facial nerve within the deep lobe of the parotid gland are affected. 
Direct anesthesia to the facial nerve can force a rapid onset that occurs while the 
anesthetic agent is being injected; reflex vasospasms of the external carotid artery 
can lead to ischemia of the facial nerve, so facial nerve palsy occurs. The patient is 
unable to wrinkle the forehead, raise the eyebrow, close the upper eyelid, retract the 
commissure of the lips to smile, and turn down the lower lip on the affected side. 
The removal of contact lenses and closing of the eye on the affected side in Bell’s 
palsy prevent corneal abrasion or drying [43, 44].
In most cases, paralysis occurs immediately after mandibular anesthesia injec-
tion, but there are also some cases in which paralysis starts lately. Cakarer et al. 
have a case report for late paralyses. They extracted simple teeth, without any 
complication, and 1 day after the patient returned with complaints of a weakness 
of the muscles of the left side of his face. On the examination, they observed Bell’s 
palsy sign on the left side and unilateral expressionless, and there was no patho-
logic sign in the wound or any herpetic lesions. They consulted the patient with 
the Department of Ophthalmology and the Department of Physical Therapy and 
Rehabilitation. For the treatment lubricant eye drop (4 × 1), tobramycin ophthalmic 
solution (4 × 1) and lanolin eye ointment (during night) supported by eye patch 
were used. For 4 weeks, galvanic stimulation of the affected side of the facial nerve 
was performed, and mime therapy was recommended. In 2 weeks all of the symp-
toms disappeared [45].
If the needle is inserted too high and deep, N. auriculotemporalis will be 
affected, and the feeling of “numbness” will occur. There has been a report of sud-
den unilateral deafness following inferior dental nerve anesthesia.
4.5 Trismus
Trismus is defined as a painful circumstance with inability to open the mouth 
normally. Several factors cause trismus such as multiple injections in a short period 
of time in the same area, intramuscular injections inside the muscle or trauma to 
muscles (either the lateral pterygoid muscle or the temporal muscle) which cause 
hematoma formation and fibrosis, needle fracture in the muscles inserting to 
styloid process, inaccurate positioning of the needle when giving the inferior nerve 
block or maxillary posterior injections or inflammation of the masseter and other 
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masticatory muscles, a low-grade infection, and excessive volumes of local anes-
thetic solution deposited into a bounded region which cause expansion of tissues. In 
the acute phase, pain from hemorrhage leads to muscle contraction and limitation 
of motion.
Once trismus develops, some cases will resolve spontaneously. Progression of 
trismus to chronic hypomobility and fibrous ankylosis may be prevented by the 
early institution of treatment consisting of heat therapy; soft diet; prescription 
of analgesics, anti-inflammatory drugs, antibiotics, muscle relaxants; or physio-
therapy. Trismus caused by an infection needs to be treated by antibiotics. Usually, 
trismus will resolve in 6 weeks, with a range of 4 to 20 weeks.
Awareness of the anatomical landmarks and muscles: palpation of bony anterior 
ramus for temporalis muscle, pterygomandibular fold for pterygoid muscle, and 
appropriate angulation of the needle and bone contact before injecting are good 
methods for avoiding trismus via local anesthesia.
Intraorally the Vazirani-Akinosi technique, the closed-mouth mandibular nerve block 
technique, or extraoral techniques can provide anesthesia to trismus patients [43, 46].
4.6 Infection
Infection complication is rare since the usage of disposable needles and glass 
cartridges. Infection may extend to tissues by penetration of the needle through a 
contaminated tissue, because of the needle being contaminated before an operation 
or improper preparation of local anesthetic diluted solutions. On the other hand, a 
latent viral infection may be reactivated due to the trauma of the procedure which 
may be responsible for neural sheath inflammation.
The area to be penetrated should be cleaned with a topical antiseptic prior to 
insertion of the needle. Antiseptic mouthwash solutions such as chlorhexidine 
gluconate should be considered for all regional techniques. The local anesthesia 
should not be injected through the infected area.
Injecting local anesthesia during the presence of infection is important to increase 
the pH of anesthetic agent in order to increase efficiency because the infected tissue 
is more acidic. This process is called anesthetic buffering and leads to patient com-
fort during injection, fast onset of anesthesia, and lower postinjection tissue injury. 
Recommendation for treatment of infection is antibiotics (penicillin V 500 mg every 
6 hour for 7–10 days), analgesics, heat, drainage, and physiotherapy [2, 31, 47].
4.7 Edema
Swelling of tissues can be due to trauma during injection, infection, allergy, 
hemorrhage, and injection of irritating solutions.
The management of edema is dependent on the cause. Allergy-induced edema 
treatment consists of intramuscular epinephrine injection as mentioned above and, 
additionally, antihistamine and corticosteroid administration and consultation with 
an allergist to determine the precise cause of the edema. Trauma-induced edema 
should be managed as a hematoma. For the treatment of edema produced by infec-
tion, antibiotics should be prescribed [27].
4.8 Hematoma
Hematoma formation as a complication of local anesthesia is the result of a 
venous or arterial laceration; intra-arterial blood pressure increase causes effusion 
of blood into the surrounding soft tissues. While injecting, if there is a high pres-
sure, it may be a warning injecting against the bloodstream. The size of a hematoma 
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depends on the density and compactness of the affected tissue; when a vein rupture 
is concerned, hematoma does not necessarily occur. Discoloration on the area, a 
bruise may accompany hematoma [48].
From the anatomical point of view, different nerve effects cause hematoma on 
specific regions such as anterior superior alveolar (infraorbital) nerve block below 
the lower eyelid, incisive (mental) nerve block at the chin area, buccal nerve block 
or any palatal injection within the mouth, and posterior superior alveolar nerve 
block extraoral in the lower buccal region of the mandible, intraoral distal to maxil-
lary tuberosity.
Hematoma formation can be prevented by aspirating before injecting the 
anesthetic solution, by using a short needle and a minimum number of needle 
penetrations into tissues. When swelling forms immediately after injection, local-
ized pressure should be applied with a minimum of 2 minutes. This will stop the 
hemorrhage.
Both swelling and discoloration usually subside in 10 to 15 days. Ice packs should 
be held for the first 24 hours after surgery following which intermittent hot moist 
packs can be used to resolve the condition and massage therapy using a heparin 
cream. Antibiotics should be prescribed if the hematoma is large in order to prevent 
the development of a wound infection [14, 49].
4.9 Gingival lesions
Gingival lesions consist of recurrent aphthous stomatitis, and herpes simplex 
can occur intraorally after a local anesthetic injection or after any trauma to the 
intraoral tissues. The exact mechanism is unknown, but any trauma to tissues by 
a needle may activate the latent form of the disease process that was present in the 
tissues with previous injection.
No management is necessary until there is severe pain. In order to relieve pain, 
topical anesthetic solutions (e.g., viscous lidocaine) may be used on affected areas. 
A concoction of identical amounts of diphenhydramine and milk of magnesia 
rinsed in the mouth effectively covers the ulcerations and provides relief from pain. 
Triamcinolone acetonide without corticosteroid can remedy pain [14, 27].
4.10 Soft tissue injury
Lip or tongue biting or chewing can occur on children with special needs or 
disabled patients, following dental local anesthesia with the unfamiliar sensation of 
being numb [50]. Shorter-acting local anesthetics such as plain mepivacaine should 
be chosen, and the patient or the guardian should be warned about eating, drinking 
hot fluids, and biting on the lips or tongue to test for anesthesia; cotton rolls can be 
placed between the teeth and soft tissues to prevent chewing. In order to accelerate 
recovery time for sensation, an alpha-adrenergic receptor, phentolamine mesylate 
(OraVerse), may be injected. For adults, the proposed dosage is 1 to 2 cartridges of 
phentolamine mesylate (a dose of 0.4 to 0.8 mg), while for children the proposed 
dosage is 0.5 to 1 cartridge (0.2 to 0.4 mg) [50, 51] Malamed [52].
Swelling may decay after 2 to 3 days. The lesion will heal over the next 10 to 
14 days. For pain complains, analgesics may be prescribed and topical local anes-
thetic gel may be applied to the area.
4.11 Ophthalmologic complications
The most common complications include diplopia (dual vision), ophthalmople-
gia (paralysis or weakening of eye muscles), ptosis, and mydriasis (dilatation of 
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4.6 Infection
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The management of edema is dependent on the cause. Allergy-induced edema 
treatment consists of intramuscular epinephrine injection as mentioned above and, 
additionally, antihistamine and corticosteroid administration and consultation with 
an allergist to determine the precise cause of the edema. Trauma-induced edema 
should be managed as a hematoma. For the treatment of edema produced by infec-
tion, antibiotics should be prescribed [27].
4.8 Hematoma
Hematoma formation as a complication of local anesthesia is the result of a 
venous or arterial laceration; intra-arterial blood pressure increase causes effusion 
of blood into the surrounding soft tissues. While injecting, if there is a high pres-
sure, it may be a warning injecting against the bloodstream. The size of a hematoma 
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depends on the density and compactness of the affected tissue; when a vein rupture 
is concerned, hematoma does not necessarily occur. Discoloration on the area, a 
bruise may accompany hematoma [48].
From the anatomical point of view, different nerve effects cause hematoma on 
specific regions such as anterior superior alveolar (infraorbital) nerve block below 
the lower eyelid, incisive (mental) nerve block at the chin area, buccal nerve block 
or any palatal injection within the mouth, and posterior superior alveolar nerve 
block extraoral in the lower buccal region of the mandible, intraoral distal to maxil-
lary tuberosity.
Hematoma formation can be prevented by aspirating before injecting the 
anesthetic solution, by using a short needle and a minimum number of needle 
penetrations into tissues. When swelling forms immediately after injection, local-
ized pressure should be applied with a minimum of 2 minutes. This will stop the 
hemorrhage.
Both swelling and discoloration usually subside in 10 to 15 days. Ice packs should 
be held for the first 24 hours after surgery following which intermittent hot moist 
packs can be used to resolve the condition and massage therapy using a heparin 
cream. Antibiotics should be prescribed if the hematoma is large in order to prevent 
the development of a wound infection [14, 49].
4.9 Gingival lesions
Gingival lesions consist of recurrent aphthous stomatitis, and herpes simplex 
can occur intraorally after a local anesthetic injection or after any trauma to the 
intraoral tissues. The exact mechanism is unknown, but any trauma to tissues by 
a needle may activate the latent form of the disease process that was present in the 
tissues with previous injection.
No management is necessary until there is severe pain. In order to relieve pain, 
topical anesthetic solutions (e.g., viscous lidocaine) may be used on affected areas. 
A concoction of identical amounts of diphenhydramine and milk of magnesia 
rinsed in the mouth effectively covers the ulcerations and provides relief from pain. 
Triamcinolone acetonide without corticosteroid can remedy pain [14, 27].
4.10 Soft tissue injury
Lip or tongue biting or chewing can occur on children with special needs or 
disabled patients, following dental local anesthesia with the unfamiliar sensation of 
being numb [50]. Shorter-acting local anesthetics such as plain mepivacaine should 
be chosen, and the patient or the guardian should be warned about eating, drinking 
hot fluids, and biting on the lips or tongue to test for anesthesia; cotton rolls can be 
placed between the teeth and soft tissues to prevent chewing. In order to accelerate 
recovery time for sensation, an alpha-adrenergic receptor, phentolamine mesylate 
(OraVerse), may be injected. For adults, the proposed dosage is 1 to 2 cartridges of 
phentolamine mesylate (a dose of 0.4 to 0.8 mg), while for children the proposed 
dosage is 0.5 to 1 cartridge (0.2 to 0.4 mg) [50, 51] Malamed [52].
Swelling may decay after 2 to 3 days. The lesion will heal over the next 10 to 
14 days. For pain complains, analgesics may be prescribed and topical local anes-
thetic gel may be applied to the area.
4.11 Ophthalmologic complications
The most common complications include diplopia (dual vision), ophthalmople-
gia (paralysis or weakening of eye muscles), ptosis, and mydriasis (dilatation of 
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pupil). In extremely rare instances, amaurosis (partial/total blindness) can be seen. 
All these complications are transient and disappear on interruption of the anes-
thetic effects [53].
Intraarterial injection or perforation of the vascular wall would stimulate the 
sympathetic fibers running alongside the internal maxillary artery until reaching 
the orbit. The intravenous injection could reach the cavernous sinus via the ptery-
goid plexus and anesthetize the oculomotor, trochlear, or abducens nerves.
Horner’s syndrome may occur after an inferior dental nerve block anesthesia 
because of penetration of the local anesthetic through the lateral pharyngeal and 
prevertebral spaces, causing barrier of the stellate ganglion [54, 55].
Alamanos et al. conducted a systematic review in 2016 on ophthalmologic 
complications following dental local anesthesia with 66 reports and 89 cases. They 
found that the Gow-Gates technique for mandibular block anesthesia is only associ-
ated with diplopia, vision impairment is more associated with inferior alveolar 
nerve blocks than with posterior superior alveolar nerve blocks, and the latter 
technique has rarely been reported as a cause of amaurosis. Ocular complications in 
the literature are mostly with an injection of lidocaine [56].
In order to minimize the possible complications, visualization of the regional 
anatomy, numerous aspirations while injection, and aspiration on at least two 
planes before administration local anesthetic are performed.
5. Conclusion
Administration of a local anesthetic can be associated with complications of 
adverse events. In order to prevent local anesthetic complications, the medical 
history of the patients should routinely be evaluated in details, and effective anxiety 
management should be performed. Doses of local anesthetics should be always 
strictly assessed with body weight, and the maximum recommended dosages 
should be considered. While administrating anesthesia, the painless injection 
should be performed, avoiding intravascular or intramuscular or direct trauma to 
the nerve. New developments should be followed by the practitioners to reduce 
possible complications associated with the local anesthesia.
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Local Anesthetic Systemic Toxicity
Divya Garg, Shikha Soni and Rakesh Karnawat
Abstract
Local anesthetics are used very often in medicine and dentistry. They have few 
adverse effects, but the increased use of these drugs has resulted in a higher inci-
dence of local and systemic anesthetic toxicity (LAST). From the initial symptoms 
to the deleterious effects on cardiac and the central nervous system, LAST is an 
important consequence of which we should be aware. LAST is known since the 
introduction and use of local anesthetics; it was originally associated with seizures 
and respiratory failure. However, in the 1970s, side effects on the heart were also 
identified, as the fatal cardiac toxicity associated with bupivacaine was discovered 
in healthy patients. Prevention and safe administration of regional anesthesia 
remains primary factors in the avoidance of the toxicity of these drugs. When a 
patient has LAST, treatment should be started immediately to reduce seizures. If 
there is cardiac arrest, follow ACLS guidelines. Intravenous lipids improve cardiac 
conduction, contractility and coronary perfusion by removing liposoluble local 
anesthetic from cardiac tissue.
Keywords: local anesthetic, toxicity, mechanism of action, prevention, management, 
lipid emulsion
1. Introduction
Systemic toxicity due to local anesthetics (LAST) is a nightmare for each anes-
thesiologist. It can have catastrophic outcome in an otherwise simple procedure, 
such as a regional dental anesthesia, local anesthesia, nerve block either peripheral, 
intravenous or peridural. The clinical phenomenon of LAST has been known for 
more than 100 years. Historically, the introduction of cocaine as the first local 
anesthetic (LA) in late nineteenth century was soon accompanied by reports of its 
systemic toxicity. The symptoms of systemic toxicity were frequently described 
as seizures or respiratory failure, but some cases also included reports of adverse 
cardiac effects [1]. These reasons demanded medical and pharmaceutical industries 
to search for new less toxic LA.
At first, manipulation of existing molecular structures after analyzing natural 
products lead to development of few drugs. It became clear that the development 
of more LA of ester group did not return the desired results. The main concern was 
short duration of action due to instability of ester bonds. The drugs were prepared 
in an oily formulation to increase the duration (which proved neurotoxic locally, or 
by enhancing the lipophilicity of the molecule which made it more toxic to central 
nervous system (CNS) as well as cardiovascular system (CVS)). Lidocaine, synthe-
sized in 1944 was the first amide LA drug to be used clinically. It gave a dependable 
block, but unfortunately was short acting. In search of an LA with a longer duration 
of action than lidocaine, a family of N-alkylpiperidines 2,6 xylidides was introduced 
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in 1950s. It was shown that increasing N-alkyl carbon chain length (to max at C4 or 
C5) increased lipophilicity, which increases duration of action, but unfortunately 
also increased systemic toxicity. Derivatives developed for clinical use included 
mepivacaine, bupivacaine, ropivacaine, levobupivacaine, etc. But in subsequent 
year’s cases of lethal LAST were documented.
Accidental intravascular injection during regional anesthesia is the most com-
mon cause of LAST. Some comorbidities may increase the risk of LAST; liver failure, 
heart disease, pregnancy and metabolic syndromes. In addition, patients at extreme 
ages have an increased risk factor of toxicity, due to the reduction in anesthetic 
clearance. Children under 4 months of age have low plasma concentrations of acid 
glycoprotein, which may result in a lower intrinsic clearance of bupivacaine [2, 3].
The incidence of LAST is extremely variable from zero events after more than 
12,000 nerve blocks to 25 per 10,000 nerve blocks. One study reported seizures 
in 79 of 10,000 brachial plexus block procedures. This complication was due to 
toxicity of the CNS as a result of intravascular LA injection. Although the published 
data are inconsistent, the prevailing goal is to prevent LAST, and when it manifests, 
it must be treated quickly and effectively [4–6].
Cardiac toxicity is the most important component of LAST since, unlike the 
CNS toxicity, it can end in cardiac arrest and death. It is often due to an intravascu-
lar injection not noticed during nerve block. LA bind and inhibit voltage dependent 
sodium channels. It leads to conduction disorders, contractile dysfunction and ven-
tricular arrhythmias. The incidence of cardiac toxicity increases with bupivacaine 
due to its affinity for inactive sodium channels during the cardiac action potential at 
a concentration of 0.2 μg/mL. This is done in a fast/slow manner, which means that 
bupivacaine binds very rapidly to a large proportion of sodium channels during the 
potential for cardiac action, but is slowly released from the channels during dias-
tole, which results in a large proportion of medication that accumulates at 60–150 
beats per minute. Lidocaine at 5–10 μg/mL will also result in a substantial blockage 
of sodium channels during a potential for cardiac action. However, in contrast to 
bupivacaine, lidocaine follows the principle of rapid entry/exit, which means that it 
is rapidly released from sodium channels during diastole. This allows faster recov-
ery and a lower incidence of cardiac toxicity compared to bupivacaine.
CNS toxicity is another important consequence of LAST. Although it is com-
posed of many initial prodromal features, it is most often manifested as seizures. 
A mechanistic theory focuses on acid-sensitive K+ channels. These pH-sensitive 
channels generate neuronal currents of leakage of potassium. LA inhibition causes 
membrane depolarization and increased neuronal excitability. As these channels 
are expressed throughout the brain, this is the suggested mechanism for seizures in 
this context. Consequently, it became mandatory to understand the mechanism of 
LAST, so that it could be prevented and managed efficiently.
This chapter reviews the mechanisms, frequency, clinical characteristics, 
prevention and treatment of LAST.
2. LAST mechanisms
LA agents are classic sodium channel inhibitors. LAST hypotheses are based 
primarily on the binding site, ion channels, signaling pathway or enzymes involved 
in the CNS and cardiac toxicity or its treatment. LA inhibit some components of 
the oxidative phosphorylation pathway, which affects the myocardium and the CNS 
that are poorly tolerant of anaerobic metabolism. These deleterious effects differ 
quantitatively between LA, doses and administration routes. It is appropriate to first 
review the ion channels implicated in LAST [7–9].
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2.1 Sodium channel blockade
LA are sodium channel blocking acting on inactivated sodium channel state and 
blocking it. They affect the initial depolarization phase and slow it down, leading to 
slow cardiac conduction. The antiarrhythmic property of lidocaine is related to this 
slowed conduction as it causes fast blockade of the channels. In contrast, bupiva-
caine and ropivacaine cannot be used as anti-arrhythmic drugs though they have 
fast blockade, but slow release of sodium channel (lasting longer than 1 s in contrast 
to lidocaine which lasts 0.15 s) [10]. Slowed conduction leads to widening the QRS 
complex, prolongation of the PR interval, AV block and, eventually, ventricular 
fibrillation due to the unidirectional blockade and re-entry phenomenon.
2.2 Potassium channel blockade
Out of three known organized potassium channels, two groups are of interest 
where LA toxicity is concerned. Out of these, one group of channels are known 
as the inward, outward and transient rectifier potassium channels, thus plays an 
important role in the potassium efflux during phases 2 and 3 of the cardiac muscle 
action potential [11]. If these channels are blocked, it will lead to prolongation 
of action potential; i.e. phase 2, delay in repolarization; i.e. phase and shift the 
resting membrane potential more positive (phase 4) to increase automaticity [12]. 
The second group of potassium channels of interest are K2p. Previously known 
as the delayed rectifier channels, these channels are believed to be responsible for 
the background or leak potassium currents. In this setting, they control the resting 
membrane potential. A blockade of these channels shifts the resting membrane 
potential towards spontaneous depolarization. K2p channels are extensively 
spread in the body. In the CNS they are mainly located in the thalamo-cortical and 
striatal neurons, where blockade leads to increased neuroexitability [13]. They are 
also present in high concentrations in the cerebral blood vessels, where blockade 
leads to vasoconstriction and decreased cerebral blood flow. K2p channels are also 
present in neurons of the auditory system, where blockade leads to tinnitus. LA 
agents are also known to have K2p mediated stimulating effect on ventilation [14]. 
They are located in the brainstem and carotid body, where they regulate the respi-
ratory response to carbon dioxide via sensing the changes of pH and expressed 
in the oxygen-sensing cells of the glomus body respectively. K2p channels are 
sensitive to changes in oxygen tension and extracellular pH and are potentiated by 
volatile anesthetic [13]. In the CVS K2p channel blockade predisposes the patient 
to re-entry dysrhythmias. It is well known that hyperkalemia exacerbates LAST, 
and that K+ATP openers (which effectively lowers intracellular K+ levels) attenuate 
the toxic effects of bupivacaine [15].
2.3 Ca2+ channel blockade
All voltage-gated Ca2+ channels are comprised of two subunits according to 
the latest research: α and β subunit. The α subunit has fairly constant chemical 
structure for all voltage gated Ca2+ channels and is the main pore- forming ele-
ment of the channel. The β subunit has highly variable structure that depends on 
the location and function of the channel for e.g. in cardiac conduction tissue β1 
subunit completes the ion channel structure. The role of the β1 subunit seems to be 
the modulation of channel opening and membrane ion trafficking [16]. In terms 
of their physiological effect, the heart has two distinct types of channels namely 
the T-type (transient) that are low voltage activated channels (LVA), and L-type 
(long lasting). On the other hand, are high voltage activated channels (HVA). 
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The T-type channels are mainly located in the pacemaker cells of the sinoatrial node, 
and the opening of these channels completes the prepotential required for the 
pacemaker potential. L-type channels are present on the surface of the myocytes of 
both atrium and ventricle, and are closely associated with the T-tubules. The plateau 
phase (phase 2) of cardiac muscle action potential is produced by opening of these 
L-type channels. LA bind to these channels and predispose them to an inactivated 
state. The consequence of this is prolongation of the action potential (phase 2) and 
depressed contractility [9].
3. LAST risk factors
Risk factors to develop LA toxicity are related to kind of LA used, the type of 
nerve block, and the patient.
3.1 LA related
The most important and most studied factors in the development of LAST are 
undoubtedly the type and dose of LA.
3.1.1 Type of LA
The kind of LA injection influence toxicity risk. Animal studies showed that [17] 
more levobupivacaine than bupivacaine was required to induce cardiac arrest and 
levobupivacaine caused fewer convulsions and arrhythmias than bupivacaine, at 
similar doses [18]. Ropivacaine may cause less motor block, but whether it is clini-
cally significantly less toxic is unknown. Other property differentiating the toxicity 
of LA is their intrinsic effect on vessels, where levobupivacaine and ropivacaine 
have intrinsic vasoconstrictors properties (that may prolong duration of action and 
slow systemic absorption), whereas bupivacaine is an intrinsic vasodilator. The 
clinical significance of this difference remains unclear. Another important concept 
in the study of LAST is the ratio of the dose required to produce cardiovascular 
collapse to that required to induce seizures, the so called CC/CNS ratio (ratio of 
dose causing cardiovascular collapse to the dose causing seizures). Bupivacaine has 
a CC/CNS ratio of 2.0 compared with 7.1 for lidocaine. Therefore, progression from 
CNS signs and symptoms to cardiovascular collapse can occur more readily with 
bupivacaine than with lidocaine.
3.1.2 Dose of LA
Determining the optimal dose of LA to use is complex and always a topic of 
debate. Using the lowest effective dose is always prudent and advisable practice 
along with consideration of patient characteristics and site of administration. 
Some may argue that the recommended doses provide a rough guide for clini-
cal use. The maximum weight-based doses have lost rationale in others view as 
such dosing does not correlate to the resulting blood level and does not take into 
account relevant patient factors or the site of injection. Other factors that ques-
tion the maximum weight based doses are variation between different texts and 
countries, no recommendation whether dose calculation is based on actual body 
weight or ideal body weight and such hard and fast dosing rules do not take into 
account the complete clinical context [19]. As a result, if dosing is calculated on 
actual body weight, the obese, pregnant, or both patients may receive a danger-
ously high dose.
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3.2 Block-related
Inadvertent intravenous injection of LA can occur during any regional anes-
thetic technique, but tends in becoming LAST only if larger volumes (5–10 mL) 
are injected, or small doses during face and neck procedures. Symptoms usually 
occur within 3–5 min and can be severe if appropriate measures are not taken. 
LAST resulting from the gradual systemic absorption of LA is characterized 
by a late presentation (20–30 min or more after a bolus injection), and usually 
occurs when a relatively high dose of LA has been administered in the presence 
of another risk factor. Local anesthetic systemic toxicity may also occur in the 
context of continuous LA infusion, in which case the onset may be hours to days 
after starting the infusion. The symptoms last until the drug metabolism reduces 
concentrations plasma levels below the toxic threshold. Prolonged monitoring and 
supportive therapy are essential.
3.2.1 Site of block
Blocking site is important since rate of absorption, chances of direct intravascu-
lar injections and thus chances of toxicity depends on the anatomical location. For 
example, interscalene block, stellate ganglion block, intercostal nerve block have a 
higher risk of direct intravascular injection and other blocks like scalp, bronchial 
mucosa, inter pleural cavity carry an increased risk of rapid absorption and toxicity 
due to the injection being in a highly vascularized area. The classic order of sites 
propensities to lead to toxicity, in order from lowest to highest: subcutaneous injec-
tion, brachial plexus, epidural, caudal, and finally intercostal blocks and topical 
mucosal anesthesia.
3.2.2 Conduct of the block
Performing the block in a safer way decreases the chances of toxicity by mani-
folds. The practice of giving the dose of LA in incremental injections, after frequent 
aspiration, adding test dose and most important is using ultrasound-guided needle 
placement to give the LA reduces the risk of toxicity.
3.3 Patient-related factors
3.3.1 General principles
Various factors are related to toxicity of LA. Most common being the free peak 
plasma concentration, perfusion at the site of injection, co-morbidities (renal, liver, 
metabolic, and cardiac diseases). As already discussed earlier, more the perfusion 
at the site of injection, more will be the peak plasma concentration as systemic 
absorption is accelerated. A low α1-acid glycoprotein (AAG) titer results in a higher 
concentration of free LA.
In patients with severe renal impairment there may be slightly increased risk of 
toxicity as these patients typically have a reduced clearance of LA, hyper dynamic 
circulation but increased AAG. So, it is prudent to reduce the initial dose by 10–20% 
according to severity of renal impairment.
In patients with liver disease, single dose blocks are unaffected, but the doses for 
repeat boluses and continuous infusions should be reduced. Such patients may also 
have renal or cardiac disease. AAG is synthesized in patients with end-stage liver 
disease, offering some protection against LAST. Patients with severe cardiac failure 
are particularly susceptible to LA-induced myocardial depression and arrhythmias. 
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The T-type channels are mainly located in the pacemaker cells of the sinoatrial node, 
and the opening of these channels completes the prepotential required for the 
pacemaker potential. L-type channels are present on the surface of the myocytes of 
both atrium and ventricle, and are closely associated with the T-tubules. The plateau 
phase (phase 2) of cardiac muscle action potential is produced by opening of these 
L-type channels. LA bind to these channels and predispose them to an inactivated 
state. The consequence of this is prolongation of the action potential (phase 2) and 
depressed contractility [9].
3. LAST risk factors
Risk factors to develop LA toxicity are related to kind of LA used, the type of 
nerve block, and the patient.
3.1 LA related
The most important and most studied factors in the development of LAST are 
undoubtedly the type and dose of LA.
3.1.1 Type of LA
The kind of LA injection influence toxicity risk. Animal studies showed that [17] 
more levobupivacaine than bupivacaine was required to induce cardiac arrest and 
levobupivacaine caused fewer convulsions and arrhythmias than bupivacaine, at 
similar doses [18]. Ropivacaine may cause less motor block, but whether it is clini-
cally significantly less toxic is unknown. Other property differentiating the toxicity 
of LA is their intrinsic effect on vessels, where levobupivacaine and ropivacaine 
have intrinsic vasoconstrictors properties (that may prolong duration of action and 
slow systemic absorption), whereas bupivacaine is an intrinsic vasodilator. The 
clinical significance of this difference remains unclear. Another important concept 
in the study of LAST is the ratio of the dose required to produce cardiovascular 
collapse to that required to induce seizures, the so called CC/CNS ratio (ratio of 
dose causing cardiovascular collapse to the dose causing seizures). Bupivacaine has 
a CC/CNS ratio of 2.0 compared with 7.1 for lidocaine. Therefore, progression from 
CNS signs and symptoms to cardiovascular collapse can occur more readily with 
bupivacaine than with lidocaine.
3.1.2 Dose of LA
Determining the optimal dose of LA to use is complex and always a topic of 
debate. Using the lowest effective dose is always prudent and advisable practice 
along with consideration of patient characteristics and site of administration. 
Some may argue that the recommended doses provide a rough guide for clini-
cal use. The maximum weight-based doses have lost rationale in others view as 
such dosing does not correlate to the resulting blood level and does not take into 
account relevant patient factors or the site of injection. Other factors that ques-
tion the maximum weight based doses are variation between different texts and 
countries, no recommendation whether dose calculation is based on actual body 
weight or ideal body weight and such hard and fast dosing rules do not take into 
account the complete clinical context [19]. As a result, if dosing is calculated on 
actual body weight, the obese, pregnant, or both patients may receive a danger-
ously high dose.
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3.2 Block-related
Inadvertent intravenous injection of LA can occur during any regional anes-
thetic technique, but tends in becoming LAST only if larger volumes (5–10 mL) 
are injected, or small doses during face and neck procedures. Symptoms usually 
occur within 3–5 min and can be severe if appropriate measures are not taken. 
LAST resulting from the gradual systemic absorption of LA is characterized 
by a late presentation (20–30 min or more after a bolus injection), and usually 
occurs when a relatively high dose of LA has been administered in the presence 
of another risk factor. Local anesthetic systemic toxicity may also occur in the 
context of continuous LA infusion, in which case the onset may be hours to days 
after starting the infusion. The symptoms last until the drug metabolism reduces 
concentrations plasma levels below the toxic threshold. Prolonged monitoring and 
supportive therapy are essential.
3.2.1 Site of block
Blocking site is important since rate of absorption, chances of direct intravascu-
lar injections and thus chances of toxicity depends on the anatomical location. For 
example, interscalene block, stellate ganglion block, intercostal nerve block have a 
higher risk of direct intravascular injection and other blocks like scalp, bronchial 
mucosa, inter pleural cavity carry an increased risk of rapid absorption and toxicity 
due to the injection being in a highly vascularized area. The classic order of sites 
propensities to lead to toxicity, in order from lowest to highest: subcutaneous injec-
tion, brachial plexus, epidural, caudal, and finally intercostal blocks and topical 
mucosal anesthesia.
3.2.2 Conduct of the block
Performing the block in a safer way decreases the chances of toxicity by mani-
folds. The practice of giving the dose of LA in incremental injections, after frequent 
aspiration, adding test dose and most important is using ultrasound-guided needle 
placement to give the LA reduces the risk of toxicity.
3.3 Patient-related factors
3.3.1 General principles
Various factors are related to toxicity of LA. Most common being the free peak 
plasma concentration, perfusion at the site of injection, co-morbidities (renal, liver, 
metabolic, and cardiac diseases). As already discussed earlier, more the perfusion 
at the site of injection, more will be the peak plasma concentration as systemic 
absorption is accelerated. A low α1-acid glycoprotein (AAG) titer results in a higher 
concentration of free LA.
In patients with severe renal impairment there may be slightly increased risk of 
toxicity as these patients typically have a reduced clearance of LA, hyper dynamic 
circulation but increased AAG. So, it is prudent to reduce the initial dose by 10–20% 
according to severity of renal impairment.
In patients with liver disease, single dose blocks are unaffected, but the doses for 
repeat boluses and continuous infusions should be reduced. Such patients may also 
have renal or cardiac disease. AAG is synthesized in patients with end-stage liver 
disease, offering some protection against LAST. Patients with severe cardiac failure 
are particularly susceptible to LA-induced myocardial depression and arrhythmias. 
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Further, lower liver and renal perfusion slows metabolism and elimination, so safe 
initial and maintenance doses of LA are correspondingly lower too. On the other 
hand, poor perfusion at the injection site may decrease peak plasma concentrations.
3.3.2 Age related factors
Extremes of age have different physiological changes making them different 
from young and adolescent age group. In elderly patients; there is a safety benefit in 
dose reduction without altering the clinical efficacy. In the geriatric patient’s nerves 
appears to be more sensitive to LA due to various factors like altered nerve mor-
phology, there is less fat tissue surrounding the nerves, and axonal function is also 
reduced. Moreover, this age group has multiple co-morbidities and decreased muscle 
mass; blood flow to organs is reduced, decreased clearance and organ function. In 
patients older than 65 years’ involuntary overdoses being responsible for some cases 
of LAST. When considering the use of LA in geriatric patients, it is mandatory to pay 
special attention to the presence of systemic disease and muscle wasting [20].
In neonates and infants, the risk of accumulation of LA with continuous infu-
sions is more than in adults as AAG levels are reduced (about half that of adult at 
birth). Children have an increased elimination half-life of LA, which in neonates is 
increased to 2–3 times that of an adult. Bupivacaine accumulates with continuous 
infusion and 2-chloroprocaine can be used as an alternative. LAST has the highest 
incidence in infants less than 6 months of age and is associated with bolus dosing 
and penile nerve blocks [21].
3.3.3 Pregnant patients
Pregnancy is one of several clinical settings in which LAST can be potentiated. 
Pregnant patients are at an increased risk of toxicity as they have increased perfu-
sion as well as decreased AAG levels; thus high peak free plasma concentration of 
LA. Some of the earliest anecdotal reports of LAST-related fatal cardiac arrests 
involved pregnant women [1]. Notably, several of the original anecdotal reports 
of LAST-related fatal cardiac arrests involved pregnant women. It has since been 
proven that pregnancy increases the risk for LAST, and subsequent guidelines 
preclude use of 0.75% bupivacaine in late gestation because this concentration was 
involved in cases of fatal toxicity in parturients [22–24].
4. Clinical presentation of LAST
Most of the LAST events happen a few minutes after the LA injection and pres-
ent with signs of the CNS, which may or may not be accompanied by changes in the 
CVS (Figure 1). Sometimes, the manifestations are atypical in terms of time and 
clinical picture. The onset of symptoms may be delayed up to 60 min after a bolus 
injection, and signs of CVS toxicity may appear in the absence of any CNS charac-
teristics. This last scenario may be more common in patients who are very sedated 
or under general anesthesia. High plasma concentrations during LAST can occur 
in three circumstances: inadvertent intra-arterial injection, intravenous injection 
or systemic absorption, each of which has a characteristic temporal course. LAST 
associated with intra-arterial injection occurs classically during nerve blockages in 
the head and neck (stellate ganglion, interscalene or deep cervical plexus blocks) 
in which there is an involuntary injection of LA in an artery that supplies the brain. 
The symptoms of the CNS, usually seizures, occur almost immediately. When 
the injected dose is small, progression to CVS collapse is uncommon. Recovery 
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is equally rapid since LA quickly redistributes from the cerebral circulation [25]. 
Figure 2 shows an intra-arterial puncture detected during the blockage of the stel-
late ganglion in a patient with herpes zoster neuropathy.
4.1 Central nervous system toxicity
Central nervous system toxicity could be presumed as a two-stage process in 
which initial blockade of Na+ channels occurs in the inhibitory neurons thus allow-
ing excitatory neurons to act unopposed which culminates in generalized convul-
sions. Higher concentrations of LA agent affect all neurons, leading to global CNS 
depression, which is clinically seen as coma and evident on EEG as slowing and 
ultimately silent EEG. In most cases, convulsions, although an impressive clinical 
entity, can be handled safely without permanent brain damage. Clinical manifesta-
tions of the systemic neurotoxicity of LA usually occur in stages; in the initial phase 
there is perioral numbness, confusion, tinnitus followed by an exciting phase that 
shows seizures and, finally, a depressive phase where there is loss of consciousness 
and respiratory depression.
Figure 1. 
Scheme showing the most important clinical manifestations of LAST.
Figure 2. 
Accidental arterial puncture during a stellate ganglion block in a patient with postherpetic neuropathy.
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Most of the LAST events happen a few minutes after the LA injection and pres-
ent with signs of the CNS, which may or may not be accompanied by changes in the 
CVS (Figure 1). Sometimes, the manifestations are atypical in terms of time and 
clinical picture. The onset of symptoms may be delayed up to 60 min after a bolus 
injection, and signs of CVS toxicity may appear in the absence of any CNS charac-
teristics. This last scenario may be more common in patients who are very sedated 
or under general anesthesia. High plasma concentrations during LAST can occur 
in three circumstances: inadvertent intra-arterial injection, intravenous injection 
or systemic absorption, each of which has a characteristic temporal course. LAST 
associated with intra-arterial injection occurs classically during nerve blockages in 
the head and neck (stellate ganglion, interscalene or deep cervical plexus blocks) 
in which there is an involuntary injection of LA in an artery that supplies the brain. 
The symptoms of the CNS, usually seizures, occur almost immediately. When 
the injected dose is small, progression to CVS collapse is uncommon. Recovery 
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is equally rapid since LA quickly redistributes from the cerebral circulation [25]. 
Figure 2 shows an intra-arterial puncture detected during the blockage of the stel-
late ganglion in a patient with herpes zoster neuropathy.
4.1 Central nervous system toxicity
Central nervous system toxicity could be presumed as a two-stage process in 
which initial blockade of Na+ channels occurs in the inhibitory neurons thus allow-
ing excitatory neurons to act unopposed which culminates in generalized convul-
sions. Higher concentrations of LA agent affect all neurons, leading to global CNS 
depression, which is clinically seen as coma and evident on EEG as slowing and 
ultimately silent EEG. In most cases, convulsions, although an impressive clinical 
entity, can be handled safely without permanent brain damage. Clinical manifesta-
tions of the systemic neurotoxicity of LA usually occur in stages; in the initial phase 
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and respiratory depression.
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Scheme showing the most important clinical manifestations of LAST.
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Accidental arterial puncture during a stellate ganglion block in a patient with postherpetic neuropathy.
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4.2 Cardiovascular system toxicity
Both the direct and indirect effects of the LA drugs on myocardium are involved 
in the mechanism of cardiovascular toxicity [26].
Clinical presentation includes hypertension and tachycardia in initial phase 
(during CNS excitatory phase), followed by intermediate phase showing myocar-
dial depression, decreased cardiac output and thus hypotension, followed by sinus 
bradycardia, peripheral vasodilatation, conduction defects and dysrhythmias in 
terminal phase.
5. Management of LAST
All medical and paramedical personnel working in operating theaters and hospi-
tal locations where LA are used should be prepared to recognize, diagnose and treat 
patients with signs and symptoms of LAST in a timely manner. The ASRA has pub-
lished and updated the guidelines recommended by experts for the management of 
LAST (Table 1) [4, 5]. The initial treatment of LAST should focus on keeping the 
airways permeable with adequate ventilation, circulatory support and the reduction 
of systemic side effects. Immediate ventilation and oxygenation to prevent hypoxia 
and acidosis can facilitate resuscitation and reduce the likelihood of progression to 
seizures or cardiovascular collapse [24, 25].
5.1 Preparation
All patients receiving LA injections in doses potentially to trigger LAST should 
have oxygen, standard monitoring which is to be continued at least 30 min after 
completion of injection to detect delayed presentation if any, and intravenous access 
applied [27, 28]. Immediate access to LAST Management Checklist is advisable, and 
all medications and resuscitation equipment required should be immediately avail-
able, preferably in the form of a “LAST Rescue Kit”.
5.2 Immediate management
Immediate management involves the general safety and resuscitation measures 
that are essential in any emergency. First, stop LA injection and call for help. The 
immediate priority is to manage the airway, breathing, and circulation. Avoid 
factors potentiating LAST like hypoxia, hypercarbia, and acidosis (metabolic or 
respiratory [24, 25, 29]).
5.2.1 Intravenous lipid emulsion therapy
Use of intravenous lipid emulsion as a therapeutic modality comes with several 
advantages. Theories suggest that it improves cardiac conduction, contractility 
and coronary perfusion by removing the liposoluble LA from cardiac tissue. Better 
understanding of the mechanism of action of lipid emulsion with recent advances 
underlines its importance as therapeutic modality in the management of LAST. First 
advantage is that lipid emulsion may shuttle any LA agent from high blood flow 
organs to detoxification organs such as the liver [30]. Secondly, lipid emulsion 
therapy may also improve the cardiac output and blood pressure. Post conditioning 
myocardial protection may also occur [31–34]. There is an unavailability of large 
scale data collection and other prospective studies to demonstrate efficacy of lipid 
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emulsion therapy due to various difficulties [24, 35, 36]; however various animal 
studies provide strong support for use of lipid emulsion therapy to reduce mortality 
when used along with resuscitative measures [37]. Early administration of 20% 
intravenous lipid emulsion therapy should, therefore, be an immediate priority 
after airway management in any LAST event that is judged to be potentially seri-
ous. A bolus of 1.5 mL/kg of 20% lipid emulsion and the subsequent infusion of 
0.25 mL/kg per minute should be administered. The infusion should be continued 
for 10 min after reaching hemodynamic stability. An additional bolus and an infu-
sion rate increase to 0.5 mL/kg per minute can be administered if stability is not 
achieved. The maximum recommended dose for initial administration is approxi-
mately 10 mL/kg for 30 min (Table 1) [4, 37, 38]. Lipid emulsion remains first-line 
therapy (in conjunction with standard resuscitative measures) in LAST. However, 
more research in humans is necessary to establish its real usefulness [36].
Checklist for LAST treatment
The pharmacologic treatment of LAST is different from other cardiac arrest scenarios
 Reduce individual epinephrine boluses to ≤1 mcg/kg
 Avoid vasopressin, calcium channel blockers, beta blockers, or other local anesthetics
• Stop injecting local anesthetic
• Get help
 ○ Consider lipid emulsion therapy at the first sign of a serious LAST event
 ○ Call for the LAST rescue kit
 ○ Alert the nearest cardiopulmonary bypass team – resuscitation may be prolonged
• Airway management
 ○ Ventilate with 100% oxygen / avoid hyperventilation / advanced airway device if necessary
• Control seizures
 ○ Benzodiazepines preferred
 ○ Avoid large doses of propofol, especially in hemodynamically unstable patients
• Treat hypotension and bradycardia—if pulseless, start CPR
Lipid emulsion 20% (precise volume and flow rate are crucial)
Greater than 70 kg patient Less than 70 kg patient
Bolus 100 mL lipid emulsion 20% rapidly over 2–3 min Bolus 1.5 mL/kg lipid emulsion 20% 
rapidly over 2–3 min
• Lipid emulsion infusion 200–250 mL over 15–20 min • Lipid emulsion infusion ~0.25 mL/kg/
min (ideal body weight)
If patient remains unstable:
• Re-bolus once or twice at the same dose and double infusion rate; be aware of dosing limit (12 mL/kg)
• Total volume of lipid emulsion can approach 1 L in a prolonged resuscitation (e.g., > 30 min)
• Continue monitoring
 ○ At least 4–6 h after a cardiovascular event
 ○ Or, at least 2 h after a limited CNS event
• Do not exceed 12 mL/kg lipid emulsion (particularly important in the small adult or child)
 ○ Much smaller doses are typically needed for LAST treatment
With permission from www.anestesia-dolor.org.
Table 1. 
Checklist for LAST treatment [4, 5].
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Use of intravenous lipid emulsion as a therapeutic modality comes with several 
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understanding of the mechanism of action of lipid emulsion with recent advances 
underlines its importance as therapeutic modality in the management of LAST. First 
advantage is that lipid emulsion may shuttle any LA agent from high blood flow 
organs to detoxification organs such as the liver [30]. Secondly, lipid emulsion 
therapy may also improve the cardiac output and blood pressure. Post conditioning 
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emulsion therapy due to various difficulties [24, 35, 36]; however various animal 
studies provide strong support for use of lipid emulsion therapy to reduce mortality 
when used along with resuscitative measures [37]. Early administration of 20% 
intravenous lipid emulsion therapy should, therefore, be an immediate priority 
after airway management in any LAST event that is judged to be potentially seri-
ous. A bolus of 1.5 mL/kg of 20% lipid emulsion and the subsequent infusion of 
0.25 mL/kg per minute should be administered. The infusion should be continued 
for 10 min after reaching hemodynamic stability. An additional bolus and an infu-
sion rate increase to 0.5 mL/kg per minute can be administered if stability is not 
achieved. The maximum recommended dose for initial administration is approxi-
mately 10 mL/kg for 30 min (Table 1) [4, 37, 38]. Lipid emulsion remains first-line 
therapy (in conjunction with standard resuscitative measures) in LAST. However, 
more research in humans is necessary to establish its real usefulness [36].
Checklist for LAST treatment
The pharmacologic treatment of LAST is different from other cardiac arrest scenarios
 Reduce individual epinephrine boluses to ≤1 mcg/kg
 Avoid vasopressin, calcium channel blockers, beta blockers, or other local anesthetics
• Stop injecting local anesthetic
• Get help
 ○ Consider lipid emulsion therapy at the first sign of a serious LAST event
 ○ Call for the LAST rescue kit
 ○ Alert the nearest cardiopulmonary bypass team – resuscitation may be prolonged
• Airway management
 ○ Ventilate with 100% oxygen / avoid hyperventilation / advanced airway device if necessary
• Control seizures
 ○ Benzodiazepines preferred
 ○ Avoid large doses of propofol, especially in hemodynamically unstable patients
• Treat hypotension and bradycardia—if pulseless, start CPR
Lipid emulsion 20% (precise volume and flow rate are crucial)
Greater than 70 kg patient Less than 70 kg patient
Bolus 100 mL lipid emulsion 20% rapidly over 2–3 min Bolus 1.5 mL/kg lipid emulsion 20% 
rapidly over 2–3 min
• Lipid emulsion infusion 200–250 mL over 15–20 min • Lipid emulsion infusion ~0.25 mL/kg/
min (ideal body weight)
If patient remains unstable:
• Re-bolus once or twice at the same dose and double infusion rate; be aware of dosing limit (12 mL/kg)
• Total volume of lipid emulsion can approach 1 L in a prolonged resuscitation (e.g., > 30 min)
• Continue monitoring
 ○ At least 4–6 h after a cardiovascular event
 ○ Or, at least 2 h after a limited CNS event
• Do not exceed 12 mL/kg lipid emulsion (particularly important in the small adult or child)
 ○ Much smaller doses are typically needed for LAST treatment
With permission from www.anestesia-dolor.org.
Table 1. 
Checklist for LAST treatment [4, 5].
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5.2.2 Seizure management
Prompt seizure prevention and termination is crucial to avoid injury and acido-
sis. Benzodiazepines are first line therapy for management of seizures due to their 
cardio stable profile. Propofol or thiopental can be used in low doses, although these 
drugs may worsen the hypotension or cardiac depression associated with LAST. It 
should be avoided in patients with cardiovascular compromise. Neuromuscular 
blockade can be considered in cases of ongoing seizures; small doses of succinyl-
choline should be administered intermittently to stop muscle activity and increased 
acidosis. Early termination of seizure activity helps to avoid metabolic acidosis and 
hypoxia that occurs due to repeated muscular contractions [24].
5.2.3 Cardiovascular support
The treatment of LA-induced cardiac arrest focuses on restoring cardiac 
output, to restore tissue perfusion, prevent and treat underlying acidosis. Chest 
compressions should be started without delay and to be continued till return of 
spontaneous circulation (as per ACLS algorithms for cardiopulmonary resuscita-
tion). If epinephrine is used, small initial doses of ≤1 μg/kg are preferred to avoid 
impaired pulmonary gas exchange and increased afterload [39]. Vasopressin is not 
recommended, as it can cause pulmonary hemorrhage. If myocardial LA levels is 
more than the threshold that corresponds to ion channel blocking concentrations, 
then the ionotropic effect of lipid emulsion therapy remains questionable. Chest 
compressions ensure the coronary perfusion that is sufficient to reduce tissue LA 
levels. In the absence of rapid recovery following ACLS measures and intravenous 
lipid emulsion therapy, early consideration should be given to cardiopulmonary 
bypass for circulatory support. For other deleterious CVS effects—such as arrhyth-
mias, conduction block, progressive hypotension, and bradycardia – standard 
ACLS algorithms should be followed with the omission of LA, such as lidocaine and 
procainamide. Amiodarone is the first-line antiarrhythmic in the event of ventricu-
lar dysrhythmia. In addition, calcium channel blockers and B-adrenergic receptor 
blockers are not recommended.
5.2.4 Post-event management
Report the case of LAST to the registry at www.lipidrescue.org [39]. Monitoring 
is mandatory for at least 2 h in isolated and recovering CNS event but for 6 h for 
LAST with CVS features.
6. Prevention
The primary objective of every anesthesiologist is always patient safety. Pre-
anesthetic evaluation, patient preparation, complete monitoring before starting 
administration of LA, and continuing this monitoring during surgery and the 
immediate postoperative period are mandatory.
6.1 Pre-procedure
• During preoperative assessment, evaluate the patient for co-morbidities, 
evaluation of the risks and benefits of regional anesthesia for that individual 
should be discussed, patient should be explained regarding procedure and 
appropriate consent to be obtained.
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• Preparation includes selection of type of LA, prior calculation of doses, label-
ing all syringes.
• All monitoring facilities to be available along with LAST rescue kit and resusci-
tative measures.
6.2 Intra-procedure
• Block to be performed with continuous monitoring attached, with a capable 
help nearby.
• The method of administration of LA should include the administration of 
incremental doses with frequent aspiration, ultrasound-guided needle place-
ment, administration of test doses. This can help in the early detection of 
accidental intravascular placement of the needle or catheter and thus avoid 
erroneous administration of the LA, avoiding toxic plasma concentrations.
• Continuous communication with the patient to detect early signs of intravas-
cular injection like perioral numbness, tinnitus etc.
6.3 Post-procedure
Clearly label any kind of spinal/epidural catheter or peripheral nerve block 
catheter; it should be documented well in patient chart also. Drug and dose already 
administered or to be administered should be well informed in instructions to the 
medical staff responsible for post-operative care of the patient. Continuous moni-
toring of vital signs in the postoperative period in suspected case of delayed LAST 
to be considered.
7. Conclusion
LAST is a serious life-threatening emergency, with protean manifestations, that 
can happen after administering LA. Anesthesiologists must understand its risks, 
prevention, and safe management. Promptly recognition and timely manage-
ment of LAST can dramatically change the clinical course. In addition to the usual 
advanced cardiac resuscitation maneuvers, the current treatment focuses on the 
administration of lipid emulsion. While the development of new treatment plans 
can help limiting the associated morbidity and mortality, prevention remains 
vitally important. It is mandatory for all the practitioners using LA to understand 
patho-physiological basis, mechanisms, risk factors, prevention and treatment 
modalities of LAST.
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5.2.2 Seizure management
Prompt seizure prevention and termination is crucial to avoid injury and acido-
sis. Benzodiazepines are first line therapy for management of seizures due to their 
cardio stable profile. Propofol or thiopental can be used in low doses, although these 
drugs may worsen the hypotension or cardiac depression associated with LAST. It 
should be avoided in patients with cardiovascular compromise. Neuromuscular 
blockade can be considered in cases of ongoing seizures; small doses of succinyl-
choline should be administered intermittently to stop muscle activity and increased 
acidosis. Early termination of seizure activity helps to avoid metabolic acidosis and 
hypoxia that occurs due to repeated muscular contractions [24].
5.2.3 Cardiovascular support
The treatment of LA-induced cardiac arrest focuses on restoring cardiac 
output, to restore tissue perfusion, prevent and treat underlying acidosis. Chest 
compressions should be started without delay and to be continued till return of 
spontaneous circulation (as per ACLS algorithms for cardiopulmonary resuscita-
tion). If epinephrine is used, small initial doses of ≤1 μg/kg are preferred to avoid 
impaired pulmonary gas exchange and increased afterload [39]. Vasopressin is not 
recommended, as it can cause pulmonary hemorrhage. If myocardial LA levels is 
more than the threshold that corresponds to ion channel blocking concentrations, 
then the ionotropic effect of lipid emulsion therapy remains questionable. Chest 
compressions ensure the coronary perfusion that is sufficient to reduce tissue LA 
levels. In the absence of rapid recovery following ACLS measures and intravenous 
lipid emulsion therapy, early consideration should be given to cardiopulmonary 
bypass for circulatory support. For other deleterious CVS effects—such as arrhyth-
mias, conduction block, progressive hypotension, and bradycardia – standard 
ACLS algorithms should be followed with the omission of LA, such as lidocaine and 
procainamide. Amiodarone is the first-line antiarrhythmic in the event of ventricu-
lar dysrhythmia. In addition, calcium channel blockers and B-adrenergic receptor 
blockers are not recommended.
5.2.4 Post-event management
Report the case of LAST to the registry at www.lipidrescue.org [39]. Monitoring 
is mandatory for at least 2 h in isolated and recovering CNS event but for 6 h for 
LAST with CVS features.
6. Prevention
The primary objective of every anesthesiologist is always patient safety. Pre-
anesthetic evaluation, patient preparation, complete monitoring before starting 
administration of LA, and continuing this monitoring during surgery and the 
immediate postoperative period are mandatory.
6.1 Pre-procedure
• During preoperative assessment, evaluate the patient for co-morbidities, 
evaluation of the risks and benefits of regional anesthesia for that individual 
should be discussed, patient should be explained regarding procedure and 
appropriate consent to be obtained.
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• Preparation includes selection of type of LA, prior calculation of doses, label-
ing all syringes.
• All monitoring facilities to be available along with LAST rescue kit and resusci-
tative measures.
6.2 Intra-procedure
• Block to be performed with continuous monitoring attached, with a capable 
help nearby.
• The method of administration of LA should include the administration of 
incremental doses with frequent aspiration, ultrasound-guided needle place-
ment, administration of test doses. This can help in the early detection of 
accidental intravascular placement of the needle or catheter and thus avoid 
erroneous administration of the LA, avoiding toxic plasma concentrations.
• Continuous communication with the patient to detect early signs of intravas-
cular injection like perioral numbness, tinnitus etc.
6.3 Post-procedure
Clearly label any kind of spinal/epidural catheter or peripheral nerve block 
catheter; it should be documented well in patient chart also. Drug and dose already 
administered or to be administered should be well informed in instructions to the 
medical staff responsible for post-operative care of the patient. Continuous moni-
toring of vital signs in the postoperative period in suspected case of delayed LAST 
to be considered.
7. Conclusion
LAST is a serious life-threatening emergency, with protean manifestations, that 
can happen after administering LA. Anesthesiologists must understand its risks, 
prevention, and safe management. Promptly recognition and timely manage-
ment of LAST can dramatically change the clinical course. In addition to the usual 
advanced cardiac resuscitation maneuvers, the current treatment focuses on the 
administration of lipid emulsion. While the development of new treatment plans 
can help limiting the associated morbidity and mortality, prevention remains 
vitally important. It is mandatory for all the practitioners using LA to understand 
patho-physiological basis, mechanisms, risk factors, prevention and treatment 
modalities of LAST.
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